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The dismal prognosis and treatment options for pancreatic ductal adenocarcinoma (PDAC) 
have seen little advances over the past decades, making PDAC one of the most lethal 
malignancies to date. Hydrogel-based in vitro modelling of this cancer and its tumour 
microenvironment (TME) is a promising avenue to bridge the gap between laboratory and 
clinical data. Current collagen gel-based approaches are limited by varying batch 
composition, little tuneability and limited mechanical properties, which preclude the accurate 
recapitulation of key PDAC features, such as matrix stiffness, desmoplasia and drug 
resistance. 
 
In this study, gelatin methacryloyl (GelMA)-based hydrogels were used for the three-
dimensional (3D) multicellular culture of PDAC and stromal cells (myeloid cells and patient-
derived fibroblasts). The hydrogel’s mechanical properties, architecture and matrix protein 
expression of embedded cells were characterised and benchmarked against collagen gels and 
native human tissues. Mechanical testing of fresh human tissues was performed to inform 
the physical properties of the model. PDAC tissues were significantly stiffer (7.4 ± 0.6 kPa, 
p<0.0001) than normal adjacent tissues (2.2 ± 0.2 kPa), prompting the modelling of these 
observed biomechanics with the use of GelMA-based hydrogels. Immunofluorescence, flow 
cytometry, metabolic activity and DNA quantification analyses confirmed the suitability of 
GelMA hydrogels for 3D PDAC research by showing high viability of embedded cells, 
spheroid formation ability, expression of cancer-associated markers and proliferation. The 
simultaneous 3D co-culture of PDAC and stromal cells led to matrix stiffening, increased 
cell proliferation and increased in vivo tumorigenicity via a stiffness-dependant upregulation 
of IL-6, IL-8, STAT3 and downregulation of ERK. Transcriptomic analyses revealed that 
3D GelMA cultures had signatures that correlated with those of cells grown in collagen gels, 
as well as primary tumour organoids cultured in Matrigel, while showing an upregulation in 
mechano-transduction pathways. Treatment with the mechano-modulating inhibitor fasudil 
led to increased chemotherapy efficiency via relaxation of matrix stiffness, downregulation 
of pro-survival and matrix gene signatures, and reduced IL-6 and IL-8 secretion. 
 
These findings demonstrated that GelMA-based hydrogels are a modular and informative 
3D cell culture platform for the investigation of functional, transcriptional and mechanical 
aspects of the pancreatic TME. The tuneable physical properties of GelMA allowed me to 
uncover the increased biomechanical functions and to assess treatment responses of PDAC 
and stromal cells in matrices of physiologically relevant stiffness, which could not be 
assessed, to this extent, in commonly-used collagen matrices. 
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1.1 Pancreatic Ductal Adenocarcinoma  
1.1.1 Prevalence and epidemiology 
Pancreatic cancer is a lethal disease with dismal prognosis and a 5-year survival that has 
changed very little over the past few decades. The median overall survival of patients is only 
6 months from diagnosis, with around 9% of patients surviving over 5 years and as little as 
1% reaching 10 years 1. This is in part due to patients presenting with late stage disease, with 
around 35% baring locally advanced disease and 52% being metastatic, all of which are 
considered surgically unresectable 2. This means that despite surgical resection being the best 
curative treatment, only 10-20% will be eligible for surgery. Moreover, of those patients 
undergoing surgery, 30% will present early recurrence, or later relapse, with only 3-12% 
achieving long-term (10 years) survival 2,3. Because of the overall limited improvement in 
treatment options and its rising incidence, pancreatic cancer is predicted to become the 
second leading cause of cancer-related fatalities in the next decade 4. This prediction reflects 
the persistence of gaps in our understanding of the mechanisms underpinning pancreatic 
cancer initiation, progression and metastasis, ultimately leading to a failure in early detection 
and efficient treatment options. In order to identify and tackle these issues, it is imperative 
to understand the aetiology and pathophysiology of pancreatic cancer. 
1.1.2 Pathophysiology of pancreatic ductal adenocarcinoma 
Pancreatic neoplasms are classified according to their histological differentiation (epithelial 
or non-epithelial) and according to their functional behaviour (benign, pre-malignant or 
malignant) 5. Epithelial neoplasms can be exocrine or endocrine depending on the site of 
initiation, with the exocrine group further divided into ductal and acinar neoplasms 5. By far 
the most common type of pancreatic neoplasm, pancreatic ductal adenocarcinoma (PDAC) 
accounts for over 90% of all pancreatic malignancies, and occurs in the pancreatic ducts 
which are responsible for transporting pancreatic juices into the duodenum during digestion. 
The remaining cases include other exocrine tumours (acinar cell, mucinous, serous, etc.) or 
neuroendocrine tumours (gastrinomas, glucagonoma, insulinoma)5, which arise in the 
endocrine pancreatic islets and generally have a far better prognosis than PDAC.  
 
Despite massive advances in oncology, medical imaging and surgery, PDAC-related deaths 
are projected to more than double from 42 000 (per annum) in 2010 to 88 000 in 2030 in the 
US alone, only second to lung cancer 4. Unsurprisingly, PDAC and lung cancer share similar 
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drawbacks that make them less targetable, in that they are both primarily environmentally 
caused and detected at late stages. PDAC remains largely unpreventable, with less than 10% 
of cases having a family history or inherited risk 6, and with risk factors (tobacco, alcohol, 
obesity, cholesterol, diabetes, etc.) only marginally increasing overall risk by a 1.5 to 2.8 factor 
in otherwise healthy individuals 7. Additionally, PDAC is usually detected at a late stage of 
disease, with advanced stage pancreatic lesions, too late to be surgically resected. 
 
1.1.2.1 Pathogenesis of PDAC 
PDAC usually derives from pancreatic intraepithelial neoplasia (PanIN) precursor lesions. 
PanIN are commonly found in the healthy pancreas, and are characterised by a ductal 
phenotype, classified as low- or high-grade depending on histological cellular and nuclear 
dimorphisms, or staged 1 to 3 8. During progression however, PanIN lesions increase from 
an average 16% in healthy individuals to 82% in PDAC patients 9, often located in the head 
(70%) or tail (6%) of the pancreas 10. PanIN progression is thought to be slow and hence 
more prone to being undetected, despite its high prevalence 11, suggesting there is a lack of 
sensitive and specific early detection methods. Traditionally, PDAC detection is conducted 
through the measurement of cancer antigen CA19-9 serum levels which, despite being a good 
marker for monitoring disease state or treatment efficacy, lacks the sensitivity and specificity 
to be employed as an early detection diagnostic tool 12. Likewise, the presence of circulating 
tumour cells carries high prognostic value, but only occurs in a subset of metastatic patients 
12. Hence detection primarily occurs via symptomatic presentation of patients, usually at late-
stage disease when very limited treatment options remain viable. In addition to 
morphological characterisation, genetic mutations driving PDAC carcinogenesis have been 
well known for many years. In murine models, activation of oncogenic KRAS alone is 
sufficient to drive PanIN formation 13. Additional driving mutations such as CDKN2A, TP53 
and SMAD4, are usually only found in high-grade PanIN and advanced disease stages, while 
KRAS mutations are frequently found, at lower frequencies, even in low-grade lesions 14. 
This suggests a progressive and possibly sequential accumulation of oncogenic mutations 
take place in the pancreas leading to PDAC progression, whose understanding is key in 
designing early detection strategies. 
 
1.1.2.2 Molecular biology of PDAC 
PDAC exhibits altered autocrine and paracrine signalling cascades that, in turn, promote cell 
proliferation, transformation, migration, invasion and metastasis. For instance, activation of 
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cell mitogenic self-sustainment, migration and invasion are documented through signalling 
via receptor tyrosine kinase (RTKs) including epidermal growth factor receptor (EGFR), 
hepatocyte growth factor receptor (HGFR), fibroblast growth factors receptor (FGFRs), 
insulin-like growth factor 1 receptors (IGF1Rs) or erbB-2 (ERBB2, HER2), HER3, and their 
respective growth factors transforming growth factor-α (TGFα), HGF, FGF, IGF 15. These 
cascades concur with the activation of pro-survival and anti-apoptotic signals including 
nuclear factor-κB (NF-κB), AKT30, signal transducer and activator of transcription 3 
(STAT3), wingless (WNT), sonic hedgehog (SHH) and NOTCH 16-18. PDAC also exhibits 
aberrant metabolism and insensitivity to growth inhibitory pathways, exemplified by 
abnormal TGFβ signalling. TGFβ directly induces PDAC cell proliferation via SMAD-4-
mediated upregulation of WNT7B, which in turn phosphorylates mitogen activated protein 
kinase (MAPK), tyrosine-protein kinase Src (SRC), and AKT 19. All of these occur in the 
context of KRAS activation and loss of the tumour suppressor p16 through CDKN2A 
mutations. Activating KRAS mutations dominate PDAC pathology which occur in >90% of 
tumours. Additional mutations inactivating TP53, CDKN2A and SMAD4 are present in 50-
80% of tumours, while relatively rarer mutations, such as TGFBR2, GLI13, MLL3 or 
ARID1A, occur in 10-15% of cases 12. However, recent advances in high-throughput 
sequencing have enabled more detailed categorisation of PDAC subtypes based on their 
mutational landscape 20-23.  
 
1.1.2.3 Molecular subtyping of PDAC 
Transcriptome-wide analyses of PDAC tissue samples led Collisson et al. to classify them 
into three molecular subtypes namely classical, characterised by expression of epithelial and 
adhesion-related genes; quasi-mesenchymal, expressing mesenchyme-related genes; and 
exocrine-like, expressing digestive enzymes genes. Survival was best for the classical subtype 
and worst in quasi-mesenchymal subtype patients 20, however correlations with sensitivity 
and resistance to current therapy regimens, including gemcitabine and nab-paclitaxel or 
FOLFIRINOX, are not known. Following this, Bailey et al. proposed four alternative 
subtypes based on whole exome sequencing and copy number variation 21. Genomic stability 
or instability were further suggested as stratification criteria by Waddell et al. suggesting 
unstable subtypes might be more susceptible to DNA-damage inducing therapeutics 
compared to stable counterparts 22. As the role of tumour microenvironment (TME) became 
evident in later years, Moffitt et al. included PDAC stroma in their classification, proposing 
an “activated” vs “normal” PDAC stroma subtypes, with the latter correlated with better 
prognosis 23. Since then, single cell RNA-sequencing (scRNA-seq) and high content digital 
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imaging advances have led to extensive characterisation and classification of PDAC in the 
context of its TME 18. Therefore, future studies should continue linking molecular and 
histomorphology data to infer prognostic relationships. 
1.1.3 The PDAC clinical landscape: challenges and prospects 
For the majority of patients, symptom presentation remains the most common form of 
detection. However, PDAC symptoms, including fatigue, jaundice, nausea and abdominal 
pain, are largely unspecific, and occasionally totally absent, often resulting in delayed 
diagnosis 12. Additionally, since symptoms arise very late during PanIN progression to 
metastatic PDAC, most patients remain largely inoperable. Another staggering reason for 
PDAC’s dismal prognosis is the absence of highly efficient treatments and low response rate 
to available therapies. Prophylactic treatments include anti-inflammatory drugs, such as 
aspirin, which appears highly controversial, especially in gastric cancers 24. 
 
1.1.3.1 Neoadjuvant, adjuvant and palliative treatments 
To date, the best potentially curative option remains surgical resection, which is performed 
with a Whipple procedure since 1935 and consists in the removal of the head of the pancreas 
as well as duodenum and bile duct, or by distal pancreatectomy and spleen removal 12. The 
surgery is highly invasive and regardless of its success, 90% of patients will relapse after 
resection 25,26. This could be associated with a lack of adequate staging options, inadequate 
neoadjuvant treatment or radiological staging, and differences in tumour aggressiveness 
leading to undetected metastases. Recent advancements in the field of radiology, 
sophisticated imaging and sequencing techniques, as well as neoadjuvant treatments, can help 
surgeons to select patients who will benefit from surgery or from different therapy options 
2. Current neoadjuvant therapy options include chemotherapy, chemo-radiotherapy and 
targeted therapies 2.  
 
For unresectable tumours, the main palliative treatment option remains chemotherapy 
(Figure 1.1). Since 1997, gemcitabine has been the first-line of treatment for newly-diagnosed 
PDAC cases 27. In 2013, new evidence showed that gemcitabine conferred a significant 
increase in survival if administered in combination with a nanoparticle albumin-bound 
version of paclitaxel (nab-paclitaxel) 28, which is used to date. Around the same time, a 
combinational therapy of 5-fluorouracil, leucovorin, irinotecan and oxaliplatin named 
FOLFIRINOX was being tested 29. Both treatment lines had similar 1-year survival rates, 
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with FOLFIRINOX being slightly less tolerated, especially in older patients 30,31. Both 
treatment options are still in use today, as both neoadjuvant (prior to surgery), adjuvant (after 
surgery) or palliative (unresectable) regime options, the latter yielding the least responses 32,33. 
 
1.1.3.2 Targeted therapies 
Several targeted therapies have been evaluated as single agent or in combination with 
chemotherapy with, unfortunately, most agents failing to improve survival significantly 26. 
These include anti-angiogenic compounds, such as sunitinib, sorafenib and axitinib or 
vascular endothelial growth factor (VEGF) inhibitors bevacizumab and aflibercept 34-37. Their 
failure could be attributed to the hypo-vascular nature of PDAC, which makes anti-
angiogenic agents largely ineffective. Agents targeting other key signalling cascades, such as 
the phosphoinositide 3-kinase (PI3K) inhibitor rigosertib 38, the multi-kinase targeting 
masitinib 39 and the anti-IGF1 antibodies ganitumab and cixutumumab 40, have also been 
ineffective in combination with gemcitabine. The only agent, currently approved, with 
statistically significant, although marginal, patient survival improvement is erlotinib. Erlotinib 
pharmacologically inhibits EGFR, which is upstream of GTPase KRAS 26. As KRAS 
Figure 1.1 Treatment options and associated median survival for PDAC patients. Patients are stratified 
according to tumour stage (resectable, borderline resectable and locally advanced unresectable, metastatic). 
FOLFIRINOX= folinic acid, fluorouracil, irinotecan and oxaliplatin; N= nab-paclitaxel; G= gemcitabine. 
Adapted from Neoptolemos et al. 2018. 
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activating mutation is highly present in PDAC patients, erlotinib is postulated to have only a 
minimal effect in this cancer type. In fact, randomised trials have reported a mere ~2 weeks 
improvement in survival with combinational erlotinib treatment over gemcitabine alone 41. 
Similarly, inhibitors of the JAK/STAT pathway, such as ruxolitinib, failed in clinical trials at 
phase II despite significantly improving survival in patients with systematic inflammation 42. 
These failures could be partially explained by advanced disease state at diagnosis, lack of 
patient stratification guidelines but most importantly by the high molecular heterogeneity of 
PDAC, as well as the highly stromal and fibrotic nature of these tumours, promoting tissue 
stiffness, reducing drug delivery, half-life and altering metabolism. 
 
1.1.3.3 Stromal targeting therapies 
The pancreatic TME has gained significant interest in the last decades, due to its ability to 
shape and influence cancer cell behaviour and determining treatment response. This 
comprises both cellular and extracellular elements which will be discussed in detail in Section 
1.2. In the effort of exploiting the stroma to enhance drug accumulation, secreted protein 
acidic and rich in cysteine (SPARC) protein was used as a prognostic biomarker. SPARC is 
produced by fibroblasts and is known to bind to albumin, thereby potentially enriching the 
concentration of nab-paclitaxel directly at the tumour site 43. However, no association was 
found between stromal SPARC levels and overall survival 43. Increased desmoplasia and 
tissue stiffness in PDAC are the result of high extracellular matrix (ECM) deposition, hypo-
vascularisation and increased intra-tumoral pressure. Therefore administration of ECM-
modulating treatments, such as the pegylated recombinant hyaluronidase PEGPH20, were 
aimed at targeting ECM molecules, hyaluronic acid (HA) in this case, intending to decrease 
tumoral fibrosis, interstitial fluid pressure and normalise vasculature 44,45. Successful 
implementation in mice, prompted PEGPH20 use in combination with gem/nab-paclitaxel 
or FOLFIRINOX in clinical trials (NCT01839487, NCT01959139). Although phase I and 
II clinical studies showed promising results in patients with high tumour HA content when 
treated with PEGPH20 and gem/nab-paclitaxel (survival of 9.2 vs 4.3 months) 46, phase III 
failed to reach primary endpoint of overall survival and was terminated 47. Earlier in 2019, 
the PEGPH20 and FOLFIRINOX arm had also been discontinued due to high treatment-
related adverse events 47. This suggested ECM targeting alone is not sufficient and that the 
cancer cell-stroma interplay might be more complex than previously thought. Importantly, 
although stroma is a physical barrier to drug delivery, it may also act as a protective barrier 
for the containment of migrating and proliferating cells. A separate study showed that 
genetical depletion of stromal fibroblasts lead to increased tumour aggressiveness and 
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decreased survival 48. Similar results were observed targeting myofibroblast growth and 
collagen deposition via the SHH pathway inhibitor IPI-926 which, despite decreasing stromal 
content and normalising vasculature, accelerated tumour metastasis 49, underlining the 
dichotomy between the cancer-supporting and restraining roles of the PDAC stroma. A 
better understanding of the complex interactions between tumour, stroma and their 
contribution to tissue architecture may pave the way to novel therapeutic strategies. 
 
1.1.3.4 Immunotherapies 
One of the “hallmarks of cancer” is the ability of cancer cells to suppress and modulate the 
immune response either directly or via alterations to other TME components 50. 
Immunosuppression mechanisms include activation of regulatory T cells (Tregs), myeloid- 
derived suppressor cells (MDSCs), inhibition of effector T cells, antigen-presenting cells 
(APCs) and modulation of macrophage populations within the tumour 26,51. Tumour and 
stromal derived ECM molecules can also create a barrier leading to immune cell exclusion, 
such is the proposed role for matrix molecules such as HA, fibronectin (FN1) and versican 
(VCAN) in PDAC 45,52. Immune response baseline status is predictive of survival in 
pancreatic cancer, therefore manipulation of immunological features of PDAC could have 
direct clinical effects 53. Among the most popular, are inhibitors of proteins involved in T 
cell modulation, also termed checkpoint blockade molecules, such as programmed cell death 
protein 1 (PD-1) or cytotoxic T lymphocyte protein 4 (CTLA4), targeted by nivolumab and 
pembrolizumab or ipilimumab respectively 54. However, PDAC’s cell plasticity, poor 
immunogenicity and low antigenicity, have so far proven refractory to these agents in 
monotherapy 55, despite being successful in many other solid tumours. This is likely due to 
the highly desmoplastic and unique PDAC stroma, that limits T cell abundance and function. 
Other immunotherapy approaches include cancer vaccines using tumour-specific antigens of 
which, the GTPase RAS peptide (vaccine TG01/GM-CSF) in combination with gemcitabine 
is currently in clinical testing with encouraging preliminary results 56.  
 
Despite no clear breakthrough of immunotherapies in this disease yet, they hold great 
potential for the future of treatment as our understanding of the immune response regulatory 
network and molecular makeup in PDAC increase. The key will be to be able to translate our 
molecular understanding into clinical significance by identifying which patients are more 
likely to benefit from each treatment strategy. This requires interdisciplinary collaboration 
from basic research to trial design and results integration from a genetic, stromal and 
immunologic point of view. 
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1.2 The plastic tumour microenvironment of PDAC  
Tumours encompass much more than just masses of malignant cells, they interact, produce 
and recruit a number of additional non-transformed cells and molecules which make up their 
TME. The non-malignant components of the TME have a plastic and often tumour-
sustaining or -promoting role at each step of carcinogenesis 57. The physiological and 
pathological relevance of the stroma began to be recognised in the 1960s when the term 
“extracellular matrix” was first coined however, a deep understanding of its involvement in 
shaping the “hallmarks of cancer” was not described until the late 2000s 50,57. Elucidating the 
bilateral interactions between tumour and its surrounding stroma is of vital importance in 
PDAC since it exhibits an unusually desmoplastic microenvironment, whereby up to 80-90% 
of the total tumour mass is made up by stromal components 58-60. 
1.2.1 The cellular components of the PDAC microenvironment 
1.2.1.1 Tumour cells 
Mounting evidence is increasing our understanding of the complex interplay between tumour 
and non-malignant cells however, the specific role of tumour cells in initiating and modifying 
their surrounding is still not well characterised. Aggressive PDAC cells display increased 
proliferating, invading, migrating behaviours at the tumour edge or “invasive front”. This 
behaviour is termed tumour-budding and is an independent adverse prognostic factor 61,62. 
These budding cells present genetic signatures and behaviours very similar to cells 
undergoing epithelial-to-mesenchymal transition (EMT), such as reduced E-cadherin 
expression, loss of β-catenin expression on the cell surface, overexpression of N-cadherin, 
Snail and zinc finger E-box-binding homeobox proteins 1 and 2 (ZEB1/2) 62. Other stromal 
components have been shown to express E-cadherin suppressors (such as ZEB1) 62, 
highlighting the establishment of a permissive microenvironment surrounding tumour cells. 
Numerous reports also link EMT to features of cancer stem cells, such as signalling through 
WNT, which links development of tumour buds and the promotion of stem cell-like 
phenotypes 21,63.  
 
Increased understanding of cancer cell behaviours in combination with improved host-
related and tumour-related biomarkers may eventually lead to better patient stratification. 
Although conventional histology is usually sufficient to determine disease state, a number of 
molecules can be useful both as in vitro cancer markers or to distinguish metastatic PDAC 
 Project Background and Introduction 
 
-  33 - 
 
cells in neighbouring tissues. PDAC cells usually overexpress cytokeratins including CK19, 
CK7, CK18 as well as mucins (MUC1, MUC4, MUC5AC) and the diagnostic CA19-9 and 
CA125 markers 5. 
 
1.2.1.2 Stromal cells 
Stromal cells in PDAC comprise fibroblasts, endothelial cells, and immune cells. The most 
abundant cell type in PDAC tissues are cancer-associated fibroblasts (CAFs), of which 
pancreatic stellate cells (PSCs) are the predominant subtype, alongside tissue-resident 
fibroblasts and mesenchymal stem cells, which can all be recruited by the tumour and 
contribute to increased desmoplasia 64,65. Well known markers of CAFs include α‐smooth 
muscle actin (α‐SMA), stromal cell‐derived factor‐1α (SDF-1), fibroblast activation protein 
(FAP), and fibroblast specific protein‐1 (FSP-1) 66 (Figure 1.2). They are activated by a 
number of growth factors including of TGF‐β, SHH, tumour necrosis factor α (TNF‐α), 
platelet‐derived growth factor (PDGF), and interleukin (IL)‐1, ‐6, and ‐10 66 (Figure 1.2). In 
turn, they secrete a number of pro-survival and pro-tumorigenic stimuli, namely through 
TGF‐β signalling, IGF and EGF secretion 66. CAFs can also induce desmoplasia namely 
through the secretion of ECM molecules including collagen types I and III, fibronectin, 
proteoglycans, hyaluronan and glycosaminoglycans, leading to increased interstitial pressure, 
stiffness and hypoxia 67. Additionally, they can contribute to a number of pro-tumorigenic 
processes including the induction of EMT, as well as cancer cell invasion, metastasis and 
chemoresistance 64 (Figure 1.2). 
 
Although desmoplasia is known to confer aggressiveness by supporting cancer cell 
proliferation and dampening immunity 44,68, many recent studies have started to shed light on 
the protective role of stroma, whereby the genetic or therapeutic ablation of CAFs led to the 
development of undifferentiated and highly metastatic tumours 48,49. This is exemplified in 
the clinical failure of CAF secretome-targeting strategies such as SPARC or PEGPH20 
therapies.  This dual pro-tumorigenic and restraining function of CAFs is also attributable to 
a high intra- and inter-tumoral heterogeneity as described by several transcriptomic, 
phenotypic and functional studies 18,69. Puleo et al. recently proposed a classification of 
PDAC samples by incorporating both the canonical tumour subtypes (basal-like, classical) 23 
as well as four distinct stromal components (structural vascularised, activated, inflammatory 
and immune), in an attempt to better represent observed heterogeneities 70. Interestingly, 
stroma-activated phenotypes were characterised by higher CAF content, lower immune cell 
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infiltrate and showed worse prognosis compared to other subtypes 70. This highlights  the 
complexity between the cellular microenvironment, or more specifically the interactions 
between the immune and stromal cell compartments. 
 
1.2.1.3 Immune cells 
PDAC exhibits an immunosuppressive landscape from early on in tumorigenesis 71. The 
presence of immunosuppressive leukocytes ultimately contributes to the lack of tumour 
infiltrating lymphocytes (TILs) and leads to the early immune escape of tumour cells, namely 
immune excluded or immune-quiescent microenvironments 71. Significant mechanisms of 
immune evasion include the expression of cell surface proteins PD-1 ligand (PD-L1), CTLA4 
and colony-stimulating factor 1 receptor (CSF1R). In addition, immunosuppressive 
Figure 1.2 The role of cancer-associated fibroblasts (CAFs) crosstalk in the PDAC tumour 
microenvironment. Shown are some of the key stromal processes orchestrated by CAFs. CAFs promote 
cancer cell proliferation, invasion, metastasis and chemoresistance, as well as stromal remodelling and matrix 
deposition involved in cell migration and hampering drug delivery. CAFs also mediate tumour angiogenesis, 
migration along neurons and affect the physiological exocrine functions of the pancreas. They also play an 
important role in shaping the immune microenvironment towards a pro-tumorigenic and immunosuppressive 
milieu by affecting the function and recruitment of various immune cells. α-SMA= alpha smooth muscle actin;  
CXCL= chemokine (C-X-C motif) ligand; FAP= fibroblast activation protein; FSP= fibroblast-specific 
protein; GEM= gemcitabine; M-CSF= macrophage colony-stimulating factor; IL= interleukin; IGF= insulin-
like growth factor; MMP= matrix metalloproteinases; PDGF= platelet-derived growth factor; PDL-1= 
programmed death ligand; SDF-1 = stromal cell-derived factor 1; TGF-β= transforming growth factor beta; 
TIMP= tissue inhibitor of metalloproteinases; VEGF= vascular endothelial growth factor; VEGFR= vascular 
endothelial growth factor receptor. Adapted from Sun et al., 2018; Monteran et al., 2019;  Kleef et al., 2016. 
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chemokines secretion (such as CXC motif chemokine 12) and cytokines (IL-1, IL-6, IL-10 
TGFβ, TNF) further induce an immunosuppressive microenvironment. PD-L1 and CTLA4 
are defined as checkpoint inhibitors, conferring inhibitory signals to prevent immune cell 
activation, and correlate with worse prognosis when expressed in the TME of PDAC 72. 
CSF1R is primarily found on myeloid cells where it’s involved in recruitment and 
differentiation 51. Its functional contribution to tumour size, maintenance and survival has 
already been established in murine models for the squamous subtype 51. Hence why many 
therapeutic strategies are targeted at reprogramming immune cells through checkpoint 
proteins, such as CTLA4 and PD-1, to induce activation 71. 
 
With regards to innate immunity, macrophages constitute the predominant subtype of the 
TME 73, and their infiltration has been correlated with poor prognosis in PDAC 72,74. The 
role of tumour associated macrophages (TAMs) in assisting tumour development, 
progression and metastasis as well as conferring resistance to chemotherapy and 
radiotherapy, has been elucidated in a number of pre-clinical models  51,75. This is because 
TAMs are seemingly a significant feature of the TME and themselves contribute to immune 
cell suppression and sustain tumour progression. For example, TAMs upregulate IL10 and 
IL13 to limit the immune response 51. TAMs have recently been shown to support a pro-
tumour microenvironment via a feedback regulatory loop mechanism through Siglec-1 
engagement, upregulation of CCL8 and M-CSF 51,73. Further to this, TAMs have also recently 
been seen to upregulate surface receptors such as CD24 as an immune escape mechanism, 
whose blockade showed to limit immune escape. A number of therapeutic interventions to 
re-educate or limit the recruitment of macrophages are currently being tested 76. One such 
example is targeting macrophages through CSF1R inhibition, whose signalling is involved in 
differentiation of myeloid progenitors into monocytes, macrophages, dendritic cells or 
osteoclasts. Therapeutic ablation of macrophages through CSF1R inhibition in murine 
models has led to tumour regression, increased cell death, T-cell activation independent of 
PD-1 inhibition, and downregulation of squamous subtype-associated genes 51. 
 
Most PDAC patients develop an immunosuppressive TME that impedes effector T cell 
infiltration, despite T cells being abundant in the stroma of primary PDAC and correlating 
with increased survival 72,77. CD8+ T-cells are activated by interacting with antigens presented 
on major histocompatibility complex (MHC) class I molecules of antigen-presenting cells. 
Low expression of MHC class I molecules on PDAC cells can inhibit T-cell activation in 
PDAC 78. Additionally, engagement of checkpoint blockade receptors inhibit activation of T 
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cells, even in highly infiltrated tumours. Other immunosuppressive mechanisms include the 
recruitment of Tregs and TAMs with an alternative polarisation, together with myeloid-
derived suppressor cells, which block the anti-tumour activities of effector CD4+ and CD8+ 
T-cells 77. The immune quiescence of these tumours, combined with low or suppressed 
adaptive immunity activation, results in scarce invasion of cytotoxic T lymphocytes into the 
TME, low immunoediting, low mutational burden and hence higher resistance to checkpoint 
immunotherapies 79. Reduced effector CD8+ T-cells and increased CD4+ Foxp3+ Tregs levels 
have also been validated histologically in resected PDAC samples 74,80. 
1.2.2 The extracellular components of the PDAC microenvironment 
Tumour-stroma interactions prompt continuous remodelling and deposition of the dense 
pancreatic ECM. In turn, the matrix provides a number of biochemical and mechanical 
stimuli which guide cells’ survival and behaviours including pro-fibrotic stimuli, 
immunosuppressive signals and architectural support. The influence of biomechanics during 
PDAC progression will be discussed in detail in the next Section (1.3 The mechanobiology 
of PDAC). While genetic alterations in tumour cells are the initiating and driving event, 
cancer progression involves a dynamic ECM which modulates virtually all functional aspects 
of tumour and tumour-associated stromal cells 81. In fact, the ECM is postulated to play a 
role and modulate all  hallmarks of cancer 81. Unsurprisingly, increased ECM remodelling is 
associated with increased risk for malignant transformation in pancreatic cells 82. Because of 
the dually sustaining and restraining roles of this dense matrix 17,48, an intimate understanding 
of the feedback between ECM and tumour is required for the development of successful 
prevention and treatment strategies. 
 
The bulk of the ECM is made up of fibrous proteins and molecules, mainly heavily cross-
linked and highly aligned collagen type I, which is largely produced by activated CAFs 58. 
Pancreatic CAFs are also responsible for the deposition of other main ECM components, 
including other collagens, fibronectin (FN1), laminins, hyaluronic acid (HA), and versican 
(VCAN) 52,83. Tumour cells and TAMs are also, although to a lesser extent, contributing to 
ECM deposition and fibrillar collagen formation 84. At the interface between cancer cells and 
stroma sits the basement membrane, a cancer cell-derived macro-structure that is disrupted 
during PDAC progression, exposing cancer cells to the surrounding matrix, promoting 
EMT, migration and subsequent tumour spread to adjacent vessels and tissues 85. 
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With the advent of high throughput “omic” techniques, it has now been possible to 
characterise pancreas, PanIN and PDAC-specific sets of commonly expressed ECM 
molecules and their cellular origin 86,87, named the matrisome. While similar analyses had been 
conducted for the study of matrisomes in colon 88, prostate 89, ovarian and breast cancers 90, 
Tian et al. were the first to characterise the PDAC matrisome using integrated proteomic 
approaches 87. Collagens, glycoproteins and proteoglycans are the three categories 
constituting the “core matrisome” 91, and their contribution to PDAC initiation and 
progression will be the focus of the next sections. 
 
1.2.2.1 Role of collagens in PDAC 
The most abundant and studied proteins of the PDAC ECM are collagens. To date, 28 types 
have been characterised 92, of which collagen I, II and V are the most common type located 
in the interstitial space, while IV, XV and laminin are predominant in the basement 
membrane 93. Through disruption of the basement membrane, PDAC cells are exposed to 
increased levels of interstitial collagens, which have known pro-survival and tumorigenic 
affects 93,94. Importantly, the majority of the desmoplastic reaction in PDAC is attributed to 
increased crosslinking and production of collagen type I 93-95. Hence increased levels of 
collagen type I deposition in PDAC have been associated with poor prognosis and reduced 
overall survival 95. On the other hand, basement membrane collagens, such as collagen type 
XV, are known to hinder EMT and invasive cell features 96, and their expression is reduced 
or lost during tumour progression. In fact, overexpression of collagen XV can inhibit the 
migratory and invasive phenotype of PDAC cells in matrices otherwise rich in collagen I 96. 
However, the role of matrix proteins in disease is not always as clear cut. Laminin and 
collagen IV for instance, are amongst the predominant components of the basal membrane, 
and while low laminin levels are associated with decreased survival 97, high levels of collagen 
IV expression in PDAC stroma are known to promote cell proliferation and invasion 98. 
Additionally, collagen IV can also be produced by tumours themselves as a protective 
mechanism against low nutrient-induced apoptosis 98. Therefore, even within the same 
structure, ECM molecules may have contrasting effects and influence on PDAC 
pathogenesis. 
 
The main mechanism by which collagens regulate PDAC pathobiology is through signalling 
via integrin receptors on the surface of malignant cells 98. Integrins are transmembrane 
heterodimeric glycoproteins with an α- and β-subunit, whose different combinations confer 
binding specificity to different collagens 98. Integrin α1β1 for instance, binds weakly to 
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collagen I but has a high affinity for collagen IV 99. Contrariwise, integrin α2β1 binds weakly 
to collagen IV and strongly to both collagen I and V 99. The binding of collagen I or V to 
α2β1 integrin receptors on PDAC cells has been shown to promote proliferation, migration, 
adhesion and prevent apoptosis of the latter 98,100. Conversely, knockdown of β1 integrins in 
PDAC cells led to reduced adhesion to collagen but also resulted in hampered tumour 
growth and metastasis after implantation in an orthotopic mouse model 101. 
 
The binding of collagen to integrin receptors leads to the activation of downstream signalling 
pathways which, in turn, are able to activate or inhibit different gene programs. For instance, 
migration of PANC-1 cells, a commonly used PDAC cell line, along collagen I is mediated 
by focal adhesion kinase (FAK) pathway activation downstream of collagen I- α2β1 integrin 
binding 102. FAK activation leads to the phosphorylation of β-catenin, activation of WNT 
signalling and loss of E-cadherin 103. Activation of FAK also leads to N-cadherin 
overexpression which, together with E-cadherin loss, results in the loss of cell adhesion and 
increased migration, all hallmarks of EMT 102,104. In addition to integrins, collagens can also 
bind and signal through dimeric transmembrane receptor tyrosine kinases (RTKs), such as 
discoidin receptor 1 (DDR1), which is overexpressed in PDAC 104. DDR1-collagen I binding 
leads to FAK pathway activation, N-cadherin expression as well as production of matrix 
metalloproteinases (MMPs) 2 and 9, proteases involved in ECM degradation 104,105. Hence, 
the ECM’s composition and collagens balance are capable of directing cell phenotype via 
induction of programs such as EMT. 
 
1.2.2.2 Role of glycoproteins and proteoglycans in PDAC 
Glycoproteins and proteoglycans are composed of core proteins that undergo post-
translational glycosylation, which affects their conformation and cell signalling function 106. 
In cancer cells, these proteins commonly undergo aberrant glycosylation which results in 
structural and functional changes 106. An example are N- and O-linked glycosylation and the 
expression of core proteins periostin, fibulin 1, galectin 1, which are upregulated in PDAC 
106-108. A common glycoprotein with important implications in PDAC pathobiology is 
fibronectin (FN1). FN1 binds to integrin receptors (α5β1) and, similarly to collagen, can 
signal through the FAK pathway 103. Importantly, FN1 retains collagen-binding sites making 
their structural and signalling role highly interlinked  109. Aside its cooperative effects, FN1 
supports PDAC cell proliferation 110, and can self-sustain its own production and overall 
ECM synthesis by CAFs by binding and releasing active TGFβ 111. Fibronectin is also known 
to mediate resistance to radiotherapy by promoting PDAC cell invasion through the basal 
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membrane, an event which is nullified by either α5β1 blocking antibodies or fibronectin 
depletion 112. Similarly, vitronectin is a major glycoprotein that binds to α5β3 integrins and 
collagens, promoting PDAC cell proliferation via IL-8 secretion 113. 
 
Amongst the major PDAC proteoglycans lumican has been associated with markedly 
increased survival 114. PDAC cells exposure to lumican in the ECM forces them into a 
quiescent state via G0/G1 cell cycle arrest, as well as inducing EGFR internalisation and 
hence inhibiting AKT and MAPK signalling 114. Additionally, proteoglycans often bind to 
hyaluronic acid (HA), a non-sulfated glycosaminoglycan whose expression is highly abundant 
in the PDAC ECM 45. Its importance is also highlighted by its ability to bind to CD44 thereby 
promoting tumour cell survival, proliferation and invasion 115,116. Unsurprisingly, HA has 
been one of the main targets of PDAC stromal therapies with the use of PEGPH20 or other 
angiotensin inhibitors 44-47,117. Versican (VCAN) is another proteoglycan known to bind to 
HA 118. VCAN is present in the interstitial ECM space of normal tissues 119, but its expression 
dramatically increases in disease, so much that it has been described as a key component in 
a matrix signature common to many solid tumours, including PDAC 120. VCAN’s role in 
PDAC is not well characterised, however recent work suggests that its production is driven 
by both epithelial and stromal cells, and its accumulation correlates with CD8+ T cell 
exclusion 52. 
 
1.2.2.3 Role of other ECM regulators 
Additional categories of the matrisome include ECM-affiliated proteins, ECM regulators and 
secreted factors. These include mucins, such as MUC5AC, MUC1 and MUC16, which are 
highly upregulated in PDAC compared to normal pancreas 121. ECM regulators include 
proteolytic and remodelling enzymes such as MMPs, adamalysins (ADAMs and ADAMTSs) 
as well as their inhibitors, tissue inhibitors of MMPs (TIMPs) and serine protease inhibitors 
(serpins), amongst many others. The role of MMPs in shaping the PDAC ECM will be 
discussed in more detail later (Section 1.3.2). Secreted factors include a plethora of cytokines 
and growth factors, many of which are implicated in PDAC, such as WNTs members, TNF-
α, TGF-β, nodal and many more 63,111,122. 
 
1.2.2.4 Defining a common matrix signature 
With the advent of quantitative mass spectroscopy proteomic approaches, as well as 
transcriptomics in recent years, a number of different studies have started to systematically 
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examine and characterise the composition and dynamics of the ECM during cancer initiation 
and progression 87,120. Using both human samples or murine models, it is now possible to 
screen the tumour proteome and ECM in search of common matrix denominators 120, assess 
their contribution to treatment response 123, correlation with overall survival 87,120, as well as 
their cells of origin 87. One such example is the matrix index (MI), a 22-gene matrisome 
signature predictive of disease level and tissue stiffness 120. Although originally characterised 
in high grade serous ovarian cancer (HGSOC), high MI correlated with shorter overall 
survival in 12 other solid tumour types, including PDAC 120. Unsurprisingly, this signature 
includes some of the described collagens (COL11A1, COL1A1), glycoproteins (FN1) and 
proteoglycans (VCAN) which have prognostic value in PDAC 52,95,124. This suggested selected 
host matrix molecules and stiffness might be eliciting a common response in human cancers. 
The role of stiffness and biomechanical processes in regulating PDAC tumorigenesis will be 
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1.3 The mechanobiology of PDAC 
Besides biochemical signalling, the ECM also retains mechanical properties that provide 
important physical cues to cells influencing, in turn, intracellular signalling cascades. The 
ECM comprises the bulk of the stroma and is responsible for increased interstitial tissue 
pressure, stiff mechanics and physicochemical cues that promote proliferation, survival and 
metastasis 85,125. The simultaneous compression of blood and lymphatic vessels leads to 
increased intratumoural pressure, reduced blood supply and hypoxia, which further 
promotes tumour growth, metastasis, resistance to treatment, as well as hampering drug 
delivery 126. Several prognostic indexes have now suggested the combination of physical, 
genetic and histochemical tumour properties for the stratification of patients, such as the 
matrix index 120, or the activated stroma index 127. 
1.3.1 Characterisation of PDAC biomechanics 
Measured tumour stiffness often varies between different regions of the same sample, 
between different patients and even based on the technique and analysis conducted. The 
majority of reports have so far employed atomic force microscopy (AFM) for the nanoscale 
assessment of local stiffness in murine healthy and diseased samples 17,128. The Young’s 
modulus describes the elastic properties of a tissue and is a measure of its stiffness. Rice et 
al. reported an increase in the Young’s modulus in murine models of PDAC progression 
from 1 kPa in C (Pdx1-Cre) mice (normal pancreas) to 2 kPa in KC PanIN mice (Pdx1-Cre; 
LSL-KrasG12D/+) up to 4 kPa in mice representing a malignant phenotype , KPC (Pdx-1 Cre, 
LSL-KrasG12D/+, LSL-Trp53R172H/+) 128. Collagen I amounts as well as collagen fibre thickness 
also progressively increased from normal pancreas (2.8 μm), to PanIN, to PDAC (3.7 μm)  
128. Similarly, Laklai et al. reported the stiffness of KPC tumours to be between 0.2 – 6 kPa 
17. Additionally, Nguyen et al. described a strong association between human PDAC cell 
stiffness and their invasive potential through upregulation of the mechanoregulating genes 
vimentin, actin and laminin A 129. More recently, Rubiano et al. described the stiffness of 
fresh, unfixed, resected human PDAC samples by unconfined compression, allowing to 
sample larger areas of tissue (1-3 mm) 130. Their results indicated that both pancreatitis (2.15 
± 0.41 kPa) and PDAC tissues (5.46 ± 3.18 kPa) exhibit a higher Young’s modulus compared 
to normal pancreatic tissues (1.06 ± 0.25 kPa). 
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1.3.2 Regulators of stiffness 
By providing mechanical cues, ECM stiffness can directly alter the behaviour and function 
of PDAC cells. Stiff collagen matrices for instance, are known to alter vimentin and E-
cadherin expression in the malignant cells, contributing to EMT via nuclear translocation of 
β-catenin 128. Stiff tumours show a markedly higher number of crosslinked collagen fibres 
17,128, which have been associated with enhanced MMP activity, a proxy for increased matrix 
digestion, migratory and invasive phenotypes 131. Equally, therapeutic abrogation of PDAC 
cell contractility resulted in reduced MMP activity, suggesting that malignant cells also play a 
direct role in influencing the mechanics of the ECM 131. ECM stiffening in PDAC is mainly 
achieved through collagen fibre crosslinking by lysyl oxidase (LOX), an extracellular copper-
dependant enzyme 132,133 (Figure 1.3). Additionally, LOX is involved in metastasis, hampers 
drug delivery and its expression is increased under hypoxia 133. Conversely, in vivo targeting 
of LOX via neutralising antibodies in KPC mice resulted in decreased proliferation and 
improved survival 133. Some of these observed effects are likely due to LOX effects beyond 
that of collagen crosslinking, as LOX inhibition also led to overall reduced desmoplasia and 
blood vessel normalisation 133-135. Consistently with these findings, increased collagen fibre 
count, thickness and stromal stiffness are associated with shorter patient survival 17 (Figure 
1.4). 
 
In addition to LOX, tissue transglutaminase 2 (TG2) is also responsible for the crosslinking 
of collagen I fibres 136. TG2 is induced by TGFβ and its expression dramatically increases 
during PDAC progression 136. PDAC cells express and secrete TG2 in the surrounding ECM, 
where it crosslinks collagen fibres while also inducing collagen I production by other 
malignant cells and CAFs, creating a positive feedback loop 136. Additionally, CAFs can 
induce desmoplasia via the secretion of other ECM molecules, collagens I and III, FN1, 
proteoglycans, and glycosaminoglycans 67. Increased ECM crosslinking can intracellularly 
activate yes-associated protein (YAP) and its PDZ-binding transcriptional coactivator 
(TAZ), which translocate to the nucleus enhancing proliferation 136 and EMT programs 137,138 
(Figure 1.3). Concordantly, YAP/TAZ nuclear localisation significantly increases in response 
to substrate stiffness 137,139, while strikingly all the gene signatures associated with increased 
ECM stiffness are also related to YAP/TAZ signalling 140. This suggests YAP/TAZ act as a 
pivotal centre in the mechanotransduction of physical ECM properties. Additionally, recent 
work found that receptor tyrosine kinase (RTK)–Ras oncogenes ability to reprogram normal 
cells into cancer precursors requires mechanical signals and increased force transmission 
between transformed cells and the ECM 139. This process leads to the build-up of cytoskeletal 
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tension and stiffening which lead to the activation and nuclear translocation of YAP/TAZ. 
The group identified Rac1 as a mediator of oncogenic mechanosignalling, sufficient and 
required for epithelial cells to be sensitised and responsive to stiffness 139.  
 
Since over 80% of patients with advanced disease show high collagen deposition, PDAC 
cells have developed a number of mechanisms that allow them to overcome this fibrotic 
barrier during metastasis 95. MMPs are the main class of enzymes involved in ECM 
degradation and matrix remodelling and one of the mechanisms underlying cell 
dissemination and metastasis 141. There are 23 human MMPs each with a specific, sometimes 
overlapping, proteolytic activity and specificity within the ECM 141. These include enzymes 
with collagenolytic activity (collagenases) such as MMP1, MMP8, MM13, gelatinases (MMP2, 
MMP9) and membrane-type (MMP14 or MT1-MMP). Collagenases specifically degrade 
collagen into denatured fragments, constituents of gelatin, which gets further degraded by 
gelatinases, both of which are expressed in high amounts in PDAC 142. Other classes include 
matrilysins (such as MMP7), which promote invasion 143, stromelysins (such as MMP3), 
involved in tumorigenesis, and their tissue inhibitors (TIMP1-4) 142. The prevalent PDAC 
membrane-bound MMP is membrane type 1-MMP (MT1-MMP or MMP14) 142,144, which is 
upregulated during EMT and, in turn, also promotes it through the release of latent TGF-β 
145. Collagen I has been shown to induce the expression of MT1-MMP suggesting, once more, 
that collagens are capable of directly regulating the expression of proteases involved in their 
remodelling 144 (Figure 1.3).  
 
TIMPs are a family of secreted enzymes with the ability to inhibit various zinc-dependant 
endopeptidases, including MMPs. TIMP1 inhibits most secreted MMPs, and is highly 
expressed in PDAC, especially in response to treatment, where it contributes to drug 
resistance 146,147. Importantly, TIMP1 expression is induced by increased tissue stiffness 147. 
TIMP2 has a dual role in that it is required for the activation of MT1-MMP, whilst also acts 
as a potent inhibitor of MMP2 146. TIMP3 is known to inhibit all MMPs and members of the 
ADAMs and ADAMTSs families, each with different specificity. TIMP3 is often 
downregulated in PDAC, with associated poor prognosis 148. Therefore, the course of ECM 
remodelling in disease is orchestrated by a delicate balance between MMPs and TIMPs 
secretion into the TME 131,147. 
 
An additional mechanism whereby cells remodel the ECM is through regulation of Rho-
associated protein kinase (ROCK) signalling. ROCK is a family of serine/threonine kinases 
that are the core regulators of actomyosin cytoskeletal arrangement, therefore controlling 
cellular contractile forces generation 149. By regulating actomyosin contractility they are also 
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responsible for ECM remodelling and overall tissue contractility 149. Crosstalk between ECM 
regulatory pathways is highlighted in PDAC, where ROCK1/2 can promote the expression 
of MMP10 and MMP13 to enhance local cell invasion via collagen degradation 150. In murine 
models, inhibition of ROCK activity resulted in reduced ECM degradation and increased 
survival 150. In humans, high ROCK expression is associated with significantly lower survival 
(Figure 1.4). Strikingly, ROCK activation alone was sufficient to significantly increase tissue 
stiffness and promote collagen deposition 151. These responses were mediated by the 
activation of β-catenin. Inhibition of factors for actomyosin contractility, downstream of 
ROCK (such as LIM kinases or myosin ATPase), was sufficient to reverse ROCK activation 
effects 151. Additionally, inhibition of FAK, which also signals through β-catenin upon 









Figure 1.3 Aberrant tissue stiffness and extracellular matrix (ECM) crosslinking promote malignant 
cell behaviours. Increased ECM crosslinking contributes to a number of pathogenic mechanisms: a) ECM 
fibres acts as guiding tracks for cell migration. b) Increased ECM stiffness can signal through integrins whose 
downstream effectors can, in turn, promote further ECM synthesis, ECM crosslinking, F-actin polymerisation, 
cell invasion and proliferation. Extracellular collagen crosslinking is mediated by enzymes such as lysyl oxidase 
(LOX) and LOX-like 2 (LOXL2). c) Proteolytic enzymes such as matrix metalloproteinases (MMPs) are 
responsible for ECM remodelling and can signal through membrane-type MMPs (MT1-MMP) to stimulate cell 
invasion. d) The ECM provides proliferative and pro-metastatic signals as well as forming a pro-survival niche 
at the metastatic sites. e) Generation of ECM fragments can trigger aberrant immune responses as well as 
guiding cell migration. f) Increased cell-ECM signalling through, for instance, discoidin domain-containing 
receptor 1 and 2 (DDR1, DDR2) leads to transcriptional activation, and expression of MMP and epithelial–
mesenchymal transition (EMT) markers. g) EMT, proliferation or angiogenesis can be triggered by growth 
factors, sequestered in the crosslinked ECM and released via proteolytic cleavage. h) The ECM acts as a barrier 
preventing immune cell infiltration and hindering the delivery and efficacy of treatments. PI3K= 
phosphoinositide 3-kinases; ROCK= Rho-associated kinases; YAP/TAZ= yes-associated protein, 
transcriptional coactivator with PDZ-binding motif. Adapted from Bonnans et al., 2014; Tang et al., 2013. 
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Tumour cells are not the sole contributors to tissue stiffness. CAFs are known to secrete 
abundant ECM components including collagens, FN1, MMPs and TIMPs 59. As opposed to 
epithelial cells, matrix remodelling is an essential physiological function of fibroblasts, and is 
therefore sustained in both normal and diseased tissues 152. However early mutations, such 
as the loss of Timp, are sufficient for the conversion to CAF phenotype, and induce cancer 
cell motility and tumour progression by unleashing MMP activity in the stroma 153. CAFs can 
also control matrix remodelling via ROCK-dependant actomyosin contractility 154, and 
therefore its targeting could have concomitant effects on tumour cells and their TME 154,155. 
Similarly to cancer cells, CAFs can also regulate actomyosin contractility via the activation of 
the YAP/TAZ axis 156. In turn, ECM stiffness can further activate YAP, leading to a positive 
feedback loop that stabilises YAP activation, a CAF-activated phenotype and induces further 
tissue stiffening 156. Finally, fibroblasts are known to respond to matrix composition and 
stiffness via the activation of TGF-β signalling which, in turn, confers them their activated, 
contractile, CAF phenotype 157,158. 
1.3.3 Targeting mechanobiology-related processes in PDAC 
Regarding the alterations in TGF-β signalling, all-trans-retinoic acid (ATRA) has been 
suggested as a therapeutic intervention in PDAC due to its ability to hinder CAF mechanical 
Figure 1.4 Kaplan-Meier survival curves for patients with high (red) and low (black) expression of 
collagen IV, hyaluronic acid (HAS2), Rho-kinase 1 (ROCK1), matrix metalloproteinases 9 and 14 
(MMP9, MMP14), lysyl oxidase (LOX). Curves were calculated from public RNA-seq databases (mRNA 
data from Gene Expression Omnibus, European Genome-Phenome Archive and The Cancer Genome Atlas) 
for a total of 177 PDAC patients and plotted via Kaplan-Meyer plotter. p-values and mean survival (months) 
are indicated for each graph. 
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activation of TGF-β 158, hence preventing perpetuation of fibrosis. In KPC mice, 
administration of ATRA in combination with gemcitabine resulted in enhanced drug 
response, increased tumour necrosis, reduced ECM deposition and fibrosis 159. The ongoing 
phase IB study STAR_PAC in PDAC is currently repurposing ATRA alongside gemcitabine 
and nab-paclitaxel as a stromal targeting agent (NCT03307148) 160. 
 
Regarding MMP targeting in PDAC, only two phase III trials have been published 161,162. The 
first one adding marimastat, a broad-band MMP inhibitor (targets MMP1, MMP2, MM7, 
MMP9 and MT1-MMP) to gemcitabine, showed the MMP inhibitor could be well-tolerated, 
but did not lead to any response or survival benefits in PDAC patients 161. The second trial 
combined BAY 12-9566 or tanomastat, another broad-spectrum inhibitor of MMP2, MMP3, 
MMP9, which was well tolerated alone but led to a lower median survival compared to the 
gemcitabine arm (3.74 months versus 6.59 months) 162. However, disappointing clinical trials 
results through MMP inhibition do not imply that MMPs do not contribute to PDAC 
progression. The lack of clinical benefits may likely be due to inclusion at advanced stage 
disease, as well as broad spectrum inhibitors lacking the efficacy and specificity to block such 
a multifaceted pathway 163. Inhibitor unspecificity may also be blocking potential tumour 
inhibitory effects of MMPs, as exemplified by MMP9 deficiency which, on a Kras(G12D) 
background enhances tumour progression and invasion 164, explaining the failure of the 
tanomastat trial 162. 
 
Two recent studies by Cortes et al. also identified G‐protein‐coupled estrogen receptor 
(GPER) as key regulator in PDAC cancer-stroma sensing, regulating tissue stiffness, hypoxia 
and desmoplasia 134,135. In this regard, they suggested the repurposing of tamoxifen, a widely 
used estrogen receptor antagonist in breast cancer, to act as a GPER antagonist in order to 
normalise the PDAC TME 134. Treatment with tamoxifen led to lower matrix crosslinking, 
lower tissue stiffness, increased vascularisation via the downregulation of hypoxia inducible 
factor 1 (HIF-1A) and increased tumour apoptosis 134, suggesting tamoxifen may be 
employed as a potential stromal-targeting therapy. Despite the promising results of the study, 
it remains to be seen whether tamoxifen may give any benefits to PDAC patients in clinical 
scenarios, where the stroma acts as both a restraining and supporting entity. 
 
More recently, Vennin et al. showed that transient ROCK tissue priming (i.e. targeting the 
tumour mechanics via ROCK inhibitors) prior to chemotherapy, was efficient in releasing 
tissue tension, sensitising PDAC cells to treatment and increasing treatment efficiency 155 
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Figure 1.5 Transient administration of stromal targeting agents (“priming”) as a strategy to increase 
chemotherapy efficiency while re-equilibrating tissue stiffness, decrease fibrosis and reduce 
metastasis. a) No targeting leads to self-sustained perpetration of fibrosis, desmoplasia and metastatic 
potential. b) Ablation of CAF and/or key ECM components via chronic anti-stromal agent targeting increases 
local invasion due to the dual restraining and promoting role of the PDAC stroma. c) Transient stromal 
targeting allows to temporarily release tissue tension and pressure, increasing the efficiency of 
chemotherapeutics, re-establishing stromal balance in both primary and secondary sites. Adapted from Vennin 
et al., 2017. 
(Figure 1.5). Importantly, mechanical priming with the ROCK inhibitor fasudil improved 
chemotherapy efficiency in both primary and secondary tumour sites and disrupted the 
movement of metastatic cells 155.  This study also demonstrated that stratified patient-derived 
tumours had a graded response to priming, suggesting tissue manipulation prior to 
chemotherapy may have clinical relevance 155. In addition, CAF treatment with fasudil led to 
a normalisation of matrix production via suppression of collagen and TIMP secretion, while 
also stimulating MMP1 and collagenase activity 165. This may have interesting therapeutic 
implications in PDAC, which is highly metastatic and notoriously untargetable by long-term 
matrix ablating treatments (such as PEGPH20) (Figure 1.5). To date, there are no reported 
uses of fasudil for the treatment of cancer in the clinic, therefore future phase I clinical trials 
will have to determine the safety and efficiency of transient ROCK tissue priming in 
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1.4 Pre-clinical models of PDAC 
The establishment of the first pancreatic cancer cell line dates back to 1963 (CaPa), and it 
was followed, over a decade after, by the establishment of PANC-1 (1975), MIA PaCa-2 
(1977), Capan-1 (1977), AsPC-1 (1982), Capan-2 (1986) and BxPC-3 (1986), which are 
amongst the most popular, and currently used, cell lines in PDAC research 166. Aside from 
the obvious lack of heterogeneity and mutational instability, one of the major disadvantages 
of the use of established cell lines is the lack of stromal and extracellular cues that constitute 
the majority of the PDAC tumour under physiological conditions. On the other hand, the 
use of well-characterised murine strains allowed recapitulation of the in vivo architectural and 
immune physiologies, but constituted a much more laborious, expensive, and complex 
system to analyse. Attempts to characterise tissue function and architecture ex vivo date back 
as far as 1912, when Alexis Carrel described the first attempts at prolonging the life of tissues 
outside of the organism, and is considered one of the first ever recorded attempts of three-
dimensional (3D) cell culture 167. Since then, many novel approaches for the 3D culture of 
cells have been developed in an attempt to bridge the gap between the simplicity of 
established cell lines and the complexity of murine models. Because of their rheological 
properties, similar to those of human tissues, ease of handling, and ability to recreate 3D 
environments in a defined and controllable manner, hydrogels have been at the forefront of 
3D cell culture research for many decades 168. 
1.4.1 Murine models of PDAC 
1.4.1.1 Xenografts 
One approach to study tumour development in vivo is the implant of immortalised cell lines 
into severe combined immunodeficient (SCID) mice thereby creating a xenograft model. 
Implantation can be made either subcutaneously or orthotopically onto the pancreas, after 
which tumour cells are capable of synthetizing and recruiting their own stroma 169. 
Xenografts therefore have some predictive value while showing more genetic and stromal 
diversity than cells grown in monolayers 170,171. However, one of the main limitations of cell 
line xenografts is their limited ability of predicting clinical outcomes to therapeutic 
interventions. Because of the immunocompromised nature of SCID mice, the tumours often 
develop free from selective pressures and immune cell infiltrates normally present in PDAC 
172. This makes them less useful compared to other models in the context of tumour evolution 
or immunotherapies. Lastly, cell-line xenografts are limited by the availability and 
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heterogeneity of established cell lines and therefore fail to represent the high phenotypic and 
genetic heterogeneity observed in patients 172. These shortcomings are highlighted in studies 
that have assessed the predictive value of xenografts and their associated clinical outcome 
171. An assessment by the NCI showed that over several decades, there was very little 
correlation between data obtained from xenografts and their clinical efficacy 171. Examples 
include the EGFR inhibitor centuximab, providing 85% regression in xenografts 173, which 
then failed in phase III clinical trials 174, similarly to endostatin 175, or thiazolidinediones 176. 
 
Patient-derived xenografts (PDX) address some of these limitations by transplanting directly 
a piece of human tumour tissue after resection or expanded primary cells into mice 172. 
Resected tumours advantageously carry surrounding stroma and ECM which are maintained 
after transplantation. Hence, PDXs retain morphological, genetical composition and 
metastatic potential of the original tumour 177. Importantly, PDXs can better replicate 
responses observed in the clinic compared to cell-line xenografts, possibly owing to their 
increased stromal content 177,178. Their transcriptomics analysis can predict sensitivity to 
anticancer drugs opening up the possibility of personalised medicine 179. Amongst the main 
drawbacks of these models is the difficulty of establishment and engraftment, which also 
negatively correlates with patient survival probably owning to the inherent aggressiveness of 
the tumour. PDX establishment can take up to 6 months 180, longer, in many cases, than the 
median patient survival after diagnosis, which limits its applications as a personalised 
diagnostic tool. The other limiting factor is the availability and size of tissue that can be 
devoted to research, as well as the very small proportion of patients that can undergo surgical 
resection in the first place (Figure 1.1) 181. Lastly, although better than cell line xenografts, 
PDXs still do not fully replicate the stromal, morphological and immunological landscape of 
the host 172. 
 
1.4.1.2 Genetically engineered mouse models 
Genetically engineered mouse models (GEMM) are created via the introduction of specific 
genetic mutations in order to recapitulate the genetic landscape of human PDAC. This was 
first achieved with the activation of KRAS in the murine pancreas, which led to PanIN ductal 
lesions capable of evolving into PDAC 182. However, the most popular and characterised 
GEMM in PDAC research is the KPC mouse, with an activating oncogenic mutation in 
KRAS, mutation in the tumour suppressor Trp53, driven by a pancreas specific (Pdx1) Cre 
(Pdx-1 Cre, LSL-KrasG12D/+, LSL-Trp53R172H/+) 183. This model is able to recapitulate many 
features of human disease including tumour evolution and genetic landscape. Additionally, 
GEMMs also exhibit the same symptoms that define the human disease, such as loss of 
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weight and appetite (cachexia), and eventually, pain 184. KPC mice retain the dense tumour 
stroma that is responsible for decreased anticancer drug delivery 44,45,58 and resistance to 
therapeutic treatment, as seen in humans 185. GEMMs have also increased our understanding 
of the dual restraining and tumorigenic role of the tumour stroma 48,49 and of mechanics of 
the TME during PDAC progression 17,128. Moreover, they retain an immune system, making 
them the only murine model in which to begin to investigate immunotherapeutic treatments.  
 
While GEMMs and KPC models represented fundamental innovations for pre-clinical 
PDAC research, their main disadvantage resides in that they are time consuming and very 
expensive 169. Additionally, significant genetic differences between mice and humans can lead 
to the formation of mutations not seen in human PDAC, as well as higher occurrence of 
unwanted mutations (such as BRCA1 which, in mice, is on the same chromosome as p53) 
186. This was exemplified with the clinical failure of the hedgehog pathway inhibitors, which 
had initially given promising results in KPC 185. In order to overcome these drawbacks, a 
plethora of 3D cell culture approaches and substrates have emerged in recent years, in an 
attempt to make tumour modelling, drug discovery and testing, faster, more accessible and 
controllable. 
1.4.2 In vitro models of PDAC 
Traditional cell culture has been based on the ability to grow, expand and passage cells by 
seeding them on glass or plastic surfaces. Despite advances in the production of suitable 
tissue-culture plastic substrates and media, traditional cell culture in monolayers fails to 
recapitulate key elements of the TME, leading to poorly translatable results 187 and limited 
potential as personalised medicine tools 188. An obvious limitation is the lack of 
multicellularity and immunity, which are pivotal elements for the assessment of therapeutic 
efficiency. Another key element is the inherent stiffness of plastic/glass surfaces, which have 
a Young’s modulus in the region of 3 GPa (or 3 x 106 kPa), incredibly higher than the 
recorded stiffness of PDAC tissues (100 Pa to 10 kPa) 130. Reduced cell-to-cell contact, 
induced apicobasal polarity, lack of multiple cell types, reduced matrix deposition, lack of 
diffusion gradients and hypoxia are among other factors responsible for an increased 
sensitivity to drugs and reduced translation potential 189. Importantly, because of all the above 
reasons, 2D culture favours the propagation of immortalised and established cell lines, 
whereas the culture of primary human PDAC cells still remains challenging 190. Efforts to 
narrow the gap between in vitro drug testing and clinical outcomes has prompted the 
development of a number of 3D approaches, whereby the combined use of tumour and 
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stromal components with a matrix or scaffold has allowed researchers to begin to understand 
and recapitulate the TME 191. These in vitro TME models allow the incorporation of multiple 
cell types, cell-matrix interactions, stiffness modulation, formation of morphological and 
functional structures, overcoming some of the limitations imposed by 2D cultures and 
beginning to reflect patient heterogeneity and clinical responses 139,192-194. These will be 
discussed in more detail in the following sections. 
 
1.4.2.1 Spheroids 
A recent review from our group screened publications related to 3D culture methods for 
PDAC research 195. From this, spheroids emerged as the most popular 3D method, 
accounting for 42% of publications regarding 3D cell culture of PDAC, followed by 
organoids (33%), scaffolds (16%) and microfluidics (9%) in 2019 195. Spheroids represent the 
oldest form of in vitro 3D culture, dating back as far as 1906 with the invention of the hanging-
drop technique 196. They are also one of the simplest techniques, as spheroid formation only 
involves either the plating of cells in ultra-low attachment plates or the use of the hanging-
drop technique, whereby the lack of direct contact between cells and a surface allows them 
to form multicellular aggregates 193. Because of their 3D architecture and limited oxygen 
diffusion, the core of the spheroid can become hypoxic and resistant to treatment, providing 
a significant improvement from 2D cultures for drug testing 197. This model allows the 
inclusion of multiple cell types, such as PDAC cells and CAFs, leading to the formation of a 
desmoplastic-like stroma, tumour-like architecture and cell morphology 193. However, the 
lack of ECM limits the cell seeding numbers, passaging and length for which these cultures 
can be kept 193. Lastly, as a high proportion of seeded cells die due to anoikis, there is a strong 
clonal selection which prevents an accurate recreation of the PDAC TME and associated 
treatment responses. This has led to the development of a number of different biomaterials, 
matrices and substrates that allow the incorporation of cells while mimicking the tumour 
architecture more closely (Table 1.1). 
 
1.4.2.2 Explants and decellularised tissue platforms 
The direct use of tissues after resection (explants), taken as whole tissue or slices, provides 
the most faithful representation of local tissue architecture, ECM and cellular composition. 
These can be used for the subsequent seeding of additional cancer cells, perfused with 
autochthonous patient serum, and used for the assessment of personalised treatment 
response 198. However, in the majority of cases, specialised imaging is required and is the only 
readout technique 198,199.   
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Table 1.1 Comparison of selected biomaterials for the 3D cell culture of PDAC cells and pancreatic TME modelling, with associated studies. 
Abbreviations: iPSC= induced Pluripotent Stem Cells, PSC= pancreatic stellate cell, RGD= Arginine, Glycine and Aspartate binding motif, MSC= Mesenchymal Stem Cells, HUVECs= 
Human Umbilical Vein Endothelial Cells. 
Matrix TME elements 
recapitulated 
Cells Advantages Disadvantages References 
Tissues 
Explants Cellular and extracellular 
structures and composition 
PANC-1, AsPC-1, Capan-1 Personalised medicine uses, authentic cellular and ECM 
arrangement and function 
Short lived, hard to maintain ex vivo, limited 
tissue availability, loss of function ex vivo, low 
reproducibility 
198,199 
Decellularised tissues ECM structure and composition Human induced pluripotent 
stem cells (iPSC)-derived 
organoids 
Conserved ECM topography, composition, and 
biochemical cues 
Partial matrix and structure loss during 




Matrigel 3D pancreatic organoid structures 
and basic stroma composition 
(CAFs) 
Murine tumour-derived cells 
and CAFs 
Matrix supports cell differentiation and 3D organoid 
formation, allows interaction with stromal cells, 
implantable 
Undefined composition, batch-to-batch 
variability, murine origins, limited stiffness 
range, no limited shape control 
201,202 
Collagen Main ECM constituent, 
predominant in PDAC, fibrillar 
structure, biochemical cues 
BxPC-3, PANC-1, MIA 
PaCa-2,  
Clinical and physiological relevance of collagen, lower 
batch variation than Matrigel, implantable 
Murine origins, requires chemical 
crosslinking, limited stiffness range, 
induction of multiple cancer pathways 
131,144,203,204 
Hyaluronan Hyaluronic acid structure and 
crosslinking, inclusion of stromal 
cells 
MIA PaCa-2, PANC-1, 
AsPC-1, FC1245, murine 
PSCs and human CAFs 
Hyaluronan plays an important role in PDAC treatment 
response, clinically relevant, wide range of sizes and 
chemical modifications 
Requires adhesive ligands (such as RGDs) 
for cell adhesion, limited stiffness range 
205,206 




On demand gelation and degradation via thrombin, 
controlled crosslinking with no added chemicals 
Not a major component of the PDAC TME, 
limited stiffness range 
207 




Two step cell encapsulation and easy cell recovery, can 
be mixed with other hydrogels 
Not a component of the PDAC TME, 
requires adhesive ligands (such as RGDs) for 
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Semi-synthetic materials 
Gelatin (methacrylated) Porous structure, biochemical 
cues, tunable stiffness, inclusion 
of stromal cells 
BxPC-3, Capan-2, MIA 
PaCa-2, PANC-1, patient-
derived CAFs, monocytes 
Allows cell attachment, MMP-cleavable, controllable 
mechanics (wide range), suitable for bioprinting, relevant 
component of the TME, transparent, high shape 
control, implantable 
Requires photo-polymerisation (UV or 
visible light) 




Fibrillar 3D structure, 
biochemical cues 
COLO-357, Human MSCs Clinically relevant, biodegradable, easy crosslinking, 
improved mechanical properties 
Reduced bioactivity, requires radical photo-
polymerisation 
208,209 
Self-assembling peptides Inclusion of stromal cells, can 
incorporate ECM molecules 
Primary PDAC cells, PSCs, 
macrophages 
Controllable cell encapsulation, bioactivity, can be gelled 
in solutions containing ECM components 
Limited shape control, costly, limited 
scalability, limited stiffness control 
Osuna de la Peña et 




Porous 3D structure COLO-357, PANC-1 Direct inclusion of cell adhesion ligands (e.g. RGD), 
wide stiffness range, transparent, controllable 
size/shape, implantable, high reproducibility 
Non-degradable backbone with little 




Porous 3D structure MIA PaCa-2 Direct inclusion of cell adhesion ligands (e.g. RGD), 
wide stiffness range, transparent, controllable size/shape 
Inert, generally very stiff for biological 




Porous 3D structure PANC-1 Biodegradable, transparent, controllable size/shape, 
implantable, can be used as drug eluting compound 




Supporting biomaterial, drug 
delivery 
No PDAC studies to date Can enable controlled drug release, biocompatible, 
implantable, suitable for bioprinting 
Limited cell adhesion, inert 215,216 
Polyacrylamide (PAM) Controllable stiffness AsPC-1, BxPC-3, Suit2-007 Allows spatial patterning and multiple ligand 
conjugation, wide stiffness range, high reproducibility  
No biological cues, inert 128 
Polydimethylsiloxane 
(PDMS) 
Resistant, supporting structure AsPC-1, Capan-2, MIA 
PaCa-2, PANC-1, PDX-
derived cells 
Used for microfluidics design, can be micropatterned to 
achieve defined shapes, direct cell migration, adhesion, 
function and control fluid flow. 
2-dimensional, stiff substrate, no biological 





Inclusion of stroma, flow 
(perfusion) and blood vessels 
AsPC-3, BxPC-3, MIA PaCa-
2, PANC-1, patient-derived 
PSCs, CAFs, HUVECs 
Incorporation of multiple cell types interacting 
physiologically, possible cell separation for subsequent 
analyses, formation of complex vascular and ECM 
networks 
Hard to assess contribution of individual cell 
components, limited scalability, require 
longer culture time 
192,219-222 
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Once resected, tissues are prone to quick degradation and necrosis, which temporally limits 
the use of these explants as well as requiring culture condition optimisation. Each section or 
tumour piece will only provide a local snapshot, which might not be representative of the 
tumour behaviour as a bulk. Additionally, the scarcity of patients which undergo surgery, the 
limited availability of tissue, and its short-lived nature (hours to few days) make this model 
low throughput and poorly scalable 199. 
 
In the context of cancer, decellularised tissue platforms are resected tumours which undergo 
several detergent washes in order to remove all original cellular components, while 
maintaining an intact ECM composition 223 and architecture. Decellularisation of pancreatic 
tissues has been reported in a number of organs from human 224, rat 200 and porcine 225 origin. 
Because of the lack of cellular components, these platforms can usually be kept for longer 
than tissue explants 199and allow the response of individual cell types to matrix stimuli. 
Despite recent improvements, it is still unclear whether the decellularisation process at all 
affects the ECM structure, composition, biomechanics or function. Additionally, in order to 
be used as a 3D model, cells are often seeded on top of the tissue, resulting in a rather two-
dimensional model unless significant invasion and remodelling occur. Interestingly, a few 
groups have lyophilised tissues after decellularization and subsequently hydrated them to 
form hydrogels, whose composition retained the same molecules present in native ECMs, 
while giving them more controllable and modular hydrogel properties 223,224. 
 
1.4.2.3 Hydrogels 
Because of their rheology, similar to that of human tissues, hydrogels are the most common 
formulation of both natural and synthetic biomaterials for 3D cell culture. Culture methods 
that allow the growth of single cells or the prolonged culture of spheroids with physiological 
stiffness are crucial in modelling cancer initiation, functions and treatment response. Matrigel 
is the most widespread gelling biomaterial for 3D cell and organoid culture. It consists of a 
mixture of basement membrane proteins derived from Engelbreth-Holm-Swarm murine 
sarcoma, with the ability of forming a gelling phase above 10°C 201. When cultured in Matrigel 
and the appropriate supplements, cells with stem-like properties can differentiate and 
proliferate to form structures reminiscent of their tissue of origin, named organoids 207,223. 
Organoids have traditionally been used to study human development, they have however, 
huge potential in the study of disease, TME modelling and pre-clinical drug screening 226,227. 
Despite this, the murine origins of Matrigel, batch-to-bath variation, and low stiffness 
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constitute the main drawbacks of its use in truly recapitulating biochemical and physical 
aspects of the TME 226. 
 
Collagen type I hydrogels are the main alternative to Matrigel, due to the high collagen 
content in both healthy and diseased tissues, especially in highly desmoplastic cancers such 
as PDAC 95. Commercially available collagen is usually of bovine or rodent origin (cowhide 
or rat tail), and provided at much lower concentrations than Matrigel. To ensure stability at 
37°C and hydrogel formation, collagen requires chemical crosslinking, thanks to which 
collagen gels have a wider stiffness range and better tunability compared to Matrigel 228. This 
has allowed the investigation of morphological and EMT phenotypes of PDAC cells in 
matrices with different stiffness 203. In addition, rat tail collagen forms disorganised fibrillar 
structures reminiscent of those formed in vivo 228. Another key advantage of collagen gels is 
the retention of MMP-cleavable sequences, which make the study of cell migration and 
invasion possible. This prompted a number of different studies and the discovery of MT1-
MMP as mediator of PDAC cell invasion and chemo-resistance 131,144,204. Nevertheless, the 
biomechanical properties of collagen gels are still limited compared to physiological 
conditions and so is their tuneability 228.  
 
Alternative biomaterials with natural origins include hyaluronic acid, fibrin, alginate, dextran 
and chitosan-based hydrogels. The main limitations of these hydrogels are the lack of cell 
adhesion motifs, the lack of physiological relevance to the PDAC TME, and their poor 
mechanical tunability 228. For this reason, important components of the TME, such as HA, 
have been chemically crosslinked to either synthetic, or semi-synthetic biomaterials in order 
to provide more stable and controllable networks for long term studies 228. Semi-synthetic 
hydrogels combine both a naturally derived elements (such as gelatin, collagen, hyaluronic 
acid) and a chemical modification to increase the resulting hydrogel’s crosslinking, stiffness, 
and stability. Examples include gelatin methacryloyl (GelMA) 229, thiolated gelatin-HA 209, or 
poly(ethylene glycol) diacrylate-HA (PEGDA-HA) 213 which have improved mechanical 
properties compared to their unfunctionalized counterparts, while retaining cell adhesion and 
cleavable motifs. Lastly, hydrogels can be derived from synthetic biomaterials including 
poly(ethylene glycol) (PEG), PEGDA, poly(lactic-co-glycolic acid) (PLGA), 
polycaprolactone (PCL) and polyacrylamide to name a few, most of which have been used 
for the 3D culture of PDAC cells (Table 1.1). Because of their intrinsic inertness, PEG and 
its derivatives grant no cell attachment or cell-mediated matrix cleavage. However, this can 
be easily solved via the addition of custom functional groups such as RGD (Arginine, 
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Glycine, and Aspartate cell binding motifs) or the on-demand incorporation of multiple 
ECM molecules 210,212. Finally, synthetic and semi-synthetic biomaterials can achieve a much 
greater range of stiffness and viscosity compared to naturally-derived hydrogels, hence 
opening the possibility for bioprinting of 3D structures 230-233. 
 
1.4.2.4 Microfluidic devices 
Also known as ‘organ-on-a-chip’, microfluidic devices aim to recapitulate complex 3D 
microenvironments on a synthetic chip, with the addition of perfused microchannels which 
allow the flow of nutrients, cells or therapeutics, mimicking the human circulatory system. 
This perfusion system can allow continuous supply of nutrients and oxygen as well as the 
removal of waste and side products from the culture 192. The main limitations of these devices 
are that they require high initial optimisation, long-term culture, and their endpoint analysis 
is usually restricted to imaging. Because of this, microfluidic devices currently remain quite 
expensive and poorly scalable. In PDAC research, the majority of microfluidic devices have 
been created through soft lithography of PDMS (Table 1.1), and loaded with cancer cells, 
CAFs, or HUVECs, usually encapsulated in either collagen type I, HA or Matrigel hydrogels 
192,220,221. Importantly, cells in the devices showed an ability to remodel the ECM 192, and 
higher resistance to chemotherapeutics compared to traditional spheroid cultures 219. Porous 
PDMS membranes have also been used for the separation of different cell types within the 
device, while allowing cell migration and vasculature-like network development using 
endothelial cells 194,220. The use of such complex 3D systems holds great promise in the field 
of PDAC research as they allow the progressive addition and modulation of a number of 
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1.5 GelMA hydrogels as a 3D cell culture platform 
Hydrogels are a network of hydrophilic polymers that crosslink and swell in water (hydro) 
thereby capturing many times their original weight 234. Physicochemical properties of 
hydrogels depend on a number of factors including their polymer composition, method used 
for crosslinking, polymerisation process, and concentration. Because of this versatility, they 
can provide different combinations of properties for any intended use and application 228. 
For the purpose of cancer modelling, hydrogels based on naturally occurring biopolymers 
are preferred, as they are biocompatible, have low immunogenicity and can retain cell-
responsive motifs. Contrariwise, synthetic materials provide a great deal of tuneability in 
terms of their mechanical, physical and structural properties, with virtually no batch-to-batch 
variation but they lack cell-instructive features 235. In this project, I employed a semi-synthetic 
hydrogel named gelatin methacryloyl (GelMA). GelMA combines the advantages of natural 
biomaterials thanks to its gelatinous derivation as well as the chemically active 
functionalisation groups (methacrylamide and methacrylate groups) that confer the 
hydrogel’s reproducible and controllable physicochemical properties. Once synthesised, the 
GelMA polymer undergoes radical photo-polymerisation to form a crosslinked hydrogel, a 
reaction which requires high wavelength UV light exposure in the presence of a 
photoinitiator (Figure 1.6 a).  GelMA is also referred to as gelatin methacrylate, methacrylated 
gelatin, methacrylamide modified gelatin, or gelatin methacrylamide in the literature by 
different groups (Figure 1.6 b). Since its first characterisation in 2000 by Van Den Bulke and 
colleagues 236, the use of GelMA has rapidly increased in popularity as a tissue engineering 
biomaterial and, more recently, as a cancer model platform (Figure 1.6 b). 
1.5.1 Biophysical properties of GelMA 
1.5.1.1 Composition and bioactivity 
Gelatin is comprised of partially hydrolysed collagen, mainly  type I, and as such is the most 
abundant protein in the human body 237. Because of its partially denatured composition, 
gelatin has a higher solubility and much lower batch-to-batch structural variations compared 
to commercial collagen 238. In fact, gelatin is neither immunogenic nor antigenic 239,240, making 
GelMA a suitable platform for the inclusion of immune cells. Importantly, the retention of 
collagen binding sites as well as cell attachment RGD sequences 241 make it an ideal matrix 
for the study of tumour-ECM interactions in a collagen-rich tumour such as PDAC or 
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ovarian cancer. Because of these inherent structural and functional similarities to GelMA, 
collagen type I gels have been used as a control matrix throughout this study. 
In solution, gelatin has the ability to form crosslinked hydrogels at low temperatures 236. With 
the introduction of methacryloyl groups (MA) onto the gelatin (Gel) amino acids, gelatin 
solutions can crosslink in a controllable manner with the assistance of a photoinitiator and 
exposure to light, through the photo-polymerisation of the functional side groups 236. This 
allows the operator to control the temporal aspect of the reaction as well as parameters 
including neutral pH, room temperature and concentration, without compromising the 
stability of the crosslinked product 229. These adjustments make GelMA hydrogels 
particularly suitable as a cell culture model, as they allow the fine-tuning of different synthesis 
parameters to match the requirements of various cell types. Owing to its stability, GelMA 
can be moulded and micropatterned in a variety of shapes, sizes and volumes to suit the 
Figure 1.6 Gelatin methacryloyl (GelMA) hydrogels synthesis and prevalence in peer-reviewed 
academic publications. a) Gelatin reacts with methacrylic anhydride (MA) forming gelatin functionalised 
with methacryloyl functional groups (GelMA). This substitution occurs on primary amines, therefore the RGD 
domains (green segments), along the gelatin backbone, are retained. Next, free radicals are generated by the 
addition of the photo-initiator, initiating polymerisation of the methacryloyl functional groups, and resulting in 
a crosslinked hydrogel. b) Number of academic GelMA-related publications, by year. The increasing popularity 
of this semi-synthetic biomaterial is accompanied by the growing number of relevant publications each year. 
GelMA hydrogels have only recently been used for biomedical applications in cancer (2014 onwards), 
underlying the novelty of this model. To my knowledge, no publications have yet used GelMA for pancreatic 
cancer research. Search terms: gelatin methacrylate, gelatin methacryloyl, gelatin methacrylamide, or 
methacrylated gelatin, as used by different research groups to refer to GelMA. Data obtained on 
www.scopus.com by screening terms in publications’ titles, abstracts and keywords as of June 2020. RGD= 
RGD= Arginine, Glycine and Aspartate binding motif. 
MA 
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intended application. Additionally, its transparency allows for easy imaging of 3D structures, 
even by simple brightfield microscopy. More recently, groups have begun to optimise 
conditions for GelMA hydrogel’s applications in 3D bioprinting 238. 
 
Generally, less than 5% wt/wt of the gelatin amino acid residues will be modified by MA 
during GelMA synthesis 236. This implies that the majority (>95%) of the functional amino 
acid residues present on the gelatin backbone (including RGD motifs and MMP-cleavable 
sites) will be retained in the resulting GelMA hydrogel. Moreover, the RGD motifs do not 
contain amine groups capable of reacting with MA, therefore they are unaffected during 
GelMA synthesis, granting good cell adhesive properties in these hydrogels 241-243 (Figure 1.6 
a). Additionally, the enzymatic degradation of GelMA hydrogels in vitro by collagenases (type 
I and type II, or MMP1 and MMP8) is significantly faster compared to other enzymatic 
approaches, underlining the retention of MMP-sensitive sites in crosslinked GelMA 
hydrogels 244,245. This will be discussed further in Chapter 4. 
 
1.5.1.2 Stiffness and porosity 
A number of different parameters allow tuning of the physical properties of GelMA 
hydrogels. Firstly, the degree of functionalisation (DoF) or amount of MA substitutions onto 
the gelatin amine groups, can determine the amount of crosslinking, and hence stiffness, of 
the resulting hydrogels 242,246. In this regard, reports have shown that the compressive 
modulus (E, kPa), or stiffness of GelMA, is directly proportional to its DoF (2.0 ± 0.18 KPa 
(for low DoF), 3.2 ± 0.18 KPa (medium DoF), and 4.5 ± 0.33 KPa (high DoF) 246. In order 
to ensure reproducibility, all the batches utilised in this study were synthetized with similar, 
high, DoFs. The concentration and nature of the photoinitiator, the UV exposure time and 
its wavelength, are among the other parameters that allow simple and precise tuning of the 
physical properties of GelMA hydrogels 229. For instance, longer UV exposure, shorter UV 
wavelength or higher photoinitiator concentration, all result in hydrogels with a higher 
compressive modulus, E. Once again, these parameters were optimised and then left 
unchanged for the duration of this study in order to return comparable and reproducible 
results. E is also directly proportional to the initial concentration (% wt/vol) of GelMA 
polymer. For instance, reports have found E values of 2, 10 and 20 kPa for 5, 10, 15% wt/vol 
GelMA respectively (with an unchanged medium DoF) 242. This simple adjustment allows to 
achieve hydrogels of equal composition and different stiffness, which will be employed 
throughout this study. The range of stiffness achieved with these semi-synthetic hydrogels 
(1-30 kPa) is much higher than that achievable with un-functionalised natural gelatin or 
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collagen, and therefore represent a good strategy for the investigation of stiffness-associated 
processes and modelling of physiological human tissue rigidities.  
 
The porosity of a material also dictates the ability of cells to adhere, migrate, proliferate and 
invade into a matrix. Once again, GelMA’s DoF or its storage (i.e. freeze-dried) can be altered 
to achieve hydrogels with controlled porosity 246. For instance, a simple change in GelMA 
DoF (low, medium, high) resulted in GelMA hydrogels with decreasing pore sizes (50, 30 
and 25 μm respectively) 246. Biomaterials with a pore size of 25-35 μm are conducive of cell 
proliferation and migration, to be favoured for cell culture applications 246,247. 
 
1.5.1.3 Cell culture in GelMA 
Migration, viability and proliferation of different cell lines within GelMA hydrogels have 
been widely studied and extensively described 229. Cells can be suspended in the GelMA 
aqueous solution prior to crosslinking in order to form cell-laden 3D hydrogels (Figure 2.1). 
Pioneering studies successfully  implemented GelMA hydrogels as 2D and 3D cell culture 
systems 248, with high viability 229,235, thanks to their high biocompatibility, bioactivity through 
cell-responsive motifs and controllable biomechanics. Evidence of cell matrix remodelling, 
migration and spreading within the hydrogels has also been extensively reported 232,242,249. 
Although its first characterisation dates back to over 20 years ago 236, GelMA’s 
implementation as a 3D cell culture system dates back to the early 2010s and was 
predominantly confined to the field of tissue engineering and regenerative medicine 
230,231,238,250,251. A few groups have now employed GelMA in the field of cancer research, 
including studies on ovarian 235,252, glioblastoma 253,254, breast 255,256, prostate 257,258 and colon 
cancer (Loessner, Ryan, unpublished). Thus far, there have been no reported uses of GelMA 
for the culture of PDAC cells. 
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1.6 Project hypothesis and aims 
The purpose of this work is to exploit the tuneability of gelatin methacryloyl (GelMA) 
hydrogels as a pre-clinical model of PDAC in order to investigate the effects of different 
tumour microenvironment components and its biomechanics. The present body of work 
aims to characterise the biomechanics of human tissues in order to recapitulate tissue 
dynamics, and to establish a hydrogel-based model system in which stiffness can be 
controlled, measured, and predicted. In an effort to mimic physiological conditions, multiple 
cell types including cancer, stromal and immune cells, will be incorporated in the model, and 
their behavioural and molecular profiles will be assessed. Wherever possible, patient-derived 
cells will be employed in order to strengthen the translational and clinical relevance of the 
model. The characterisation and validation of such platform requires an interdisciplinary 
approach whereby the material sciences and engineering hydrogel design considerations meet 
the functional, molecular and -omics analyses of the cultured cells. Additionally, findings will 
be benchmarked and compared against another popular 3D cell culture system, namely 
collagen type I gels. I hypothesise that this GelMA-based model will not only allow the 
investigation of stiffness-related cell behaviours and gene signatures, but also allow the 
investigation of stromal and biomechanics-targeting combination therapy regimes, in the 
attempt to bridge the gap between laboratory and clinical efficacy (Figure 1.7). 
 Figure 1.7 Schematic outline of thesis rationale and workflow. 
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The overarching hypothesis of the presented work will be investigated with the following 
proposed aims: 
1. Describe differences in stiffness between tumour-bearing and tumour-naïve tissues 
and assess direct correlations with matrix production, in order to recapitulate 
physiological tissue properties using GelMA hydrogels and collagen type I controls. 
2. Characterise GelMA hydrogels and assess their potential as a 3D PDAC cell culture 
system, by investigating various cancer cell functions in hydrogels with different 
biomechanical properties. Concomitantly, increase the complexity of the model, by 
adding multiple cellular components of the TME, and study their effect on stiffness 
and in vivo tumorigenicity. 
3. Explore the transcriptional profile of PDAC cells in GelMA hydrogels of increasing 
stiffness and collagen control gels, in order to uncover associations with 
mechanobiology and other matrix signatures. 
4. Test the translational value of this 3D PDAC model by targeting pathways and 
processes important in the mechanobiology of PDAC. 
 
Fresh tissues from pancreatic cancer patients were used wherever possible. Due to the limited 
availability of patient-derived material, ovarian cancer tissues and ascites were also used for 
characterisation and cell isolation as indicated in Table 2.1. The high grade serous ovarian 
cancer (HGSOC) cell line OvCar-4 was used as a proof of concept in the initial stages of 
GelMA hydrogels optimisation and treatment assessment, due to the work previously 
conducted by my group 229,249,252, and expertise in my Centre 123,259,260. Similarly to PDAC, 
HGSOC is a peritoneal cancer characterised by poor prognosis and survival, as patients often 
present at a late stage, after disease spread 261. Importantly, both PDAC and HGSOC present 
complex TMEs, the understanding of which may have therapeutic implications. Therefore 
the engineering of pre-clinical 3D cell culture platforms for both solid tumours is particularly 
relevant. 
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Chapter 2 - Materials and 
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2.1 Patient-derived tissues and cell culture 
2.1.1 Cell culture and passaging 
All assays were carried out using PDAC cells BxPC-3, Capan-2, MIAPaCa-2 and PANC-1 
(ATCC, CRL1687, CRL1420, CRL1469), the THP-1 (ATCC TIB202) monocytic cell line, 
and HGSOC cells OvCar-4 (gift from Lockley Lab) as stated in each experiment. Cells were 
cultured at 37°C and 5% CO2 in high glucose Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco), supplemented with 10% foetal bovine serum (FBS) (Gibco) and 1% 
penicillin/streptomycin (P/S) (Thermo Fisher Scientific). Cells were passaged with either 
0.5%/0.2% (v/v) trypsin/ Ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich) or 
TrypLE (Thermo-Fisher Scientific) and used for a maximum of 20 passages. Cell viability 
was routinely checked after passaging and kept above 90%. Mycoplasma tests were 
conducted monthly to ensure cells were contamination-free. 
2.1.2 Patient-derived tissues 
Patient-derived tissues were collected through the Barts Pancreas Tissue Bank for PDAC 
tissues (REC: 18/SC/0630), or the Barts Gynae Tissue Bank ethics for OvCa tissues and 
ascites (REC: 15/EE/0151) with full written informed consent between 2017 and 2019. 
Tissue samples were either used for primary cell isolation and cell culture or left in 
Dulbecco’s phosphate buffered saline (PBS) (Sigma-Aldrich at 4°C for mechanical testing 
(usually carried out within 24 hours from surgery). Samples from patients that had received 
chemo- or radiation therapy prior to surgery were labelled accordingly. ‘Adjacent normal’ 
tissue was only available from surgeries accompanying other conditions such as cancer 
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Anonymised ID Received Diagnosis Analysis 
Ascites 
 
1 PT0634 19/07/2018 Bilateral ovarian serous borderline tumours with focal 
microinvasion and micropapillary proliferation. 
CAF isolation for 3D cultures 
2 PT0849 26/04/2019 HGSOC, tubo-ovarian type. FIGO 4a CAF isolation for 3D cultures 
3 PT0928 07/08/2019 HGSOC, tubo-ovarian type. FIGO 3c CAF isolation for 3D cultures, SEM 
Ovarian cancer 
tissue 
4 PT0873 21/05/2019 Carcinosarcoma with heterologous differentiation. Mechanical testing, H&E 
HGSOC tissue 
 
5 PT0685 19/09/2018 Interval debulking surgery; HGSOC of left tubal origin 
showing near total response to chemotherapy; CRS 3/3. 
Mechanical testing, H&E 
6 PT0601 21/09/2018 Interval debulking surgery; right tubo-ovarian HGSOC 
with widespread peritoneal metastasis; CRS 2/3. 
Mechanical testing, H&E 
Normal ovary 
tissue 
7 PT0674 04/09/2018 Left ovary normal. NF isolation for 3D cultures 
8 PT0672 11/09/2018 Normal ovary. Mechanical testing, H&E 
9 PT0677 20/09/2018 Normal ovary. Mechanical testing, H&E 
10 PT0701 25/10/2018 Normal right ovary. Mechanical testing, H&E 
11 PT0715 02/11/2018 Normal left ovary. Mechanical testing, H&E 
12 PT0719 09/11/2018 Normal ovary. Mechanical testing, H&E 
Diseased 
omental tissue 
13 SGH002 08/11/2019 HGSOC primary debulking surgery, stage 3c CAF isolation for 3D cultures, IF 
14 G518 13/01/2020 Clear cell adenocarcinoma of the ovary, stage 1a CAF isolation for 3D cultures 
15 G522 30/01/2020 Mucinous adenocarcinoma of the ovary, stage 1c CAF isolation for 3D cultures 
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Anonymised ID Received Diagnosis Analysis 
PDAC tissue 16 B01 P0556A AA01 04/09/2018 PDAC CAF isolation for 3D cultures 
17 B01 PO570B AA08 18/09/2018 PDAC CAF isolation for 3D cultures 
18 B01 P0611B AA06 26/11/2018 Pancreatic adenosquamous carcinoma H&E, IHC 
19 B01 P0655A AA05 05/02/2019 PDAC Mechanical testing, H&E 
20 B01 P0664B AA04 11/03/2019 PDAC Mechanical testing, H&E, IHC 
21 B01 P0706B AA05 28/05/2019 PDAC Mechanical testing, H&E, IHC 
22 B01 P0728A AA05 04/06/2019 PDAC Mechanical testing, H&E, IHC 
23 B01 P0781B AA05 31/10/2019 PDAC Mechanical testing, H&E 
24 B01 P0791B AA01 13/12/2019 PDAC H&E, IHC 
Pancreatic 
cancer tissue 
25 B01 P0540B AA04 10/08/2018 Cholangiocarcinoma H&E, IHC 
26 B01 P0742B AA06 23/07/2019 Ampulla adenocarcinoma Mechanical testing, H&E 
Tumour-
adjacent tissue 
25 B01 P0540B EE04 10/08/2018 Adjacent to diseased ‘normal’ tissue, matched sample H&E, IHC 
17 B01 PO570B EE05 18/09/2018 Adjacent to diseased ‘normal’ tissue, matched sample NF isolation for 3D co-culture studies 
18 B01 P0611B EE06 26/11/2018 Adjacent to diseased ‘normal’ tissue, matched sample H&E, IHC 
19 B01 P0655A EE05 05/02/2019 Adjacent to diseased ‘normal’ tissue, matched sample Mechanical testing, H&E 
20 B01 P0664B EE05 11/03/2019 Adjacent to diseased ‘normal’ tissue, matched sample Mechanical testing, H&E, IHC 
22 B01 P0728A EE05 04/06/2019 Adjacent to diseased ‘normal’ tissue, matched sample Mechanical testing, H&E, IHC 
26 B01 P0742B EE06 23/07/2019 Adjacent to diseased ‘normal’ tissue, matched sample Mechanical testing, H&E 
24 B01 P0791B EE06 13/12/2019 PDAC H&E, IHC 
HGSOC=High-grade Serous Ovarian Cancer tissues; CAF=Cancer-Associated Fibroblasts; NF=Normal Fibroblasts; FIGO=International Federation of Gynaecology and Obstetrics staging; 
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2.1.3 Patient-derived cell isolation 
Normal fibroblasts (NF) and cancer-associated fibroblasts (CAFs) were isolated from normal 
or diseased tissues respectively. Briefly, tissue was sectioned with a sterile blade (Corning) 
and placed in a 50 ml tube in 0.05% Collagenase V in Roswell Park Memorial Institute 
(RPMI) medium. The tube was placed at 37C/100 rpm in a Brunswick Innova 40 shaker 
(Eppendorf) for 1-3 hours. The tube was then centrifuged, cell were washed once in 
DMEM/F12 medium, and then plated in T25 cell culture flasks (Corning) in complete 
supplemented DMEM. 
 
Cell composition of ascites fluid was characterised by Dr Juliana Candido via flow cytometry. 
CAFs were also isolated from ascites following filtering through a 70 µm mesh and 
centrifugation at 1500 rpm for 10 min. The resulting pellet was treated for 10 minutes with 
Red Blood Cell Lysis Buffer (Thermo Fisher Scientific) at room temperature (RT) and then 
washed in PBS. Following 5 minutes of centrifugation, cells were resuspended in 20% 
FBS/DMEM and plated in T75 cell culture flasks at 0.3 x 106 cells/ml. 
 
Following isolation, fibroblast’s phenotype was characterised via flow cytometry (FC) and 
immunofluorescence (IF) as indicated in the above Table 2.1. Patient-derived NF or CAFs 
were initially incorporated in collagen and GelMA hydrogels, for 14 days of culture in a 2:1, 
4:1 and 1:4 ratio (cancer cells : CAFs) and a final cell density of 3.5 x 105 cells/ml. For triple 
culture and indirect co-culture experiments (see section In vitro treatment studies), cells were 
incorporated in either a 2:2:1 or 1:2:2 ratio (cancer cells : THP-1 : CAFs). 
 
  
 Materials and Methods 
 
-  68 - 
 
2.2 Hydrogel synthesis, characterisation and 3D cell culture 
2.2.1 GelMA hydrogel synthesis and storage 
GelMA batch synthesis was performed by Dr Daniela Loessner, Dr Juliana Candido and Dr 
Laura Lecker as previously described 229. The resulting liquid was freeze-dried in a Labconco 
4.5 Plus benchtop freeze-drier (Labconco) over 4-5 days under sterile conditions. 
Lyophilisation yielded a fluffy white foam, which was kept at -80 °C to -20°C for long-term 
storage. 
2.2.2 Characterisation of GelMA functionalisation 
2.2.2.1 TNBS Assay 
The TNBS assay was used to quantify the amount of free amino groups on the gelatine 
backbone (qualitative measurement of amines, sulfhydryls, hydrazides and quantitative 
measurement of ε-amino groups).  A high degree of gelatine functionalisation (GelMA with 
high degree of functionalisation) would result in a low amount of free amino groups. TNBS 
(also known as Picrylsulfonic acid) is used in this assay as it reacts with primary amines or 
hydrazine groups to give an orange-coloured derivate, quantifiable via an absorbance 
measurement.  
 
For this, GelMA foam and un-functionalised gelatin (Sigma-Aldrich) were dissolved in 0.1 
M sodium bicarbonate (Sigma-Aldrich) at 500 µg/ml concentration. A standard dilution of 
GelMA and gelatine ranging from 0 to 500 μg/ml was prepared and pipetted in a 96-well 
plate (Costar). 0.01% TNBS/0.1 M sodium bicarbonate was added in a 1:2 ratio onto each 
well (final volume 255 µl) and incubated for 5 minutes at RT and subsequently for 2 hours 
at 37°C in the dark. The absorbance of the samples at 335nm was read on a BMG Labtech 
FLUOstar Optima Microplate reader (Labtech) against the serial dilution of gelatin. To 
calculate the degree of functionalisation (DoF), regression lines were calculated for each 
GelMA batch 𝑚𝐺𝑒𝑙𝑀𝐴 and compared to the gelatine solution regression line 𝑚  using the 
equation: 
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2.2.2.2 Ninhydrin Assay 
Gelatin and GelMA foam were dissolved at a 35 mg/ml concentration in MilliQ water 
(Merck-Millipore) and warmed up to 40ºC - 50ºC until fully dissolved. Different dilutions of 
the gelatin solution (0-80%) were prepared in MilliQ water (Merck-Millipore) to obtain a 
standard curve. A 0.5 M citric acid (Sigma-Aldrich) solution was prepared, adjusted to pH 
5.5 and then added to two parts of glycerol (Sigma-Aldrich) in a 1:2 ratio. Ninhydrin (2,2-
dihydroxyindane-1,3-dione) (Sigma-Aldrich) was then added to the citric acid/glycerol 
solution at a 2.5 mg/ml concentration. 50 µl of GelMA or gelatine standard were added to 
an Eppendorf tube in duplicates, following which, 0.950 ml of ninhydrin solution were 
added. 50 µl of water were used as blanks. The Eppendorf tubes were then placed in a boiling 
water bath (Grant Instruments), protected from light for 13 minutes and then left to cool at 
RT for 1 hour. Ninhydrin reacts with free primary and secondary amine groups to produce 
a purple colour solution. Next, 250 µl of sample were pipetted from each Eppendorf in 
triplicates into a 96-well plate (Costar) and absorbance was read at 570 nm emission on a 
BMG Labtech FLUOstar Optima Microplate reader (Labtech). The degree of 
functionalisation was calculated by finding the gradient of the gelatine solution regression 
line 𝑚 and the average absorbance of the sample ?̅? and using the equation: 





2.2.2.3 Fluoraldehyde Assay 
Fluoraldehyde (Thermo Scientific) can be used for the detection of primary amines as its 
active compound, o-phthalaldehyde, becomes fluorescent linearly with the presence of the 
latter. For this, GelMA foam was dissolved at 0.5 mg/ml alongside gelatine (1 mg/ml) in 
PBS (Thermo Fisher) at 37 ⁰C until fully dissolved. A serial dilution of gelatine ranging from 
0.02 to 1 mg/ml was prepared in PBS (Thermo Fisher). Next, 500 µl of GelMA or gelatine 
serial dilutions were mixed in a 1:1 ratio with fluoraldehyde (Thermo Fisher). Fluorescence 
was measured with emission 450 nm and excitation wavelength of 360 nm using a BMG 
Labtech FLUOstar Omega Microplate reader (Labtech). The degree of functionalisation was 
calculated by finding the gradient of the gelatine regression line 𝑚 and the average 
absorbance of the sample ?̅? with the following equation: 
𝐷𝑜𝐹 = ((0.5 −
?̅? 
𝑚
) 0.5⁄ ) 100 
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2.2.2.4 Nuclear Magnetic Resonance (NMR) 
Proton nuclear magnetic resonance (1H NMR) was also used to measure the degree of 
methacrylic anhydride (MA) onto the gelatin backbone, by comparing the NMR spectra of 
gelatin to the one of functionalised gelatin (GelMA). 1H NMR was performed by Andrew 
McCormack at the Heriot-Watt University in Edinburgh. Briefly, GelMA samples and gelatin 
were separately dissolved at around 50 mg/mL in deuterium oxide, and the chemical shift of 
each sample was measured 242,262. This method looks at the lysine methylene proton existing 
on the carbon atom that joins the amino group (which then gets functionalised with 
methacrylic anhydride, MA). This proton gives a peak around 3 parts per million (ppm). This 
peak was highest on gelatin NMR spectra and decreased in GelMA congruently with MA 
addition, indicating the amino groups were now connected to methacryloyl groups. 
Annotating the spectra allows to quantify the area under each NMR peak (λ), which can be 
used to calculate the degree of functionalisation. The DoF can be calculated as follows: 
𝐷𝑜𝐹 = [1 − (
𝜆 𝑜𝑓 𝑙𝑦𝑠𝑖𝑛𝑒 𝑚𝑒𝑡ℎ𝑦𝑙𝑒𝑛𝑒 𝑝𝑟𝑜𝑡𝑜𝑛 𝑜𝑓 𝐺𝑒𝑙𝑀𝐴
𝜆 𝑜𝑓 𝑙𝑦𝑠𝑖𝑠𝑛𝑒 𝑚𝑒𝑡ℎ𝑦𝑙𝑒𝑛𝑒 𝑝𝑟𝑜𝑡𝑜𝑛 𝑜𝑓 𝑔𝑒𝑙𝑎𝑡𝑖𝑛
)] × 100% 
To help normalise the intensities of signals between runs, the λ of aromatic moieties in each 
spectra was made constant ≃100, as this peak doesn’t change during the reaction, and can 
therefore be used for calibration. 
2.2.3 GelMA 3D cell culture 
GelMA hydrogels were prepared by dissolving dried GelMA foam in PBS at 3%, 5%, 7.5% 
or 10% wt/vol for 1 hour at 37°C. A 10 mg/ml stock of photo-initiator was prepared by 
dissolving 2-Hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure D-2959, 
Sigma-Aldrich) in PBS at 70°C for 10 minutes and then sterilised using a 0.2 μm syringe filter 
unit (Millipore). The photo-initiator solution was added into the dissolved GelMA (final 
photo-initiator concentration: 0.5% vol/vol). Next, cells were harvested and pelleted at the 
desired concentration (3.5 x 105 cells/ml unless otherwise stated) prior to mixing with the 
GelMA/photo-initiator mixture to establish the GelMA precursor solution (this step was 
omitted when obtaining acellular hydrogels) (Figure 2.1a). The precursor solution was casted 
into sterilised custom-made Teflon moulds (Queensland University of Technology) and 
sealed with glass slides (VWR). The precursor solution was crosslinked in a CL-1000 
Ultraviolet Crosslinker (UVP) at 365 nm for 10 minutes (Figure 2.1b), after which the 
hydrogel was removed from the mould by lifting the glass slide. Note that for 3% wt/vol 
hydrogels a 12 minutes UV crosslinking time was used instead, to allow full crosslinking. The 
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resulting hydrogels were cut in equal sized 4 mm x 4 mm x 2 mm constructs using sterile 
PMMA cutting guides (Queensland University of Technology) and scalpel (Swann-Morton) 
(Figure 2.1c). Each hydrogel was placed free-floating in a separate well of a 24-well plate 
(Costar) in supplemented 10%-FBS/1%-P/S/DMEM (Figure 2.1d). The latter was replaced 
after 2 hours to ensure photo-initiator removal and subsequently replaced twice per week. 
The resulting cultures were labelled ‘monocultures’ when only containing one cell type and 
‘co-/triple-culture’ when NFs, CAFs, THP-1 were added to the cancer cells. Cell-containing 
GelMA cultures were kept for 14 days, unless otherwise noted. 
 
 
Figure 2.1 Schematic representation of cell-laden GelMA hydrogels preparation procedure. (a-b) The 
cell-containing precursor solution (comprising GelMA foam, PBS and diluted photo-initiator) was casted into 
a customised Teflon mould, covered with a glass slide, and polymerised via photo-crosslinking (10 minutes at 
365nm UV light). (c) Hydrogels were cut to obtain identical-sized constructs, using a scalpel and cutting guide. 
(d) Constructs are transferred into a multi-well plate with appropriate cell culture medium, in which the 
hydrogels are free-floating, allowing formation of multicellular spheroids over time (green: live cells; red: dead 
cells). 
2.2.4 Collagen hydrogels synthesis and 3D cell culture 
Collagen mixture (1mg/ml) was obtained by mixing 1:3 of rat-tail Collagen type-I (Thermo 
Fisher), 10:10 10X DMEM (Sigma), 1:58 1M sodium hydroxide (Acros Organics), 1:19 sterile 
water (Sigma), and 1:2 of cells in DMEM (Gibco) at the desired concentration (3.5 x 105 
cells/ml unless otherwise stated). Cell-free media alone was added for the formation of 
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acellular hydrogels. Modified concentrations to the above mixture ratios were made to obtain 
4, 6, and 8 mg/ml hydrogels during optimisation phase. The optimal collagen mixture 
volume for plating and hydrogel formation was found to be 100 µL (+10% excess). This was 
added directly into each well of a 96-wells plate (Costar), and incubated at 37C for 30 
minutes to set (Figure 2.2). Once set, 100 µL of cell culture media were added into each well 
and incubated overnight at 37C/5%CO2. The following day hydrogels were scooped out of 
the well with the aid of a sterile metal spatula (Sigma Aldrich) and placed individually into a 
24-wells plate, free-floating in 10%FBS/1%P-S/DMEM. Cell-containing collagen hydrogels 
were handled and treated the same as their GelMA counterparts, with media change twice 
per week and culturing over 14 days, unless otherwise noted. For treatment experiments, gels 
were made in a minimum of sextuplicate per treatment group to allow for proliferation, 
imaging, mechanical properties and other analyses. 
 
 
Figure 2.2 Schematic representation of collagen hydrogel preparation procedure. (a) After passaging, 
cells at the desired concentration were added to rat-tail collagen type-I and crosslinked in 10X DMEM and 1M 
NaOH. The mixture was then casted directly into a 96-wells plate and left to crosslink at 37°C for 30 minutes. 
Following media addition, the hydrogels were left in the plate overnight. (b) Set hydrogels were scooped out 
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2.3 In vitro treatments and in vivo studies 
2.3.1 MMP and ROCK inhibitors: monotherapy studies 
Collagen, 5% and 7.5% GelMA hydrogels were synthesised as previously described 
incorporating either the PDAC cell lines BxPC-3, Capan-2, MIAPaCa-2 and PANC-1 or the 
HGSOC cell line OvCar-4 as monocultures. Hydrogels were treated with either the broad-
band MMP inhibitor ilomastat (20 M, GM6001, targeting MMP-1, -2, -3, -8, -9) (Merck), 
the ROCK inhibitor fasudil (10 M, Tocris) or the GM6001 negative control peptide in 
dimethyl sulfoxide (DMSO) (20 M, Merck). The treatments were dissolved directly into 
10%FBS/1%P-S/DMEM. Treatment started on day 1 post-cell-encapsulation and replaced 
every 72 hours for 14 days of culture. Experiments were conducted in four technical 
replicates and three biological repeats. 
2.3.2 ROCK inhibitor and chemotherapy: combinational studies 
BxPC-3 or PANC-1 cancer cells, patient-derived CAFs and THP-1 triple cultures (in a 1:1:2 
and 1:2:2 ratio) were incorporated in either collagen, 5% or 7.5% GelMA hydrogels as 
previously described. Appropriate monoculture controls (PDAC only) and stroma (CAFs 
and THP-1s) controls were also set up. CAFs isolated from patients 2, 3, 14 and 15 were 
used for these experiments (see Table 2.1). Hydrogels were cultured in complete 
10%FBS/1%P-S/DMEM cell culture media. On day 7, cultures were treated with 10 µM 
fasudil (Tocris) in complete media or media alone as control. Cultures were subsequently 
treated on day 10 with 100 nM gemcitabine and 100 nM nab-paclitaxel (abraxane) in 
complete media (used fresh, both were a kind donations of the St Bartholomew’s Hospital, 
UK) or media alone. Experiments were conducted in four technical replicates and three 
biological repeats. 
2.3.3 Indirect co-culture: conditioned medium studies 
3D indirect co-culture experiments were set up to study the effect of stromal-cells secreted-
factors (THP-1s and CAFs) on PDAC pro-survival cell signalling pathways and vice versa, 
via indirect stimulation. For this, either PANC-1 cells or THP-1 and CAF cells (stroma) were 
embedded in collagen, 5% and 7.5% GelMA hydrogels. CAFs isolated from patients 13 and 
14 were used for these experiments (see Table 2.1). Next, 6 hydrogels were placed in each 
well of a 12-well plate (Corning) in 1 ml of supplemented media, either as monocultures 
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(either 6 PANC-1 hydrogels or 6 stroma hydrogels) or as indirect co-cultures (3 PANC-1 
and 3 stroma hydrogels in the same well). Plates were incubated for 72 hours, after which 
PANC-1 and stroma hydrogels were separated using an inverted microscope (Thermo-Fisher 
Scientific) for subsequent protein extraction and analysis. 
2.3.4 Orthotopic xenograft study 
All animal in vivo work was performed by Dr Juliana Candido with the help of Colin Pengrum 
in the Biological Services Unit of the Barts Cancer Institute. All experiments were conducted 
in compliance with UK Code of Practice for the housing and care of animals bred, supplied 
or used for scientific purposes and approved by the Institute. 5% GelMA hydrogels were 
made as previously described with BxPC-3 or PANC-1 cells +/- THP-1 monocytes in a 1:2 
ratio and cultured for 14 days. One hydrogel was implanted into the flank of severe combined 
immune deficiency spontaneous mutation (NOD/SCID) mice, with 6 mice used per 
condition. Animal appearance and weight was recorded weekly and once tumours reached a 
palpable size, after 10-14 weeks, animals were sacrificed. Presence of ascites and metastases 
was noted, GelMA hydrogels, tumour and liver tissues were surgically removed, and the latter 
were taken histological and immunohistochemical analysis. 
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2.4 Analysis of mechanical properties 
2.4.1 Flat-end Indentation 
Indentation testing was performed on fresh, unfixed patient-derived and murine ovarian and 
pancreatic tissues, (see patients 4-6; 8-12 for OvCa tissues and 19-23 and 26 for PDAC 
tissues in Table 2.1). Fresh mice whole ovaries and pancreas were provided by Colin 
Pengrum, from adult female mice with a Pax8--, Cre-- background. Wherever possible, 
specimens were tested within 24 hours from surgery. Samples were kept at 4°C in PBS until 
tested and were allowed to reach ambient temperature prior to testing. If the sample did not 
present with flat, parallel surfaces at resection, the sample was sliced using a scalpel (Swann-
Morton). 
 
Indentation testing was performed on an Instron ElectroPuls E1000 machine (Instron) 
equipped with a 10N load cell with a 0.1 mN resolution and a metal flat-end cylindrical 
indenter (Øi: 1-4 mm) as previously described 263. Samples were hydrated in PBS during 
testing to prevent drying out. Sample height was recorded as the plate to sample top 
displacement prior to indentation. A preload of 0.2 mN was applied. Specimen diameter (Øs) 
was measured with a digital calliper to ensure Øs:Øi was kept ≥ 3:1 for testing accuracy. The 
specimen thickness (Ts) to indenter diameter (Øi) ratio (x) was kept 1:1  x  2:1, as this 
minimises modulus calculation bias 263. Immediately prior to testing, green tissue dye 
(Thermo-Fisher Scientific) was applied to the indenter metal head in order to mark the exact 
position of indentation points on the specimen. This was later used to correlate stiffness with 
matrix protein expression via immunohistochemistry. Testing was conducted with a 
displacement control mode protocol with a compression phase (20% or 30%) at a 1% s-1, 
displacement-hold (600 seconds) and unloading (to 0% specimen strain at 1% s-1). For big 
samples (> 4 mm), multiple indentation tests were performed in distinct areas (up to 4). 
Following testing, the samples were fixed in 10% formalin (Sigma-Aldrich) and sent for 
embedding, sectioning and immunohistochemical analysis.  
 
Data from flat-end indentation testing were processed in MATLAB R2019 (MathWorks) 
using the code provided in 9.1 Appendix Chapter 2. Tissue moduli (E) was calculated from 
the resulting experimental data load-displacement curve using a corrected mathematical 
model 263. This also allowed comparison with stiffness data obtained via unconfined 
compression.  
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Shortly, the reduced modulus (Er) is related to the indenter contact area A=πa
2 and the elastic 




















where m is the slope of the force-displacement curve [N/mm] calculated on MATLAB. 
Next, the elastic modulus (E)[MPa] was calculated as follows: 
𝐸 = 𝐸𝑟(1 − 𝜈
2) 
where v is the Poisson’s ratio and it’s assumed to be 0.5 as tissues behave as incompressible 
materials. 
2.4.2 Unconfined compression 
Unconfined compression was used for the bulk testing of both acellular and cell-laden 
GelMA hydrogels. For the latter, hydrogels were cultured for 14 days prior to testing, unless 
otherwise stated. Varying polymer concentrations (3-10% wt/vol) were tested. Compression 
testing was performed on an Instron 3342 machine (Instron) equipped with a 10N load cell 
as previously described 263. Natural logarithms of the recorded stress and strain values were 
used to obtain a load-displacement curve for each sample. The Young’s modulus (E) was 
calculated as follows:  













Sample height was recorded on the machine prior to testing, while the surface area of the 
hydrogels was measured from pictures via ImageJ (NIH) and found to be between 9-16 mm2. 
The slope of the stress strain curve at 15-20% strain was taken as the compressive modulus 
(E)[kPa]. Samples were tested in a minimum of quadruplicates per test group. 
2.4.3 Rheometry 
Rheometry testing was used for the bulk testing of both acellular and cell-laden collagen 
hydrogels. For the latter, hydrogels were cultured for 14 days prior to testing, unless 
otherwise stated. Rheometry was used as collagen hydrogels present irregular surface 
geometries and were too soft to be tested by either indentation or compression. Testing was 
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performed on a DHR3 Rheometer (TA Instruments) equipped with an 8 mm plate geometry, 
and analysis was conducted using TRIS®DHR3 software. Before testing, samples were left 
equilibrating for three minutes to allow them to reach room temperature and mechanical 
equilibrium. Loss modulus was averaged in sweep frequency testing between 0 and 0.2Hz 
while storage modulus was taken in amplitude sweep at 5.9-6.3 rad and converted to 
compressive modulus (E) as follows:  
𝐸 = 2𝐺(1 + 𝑣) 
where G is the measured shear modulus and v is the Poisson’s ratio, assumed to be 0.5 in 
incompressible materials. Samples were tested in triplicates for each test group. 
2.4.4 Atomic Force Microscopy (AFM) 
Rheometry testing was used to measure at a nano-scale the stiffness of acellular and cell-
laden GelMA hydrogels with and without GM6001 (Merck) treatment (regime is detailed in 
MMP and ROCK inhibitors: monotherapy studies). AFM testing was performed and 
analysed by Dr William Megone. Interfacial AFM was performed using an NT-MDT Ntegra 
Atomic Force Microscope (NT-MDT Spectrum Instruments). ORC 8 – 10 
Contact AFM tips (Bruker) were used, with spring constants of ~0.05 N/m. Before testing, 
the tips were plasma oxidised and calibrated (nA to nm conversion) by indenting a silicon 
wafer before testing the hydrogel interfaces. Each sample was indented on three separate 
1x1m areas, in which 100 indents were performed. The time for each curve was set at 1 s. 
The indentation depth was kept between 500 – 1000 nm depending on the sample. Acellular 
hydrogels were used as calibration, allowing the precise detection of ‘spheroids’ and cell 
cluster’ areas within cell-laden hydrogels. A minimum of three samples for each condition 
were tested. 
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2.5 Functional assays 
2.5.1 IncuCyte proliferation assay 
The kinetic proliferation assay was performed on the IncuCyte ZOOM (Essen Bioscience) 
using 96-well plates (Corning) and analysed on the IncuCyte ZOOM software (Essen 
Bioscience). Prior to cell seeding, 96-wells plates (Corning) were coated with 10 g/l of 
either poly-L-lysine (Sigma) or rat-tail collagen type-I (Gibco) and incubated overnight at 
4C. 24 hours prior to the assay set up, cells were washed and subsequently starved with 
1%FBS/1%P-S/DMEM. Cells were then detached and counted as previously described (see 
Cell culture and passaging). Cells were seeded at a 5 x 103 cells/well density (except Capan-2 
cells which were seeded at 10 x 103 cells/well) and imaged over 7 days in complete medium 
or medium with the addition of either 20 M of GM6001 (Merck), 10 M fasudil (Tocris), 
or 100 nm of both gemcitabine and abraxane (used fresh, kindly donated by the St 
Bartholomew’s Hospital). A minimum of 5 wells was used for each cell line and treatment 
condition. Image analysis, confluency (%) assessment, and growth data was obtained via the 
IncuCyte Zoom (Essen Bioscience).  
2.5.2 IncuCyte scratch-wound assay 
Scratch-wound and cell migration assays were performed using the IncuCyte Zoom (Essen 
Bioscience) in conjunction with 96-well Image Lock plates (Essen Bioscience). Plates were 
coated and cells seeded as described in the previous paragraph at a 1 x 105 cells/well density 
(except Capan-2 cells which were seeded at 1.2 105 cells/well) and incubated at 37C 
overnight to allow cell adhesion onto the plate. The scratches were generated using a 
IncuCyte Wound Maker (Essen Bioscience), after which wells were washed in PBS (Sigma-
Aldrich) once, prior to the addition of treatments as detailed above, or control media alone. 
Wells were imaged for up to 5 days, with minimum of 5 wells was used for each cell line and 
treatment condition. Image analysis, wound confluency (%), wound width (m), and cell 
migration data was obtained via the IncuCyte Zoom (Essen Bioscience) cell migration 
software. 
2.5.3 Transwell invasion assay 
Invasion assays were performed in 24-well multi-well cell culture inserts (Merck) with 8 µm 
pores as previously described 264. Briefly, 10% FBS/DMEM was placed in the lower chamber 
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to act as a chemoattractant. 8 μm pore-sized transwell permeable supports were coated with 
either 60 µl of Matrigel (Corning) or rat-tail collagen type I (Gibco). Cells were seeded in 350 
µL at a 1 x 105 cell concentration in serum-free medium containing 0.1% (w/v) bovine serum 
albumin (BSA)(Sigma Aldrich) and 20 µM GM6001 (Merck). This was pipetted directly into 
the top chamber of the transwell. Control inserts at the same cell seeding density and 
containing 350 µL of serum-free medium with 0.1% (w/v) BSA with 20 µM GM6001 control 
peptide (20 µM) were also set up. Wells containing cells in media with no FBS in the top 
chamber and no chemoattractant FBS in the bottom chamber were used as controls for 
random invasion of cell from the top chamber to the bottom (none of which was observed). 
Transwells were incubated at 37C/5%CO2 for 48 hours, after which cells remaining on the 
upper surface of the insert were removed using a cotton bud. To quantify the number of 
cells that migrated or invaded to the bottom of the insert, inserts were fixed with 100% ice-
cold methanol (Sigma-Aldrich), stained with 1% (w/v) crystal violet (Fluka)/ 20% (v/v) 
methanol and the stain was extracted using 10% (v/v) acetic acid (Sigma-Aldrich). 
Absorbance was read at 595 nm. Invasion assays were performed in three biological and 
technical replicates for each cell line. 
2.5.4 Viability assay 
Cell viability in GelMA and collagen hydrogels was visually assessed using a Live/Dead 
Viability/cytotoxicity kit for mammalian cells (Life Technologies). Briefly, media was 
diffused of the hydrogels by placing them in PBS for 30 minutes at 37C. The kit comprises 
of two dyes, calcein-AM (Ca-AM) and ethidium-homodimer 1 (EtH1). Live cells are stained 
based on their cytoplasmic esterase activity, which hydrolyses calceinacetoxymethyl (2 µM) 
into fluorescent Ca-AM (green). Dead cells are stained based on their membrane 
permeability, which allows EtH1 (4 µM, red) to bind to DNA. Cells were then imaged by 
confocal microscopy on a Zeiss Laser Scanning Microscope LSM710 (Zeiss). 
2.5.5 Metabolic activity assay 
Hydrogels in triplicates (minimum) were collected at day 1 and endpoint (day 14 unless 
otherwise specified) for this analysis, from at least 3 biological replicates. Cell metabolic 
activity was used as a proxy for viability and assessed via AlamarBlue® assay (ThermoFisher 
Scientific) using cell-laden GelMA and collagen hydrogels as previously described 229. 3D cell 
cultures were incubated with 4% (vol/vol) Alamar Blue reagent in phenol-red-free DMEM 
(Gibco) and left in a humidified incubator, in the dark, for 6 hours. Cell-free hydrogels 
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and/or cell culture medium only, served as controls. Supernatant’s fluorescence was 
measured by spectrophotometry (POLARStar OPTIMA plate reader, BMG Labtech) in a 
black 96-well-plate with clear bottom (Nunc, Thermo-Fisher Scientific) using an excitation 
wavelength of 544nm and emission of 590nm. Hydrogels were then incubated in PBS at 
37°C until they lost the blue coloration and were then stored at -80°C for successive DNA 
content quantification. The fluorescence values of media-only controls was subtracted from 
all the samples during analysis. 
2.5.6 3D proliferation assay 
PBE buffer was made as follows: 20mM Na2HPO4 (Merck), 30mM NaH2PO4 in H2O 
(Merck), 5mM Na2EDTA (AJAX Chemical), adjusted to pH 7.1 and autoclaved at 121C for 
15 min. Hydrogels were collected at day 1 and endpoint (day 14 unless otherwise specified) 
for this analysis, from at least 3 biological and technical replicates. Proliferation in 3D cultures 
was evaluated via DNA content quantification using a CyQUANT cell proliferation assay kit 
(Invitrogen). Following metabolic activity quantification as described above, hydrogels were 
stored at -80°C for >24 hours. Hydrogels were then digested in 300 l of 0.5 mg/ml 
proteinase K (Invitrogen)/PBE buffer at 65°C overnight. 50 µl of each sample was added to 
a black 96-well plate with clear bottom (Corning) in duplicates. Samples were treated with 
1.4 U/ml RNAseA (Invitrogen) dissolved in cell lysis buffer (Invitrogen), 180 nM sodium 
chloride (Sigma-Aldrich) and 1mM EDTA (Ambion) for 1 hour at ambient temperature. 1x 
CyQUANT® dye solution (Invitrogen) was diluted in cell lysis buffer and added to the plate. 
Fluorescence was measured after 5 minutes via spectrophotometry using an excitation 
wavelength of 485 nm and emission 520 nm on a BMG Labtech FLUOstar Optima 
Microplate reader (Labtech). A λDNA standard (0-2000 ng/ml) was used to convert 
fluorescence values into DNA content. 
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2.6 Imaging and image analysis 
2.6.1 Brightfield microscopy 
Brightfield imaging was performed on cell-laden GelMA and collagen hydrogels at multiple 
time points with an EVOS XL Core Cell-Imaging-System (Thermo-Fisher Scientific). Where 
necessary, image analysis was performed on ImageJ (NIH). 
2.6.2 Confocal microscopy 
For immunofluorescent (IF) analysis of 3D cultures, hydrogels were permeabilised with 0.2% 
Triton X-100 (Sigma-Aldrich) for 1 hour at room temperature, washed with 0.1 M 
glycine/PBS (Thermo-Fisher Scientific). Primary antibodies were diluted in 2% BSA (Sigma-
Aldrich) in PBS and incubated overnight at 4°C. After washing, the hydrogels were incubated 
with secondary antibodies in 2% BSA/PBS, phalloidin (0.3 U/ml, Invitrogen) and 4ʹ,6-
diamidino-2-phenylindole (DAPI) (2.5 g/ml, Invitrogen) for 1 hour at RT. Fluorescence 
microscopy was performed on a Zeiss Laser Scanning Microscope LSM710 (Zeiss). z-Stacks 
were acquired with 10 µm slice thickness for a minimum of 10 sections. 
 
For cells grown in monolayer, 20 x 103 cells were plated on round sterile coverslips (VWR) 
in a 24-well plate (Corning) and placed in a humidified incubator overnight to allow cell 
adhesion. Coverslips were then rinsed in PBS for 5 minutes and subsequently fixed in 4% 
paraformaldehyde (PFA)(Sigma-Aldrich) for 10 minutes. Following two PBS washes, the 
coverslips were permeabilised with 0.1% Triton (Sigma-Aldrich)/PBS for 5 minutes and then 
washed twice again in PBS. Coverslips were blocked for 90 minutes in 2% BSA/5% goat 
serum/ 0.3 M glycine/ 0.1% Triton/PBS after which primary antibodies were added in 
blocking buffer overnight at 4°C. Washing, secondary antibody staining, addition of DAPI 
and imaging was performed as described above. Coverslips were mounted onto glass slides 
(VWR) with ProLong Gold antifade reagent (Invitrogen) prior to imaging. 
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Table 2.2 Table of antibodies used for immunofluorescence. mAb=monoclonal antibody; 
pAb=polyclonal antibody 
 
Table 2.3 Secondary antibodies and other immunofluorescent dyes used. 
Secondary antibody/dye Dilution Species Cat. no Supplier 
Anti-rabbit AlexaFluor 488 1:1000 Goat A-11008 Thermos-Fisher Scientific 
Anti-mouse AlexaFluor 488 1:1000 Goat A-11001 Thermos-Fisher Scientific 
Anti-rabbit AlexaFluor 568 1:1000 Goat A-11035 Thermos-Fisher Scientific 
Anti-mouse AlexaFluor 568 1:1000 Goat A-11004 Thermos-Fisher Scientific 
Anti-rabbit AlexaFluor 633 1:1000 Goat A-21070 Thermos-Fisher Scientific 
Anti-mouse AlexaFluor 633 1:1000 Goat A-21050 Thermos-Fisher Scientific 
Phalloidin AlexaFluor 647 1:300 (0.3 U/ml)  A22287 Thermos-Fisher Scientific 
DAPI 1:10 000 (1 g/ml)  D1306 Thermos-Fisher Scientific 
Calcein-AM 1:2000 (2 M)  L3224 Thermos-Fisher Scientific 
Et-H1 1:500 (4 M)  L3224 Thermos-Fisher Scientific 
2.6.3 Scanning Electron Microscopy (SEM) 
Scanning Electron Microscopy (SEM) was performed on both GelMA and collagen cell-
laden hydrogels in order to visualise their nano-structure and cell-matrix interaction patterns. 
Imaging was performed with the help of Russell Bailey (lead technician, Nanovision Lab, 
Queen Mary University of London). Hydrogels were prepared as previously described with 
a 3.5 x 103 cells/ml initial cell density (both as monocultures and PANC-1, THP-1, CAF 
triple cultures) and cultured in both 5% GelMA and collagen hydrogels for 14 days. Samples 
were fixed for >24 h with 4% PFA at room temperature. To dehydrate the hydrogels, these 
were immersed in sequential ethanol solutions of increasing concentration (25%, 50%, 70%, 
80%, 90%, 95%, 100%), twice in each solution for 5 min. Samples were then dried in a K850 
critical point dryer (Quorum Technologies). Specimens were placed in a ‘Mini’ sputter coater 
(Quorum Technologies) for gold coating (current of 20 mA, resulting in 10nm gold film 
thickness). Samples were imaged on an Inspect F50 microscope (FEI).  SEM micrographs 
fibres thickness was quantified via ImageJ (NIH) from 4 distinct gels. 
Antibody Dilution Species Clonality Cat. number Supplier 
SMA 1:70 Rabbit pAb ab5694 Abcam 
FN 1:100 Rabbit pAb ab2413 Abcam 
KRT19 1:200 Rabbit EP1580Y ab52625 Abcam 
p-H2A.X (Ser139) 1:500 Mouse JBW301 05-636 Merck 
VIM 1:100 Mouse mAb M0720 Dako 
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2.6.4 Sectioning, histology and immunostaining 
2.6.4.1 Specimen embedding and sectioning 
Primary PDAC and HGSOC tumours, GelMA and collagen hydrogels were fixed in 4% PFA 
for >24 h, placed in 70% ethanol and sent for paraffin embedding and sectioning by the 
Barts Cancer Institute Pathology unit. Samples were sliced into 7 µm sections on a 
microtome, mounted onto glass slides and deparaffinised with xylene, 100% ethanol and 
70% ethanol solutions (10 min each). The sections were then rehydrated with distilled water. 
After deparaffinising, slides were used for either haematoxylin and eosin (H&E) staining, 
Masson’s trichrome staining, immunohistochemistry (IHC) staining, or IF staining as 
described above. 
2.6.4.2 Haematoxylin and eosin (H&E) 
H&E staining was performed in order to visualise cell nuclei, cytoplasm and ECM with 
Mayer’s haematoxylin for 5 min and eosin Y (Sigma-Aldrich) for 10 min by the Barts Cancer 
Institute Pathology unit. 
 
2.6.4.3 Masson’s trichrome  
Masson’s trichrome staining kit (all Sigma) was used in order to visualise collagen fibres 
(blue), keratins and muscle fibres (red) and nuclei (black) in both tissues and hydrogels. 
Briefly, after deparaffinising, slides were submerged in warm (60°C) Bouin’s solution, 
followed by Weigert’s solutions A and B and the working Weigert’s Iron Haematoxylin 
solution for five minutes. Next, the slides were washed in tap water prior to incubation in 
the Biebrich Scarlet/Acid Fuchsin Solution for 15 minutes. Following another wash in 
deionised water, the slides were incubated in phosphomolybic/phosphotungstic acid for 15 
min and then aniline blue solution for 10 min. Following washing in deionised water slides 
were incubated in 1% acetic acid for 5 min. Slide dehydration was performed with two 
subsequent washes in 95% ethanol and 100% ethanol (Thermo-Fisher Scientific), xylene 
(Thermo-Fisher Scientific) and mounted in DPX (Sigma-Aldrich) with a coverslip (VWR). 
Definiens Tissue Studio software (Definiens AG) was used with a modified protocol for the 
analysis and quantification of stained areas (blue) over total area. Fibres and fibre bundle 
thickness was measured using CaseViewer (3DHISTECH) for 4 matched patient tissues in 
3 random fields of view and 5 spots each.  
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2.6.4.4 Immunohistochemistry (IHC) 
10x Tris-buffered saline (TBS) was made as follows: 1.5M NaCl (Sigma-Aldrich), 200mM 
Trizma base (Sigma-Aldrich) in deionised H2O (dH2O), pH adjusted to 7.6 with >20 ml 
hydrochloric acid (Thermo-Fisher Scientific). TBST was made by dilution TBS 1:10 in dH2O 
with 0.05 % v/v Tween 20 (Sigma-Aldrich). The staining shown and antibody dilution 
optimisations were performed in part by Dr Juliana Candido, Shreya Sharma or Niamh 
Leonard. Heat-induced antigen retrieval was performed at 95°C for 20 min in a water bath 
in sodium citrate buffer (pH 6) unmasking solution (Vector Laboratories). Endogenous 
horseradish peroxidase (HRP) activity was blocked with 0.6% hydrogen peroxide (Thermo-
Fisher Scientific) in methanol for 20 minutes. Primary antibody (Table 2.4) was diluted in 
antibody diluent (Zytomed Systems) and incubated at room temperature for 1 h or overnight 
at 4C, followed by 3 washes in TBST and incubation with HRP-conjugated secondary 
(Invitrogen) for 1 h at room temperature. Meanwhile, Vectastain ABC HRP solution (Vector 
Laboratories) was prepared according to manufacturer’s instructions and, after 3 washes in 
TBST, was incubated onto the slides for 1 h. Brown colour development was achieved with 
a 3,3'-diaminobenzidine (DAB)–based Super Sensitive Polymer-HRP IHC detection system 
(Biogenex). Mayer’s haematoxylin (Sigma-Aldrich) served as counterstain. Sections where 
subsequently dehydrated in 100% ethanol and two xylene incubations of 5 minutes each. 
Sections were sealed with DPX mountant (Sigma-Aldrich) and imaged on a Pannoramic 250 
Flash III scanner (3DHISTECH). Positive and negative control tissues were stained for all 
antibodies during the optimisation phase. Definiens Tissue Studio software (Definiens AG) 
was used for the analysis and quantification of stained areas (brown) over total area. 
Expression of the protein of interest was quantified as (%) staining as follows: 
% 𝑆𝑡𝑎𝑖𝑛𝑒𝑑 𝑎𝑟𝑒𝑎 = (
𝐼𝐻𝐶 𝑚𝑎𝑟𝑘𝑒𝑟 𝑎𝑟𝑒𝑎 (𝑏𝑟𝑜𝑤𝑛)
𝑡𝑜𝑡𝑎𝑙 𝑡𝑖𝑠𝑠𝑢𝑒 𝑎𝑟𝑒𝑎
) × 100 
In collagen and GelMA hydrogels, the staining was further quantified by selecting 8 
spheroids or cell aggregates at random for each hydrogel. Percentage (%) of staining was 
therefore quantified in proximity of cell clusters to avoid noise and quantification of the 
staining coming from the hydrogel (which often stained brown, as in the case of COL-1 and 
FN1). A modified protocol was optimised on Definiens (Definiens AG) for the 
quantification of collagen fibres (blue) on Masson’s Trichrome staining. 
  
Materials and Methods 
- 85 -
Table 2.4 Staining reagents, primary and secondary antibodies used for immunohistochemistry. 
Antibody Dilution Species Clonality Cat. number Supplier 
Biotinylated HABP 1:100 Stain 385911 Merck 
CD68 1:50 Mouse PG-M1 ab783 Abcam 
COL-1 1:3000 Rabbit EPR7785 ab138492 Abcam 
FN1 1:500 Rabbit pAb F3648 Sigma-Aldrich 
KRT19 1:400 Rabbit EP1580Y ab52625 Abcam 
VCAN 1:250 Rabbit pAb HPA004726 Sigma-Aldrich 
αSMA 1:200 Rabbit pAb ab5694 Abcam 
Biotinylated anti-rabbit IgG 1:200 Goat BA-1000 Vector Lab 
Biotinylated anti-mouse IgG 1:200 Horse BA-2000 Vector Lab 
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2.7 Hydrogel digestion, cell retrieval and viability assessment 
2.7.1 GelMA hydrogel digestion 
GelMA hydrogel digestion for retrieval of cells with a high viability had not been previously 
optimised. Five approaches were used to digest cell-laden GelMA-based hydrogels (Table 
2.5). Their efficiency in hydrogel degradation, and viability of recovered cells was assessed 
via flow cytometry. We published this method in Methods in Molecular Biology, 2019 235.  




Name, origin, diluent Working 
concentration 
Catalogue number 
1 Trypsin/EDTA 0.5%/0.2% Sigma-Aldrich 59418C 
2 Collagenase I from Clostridium histolyticum in 
serum-free DMEM 
1 mg/ml Life Technologies 
17018029 
3 Collagenase V from Clostridium histolyticum in 
Hank's Salt Balanced Solution 
1 mg/ml Sigma-Aldrich C9263 
4 Dispase II from Bacillus polymyxa in PBS 2.5 U/ml Stem Cell Technologies 
7913 
5 Collagenase XI from Clostridium histolyticum 
and Dispase II from Bacillus polymyxa in 




Stem Cell Technologies 
7913 
GelMA hydrogels were incubated with the above solutions until digestion was complete (20- 
40 min) and then taken for flow cytometry staining as described in the “flow cytometry” 
section below. 
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2.8 Gene expression analyses 
2.8.1 RNA extraction from 3D cell cultures 
Gene expression was assessed by reverse transcription–quantitative polymerase chain 
reaction (RT-qPCR). Cells were either detached from monolayers for 2D expression analysis 
or cultured for 14 days in either GelMA or collagen hydrogels as previously detailed. Six 
hydrogels were pulled for this analysis into one gentleMACS orange tube (Miltenyi Biotec) 
containing 600 µL of TRIzol Reagent (Invitrogen). Hydrogels were disrupted with a 
gentleMACS Dissociator tissue homogeniser (Miltenyi Biotec) using an RNA program for 
84 seconds. Tubes were then spun at 1000 g for 3 minutes to collect homogenised hydrogel 
at the bottom of the tube. This procedure was repeated three times, after which the 
homogenised solution was moved to a RNAse-free tube (Ambion). Chloroform (Sigma-
Aldrich) was added as 1/5 of the TRIzol volume, vortexed, and centrifuged at 16 000 g for 
15 minutes to allow RNA separation. The aqueous fraction was moved to a fresh tube 
(Ambion) and mixed with equal amounts of isopropanol (Sigma-Aldrich) in order to 
precipitate the RNA. Following centrifugation at 16 000 g for 30 min, further precipitation 
was achieved by sequential washes with 70% ethanol/water and 100% ethanol, with 16 000 
g for 5 min centrifugation step following each. Samples were left to air-dry for > 30 min and 
dissolved in RNAse-free water (Ambion). RNA quality and concentration were measured on 
a Nanodrop 2000 spectrometer (Thermo-Fisher Scientific). 
2.8.2 RT-qPCR 
RNA amounts were normalised to 500-1000 ng of total RNA and reversed transcribed with 
a High-Capacity cDNA Reverse Transcription kit (Thermo-Fisher Scientific) on a T100 
thermal cycler (Biorad) following manufacturer’s instructions. Briefly, temperature was held 
at 25C for 10 min, then raised to 37C for 2 h to allow reverse transcriptase activity and 
lastly at 85C for 5 min to ensure enzyme denaturing. The resulting cDNA solutions were 
diluted 1:40 and stored at −20 °C. For qPCR, a total 10 µL reactions were prepared by mixing 
4 µL of cDNA to 0.5 µL of gene-specific primers (Thermo-Fisher Scientific, see Table 2.6), 
0.5 µL of HPRT1 housekeeping probe (Thermo-Fisher Scientific) and 5 µL of TaqMan 2x 
Master Mix (Thermo-Fisher Scientific) in a minimum of duplicates in a PCR 96-well plate 
(Thermo-Fisher Scientific). Plates were sealed with PCR film (Thermo-Fisher Scientific) and 
run on a StepOnePlus Real-Time PCR System (Thermo-Fisher Scientific). The thermal 
cycling conditions used were two hold phases at 50C and 90C for 2 and 10 min respectively, 
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a 15 seconds denaturation step at 95C, a primer annealing and extension phase at 60C for 
1 minute, repeated for 40 cycles. Alternatively, qPCR was carried out using the SYBR Green 
method. For this, cDNA solutions were diluted to 5 ng/µL for storing. A total 10 µL reaction 
was prepared in 384-well PCR plates (Thermo-Fisher Scientific), by adding 2 µL of cDNA 
to 5 µL of PerfeCTa SYBR Green FastMix Low Rox (Quanta Biosciences), 2.8 µL of RNase-
free water (Invitrogen), 0.2 µL of gene-specific primers and run on a QuantStudio 7 system 
(Applied Biosystems) (see Table 2.7). RPS13 was used as housekeeping gene internal control. 
Results were interpreted using the Ct method with expression normalised to housekeeping 
gene. Relative expression was calculated as follows: 
𝐸𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 = 2(𝐶𝑡(ℎ𝑜𝑢𝑠𝑒𝑘𝑒𝑒𝑝𝑖𝑛𝑔)−𝐶𝑡(𝐺𝑂𝐼)) 
where GOI is the target gene of interest and housekeeping refers to HPRT1 or RPS13. 
Table 2.6 qPCR TaqMan primer details, all Thermo-Fisher Scientific. 
Target gene Exons targeted Amplicon length 
(bp) 
Fluorophore and quencher 
COL11A1 Hs01097664_m1 56 FAM-MGB 
COL1A1 Hs00164004_m1 66 FAM-MGB 
CTSB Hs00947439_m1 99 FAM-MGB 
FN1 Hs01549976_m1 81 FAM-MGB 
HPRT1 Hs02800695_m1 82 VIC-MGB 
MMP9 Hs00957562_m1 67 FAM-MGB 
TGFBI Hs00932747_m1 63 FAM-MGB 
VCAN Hs00171642_m1 72 FAM-MGB 
VIM Hs00958111_m1 65 FAM-MGB 
YAP1 Hs00371735_m1 64 FAM-MGB 
Table 2.7 qPCR SYBR Green primer details. 
Target 
gene 
Forward primer Reverse primer Amplicon 
length (bp) 
CDH1 CCCACCACGTACAAGGGTC CTGGGGTATTGGGGGCATC 94 
MMP2 GTGAAGTATGGGAACGCCGA AGAAGCCGTACTTGCCATCC 154 
MMP3 CACTCACAGACCTGACTCGG CATCCACGCCTGAAGGAAGA 20 
MMP9 TTCTGCCCGGACCAAGGATA ACATAGGGTACATGAGCGCC 109 
RPS13 TCGGCTTTACCCTATCGACGCAG ACGTACTTGTGCAACACCATGTGA 153 
TIMP1 GGGGATGCCGCTGACATCCG CTCGCTGCGGTTGTGGGACC 87 
VIM GACAATGCGTCTCTGGCACGTCTT TCCTCCGCCTCCTGCAGGTTCTT 236 
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2.8.3 RNA-sequencing 
RNA-sequencing (RNA-seq) sample preparation, RNA extraction optimisation and quality 
controls were performed with Dr Juliana Candido. For transcriptomics analysis, RNA was 
extracted from BxPC-3 and PANC-1 cells cultured in collagen, 5% GelMA and 7.5% GelMA 
for 7 days with an initial cell seeding density of 7 x 105 cells/ml. As an additional comparison, 
primary PDAC cells (from patients 12556, 12560 and 12975) were grown as organoids in 
Matrigel basement membrane matrix (BD Biosciences) by Dr David Osuna de la Peña. 
Hydrogels were formed by mixing 25 000 cells with 100 µL of Matrigel, stabilised for 10 
minutes, and cultured for 7 days in DMEM/F12 (Gibco) supplemented with 2% B27 
(Gibco), 20 ng/mL FGF-2 (PeproTech UK) and 2 mM L-glutamine (Gibco). 
 
RNA extraction was performed as described above, with 6 hydrogels pulled for each 
condition, in duplicates for each stiffness/cell line (for a total of 6 conditions + 3 Matrigel 
organoids conditions). After removal of the aqueous phase, RNA clean-up was performed 
using a RNeasy Mini kit (Qiagen) following the manufacturer’s instructions and stored at 
−80 °C prior to processing. As an additional quality control, the RNA Integrity Number 
(RIN) was measured using a High-Sensitivity D1000 Screen Tape system (Agilent) and run 
on a 4200 TapeStation (Agilent). RNA with RIN<8 was excluded from sequencing. Total 
RNA (100 ng) in water was prepared in fully skirted 96-well plate (Thermo-Fisher Scientific), 
sealed with film (Thermo-Fisher Scientific) and sent on dry ice for poly-A capture sequencing 
by the Oxford Genomics Centre (Oxford, UK). RNAseq bioinformatics data analysis and 
graphing was entirely performed by Dr Eleni Maniati.  
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2.9 Protein expression analyses 
2.9.1 Protein extraction from 3D cultures 
Protein extraction from GelMA hydrogels for downstream immunoblotting analysis had not 
been previously optimised. For this, digestion with 0.3 mg/ml Liberase (Roche) was 
attempted, as this enzyme is routinely used for tissue dissociation and is posed to increase 
the quality and reproducibility of dissociation compared to Clostridium histolyticum’s traditional 
collagenase. This method was efficiently used for protein extraction from cell-containing 
collagen and GelMA hydrogels, at day 14 of culture unless otherwise stated. Hydrogels were 
incubated for 30 minutes in PBS at 37C to allow medium and FBS to diffuse out of the 
hydrogel (as these have been found to give false positive results during protein 
quantification). Six to eight hydrogels per condition were pulled into one vial (Eppendorf) 
containing 1 ml of 0.3 mg/ml Liberase (Roche) dissolved in serum-free DMEM (Gibco). 
Vials were placed on a heated 37C Brunswick Innova 40 shaker (Eppendorf) at 100 rpm 
for 20 min. After 10 min the content of the vials was pipetted vigorously with a P1000 
(Gilson) to speed the digestion process with mechanical disruption. (Complete) Radio-
Immunoprecipitation Assay (RIPA) buffer was prepared as follows: 10 ml RIPA buffer 
(Thermo-Fisher Scientific) one tablet of protease inhibitor cocktail I (Roche), and 1% 
phosphatase inhibitor cocktail II (Sigma-Aldrich). After digestion, vials were centrifuged at 
4C for 5 minutes at 16 000 g, resuspended in 30 l of complete RIPA buffer (Thermo-
Fisher Scientific), vortexed and incubated on ice for 15 minutes. The centrifugation step was 
repeated, the clear aqueous phase was collected in a fresh tube (Eppendorf) and samples 
were aliquoted and frozen at -80C. 
2.9.2 Flow cytometry 
Flow cytometry buffer was prepared as follows: 2.5% wt/vol BSA (Sigma-Aldrich), 2 mM 
EDTA (Ambion) in PBS (Sigma-Aldrich), adjusted to pH 7.2. Characterisation of cell 
viability was conducted following cell retrieval from GelMA hydrogels to establish the 
efficiency of hydrogel digestion. Following retrieval, cells were centrifuged, resuspended in 
flow cytometry buffer (2.5% BSA/2mM EDTA/PBS), stained with Ca-AM (50 μM) for 
viable cells and DAPI (1 µg/ml) and EtH1 (20μM) for dead cells. Appropriate fluorescence 
minus one controls were used, as well as unstained and stained 2D-culture live and dead cells 
as positive and negative controls. A condition with 50:50 live:dead cells was created by mixing 
GelMA-recovered cells with ethanol killed cells in a 1:1 ratio. Flow cytometry data was 
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acquired on LSR Fortessa I Cell Analyser (BDBIoscience). Data analysis was performed in 
FlowJo version 10.0.8 (Treestar Inc.). A detailed protocol can be found in our publication 
235. 
 
Flow cytometry was also used for the characterisation of patient-derived fibroblasts after 
isolation from tissues and ascites. For this, cells were detached from the plate, resuspended 
in 0.5 ml of flow cytometry buffer, stained with 1:20 α-SMA (APC, Biolegend), 1:20 FAP 
(PE, Biolegend), 1:100 EpCAM (AF488, Thermo Fisher Scientific) in flow cytometry buffer 
and incubated for 20 min in the dark. After washing, 1:450 Fixable Viability Dye (Biologend) 
in PBS was added and incubated for 25 minutes. After washing, cells were resuspended in 
4% paraformaldehyde for 10 minutes at RT, washed twice in flow cytometry buffer and 
acquired on LSR Fortessa I Cell Analyser (BDBIoscience) the following day. 
2.9.3 Electrophoresis and Western blotting 
Protein concentration was determined with a Pierce BCA protein assay kit (Thermo-Fisher 
Scientific) following manufacturer’s instructions. Samples were normalised to 18 µg unless 
otherwise stated, to which were added 5 l of NuPAGE LDS Sample buffer (Invitrogen), 2 
l of NuPAGE Sample Reducing Agent (Invitrogen) and adjusted to a final volume of 20 
l. Samples were denatured at 90 °C for 10 min. 3-(N-morpholino)propanesulfonic acid 
(MOPS) running buffer was prepared as follows: 50ml NuPAGE® MOPS sodium dodecyl 
sulphate (SDS) running buffer (20x) (Thermo-Fisher Scientific) in 950 ml of dH2O, 0.25% 
NuPAGE antioxidant (Thermo-Fisher Scientific). Protein separation was performed via 
SDS-PAG Electrophoresis with 4-12% NuPAGE Bis-Tris precast gels (10- or 15-well, 
Invitrogen) in MOPS running buffer with 0.25% NuPAGE antioxidant (Thermo-Fisher 
Scientific) at 100 V for 1.5 h. Next, transfer buffer was prepared as follows: 50ml NuPAGE® 
transfer buffer (20x) (Thermo-Fisher Scientific), 200 ml methanol (Thermo-Fisher Scientific) 
in 750ml of dH2O. A this point a GelCode Blue Safe Protein Stain (Thermo-Fisher Scientific) 
was performed on the gel or, alternatively, proteins were blotted onto a polyvinylidene 
fluoride membrane by wet transfer in 20% methanol/NuPAGE Transfer Buffer (Invitrogen) 
at 60V for 2 h. Membranes were blocked in 5% wt/vol non-fat dry milk (Marvel)/TBST for 
1 h at room temperature and incubated with primary antibodies overnight unless otherwise 
stated (see Table 2.8). Polyvinylpyrolidine (PVP) was prepared by mixing 5% wt/vol 
Polyvinylpyrolidine (Sigma-Aldrich) in 1x TBST. Phospho-antibodies were diluted in 5% 
(PVP)(Sigma-Aldrich)/TBST while 5% milk (Marvel)/TBST was used for all other 
antibodies. Membranes were then washed in TBST, three times for 5 min each and incubated 
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with HRP-linked species-specific secondary antibody for 1 h at room temperature. ECL 
Prime Western Blotting detection reagent (GE Healthcare) was incubated with the 
membrane for 1 min prior to chemiluminescent detection on an Amersham Imager 600 (GE 
Healthcare) and analysed by densitometry on ImageJ (NIH). 
 
Table 2.8 Primary and secondary antibodies used for western blotting. 
 
ON=overnight; RT=room temperature; PVP=5% polyvinylpyrolidine/TBST; Milk=5% milk/TBST 
Antigen Dilution and 
incubation 






CDH1 1:1000, 1 h 
RT 
Milk Mouse 97 610182 BD 
Biosciences 
GAPDH 1:5000, 1 h 
RT 
Milk Rabbit 37 D16H11 Cell 
Signaling 
KRT19 1:1000, 1 h 
RT 





Milk Mouse 14 05-636 Merck 
p44/42 MAPK 
(Erk1/2) 
1:1000, 1 h 
RT 













PVP Rabbit 79/86 9145 Cell 
Signaling 
STAT3 1:1000, 1 h 
RT 
PVP Mouse 79/86 9139 Cell 
Signaling 
TUBA1A 1:5000, 1 h 
RT 
Milk Rabbit 50 11H10 Cell 
Signaling 
VCL 1:2000, 1 h 
RT 
Milk Mouse 117 SAB4200080 Sigma-
Aldrich 
VIM 1:1000, 1 h 
RT 

















Horse  7076 Cell 
Signaling 
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2.9.4 Analysis of secreted factors 
GelMA and collagen-cultured cell-secreted chemokines were analysed through the novel 
electrochemiluminescent multiplex immunoassay platform Meso Scale Discovery (MSD). 
This MSD V-Plex human Cytokine kit (MesoScaleDiscovery) was used to measure the levels 
of 30 human cytokines in single samples, IFN-γ, IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, 
IL-8, IL-10. A total of 40 conditions were run on this assay, including supernatant from 
BxPC-3 and PANC-1 cells cultured in collagen, 5% and 7.5% GelMA and triple culture 
hydrogels as detailed below. 
 
PANC-1 cells were grown either as monoculture or as triple culture in a 1:2:2 ratio with 
patient-derived CAFs and THP-1 for 14 days in either collagen, 5% or 7.5% GelMA. CAFs 
used for this experiment had been isolated from patient 3 (see Table 2.1). Appropriate 
monoculture controls were also included. Hydrogels were treated +/- fasudil (10 M, Tocris) 
on day 7 and +/- gemcitabine/abraxane (100 nm each, donation from St Bartholomew’s 
Hospital) as detailed in ROCK inhibitor and Chemotherapy: combinational studies. On day 
14 of culture, supernatant was pulled for each condition into a single tube (Eppendorf), 
centrifuged at 1000 g for 5 min to remove cellular residuals and stored at -80C. The MSD 
Cytokine kit (Meso Scale Discovery) was run in duplicates for each condition by Dr Juliana 
Candido, as per manufacturer’s instructions. Plates were read on a MSD plate reader model 
1250 (Meso Scale Discovery), in three separate batches. In order to account for inter-batch 
variability, values were normalized to controls present on each respective plate to generate a 
‘fold change’ score compared to the controls. 
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2.10 Statistical analysis 
All images, including micrographs, immunofluorescence, immunoblots, etc., were processed 
and analysed using ImageJ (NIH, US) with the exception of immunohistochemistry staining 
which were processed using Definiens Tissue Studio software (Definiens AG). Output files 
from flat-end indentation testing were processed in MATLAB R2019 (MathWorks). RNAseq 
analysis was performed by Dr Eleni Maniati in R 3.5.2 (R Foundation). All other numerical 
data were analysed and plotted on Prism v8.3 (GraphPad). 
 
A Shapiro-Wilk test was used to check for data’s normality. Significance was tested with a 
two-samples t-test (for normally-distributed data) or Mann-Whitney U test (for non-
parametric data) and presented as mean ± standard deviation (SD), unless otherwise stated. 
Analysis of variance (ANOVA) with Bonferroni correction and Tuckey post-hoc analysis 
was used for comparisons amongst multiple groups, Kruskal-Wallis one-way ANOVA was 
used for non-parametric dataset comparisons. The statistical test conducted is explicitly 
stated in the caption of the corresponding graphs. Significance was conventionally 
reported as p≤0.05 (*), p≤0.01 (**), p≤0.001 (***). 
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3.1 Background 
A high ECM content, stiffness and desmoplasia have been associated with poorer prognosis 
across a number of solid tumours, including PDAC and HGSOC 130,259. In the pancreas, 
increased ECM remodelling and cross-linking result in progressive tissue stiffening 
concordant with disease progression from normal tissues (1 kPa) to PanIN (2 kPa) and 
PDAC (4 kPa) 128. Pancreatic cancers are in fact, amongst the stiffest solid tumours 128, and 
this is reflected in the presence of a highly desmoplastic stroma. This increased matrix 
stiffness is documented to stimulate a number of pro-survival signalling pathways and cell 
behaviours including EMT 128, cell invasion 129, and treatment response 134,265. Despite its 
established role in promoting tumorigenesis, the stiffness of patient-derived, fresh tumour 
tissues has not been extensively characterised in the organs of origin in either PDAC or 
HGSOC. Thus far, only two groups have investigated the effect of PDAC tissue stiffness on 
disease progression on murine128 and human130 specimens. Work performed in our Centre 
has previously shown a positive correlation between tissue stiffness and extent of disease in 
a multi-layered tumour microenvironment (TME) analysis of the omental metastases of 
HGSOC 123,259. Therefore, I firstly aimed to characterise the biomechanics of diseased 
pancreas and ovary tissues and compare them to their healthy counterparts. 
 
Recent work in HGSOC 259 began to shed some light into a common matrix signature (the 
‘matrix index’) that is associated with poor prognosis and increased matrix stiffness. 
Although it was first characterised in HGSOC, this matrix signature was found to be a 
common denominator in a number of solid tumours including PDAC. Fibronectin (FN1), 
versican (VCAN) and collagen type-I alpha-1 (COL1A1) are part of this signature. Therefore, 
in addition to mechanical characterisation, I began investigating the ECM landscape and 
matrix proteins involved in increased tissue fibrosis and stiffness which, in PDAC, are poorly 
characterised.  
 
Lastly, I sought to show that recapitulation of the measured stiffness could be achieved 
through the use of modular 3D cell culture platforms. For this purpose, I began 
characterising the mechanical properties of hydrogels commonly used for 3D cell culture 
(namely collagen type-I hydrogels) and that of semi-synthetic hydrogels, gelatin methacryloyl 
(GelMA). A simple adjustment in the initial GelMA polymer concentration (%wt/vol), and 
crosslinking time during hydrogel synthesis, resulted in a range of stiffness which was 
measured using unconfined compression and predicted with a simple mathematical model. I 
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hereby describe a thorough characterisation of the mechanical properties of GelMA 
hydrogels and how they can be exploited to model tissue stiffness in vitro. Matrix protein 
expression in these matrices was also investigated. This chapter provides the biomechanical 
framework in which the functional and transcriptomics characterisation of GelMA-
embedded cells were later conducted.  
3.2 Aim and objectives 
In this Chapter, differences in stiffness between tumour-bearing and tumour-naïve tissues, 
as well as any direct correlations with matrix production, will be characterised and quantified. 
The biomechanics of human tissues will then be recapitulated using different 3D cell culture 
hydrogel models. 
I will investigate: 
• Alterations in tissue stiffness during disease progression in PDAC and HGSOC 
• Involvement of matrix proteins in the modulation of stiffness 
• Whether tissue stiffness can be mimicked and maintained in different 3D models 
• Whether matrix production can be replicated upon cell culture in 3D models. 
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3.3 Results 
3.3.1 Tissue stiffness is directly modulated by tumour burden 
Flat-end indentation testing was conducted in order to quantify the mechanical properties of 
human tumour tissues and compare them to tumour-naïve tissues. Young’s modulus (E) 
describes the stiffness of a given material and is defined by the relationship between stress 
(the force per unit area applied during indentation) and strain (the directional deformation 
of the specimen) during unidirectional deformation. Tissue modulus was measured on 5 
normal and 3 diseased human ovary specimens as well as 4 matched (diseased and adjacent 
normal, total 8) and 2 diseased human pancreas samples. I hypothesised that tumour burden 
would impact the biomechanics of a sample at a whole-tissue level. 
 
 
Figure 3.1 Schematic representation of patient-derived tissue analysis. Macroscopic images of human 
pancreas specimen and human ovary specimen (both non-diseased). Samples were taken for indentation testing 
in order to assess their mechanical properties. The setup included an Instron 5967 machine with a stage, sample 
holder, mobile 10N load cell and metallic indenter head. Green tissue dye was applied onto the indenter head 
just before testing. The sample was fully submerged in PBS during this procedure. The tissue dye marked the 
indentation spots after testing, therefore the sample could be fixed and taken for embedding ad sectioning, 
vertically along the indentation axis. 
A 10 N load cell equipped with a flat, rigid cylindrical indenter head was used to measure 
tissue modulus of fresh, unfixed and fully-hydrated samples. The strain range was set at 20-
30% with a 1% per second rate, meaning the sample was compressed to a maximum of 30% 
of its initial height in order to preserve tissue integrity. The deep modulus, defined as the 
modulus reached in the 10-30% strain region, was used for this analysis and graphed. 
Relaxation of the tissues was also measured. This is defined as the percentage recovery that 
the sample achieves after deformation, along the axis on which such deformation happened. 
For all analysed tissues, relaxation was near or >100% indicating the tissues exhibit a highly 
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viscoelastic behaviour. A green tissue dye was used on the indenter head during this process, 
allowing to exactly locate the indentation sports once the tissue had been sectioned. This 
allowed to perform direct correlation analyses between local tissue stiffness and protein 
expression as shown in Figure 3.1. 
 
Mechanical testing of PDAC and tumour-adjacent normal tissues revealed a significant 
increase in Young’s modulus in tumour compared to normal tissues (Figure 3.2). After 
indentation, histological analysis was performed to ensure the specimen either showed a 
normal pancreas structure or the typical PDAC features (Figure 3.3). The Young’s modulus 
(10-20% strain) of histologically normal tissues was found to be 2.2 ± 0.2 kPa (n=4, mean ± 
SEM) while the modulus of tumour tissues was 7.4 ± 0.6 kPa (n=6), indicating a significant 
increase in tissue stiffness (Figure 3.2 a). Additionally, when plotted on a single histogram, 
the frequency of PDAC and normal tissues stiffness values produced two distinct peaks 
(Figure 3.2 b), indicating a separation in the value distributions. In the ovaries, the Young’s 
modulus (20-30% strain) did not significantly differ in diseased tissues (8.52 ± 1.13 kPa, n=3) 
compared to healthy samples (8.85 ± 1.71 kPa, n=5), and this was reflected in the stiffness 
value frequency distribution plot, where the two peaks overlap with no clear separation 
(Figure 3.2 c-d). 
 
It is worth mentioning that all “normal” and “healthy” ovary tissues had been removed 
during surgeries aimed at reducing the risk of some other gynaecological disorders, such as 
endometriosis in the case of oophorectomy. Bearing of another disease may have, per se, 
affected the stiffness of the “normal” ovaries due to local inflammation or abnormal 
function. For the analysis of ovarian tissues, five normal ovaries, one ovarian cancer and two 
high grade serous tissues were analysed. All HGSOC samples were from patients that had 
previously undergone chemotherapy which, in turn, would have affected the quality of the 
resected tissue, tumour, and its biomechanics. This might help explain why very little 
difference is seen in healthy versus diseased ovaries. Similarly, all matched “normal” 
pancreatic tissues were taken from patients with pancreatic cancers in a different site of the 
pancreas, but they underwent accurate histological characterisation following mechanical 
testing to ensure they could be classified as such. Our group did not have access to healthy 
pancreas as collection was not covered by the “Barts Pancreatic Tissue Bank” ethics. 
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The use of green dye on the indenter head allowed to precisely locate the indentation spots 
from each tissue sections (Figure 3.3 a-b). Haematoxylin and eosin (H&E) micrographs 
(Figure 3.3 c, purple circles) showed the structure of normal pancreas with the typical acinar 
cell morphology. On the right (Figure 3.3 c, blue circles), the typical histomorphology of 
PDAC showed small to medium-sized irregular glands dispersed in a dense, desmoplastic 
stroma, consisting of ECM proteins, stromal and inflammatory cells (Figure 3.10, Figure 
3.11) 5. Neoplastic regions were characterised by a loss of the triangular acinar cell 
morphology. The irregular PDAC tumour glands resembled disorganised ducts and were 
morphologically extremely heterogeneous within and between patients. Other histological 
features that contribute to the grading and staging of PDAC include variability in cell size, 
shape and number (pleomorphism), nuclei (polymorphous) and mitotic state 5.  
Figure 3.2 Stiffness analysis of fresh human (a-b) PDAC and (c-d) OvCa tumours and respective 
normal tissues. (a) Young’s modulus of adjacent normal tissues (2.2 ± 0.2 kPa ) and matched PDAC tissues 
(7.4 ± 0.6 kPa), n= 4 adjacent normal tissue and n=6 PDAC specimens, t-test <0.0001; (b) Pancreatic tissues 
stiffness values frequency histogram with distribution overlay reveals normal distribution of the two datasets 
with separated peaks, 4.86 kPa ± 3.23 kPa, 2 bin width (grey=number of adjacent tissue stiffness values, 
red=number of PDAC stiffness values); (c) Young’s modulus of normal ovaries (8.85 ± 1.71 kPa) and non-
matched OvCa tissues (8.52 ± 1.13 kPa), n=5 normal ovaries, n=2 HGSOC chemo-treated samples , n=1 
OvCa treatment-naive sample, Mann-Whitney U test p=0.53; (d) Ovarian tissues stiffness values frequency 
histogram with distribution overlay reveals non-normal distribution of the datasets with no clear peak 
separation, 8.71 ± 5.88 kPa, 2 bin width (grey=number of normal ovary stiffness values, red=number OvCa 
stiffness values) 
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To summarise, pancreatic tissue Young’s moduli were significantly increased in tumour 
tissues compared to “adjacent normal” tissues. Such difference was not observed in the 
ovarian specimens when comparing “normal” ovaries to HGSOC ovaries; however, the 
latter group had a sample size which was too small to infer any significant differences.  
Figure 3.3 Representative haematoxylin and eosin (H&E) staining of (a) adjacent normal tissues and 
(b) PDAC tissues post-indentation. Green tissue dye marked the exact indentation spots, to which its 
specific Young’s modulus value could be assigned. H&E micrographs depict a distinct desmoplastic reaction 
and altered structural features in diseased pancreas compared to its normal counterpart. Scale bars, 500 m, 
inserts 50 m; (c) Representative H&E staining of adjacent normal (purple circles) and diseased (blue circles) 
tissues from patients 19-26 (see Table 2.1). Scale bar applies to all, 50 m. 
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3.3.2 High ECM protein content correlates with tissue stiffness in PDAC 
In PDAC, increased desmoplasia, fibrosis and stiffness, accompanied by a loss of defined 
architectural features, such as the typical acinar cell structures, was already evident when 
looking at the H&E staining (Figure 3.3). For further characterisation, I submitted normal 
and PDAC samples for immunohistochemical (IHC) analysis after mechanical testing. 
Following on from the work of Pearce et al. 259, I sought to investigate and quantify the 
expression of proteins that are linked with poor overall survival and may be part of a 
common matrix response in solid tumours. In particular, I was interested in determining any 
potential correlations between matrix protein expression and tissue stiffness, which has not 
been done in PDAC. 
 
IHC analysis was performed for FN1, VCAN, COL1 as well as Masson’s Trichrome (MT) 
on post-indentation samples. The overall amount of chromogen (% area), brown in the case 
of IHC and blue representing all collagens from MT staining, was quantified using the 
Definiens Tissue Studio software (Definiens). Whole tissue analysis on serial sections was 
used for this analysis. All the investigated matrix proteins were upregulated in PDAC tissues 
compared to tumour-adjacent normal tissues from the same patient (Figure 3.4), indicating 
that tumour cells play a role in increased stiffness as well as ECM production. Distal 
“normal” specimens taken from diseased patients still retained a typical pancreas histology 
with clear acinar cell morphology and limited intracellular matrix secretion. MT stains blue 
all collagens and some fibrous connective tissues, while pink or red represent the cytoplasm, 
keratins and muscle fibres. Darker brown/black features represent cell nuclei. High amounts 
of disorganised “blue staining” in PDAC samples was indicative of increased tissue fibrosis 
and deregulated collagens and matrix production. 
 
Despite the limited sample number, Definiens quantification of staining revealed a significant 
increase in the production of FN1 (p=0.018), VCAN (p<0.0001), COL1 (p=0.031) and 
overall collagens/connective tissue (p=0.022) in PDAC samples compared to matched 
tumour-adjacent normal samples (Figure 3.5). Collagen fibres and bundles thickness was 
quantified using CaseViewer (3DHISTECH) on the MT micrographs. Thickness analysis 
revealed an increase in collagen and connective tissue fibre diameter in PDAC tissues 
compared to tumour-adjacent normal (Figure 3.5 b). Diameter of fibres in PDAC tissues 
were over >4 times larger than adjacent tissues, suggesting single fibres might be merging 
together to form bigger bundles, contributing to crosslinking, fibrosis and tissue stiffening. 
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Figure 3.4 Immunostaining of the matrix proteins fibronectin (FN1), versican (VCAN), collagen-I 
(COL1) and Masson’s Trichrome (MT) staining in a representative human tumour-adjacent normal  
(left) and matched PDAC tissue specimen (right). For FN1, VCAN and COL1, positive cells are visualised 
with DAB staining (brown chromogen). MT micrographs (bottom row) stain blue for collagens and some 
fibrous connective tissue, black for nuclei and pink/red for cytoplasm, keratins and muscle fibers. Normal 
pancreas (left) retained an orderly architecture with a typical acinar cell structure accompanied by overall low 
FN1, VCAN, COL1 and total collagens staining. PDAC tissues (right) presented with a fibrotic architecture, 
no clear exocrine cell structures and an overall increase in tumour-associated matrix production. Representative 
micrographs from patient 21 (see Table 2.1) are shown. Scale bars apply to all 100 m, inserts 1000 m. 
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I therefore hypothesised that fibre disorganisation, thickness and increased matrix 
production may be directly responsible for the observed increased tissue moduli. In order to 
investigate this further, I measured the percentage area stained from the regions immediately 
below the green tissue dye and matched it with the tissue stiffness, to unveil potential 
correlations between local matrix production and local stiffness (Figure 3.6 a). The analysis 
was performed on stained tissues from patients 20, 21, 22 (see Table 2.1), with 1-3 
indentation points identifiable with green tissue dye in each sample. Of the three analysed 
proteins, VCAN expression showed the highest correlation with local stiffness (R2=0.812, 
p<0.0001), followed by FN1 (R2=0.634, p<0.001) and COL1 (R2=0.613, p=0.0172; Figure 
3.6 b). When taken alone (Figure 3.6 c), tumour samples showed lower correlation with 
stiffness (lower R2), and showed a positive significant correlation only in the case of VCAN 
and COL1 (despite lower p-values). Unfortunately, only a few specimens fitted the criteria 
for this analysis (n=3 patients), hence a larger sample cohort would be needed to ascertain 
the robustness of these results. In the case of tumour tissue analysis (Figure 3.6 c), a larger 
Figure 3.5 Expression of fibronectin (FN1), versican (VCAN), collagen-I (COL1), total collagen 
content (MT) and collagen fibre thickness is higher in PDAC compared to tumour-adjacent normal 
tissues. (a) Definiens Tissue Studio quantification of FN1, VCAN, COL1 and MT staining (representative 
micrographs shown in Figure 3.4). Each dot represents a different patient. For this analysis, stained percentage 
of total tissue area was calculated as follows: Positive protein area stained (%) = area IHC marker stained 
(m2)/total tissue area (m2). Mann-Whitney U-test, FN1 p=0.0178, VCAN p<0.0001, COL1 p=0.0305, total 
collagens p=0.0220. (b) Thickness quantification of collagen fibres and bundles in MT micrographs (blue 
staining), insert diameter 500 m for scale. For this, three fields of view were taken per tissue at 63x 
magnification with five random areas quantified in each. Each colour represents a patient: black=patient 18, 
blue=patient 21, white= patient 22, brown=patient 24. Fibres in PDAC tissues were significantly thicker (3.93 
± 0.23 m, n=60) compared to those in adjacent normal tissues (1.76 ± 0.11 m, n=45), Mann-Whitney U-
test p<0.0001.  
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sample pool would potentially allow to detect much higher interpatient variability, greatly 
affecting the outcome of the analysis. 
 
In summary, correlations between matrix protein expression and tissue stiffness both at a 
whole-tissue level and subsequently at a local level were shown in this section. Expression of 
FN1, VCAN, COL1 as well as total collagens were significantly increased in PDAC tissues 
compared to tumour-adjacent normal tissues. Analysis of Masson’s trichrome-stained 
collagen fibres revealed an increase in fibre size and bundle formation in diseased tissues. 
Finally, FN1, VCAN and COL1 were directly involved in matrix stiffening, as Young’s 
modulus positively correlated with percentage area stained for the tested matrix proteins in 
the exact area of testing.  
Figure 3.6 Correlation of precise local tissue stiffness and percentage stained area of FN1, VCAN and 
COL1 immediately below indentation location. (a) Green tissue dye (arrow) marked the exact location 
where mechanical testing (indentation) was performed. Green box (width 1 mm for scale) indicates the area, 
immediately below the testing area, which was used for staining analysis. Positive percentage area stained was 
calculated with the Definiens Tissue Studio software (Definiens). Representative micrographs show a low (left) 
and high (right) positive area staining of two different proteins (FN1 and VCAN) on the same tissue region 
(3.53 kPa); (b) XY plots of tissue stiffness (x-axis) and (%) positive area stained (y-axis) for FN1, VCAN and 
COL1. Semi-log curve fitting with 95% confidence band is shown, with line equation reported on the bottom 
right of each graph. Tissues from patients 20, 21, 22 (see Table 2.1) were used for this analysis. Spearman 
correlation, R2 on graph, p=0.0011 (FN1), p<0.001 (VCAN), p=0.017 (COL1). (c) XY plots of tissue stiffness 
(x-axis) and (%) positive area stained (y-axis) for FN1, VCAN and COL1. Linear fitting with 95% confidence 
band shown for tumour tissues only, p=0.25 (FN1), p=0.019 (VCAN), p=0.053 (COL1). 
a 
b 
adjacent normal tissue PDAC tissue 
Low % area stained High % area stained 
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3.3.3 A tuneable 3D model mimics tumour stiffness 
After characterising the stiffness of human tissues, I sought to investigate the mechanical 
properties of their murine tissue equivalents, as an additional comparison. Whole-tissue 
healthy ovaries and pancreas from female mice with Pax8-; Cre-p; p53 f/f; PTEN f/f; BrCa2 
f/wt background were used for this. Following this characterisation, the range and 
biomechanics of human tissues was recapitulated with the use of 3D models. The elastic 
modulus of commonly-used collagen type-I gels, as well as that of semi-synthetic gelatin 
methacryloyl (GelMA) hydrogels, was assessed and compared to human data. GelMA allows 
precise tuning of the resulting hydrogel’s mechanical properties through adjustment of the 
initial GelMA polymer concentration and crosslinking time. I was therefore able to establish 
a simple mathematical equation allowing the prediction of GelMA hydrogel stiffness based 
on the initial concentration (% wt/vol) and crosslinking time (min) used. 
 
The tissue modulus of murine tissues was characterised via flat-end indentation of fresh, 
unfixed samples, the same technique used for human samples. For GelMA hydrogels, 
Young’s modulus was calculated from whole-hydrogel compression data on an Instron 
E1000 machine and adjusted to be comparable to data obtained via indentation, as previously 
reported 263. Because collagen gels presented irregular topographies, and were too soft to be 
tested via either indentation or compression, their Young’s modulus was measured via 
rheometry on a Discovery Hybrid Rheometer (TA Instruments). 
Despite providing a molecular, immunological and architecturally complex 
microenvironment, murine tissues were extremely soft compared to healthy human 
equivalents (Figure 3.7 a) and were therefore not a viable option for the recapitulation of 
human tissue stiffness. Collagen gels presented as soft matrices (1 mg/ml = 1.26 ± 0.04 kPa) 
even at increased concentrations (8 mg/ml collagen = 1.44 ± 0.085 kPa; Figure 3.7 d). Other 
standard matrices, such as 4.4, 8, and 17 mg/mL Matrigel have a stiffness of approximately 
20, 70, and 300 Pa, respectively 266. The stiffness range achieved with GelMA hydrogels was 
much greater (1.1 ± 0.5 kPa to 17 ± 2.35 kPa) and was tuneable by simply altering the initial 
GelMA polymer concentration (3–10% wt/vol). Based on experimental Young’s modulus 
measurements, I optimised an equation which allowed the prediction of GelMA hydrogel 
stiffness based on UV crosslinking time and initial polymer concentration (Figure 3.7 b, d 
blue bars, 3% = 1.1 kPa, 5% = 3.4 kPa, 7.5% = 8.6 kPa, 10% = 16.6 kPa): 





(1 − 𝑒−(𝑡−𝐴)/𝜏))       with 3 ≤ C ≤ 20 and 5 ≤ t ≤ 30 
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Figure 3.7 Biomechanical characterisation of murine and human tissues, collagen and GelMA 
hydrogels reveals tuneability of this semi-synthetic platform. (a) Characterisation of the mechanical 
properties of murine healthy pancreas and ovaries by indentation shows that in mice, these organs are much 
softer than their human equivalents. Pancreas: murine 0.96±0.44 kPa (n=7), human 2.62±0.78 kPa (n=4), 
Mann-Whitney U-test p=0.005; ovary: murine 3.30±1.9 kPa (n=14), human 8.84±7.1 kPa (n=5), Mann-
Whitney U-test p=0.0069; (b) Measured Young’s modulus of 3-10% wt/vol GelMA hydrogels (black) matches 
predicted stiffness (blue) as obtained with through our optimised equation. Experimental values: 3% GelMA 
1.24±0.46 kPa, 5% GelMA 3.62±0.70 kPa, 7.5% GelMA 8.37±0.78 kPa, 10% GelMA 17.04±2.36 kPa. 
Predicted values:  3% GelMA= 1.1 kPa, 5% GelMA= 3.4 kPa, 7.5% GelMA= 8.6 kPa, 10% GelMA= 16.6 
kPa; (c) Experimental setup for compression testing of GelMA hydrogels included an Instron E1000 machine 
equipped with a 10N load cell. (d) Young’s modulus of acellular collagen (0.1-0.8% wt/vol) and GelMA (3-
10% wt/vol) hydrogels as measured by rheometry and unconfined compression respectively (n=9). The blue 
bars represent the predicted stiffness for 3-10% wt/vol GelMA hydrogels after 10 min of crosslinking with a 
365 nm wavelength. The Young’s modulus of fresh adjacent non-diseased pancreas and PDAC tissues as 
measured by flat-end indentation (n=4, 6). 
where the compressive modulus (E, kPa) of GelMA hydrogels was calculated based on 
GelMA polymer concentration (C, % wt/vol) and UV crosslinking time (t, min), with Emax 
corresponding to 7995, n=2.28, A=4.2 and τ =11.5. The modulus of cell-free GelMA 
hydrogels matched the prediction (Figure 3.7 d). Similarly to the human tissues, hydrogels 
exhibit highly viscoelastic properties reflected in high relaxation (~100%) values. Lastly, the 
stiffness of human tumour-adjacent normal and PDAC tissue samples closely resembled that 
of 5-7.5% GelMA hydrogels, hence why these conditions were chosen for treatment studies 
presented in Chapter 6. Collagen gels were used throughout this study as a soft matrix control 
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Next I wanted to ascertain whether the mechanical properties of the hydrogels were 
maintained upon incorporation of cells. For this I set up 3-10% (wt/vol) GelMA hydrogels 
with four commonly used PDAC cell lines: BxPC-3, Capan-2, MIAPaCa-2 and PANC-1. 
Cell-containing hydrogels were kept for 14 days in culture prior to mechanical testing. 
Hydrogel characterisation, functional analyses and viability of incorporated cells will be 
extensively described in Chapter 4. As shown in Figure 3.8 a, the stiffness of cell-containing 
GelMA hydrogels matched the prediction (n=5), where dotted lines represent prediction 
values for each stiffness. Hydrogel’s Young’s modulus was also maintained upon 
incorporation of the HGSOC cell line OvCar-4, as reported in our publication 235.  
 
 
Figure 3.8 GelMA hydrogels are a tunable and reproducible platform for 3D stiffness modulation, even 
upon cell incorporation. (a) Young’s modulus of cell-containing GelMA hydrogels at varying polymer 
concentrations (3-10% wt/vol) matched the prediction (dotted lines) upon incorporation of four PDAC cell 
lines at day 14 of culture. (b) Stiffness of 5% GelMA hydrogels using 5 different GelMA batches. Upon 
characterisation, Batch 1 showed low degree of methacryloyl substitution onto the gelatin backbone and was 
not used for 3D cell culture. Batches 2-5 produced hydrogels with consistent and reproducible stiffness. 
 
Five different GelMA batches were synthesised by my group (Batch 1-5), of which Batches 
3-5 were utilised in this thesis for 3D cell cultures. Figure 3.8 b shows no significant variation 
was found in the mechanical properties of hydrogels across the different batches used. The 
degree of methacryloyl substitution onto the gelatin backbone (GelMA’s “degree of 
functionalisation” or DoF) was found to affect the mechanical properties of the resulting 
hydrogels. In particular, lower degree of substitution resulted in lower hydrogel crosslinking 
ability and therefore softer hydrogels (as it was the case with Batch 1). Hydrogels from 
batches with a low degree of substitution (<65%) do not follow the stiffness prediction 
described above and were therefore not used for this project. Low-degree-substitution 
batches are, however, widely used throughout the literature and have been reported to be 
softer compared to high-degree-substitution batches 242. Quantification of the degree of 
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functionalisation for each batch will be detailed in Chapter 4, where the overall hydrogel and 
cell viability characterisation is analysed in more depth. 
 
Overall, GelMA represented a suitable system for in vitro stiffness modulation. The resulting 
hydrogels had a stiffness ranging from 1 to 17 kPa making it a highly modular system when 
benchmarked against commonly used collagen gels. GelMA hydrogel’s mechanical 
properties were predicted through a simple mathematical equation and reproducible across 
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3.3.4 GelMA and collagen hydrogels mimic key architectural features of 
PDAC tissues 
3.3.4.1 The nanostructure of GelMA and collagen hydrogels 
To further characterise these 3D cell culture systems, I investigated whether cells embedded 
in both matrices exhibited growth patterns and protein expression to resemble the 
architecture of native tissues. As shown in Figure 3.4, PDAC is characterised by a tightly 
packed interstitial ECM with very little vascularity. Like most epithelial tissues its stromal 
composition consists primarily of fibrous collagens assembled into bundles and fibrils. In 
addition to stiffness, recreating these architectural features is a prerequisite for a realistic 
model of the cellular TME for further functional and transcriptomics analyses. In order to 
validate collagen and GelMA hydrogels in this regard, their ultrastructure was determined via 
Scanning Electron Microscopy (SEM), and cellular structure via immunostaining.  
 
For a more faithful recreation of tumour tissues, PANC-1 or BxPC-3 PDAC cells were 
embedded together with the monocytic cell line THP-1 and patient-derived CAFs (1:2:2 
ratio) in both 0.1% collagen (1mg/ml) and 5% (wt/vol) GelMA hydrogels and grown for 14 
days prior to SEM and IHC analyses. Both PDAC and THP-1 cells proliferated to form 
multicellular spheroids when cultured in the 3D models. Patient-derived CAFs had a much 
lower proliferation rate, even on tissue culture plastic, and in 3D they exhibited the typical 
elongated, fibroblastic morphology, remaining viable throughout the 14 days of culture. 
 
The spatial distribution of cells and hydrogel topography differed between the two matrices. 
Qualitative analysis of GelMA hydrogels via SEM showed a highly compact and dense matrix 
in which cell clusters are interspersed (Figure 3.9 a-b). GelMA hydrogels presented as a much 
more compact matrix compared to collagen as their initial gelatin concentration (50 mg/ml) 
is 500-fold higher compared to that used for collagen gels synthesis (1 mg/ml). The pattern 
of cell growth in GelMA resembled tight cell clusters and multicellular spheroids surrounded 
by a dense cell- and hydrogel-derived matrix. Cells were therefore subjected to higher 
stiffness and interstitial pressure from their dense surroundings and exposed to higher matrix 
contents, similarly to what they would experience physiologically in tissues. Cross-sectional 
micrographs of the hydrogels showed an even distribution of spheroids (Figure 3.9 b). Some 
cells or entire clusters exhibited a ‘budding’ phenotype as they broke down the matrix and 
migrated out of the hydrogel. This phenotype was less prominent upon treatment with an 
broad-band MMP inhibitor, described later in Chapter 6. 
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Figure 3.9 Characterisation of the nanostructure of collagen and GelMA hydrogels via Scanning 
Electron Microscopy (SEM). (a) Representative SEM micrographs of PANC-1 cells in collagen (upper row) 
and GelMA (bottom row) hydrogels at day 14 of culture. (b) Representative cross-section SEM micrographs 
of collagen and GelMA-encapsulated cells. Scale bars as indicated on each micrograph. (c) Analysis of collagen 
microfibre diameter as measured via ImageJ, average thickness= 23.5 ± 9.72 nm, n=4. 
 
Micrographs of collagen gels revealed the characteristic collagen fibres that these hydrogels 
are known to form during crosslinking (Figure 3.9 a-b). Despite the low concentration 
(0.1%), a high number of dense, disorganised fibres was observed. Quantification of collagen 
gel microfibres revealed a thickness of 23.5 ± 9.72 nm (n=4 gels), which was not quantifiable, 
with this resolution, in IHC micrographs (Figure 3.9 c). This is consistent with the reported 
average collagen microfibre (1-20 nm) and fibril (20-40 nm) diameter, which can generally 
range to up to 10 m (fibres) and further increase to up to 1 cm once assembled in tissues 





 Biomechanics and Matrix Proteins of the Tumour Microenvironment 
 
-  112 - 
 
3.3.4.2 Extracellular components of the pancreatic TME 
Given their biophysical properties, GelMA and collagen hydrogels provided adequate 
architectural support for the 3D culture of cells. Next, I sought to assess whether 
encapsulated cells displayed a matrix protein expression pattern similar to that observed in 
patient tissues. The pancreatic niche is composed of collagens, glycoproteins, proteoglycans, 
ECM regulators, ECM-affiliated proteins and secreted factors 268,269, whose different 
functions and contributions to pathogenesis were detailed in Section 1.2.2. Recent work by 
Tian and colleagues 86,87, characterised the first human PDAC matrisome revealing protein 
changes associated with human pancreatitis, PanIN and progression to PDAC. Stromal- and 
tumour-derived ECMs not only contribute to tissue architecture and stiffness (Figure 3.5, 
Figure 3.6) but also promote cancer cell behaviours and is consequently associated with 
clinical outcome 95,259. I therefore assessed the expression of tumour-associated ECM 
proteins FN1, VCAN, COL1 and total collagens (MT) in cell-containing GelMA and 
collagen hydrogels and compared them to normal pancreas and PDAC tissues. For this, 
PDAC cells were co-cultured with THP-1 monocytes or in triple cultures with CAFs (1:2:2 
ratio) for 14 days, as detailed in each figure legend. 
 
Collagens make up the largest component of the PDAC-specific ECM 268. Collagen type-I in 
particular is known to interact with a number of pro-survival signalling molecules including 
activation of focal adhesion kinase (FAK)103 and Smad-interacting protein 1, which leading 
to a loss of E-cadherin, a crucial step during EMT 270. High collagen type-I expression was 
found in both primary PDAC and metastatic lesions and was linked to an 8.2 months 
reduction in overall patient survival (6.4 months for high vs 14.6 months for low expression 
levels) 95. Its abundance as a matrix protein, combined with its tumour-promoting and clinical 
role, make collagen a highly relevant and popular matrix for the 3D culture of PDAC cells. 
I therefore used collagen gels as a control matrix throughout this study. Because of their 
prominent role in PDAC progression, both COL1 and overall collagen expression was 
assessed via immunostaining in human tissues and 3D cell cultures (Figure 3.10, COL1 and 
MT). COL1 was highly upregulated in PDAC compared to adjacent tissues, and its 
expression was maintained in both 3D matrices. Both collagen and GelMA hydrogels 
provide a dense collagen-based scaffold (stained blue in MT) tightly surrounding cellular 
components, similarly to what is observed in PDAC tissues. 
 
Fibronectin (FN1) is an ECM glycoprotein mainly secreted by pancreatic stellate cells and 
fibroblasts. Its main role is to bind to integrin receptors and collagens inducing cell-ECM 
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adhesion, cell migration and differentiation 271. FN1 expression was highly upregulated in 
PDAC and maintained in the 3D cell cultures (Figure 3.10). Because of its interactions with 
collagens and the presence of gelatin-binding domains 109, FN1 immunostaining was positive 
in both GelMA and collagen, in the hydrogel itself. Its affinity to collagen and overexpression 
in tumours make FN1 a clinically relevant protein. In fact, FN1 has been reported to impede 
PDAC cell apoptosis and necrosis, leading to an increased tumour size in patients 124. 
 
Although its role has not been well characterised in PDAC, versican (VCAN) is an ECM 
proteoglycan whose expression is driven by both epithelial and stromal cells 52. Its 
accumulation is common during PDAC progression and correlates with CD8+ T cell 
exclusion 52. Together with COL1 and FN1, VCAN is part of  the “matrix index”, a matrix 
signature common to many solid tumours and associated with poor prognosis 259. VCAN 
protein expression increased from adjacent to PDAC tissues and was recapitulated in both 
collagen and GelMA 3D cell cultures (Figure 3.10). In GelMA triple cultures, all three cell 
types (PDAC and THP-1 cells, patient-derived CAFs) showed a high VCAN expression. The 
use of such 3D culture systems allows us to begin to investigate the cellular origin of ECM 
proteins in a direct and inexpensive fashion. 
 
One of the most noticeable differences between hydrogel cultures and the human tissues 
was the level of cellularity, which is a common limitation of most in vitro culture systems. The 
average tumour is reported to contain around 1x105 cells/µL 272 (or 1x108 cells/ml) which is 
almost 300 times higher than the initial seeding density of GelMA monocultures (3.5x105 
cells/ml) and almost 60 times higher than triple culture seeding densities (1.75x106 cells/ml). 
Patient-derived tissue and cell supply are the main limitations to increase cell numbers for 
3D culture in these matrices. Very high seeding densities also resulted in high numbers of 
cells migrating out of the hydrogels during the 14 days of 3D culture. 
 
Given that the expression of core matrix proteins was replicated in GelMA, I sought to 
investigate the expression of other PDAC-related markers in these hydrogels. Another key 
extracellular component of the pancreatic TME is hyaluronic acid (HA), a non-sulphated 
glycosaminoglycan known to be secreted by both tumour cells and CAFs. Similarly to COL1, 
HA expression was found in both primary and metastatic lesions, with high HA protein 
levels resulting in an average 15 months reduction in overall patient survival compared to 
low levels 95. Among all ECM components, HA has been extensively studied in PDAC in 
relation to its high abundance and accumulation in the tumour 44, and its prominence in 
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clinical trials via pegylated recombinant human PH20 hyaluronidase (PEGPH20) depletion46. 
HA expression was assessed in human tissues and hydrogels via HA-binding protein (HABP) 
staining. HA was expressed in PDAC cell spheroids but not by the smaller THP-1 cell 
clusters (indicated by arrows, Figure 3.11). 
 
3.3.4.3 Cellular components of the pancreatic TME 
Lastly, I investigated the expression of cellular components of the TME by imaging 3D 
cultures with cell type-specific markers (Figure 3.11). PDAC cells and THP-1 were co-
cultured in 5% GelMA hydrogels for 4 days prior to immunostaining. Unfortunately, no 
Figure 3.10 Immunostaining of FN1, VCAN, COL1 and total collagen (MT) staining in matched human 
tumour-adjacent pancreatic and PDAC tissues and in 3D triple cultures of PDAC and THP-1 cells and 
CAFs. FN, VCAN and COL1 positive cells are visualised with DAB staining (brown chromogen) while MT 
shows collagens stained blue. In the hydrogels, both THP-1 and PDAC cells grow as spherical multicellular 
aggregates while patient-derived CAFs (indicated by arrows) maintain their elongated fibroblastic morphology. 
Scale bar applies to all, 100 µm. 
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CAFs were incorporated for the purpose of this staining. Cytokeratin-19 (KRT19) is a 
cytoskeletal protein whose overexpression has been associated with PDAC tumorigenesis, 
progression and poor outcome273. KRT19 was used as a cancer marker and its expression in 
3D cultures characterised further in Chapter 4. Additionally, KRT19 expression is linked to 
increased invasion and mechano-sensing via interactions with β-catenin and RAC1 274. More 
about the mechano-transduction pathways upregulated in GelMA-cultured cells will be 
discussed in Chapter 5. KRT19 was strongly expressed by PDAC cell spheroids in GelMA 




Figure 3.11 Immunostaining of KRT19, αSMA, CD68 and HABP in matched human tumour-adjacent 
pancreatic and PDAC tissues and 3D co-cultures of PDAC and THP-1 cells. Positive cells are visualised 
with DAB staining (brown chromogen). Arrows pointing at THP-1 spheroids, which become CD68 positive 
when co-cultured with cancer cells in GelMA. Scale bar applies to all, 100 µm. 
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Alpha-smooth muscle actin (αSMA) was used as a marker for CAFs. Immunostaining 
indicated both a higher αSMA expression and fibroblast disorganisation in PDAC tissues 
compared to tumour-adjacent normal tissues (Figure 3.11). PDAC and THP-1 co-cultures in 
GelMA showed no staining for this marker. In the future, it would be beneficial to repeat 
this stain on CAF-containing GelMA hydrogels to confirm the specificity of the stain. Finally, 
cluster of differentiation-68 (CD68) was used as a macrophage marker. Limited CD68+ cells 
were detected in our tissues (Figure 3.11). Interestingly in GelMA cultures, co-culture of 
PDAC cells with THP-1 monocytes led to differentiation of the latter into CD68+ 
macrophages. 
 
In summary, the use of 3D culture approaches allowed us to begin to recapitulate some of 
the key architectural, cellular and extracellular features of the pancreatic TME. Upregulation 
of tumour-associated matrix proteins, such as FN1, VCAN, COL1 and HA, was observed 
in human PDAC compared to adjacent normal tissues and was induced in GelMA and 
collagen cultures. Patterns of cell growth and hydrogel nanostructure were visualised by SEM 
and IHC. Cellular components of the TME retained their cell-type-specific marker 
expression in the 3D matrices. 
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3.4 Conclusions 
This chapter covered the characterisation of the biomechanics of human pancreatic and 
ovarian tissues and two 3D hydrogel-based cell culture models, using three techniques that 
can be applied for any biomaterial characterisation. Indentation testing revealed that for 
pancreatic tissues, tumours were significantly stiffer than matched, histologically normal 
tissues. Despite previous research having characterised the elastic modulus of human normal 
pancreas 275,276 and that of PDAC progression in mouse models 128, only one recent study has 
performed this analysis on fresh, human resected tissues 130. As shown in Figure 3.7, murine 
tissues were softer than their human counterparts as well as more laborious compared to in 
vitro models.  
 
My results show adjacent normal tissues had a stiffness of 2.2 ± 0.2 kPa which increased to 
7.4 ± 0.6 kPa in matched tumours. This is consistent with previous work 130 where normal 
tissues where found to be 1.06 ± 0.25 kPa, increasing to 2.15 ± 0.41 kPa in pancreatitis and 
5.46 ± 3.18 kPa in tumours. Though tumours are significantly stiffer in both cases, the 
adjacent tissues characterised in this study present a stiffness range that overlaps with that of 
chronic pancreatitis or PanIN of previous reports, being stiffer than normal tissues 130. This 
is unsurprising as tumour-adjacent tissues probably present with a degree of inflammation 
accompanying the tumour, which might have still induced stromal activation, reduced 
permeability and increased tissue desmoplasia leading to higher tissue stiffness 277. This was 
not the case for ovarian tissues, where no significant difference was found between diseased 
and healthy tissues (Figure 3.2). However, normal ovaries were surgically removed only when 
accompanying a gynaecological disorder, which might have contributed to an overall tissue 
inflammation and stiffening. Additionally, the tissues classed as ovarian tumours came from 
patients which had previously undergone chemotherapy. This affected the tissue architecture, 
cellularity (as detected by H&E staining, not shown) and, in turn, stiffness. Because of these 
limitations, ovarian tissues were not taken further for matrix protein analysis, which was 
instead conducted on pancreatic tissues. 
 
Importantly, this analysis enabled me to directly compare these values to the stiffness of our 
3D cultures, allowing for mechanics to be used as a readout. Over the last decades, basic 
research has begun to uncover the importance of substrate mechanics in the regulation of 
PDAC cell proliferation128, invasion 129,278, EMT 128,203 and response to treatment 265,279. 
However in vivo, stiffness is neither static or two-dimensional, and cell-ECM signalling has 
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been shown to play a role in governing tissue biomechanics 17,265. My project focused on cell 
functions and molecular processes involved in proliferation and response to treatment, while 
being able to directly link these behaviours to changes substrate mechanics (Chapter 6). 
 
I next conducted immunostaining for key ECM proteins on tissues post-mechanical testing. 
Unsurprisingly, the expression of all tested tumour-related matrix proteins, namely COL1, 
FN and VCAN, was significantly higher in tumour tissues compared to tumour-adjacent 
normal tissues. All three proteins, as well as overall collagen content, have been described as 
being highly expressed in PDAC and linked to shorter survival 52,95,124,268. I also characterised 
collagen fibre thickness (Figure 3.5), which was significantly higher in tumour compared to 
tumour-adjacent tissues, similarly to previous reports 128. Thanks to the use of tissue dye, I 
was next able to correlate percentage area marker stained with exact stiffness in each testing 
location, which is, to my knowledge, a novel characterisation technique. Ideally, I would like 
to extend this analysis to a larger sample pool (n>15), to increase the robustness and 
significance of the results.  
 
Expression of all three proteins positively correlated with tissue stiffness, suggesting a 
combination of histological and mechanical assessment of the tumour may be predictive of 
disease. In physiologically normal conditions, soft and compliant matrices are rich in 
proteoglycans (such as VCAN) and hyaluronan, while rigid and stiff matrices are enriched in 
collagens and fibrous proteins (such as fibronectin) 118. However, in disease, deregulated 
matrix production leads to a disturbance in tissue architecture and function. Proteins like 
VCAN, transit to a more fibrous, highly cross-linked ECM, which is conductive of tissue 
stiffening, promoting tumour cell proliferation 119. Such ECM disturbance may impact the 
course of pathogenesis and also offer alternative therapeutic and/or stroma-targeting 
strategies (as it is the case for PEGPH20) 46,47,117. 
 
Next, I characterised the mechanical properties of commonly-used collagen type-I gels and 
GelMA-based hydrogels. The stiffness of 3-10% (wt/vol) GelMA ranged between 1 to 17 
kPa, which is in concordance with the literature 230,242. Stiffness was highly reproducible across 
different batches and influenced by the degree of methacryloyl (MA) substitution onto the 
gelatin backbone 242. Additionally, a simple mathematical relationship was established to 
predict GelMA hydrogel stiffness based on the initial concentration and crosslinking 
parameters. As this is only valid for GelMA with a high degree of substitution (DoF ≥ 65%), 
future work should consider into including the degree of substitution as a further parameter 
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in the equation. This tuneability, reproducibility and stiffness range is one of the key 
advantages of GelMA hydrogels over the commonly-used collagen type-I gels. 
In order to be able to investigate stiffness changes upon treatment (Chapter 6), mechanical 
properties of both hydrogel platforms had to be maintained upon cell incorporation (Figure 
3.8). Cell contractility, matrix protein production and deposition, matrix digestion and 
crosslinking, are processes which will be investigated in more detail in the following chapters, 
in relation to their association with matrix stiffness. For consistency, mechanical properties 
were assessed at day 14 of 3D cell culture throughout this study with limited variation in the 
final concentration of cells embedded in order to achieve comparable results between 
experimental conditions. Since cancer cells themselves are softer (~400-900 Pa) than the 
matrices they are embedded in, reasonable variations in cell numbers alone is not likely to be 
responsible for matrix stiffening 280. 
 
Lastly, I wanted to ensure that the production of key pancreatic TME proteins by cancer and 
stromal cells would be maintained in the 3D culture systems. SEM analysis of the 
nanostructure of GelMA and collagen hydrogels revealed the pattern of cell growth differed 
between both models. Up to 80-90% of pancreatic tumours, depending on reports, can be 
made up by ECM and stroma, with very little vascularity and only a fraction of the tumour 
bulk comprising cancer cells 59,192,281. With this in mind, GelMA hydrogels provided a dense, 
compact matrix, in which cancer cells grew as multicellular spheroids (Figure 3.9). In addition 
to structural support, GelMA-embedded cells retained the expression of key extracellular and 
cell-specific markers, namely FN1, VCAN, COL1, HA and KRT19, CD68. PDAC spheroids 
expressed all the tumour-associated ECM markers analysed, with darker stain rims along the 
spheroid edges, suggesting cells were able to produce they own matrix within the hydrogels. 
Further proteomics analyses could be conducted on these matrices to characterise overall 
changes in matrix molecules with successive incorporation of additional cellular components 
or, later on, with treatment. 
 
Starting with the patient material available, my initial aim was to understand tissue 
biomechanics and related ECM protein expression in order to recapitulate them with the use 
of 3D cell culture platforms. The presented 3D culture approaches were able to mimic some 
of the key biomechanical, architectural, cellular and extracellular features of the PDAC 
microenvironment. The next chapters will focus on characterising behaviours, functions and 
transcriptomics of GelMA-encapsulated cells in order to decipher and target processes 
related to the mechano-biology of PDAC. 
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Chapter 4 - GelMA Hydrogels as 
a 3D Platform to Study Cell 
Behaviours
GelMA Hydrogels as a 3D Platform to Study Cell Behaviours 
- 121 -
4.1 Background 
The use of 3D cell culture platforms is an innovative and fairly recent approach to bridging 
the gap between traditional 2D cell culture, animal models, and clinical results. The 
advantages of such models include control over the inclusion of  cellular and extracellular 
components of the TME, in order to unveil their individual and joint contributions to disease 
and treatment 249. Increased need for biologically and architecturally accurate model systems 
has led to the development of a plethora of 3D platforms, with hydrogels (whether naturally-
derived, semi-synthetic or synthetic) being of particular interest due to their rheology, and 
relatively easy and inexpensive synthesis. 
Our group’s 3D cell culture platform of choice is based on the use of a semi-synthetic 
biomaterial, named gelatin methacryloyl (GelMA), and its ability to crosslink to via photo-
polymerisation to form biocompatible hydrogels. GelMA combines the advantages of both 
natural and synthetic hydrogels by retaining integrin cell-binding and protease-cleavage 
domains (from the gelatin backbone), as well as the chemically reactive substitution groups 
(methacryloyl groups) that allow tunable and reproducible mechanical and chemical 
properties 229. This allows for cell adhesion, proliferation, migration and proteolytic 
degradation to take place within the hydrogel, while allowing the operator to finely tune 
hydrogel crosslinking and stiffness parameters (such as time, energy, source, photo-initiator, 
concentration, degree of substitution, etc.). 
In the previous chapter, I have shown how GelMA’s properties can be altered to obtain a 
desired hydrogel stiffness to match physiological conditions, and how expression of key 
matrix proteins was maintained by GelMA-embedded cells. In this chapter, I explore the 
establishment of GelMA as a novel PDAC cell culture system and how this was used to 
conduct a range of quantitative in vitro and in vivo analyses. I also describe validation steps for 
the characterisation of GelMA itself (degree of substitution) as well as the development of 
protocols for hydrogel digestion, cell recovery 235 and downstream gene and protein analyses. 
Although GelMA has been studied for decades 236, its implementation as a cell culture system 
dates back to less than ten years ago 229, and almost exclusively limited to applications in the 
field of tissue engineering and regenerative medicine 231,232,238,250,251. A handful of groups have 
now used GelMA as a cancer cell culture platform, mainly focusing on ovarian 235,252, 
glioblastoma 253,254, breast 255,256, prostate 257,258 and more recently colon cancer (Loessner, 
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Ryan unpublished). Thus far, there have been no reported uses of GelMA for the study of 
pancreatic cancer and the inclusion of patient-derived cells. 
 
Following the approximation of the fibrotic PDAC matrix stiffness and tissue architecture 
(Chapter 3), the model was subjected to a systematic characterisation of GelMA-embedded 
cell behaviours and how these were altered in response to physicochemical changes. Finally, 
I looked at the incorporation of additional cell types for the formation of a multicellular 
pancreatic TME model. I assessed the effects of the inclusion of stromal and myeloid cells 
on cancer cell proliferation, matrix stiffness as well as in vivo tumorigenicity. The use of such 
3D cell culture model allowed me to begin to evaluate the individual contributions of 
different elements of the pancreatic TME in cancer-related processes. 
4.2 Aim and objectives 
The aim of this chapter is to characterise GelMA hydrogels and assess their potential as a 3D 
PDAC cell culture system, by investigating various cancer cell functions in hydrogels with 
different biomechanical properties. I also aimed to increase the complexity of the model, by 
studying cancer cell interactions with additional cellular components of the TME and their 
effect on matrix stiffness. 
I will: 
• Characterise GelMA’s degree of substitution (batch-to-batch consistency) 
• Analyse biological characteristics and functions of GelMA-embedded cells 
• Optimise techniques required for the analysis of GelMA-embedded cells 
• Assess the degree of UV-induced DNA-damage in GelMA 
• Understand the effects of additional TME components and multicellularity in 
GelMA hydrogels and how these affect cell growth, in vivo tumorigenicity, cytokine 
secretion and pro-survival signalling pathways  
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4.3 Results 
4.3.1 Degree of functionalisation analyses show high GelMA batch 
consistency  
In recent years, gelatin-methacryloyl (GelMA) has become one of the most commonly used 
photocrosslinkable materials in bio-applications 262. The ‘degree of substitution’ or ‘degree of 
functionalisation’ (DoF) refers to the amount (%) of methacrylic anhydride (MA) that 
attaches onto the gelatin primary amine groups during GelMA synthesis (Figure 4.1 a). DoF 
can be broadly classified into high (≥65%), medium (30%≥ x ≥65%) or low (<30%). The 
DoF directly regulates the amount of crosslinking that the hydrogel can undergo during UV 
polymerisation, and therefore directly affects hydrogel’s physicochemical properties, its 
highest achievable density, stiffness and porosity, all factors which ultimately affect cell 
behaviour. When other parameters (such as concentration and crosslinking time) are 
unchanged, a higher DoF leads to stiffer hydrogels, higher cross-linking density, improved 
shape maintenance230, decreased pore size246 and, importantly, higher consistency between 
hydrogels. Since cell behaviour can be influenced by these factors, and since hydrogel 
stiffness was used as a readout, I used DoF as a batch quality control to ensure result 
reproducibility. For my purposes, a high DoF was desirable as it resulted in higher 
consistency of crosslinked hydrogels. 
 
After synthesis of each batch, I employed various analytical techniques in order to determine 
the DoF and conducted mechanical analysis of the resulting hydrogels (Figure 3.8 b). Most 
DoF characterisation methods work through quantifying the amount of free primary amine 
groups that are present on the gelatin backbone 229. Since MA binds to amine groups during 
GelMA synthesis, a higher degree of substitution will lead to a lower amount of free amine 
groups. Colorimetric assays allow to compare the fluorescence/absorbance of GelMA 
against the gelatin used for its synthesis, and to infer DoF from the spectroscopy shift 229. 
Three such methods were employed for DoF analysis of our in-house batch 1 (low DoF 
control) and batches 3-5 (used throughout this study): namely ninhydrin, fluoraldehyde and 
2,4,6-trinitrobenzenesulfonic acid (TNBS) assays (Figure 4.1 b). All three methods returned 
consistent results with no significant difference between different methods used or between 
different batches (3-5). Our low DoF control batch 1 showed higher variation in the results 
as well as higher variation in the stiffness of the resulting hydrogels (Figure 3.8 b) underlining 
the importance, for the purpose of this study, of using higher DoF batches. These assays 
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work with the assumption that the reduction in free amine groups is solely due to MA 
substitution with 100% substitution efficiency. As this is not always the case, these methods 
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Figure 4.1 Analysis of GelMA degree of functionalisation (DoF) via spectrophotometric and 1H NMR. 
(a) Schematic representation of the synthesis of gelatin methacryloyl (GelMA) through functionalisation of 
gelatin's primary amine groups by methacrylic anhydride (MA) addition. The DoF is defined as the percentage 
of MA substitution (functional groups) onto primary amines. The less residual amine groups are left onto the 
GelMA gelatin backbone, the higher the DoF is. GelMA’s DoF can be adjusted by changing synthesis 
parameters such as MA feed ratio, gelatin concentration, reaction temperature to obtain GelMA with defined 
high, medium or low DoF. (b) GelMA DoF for batches 1 (low DoF), 3-5 (high DoF) as measured through 
three independent assays: ninhydrin (n=3), fluoraldehyde (n=3) and 2,4,6-trinitrobenzenesulfonic acid (TNBS) 
(n=1). All three assays are indirect measures of DoF through quantification of free amine groups in GelMA’s 
gelatin backbone and comparison against unfunctionalised gelatin. Only batches 3-5 were used for this project. 
(c) Proton nuclear magnetic resonance (1H NMR) spectra of gelatin and GelMA batches 1, 3-5 for DoF 
verification. The blue band highlights the lysine methylene proton peak for each spectra, where λ is the 
measured area under the peak. Higher λ indicates higher number of methylene protons (2H) of unreacted lysine 
groups. 
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To validate these results, proton nuclear magnetic resonance (1H NMR) was performed on 
unfunctionalised gelatin and the different GelMA batches (Figure 4.1 c). This method looks 
at the lysine methylene proton present on the carbon atom that joins to the amino group 
(where the MA functionalisation takes place). This proton is known to give a peak 
(highlighted in blue in Figure 4.1 c) at 3 parts per million (ppm). The peak was highest in the 
gelatin NMR spectra and decreased as the amino group was connected to a methacryloyl 
group in GelMA. The annotated values indicate the integration number of each peak (λ), 
reflecting the area under the peak. DoF was calculated from the gelatin and GelMA NMR 
spectra, as follows: 
𝐷𝑜𝐹 = [1 − (
𝜆 𝑜𝑓 𝑙𝑦𝑠𝑖𝑛𝑒 𝑚𝑒𝑡ℎ𝑦𝑙𝑒𝑛𝑒 𝑝𝑟𝑜𝑡𝑜𝑛 𝑜𝑓 𝐺𝑒𝑙𝑀𝐴
𝜆 𝑜𝑓 𝑙𝑦𝑠𝑖𝑠𝑛𝑒 𝑚𝑒𝑡ℎ𝑦𝑙𝑒𝑛𝑒 𝑝𝑟𝑜𝑡𝑜𝑛 𝑜𝑓 𝑔𝑒𝑙𝑎𝑡𝑖𝑛
)] × 100% 
 
The resulting DoF calculated were 12% for batch 1, 71% for batch 3, 69% for batch 4 and 
66% for batch 5. The accuracy on this method rests on the assumption that MA 
functionalisation will not be affecting proton distribution on any of the remaining free amino 
groups. Since this is not always the case, this method could be slightly underestimating the 
overall DoF. 
 
To summarise, all batches used during this study had a high degree of substitution when 
measured with both indirect amine quantification methods (73-86%) or 1H NMR (66-71%). 
No single method gave an absolute quantification of MA functionalisation onto gelatin, 
however batch-to-batch consistency was evident regardless of the method used. Additional 
controls such as hydrogel stiffness and nanostructure were discussed in the previous chapter. 
A consistent, high DoF was important for reproducibility and consistency in GelMA 
hydrogel stiffness, stiffness predictability, biochemical properties and, in turn, biological 
effects. 
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4.3.2 GelMA hydrogels as a 3D platform to study cell behaviour 
4.3.2.1 GelMA supports cell viability, proliferation and long-term 3D cell culture 
Following mechanical and chemical characterisation of GelMA hydrogels, I aimed to assess 
the suitability of GelMA-based hydrogels for biological applications in PDAC research. Cell 
viability is a crucial parameter that any platform designed for cell culture must adequately 
support. For this, I incorporated BxPc-3, Capan-2, MIAPaCa-2, PANC-1 PDAC cells and 
the HGSOC cell line OvCar4 in 5% (wt/vol) GelMA hydrogels and observed the pattern of 
cell growth over time. A live/dead assay was used, looking at esterase activity (494/517 nm: 
calcein-AM Ca-AM) and loss of membrane integrity (528/617 nm: ethidium homodimer-1 
Et-H1) as proxies for cell viability and cell death, respectively. Brightfield micrographs as 
well as live/dead confocal analysis of the cultures was conducted on day 1, 7, 14 and 28 post 
cell-encapsulation. 
 
OvCar4 cells formed multicellular spheroids (Figure 4.2) already visible at day 7 of culture 
and ranging up to 500 µm in diameter by day 28 (Figure 4.3 a). Cells maintained a high 
viability throughout culture in GelMA, as indicated by the low amounts of red Et-H1 dye 
compared to green, viable cells. Spheroid diameter analysis revealed an increase from an 
Figure 4.2 Cell proliferation and viability of OvCar4 cells in GelMA hydrogels. (top) Confocal z-stack 
micrographs show a high cell viability on day 1 to 14; live OvCar-4 cells were stained with green-fluorescent 
calcein-AM (Ca-AM, 494/517 nm); dead cells were stained with red-fluorescent ethidium homodimer-1 (Et-
H1, 528/617 nm). Scale bar, 200 µm, applies to all. (bottom) Representative brightfield images indicate that 
GelMA hydrogels supported OvCar4 cell growth after encapsulation in 5% GelMA and allowed multicellular 
spheroids formation over 14 days of culture. Scale bar 500 µm, applies to all. 
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average 81.5 ± 64 µm on day 14 to almost double to 154.7 ± 101 µm on day 28 of culture 
(Figure 4.3 a). Heterogeneity of spheroid size is reflected in a large SD for these 
measurements. 
 
The same analysis was conducted on four PDAC cell lines. Similarly to OvCar4, PDAC cell 
lines proliferated in 5% (wt/vol) GelMA to form spheroids by day 14 of culture, after which 
the hydrogels appeared overcrowded and cells began to migrate out of the hydrogel towards 
the bottom of the wells. Cultures were therefore kept for 14 days to prevent cell loss. 
Diameter quantification at day 14 of culture suggested that different cell lines proliferated at 
different rates within 5% GelMA hydrogels, reflected in different spheroid sizes, with MIA 
PaCA-2 cell forming the largest spheroids (188.7 µm), followed by PANC-1 (170.2 µm), 
Capan-2 (79.5 µm) and BxPC-2 (78.0 µm). 
 
The spheroids were reminiscent of tumour cell aggregates seen in PDAC patients (Figure 4.3 
b) as well as spheroids that are found disseminating in tumour fluid (ascites) of cancer-
Figure 4.3 Spheroid-forming ability of HGSOC and PDAC cell lines in 5% GelMA. (a) Quantification 
of OvCar-4 spheroid diameter (µm) from day 1 to 28 of culture as measured via ImageJ. Median and 
interquartile ranges shown. (b) Quantification of spheroid diameter (µm) of 5 PDAC and HGSOC cell lines 
and on day 14 of culture as measured via ImageJ. Median and interquartile ranges shown. (c) PANC-1 cells 
formed multicellular spheroids in 5% GelMA. Haematoxylin and eosin (H&E) staining of 5% GelMA hydrogel 
section at day 14 of culture (left), single spheroid (middle) and PDAC patient tissue (right). Scale bars,100 µm, 
50 µm, 50 µm. 
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bearing patients, distinctively at late-stage disease 252. PDAC cell viability was also ensured 
via live/dead imaging of 5% wt/vol GelMA cell cultures at day 1, 14 and 28 (Figure 4.4). 
Cell-containing GelMA hydrogels were kept for over four weeks in culture without 
compromising cell viability. The expression of the PDAC cancer-associated marker 
cytokeratin-19 (KRT19) 273 was also maintained over 14 days of culture assessed via whole-
gel immunofluorescence (Figure 4.4 b). This confirmed the results obtained via 
immunohistochemistry in Chapter 3 (Figure 3.11) and underlines the amenability of GelMA 
hydrogels to various cell and molecular analyses. 
 
Figure 4.4 Cell proliferation and viability of BxPC-3, Capan-2, MIA PaCa-2 and PANC-1 cells in 
GelMA hydrogels. (a)(top) Confocal z-stack micrographs show a high cell viability on day 1 and 14; live cells 
were stained with green-fluorescent calcein-AM (Ca-AM, 494/517 nm); dead cells were stained with red-
fluorescent ethidium homodimer-1 (Et-H1, 528/617 nm). Scale bar, 100 µm, applies to all. (bottom) 
Representative brightfield images at day 28 of culture after encapsulation in 5% GelMA. Scale bar 50 µm, 
applies to all. (b) Immunofluorescence images reveal high cytokeratin 19 (KRT19, 488 nm) expression in 
PANC-1 cells, cytoskeleton stained with phalloidin (647 nm), nuclei stained with DAPI (358 nm). Scale bar, 
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4.3.2.2 Hydrogel stiffness influences PDAC cell proliferation 
Next, I sought to quantify cell viability and proliferation by incorporating my four PDAC 
cell lines in GelMA hydrogels with increasing stiffness (3-10% GelMA). The proliferation of 
OvCar4 cells was also measured, and is presented in our publication 235. The cells showed 
different proliferative and spheroid-formation abilities within different matrices (Figure 4.5).  
10% GelMA hydrogels, corresponding to 16 kPa, were not conducive of high cell 
proliferation in any of the cell lines, probably owning to its high stiffness. Capan-2 and BxPC-
3 cells, which present with a more epithelial cell phenotype 203,282, did not grow very well in 
soft matrices but proliferated preferentially in matrices with medium-low (5% = 3.4 kPa) and 
medium-high stiffness (7.5% = 8.6 kPa). These values were also the ones closest to the 
stiffness of adjacent normal and diseased human tissues (Figure 3.2). On the other hand, 
micrographs of cell lines of a semi-mesenchymal (PANC-1) and mesenchymal (MIA PaCa-
Figure 4.5 Representative brightfield micrographs of BxPC-3, Capan-2, MIA PaCa-2, PANC-1 cells 
embedded in GelMA hydrogels of increasing stiffness (3-10% wt/vol) at day 14 of culture. Scale bar, 1 
mm, applies to all. 
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2) phenotype 203,282, showed cells proliferated regardless of matrix stiffness. In addition, MIA
PaCa-2 cells grew to form tight round spheroids in low-stiffness matrices whereas its growth 
pattern became disorganised and highly migratory (with high numbers of cells moved 
towards the edge and outside the hydrogels) in stiffer matrices, due to the mesenchymal 
nature of this cell line. 
Cell metabolic activity and DNA quantification analyses were performed on hydrogels on 
day 1 and day 14 of cell culture in order to quantify cell proliferation (Figure 4.6). MIA PaCa-
2 cells showed the highest inconsistencies in fluorescence measurements, due to their 
tendency to move outside of the hydrogel once confluency is reached. Quantification data 
strengthened the notion that cell’s EMT status may play a role in stiffness-related 
proliferation as Capan-2 and BxPC-3 show behaviours opposite to PANC-1 and MIA PaCa-
2 cells. In addition to their physiological relevance, 5% and 7.5% (wt/vol) GelMA (3.4 – 8.6 
kPa) were the matrices in which cells showed the highest proliferation rates, across all four 
cell lines (Figure 4.6 a), and were therefore taken further for transcriptomics studies in 
Chapter 5 and treatment studies in Chapter 6. 
To summarise, GelMA-based hydrogels provided the adequate support for 3D culture of 
HGSOC and PDAC cells by allowing spheroid formation and quantification of cell viability, 
cell proliferation and cell-specific marker expression. Culture of PDAC cells in this matrix 
had not been previously characterised. 
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Figure 4.6  BxPC-3, Capan-2, MIA PaCa-2, PANC-1 cell viability and proliferation in GelMA hydrogels 
of increasing stiffness (3-10%) as measured via quantification of (a) endogenous cellular reducing 
ability and (b) DNA content. (a) Alamar Blue quantification of cells’ metabolic activity was performed on 
day 1 and day 14 of culture, n=3. (b) CyQUANT quantification of DNA content was performed at day 14 of 
culture, n=3. 
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4.3.3 Optimisation of hydrogel digestion and cell retrieval for downstream 
analyses 
For the successful implementation of GelMA as a 3D cell culture platform, it was next 
necessary to optimise various techniques for the isolation of GelMA-cultured cells whereby 
maintaining high viability, as well as quick hydrogel digestion for downstream molecular 
analyses 235. I analysed the efficiency of five different enzymatic approaches for the 
degradation of cell-containing GelMA hydrogels by assessing their hydrogel digestion 
efficiency and performing flow cytometry analysis of the retrieved cells. OvCar4 and MIA 
PaCa-2 cells grown in 5% (wt/vol) GelMA were used for this analysis. As collagen is the 
main component of gelatin 283, the efficiency of different collagenases was assessed. 
Additionally, other enzymes and reagents such as dispase II and a combination of trypsin 
and EDTA were also used (Table 4.1). All the tested enzymatic approaches resulted in 
complete hydrogel degradation, although at different completion rates, suggesting different 
digestion approaches can be used depending on the intended downstream application. 
Table 4.1. Digestion protocol specifications including enzyme names, origin, final concentration and 
representative pictures. EDTA= Ethylenediaminetetraacetic acid; PBS= Phosphate Buffered Saline; 
DMEM= Dulbecco’s Modified Eagle Medium; FBS= Foetal Bovine Serum; P/S= penicillin/streptomycin 
Time (min) 
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Next, the viability of the retrieved cells was assessed via flow cytometry. Figure 4.7 shows 
the general gating strategy for the sequential exclusion of cell debris (SSC-A/FSC-A), 
doublets (SSC-W/SSC-A and FSC-H/FSC-A) and detection of live cells. Following this 
analysis, all digestion protocols returned cells with high viability (>50%) with collagenase I 
achieving digestion with the highest number of viable cells (95%) and dispase II being the 
only condition with significantly lower cell viability (67%). Dispase is a protease which 
cleaves fibronectin (a component of GelMA, as shown in Figure 3.10), collagen IV, and to a 
lesser extent, collagen I 284 (the main component of GelMA). Increased specificity to collagen 
I and reduced digestion time might explain the higher efficiency of collagenase I digestion 
compared to other proteases. Trypsin also possesses collagenolytic activity 285 , but its 
digestion rate of GelMA was reduced compared to other enzymatic treatments making it a 
less attractive option for downstream applications. Prolonged cell exposure to trypsin is 
known to interfere with a number of cell surface molecules including integrins 286, hence why 
this digestion approach is not favourable for downstream molecular analyses. 
In order to further validate these results, an optimisation of live/dead viability/cytotoxicity 
dyes (Ca-AM and Et-H1) for flow cytometry was conducted. The two dyes (Ca-AM: 494/517 
nm; Et-H1: 528/617 nm), together with DAPI (358/461 nm) staining were used to 
determine MIA PaCA-2 cell viability after retrieval (Table 4.2). For consistency, collagenase 









































































Figure 4.7 Flow cytometry and detection of MIA PaCa-2 cell viability after GelMA hydrogel digestion. 
(a) Representative flow cytometry gating strategy for exclusion of cell debris and doublets and detection of 
viable cells using DAPI (450/50, X-axis). (b) High cell viability was achieved across the five enzymatic 
approaches tested, with collagenase I: 95.5 ± 0.5%, trypsin/EDTA: 89.0 ± 2.6%, collagenase XI/dispase II: 
85.5 ± 4.4%, collagenase V: 78.9 ± 3.7% and dispase II: 67.7 ± 6.0% cell viability (n = five biological replicates 
with five gels each). ANOVA (Tuckey multiple comparisons), p= 0.0015. 
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Table 4.2. Conditions for flow cytometry and details of calcein-AM (CaAM)/ethidium homodimer-1 (EtH1)/ 4′,6-diamidino-2-phenylindole (DAPI) staining of GelMA-
retrieved MIA PaCa-2 cells following collagenase I digestion. 
Test 
conditions 








1 Manufacturer’s instructions; 
without DAPI 
0.1 μM Ca-AM, 8μM Et-H1 84.5 7.0 0.3 Live 
2 Manufacturer’s instructions; with 
DAPI 
0.1 μM Ca-AM, 8μM Et-H1, 1 
μg/ml DAPI 
90.5 7.3 91.2 Live 
3 Double concentration 0.2 μM Ca-AM, 16 μM Et-H1, 






4 Ca-AM dye only 0.2 μM Ca-AM 89.9 - - Live 
5 Et-H1 dye only 16 μM Et-H1 - 18.5 0.5 Live 
6 Manufacturer’s instructions; UV-
treated 
0.1 μM Ca-AM, 8 μM Et-H1, 
1 μg/ml DAPI 
3.4 81.7 5.8 Dead 
7 Manufacturer’s instructions; 
ethanol-treated: live cells (50:50) 
0.1 μM Ca-AM, 8 μM Et-H1, 
1 μg/ml DAPI 
49.6 58.0 47.6 50:50 
8 Manufacturer’s instructions; 
phenol-red-free DMEM 
0.2 μM Ca-AM, 8 μM Et-H1, 
1 μg/ml DAPI 
81.3 7.8 93.5 Live 
9 Unstained control Unstained - - - - 
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Ca-AM and Et-H1 dyes were used either individually or in conjunction with DAPI staining 
during optimisation, at both recommended concentrations and double concentration. UV-
treated cells (40 min UV, 365 nm) and ethanol-treated cells, were used as dead cell controls, 
either on their own, or in a 50:50 mix with live cells to determine the accuracy of the 
live/dead staining (Table 4.2). Results from the three stainings were mostly in agreement and 
consistent. The removal of phenol-red from the digestion media did not have a significant 
effect on the staining as the cells underwent several wash rounds prior to flow cytometry, 
preventing any possible autofluorescence. Representative flow cytometry gating strategy for 
conditions 2 and 7 are shown in Figure 4.8 4a and 4b. These optimised procedures were 
published in our book chapter 235. 
1  2 3 
4a 
4b 
Figure 4.8 General flow cytometry gating strategy for Ca-AM/Et-H1/DAPI staining optimisation. 
CaAM/EtH1/DAPI staining of GelMa-retrieved cells is shown, following (1) exclusion of cell debris and (2-
3) exclusion of doublets. Representative plots are from triple staining detection of (4a) samples 2 (Table 4.2; 
DAPI 450/50, EtH1 610/20, CaAM 530/30, X-axis) and (4b) sample 7 (Table 4.2; DAPI 450/50, EtH1 
610/20, CaAM 530/30, X-axis), n=3.
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In order to avoid affecting the expression profile of cells by exposing them to proteolytic 
enzymes, I also optimised a method for mechanical disruption of hydrogels, desirable when 
performing high-sensitivity assays (such as RNA analyses). This technique yielded a much 
lower number of cells compared to hydrogel digestion and did not ensure cell 
integrity/viability (as required for analyses such as flow cytometry). However, it allowed for 
a faster and enzyme-free hydrogel dissociation. Lastly, western blot analysis from GelMA-
recovered cells was carried out successfully with the use of either collagenase I (1 mg/ml) or 
liberase (0.3 mg/ml) hydrogel digestion (Chapter 4, Chapter 6). The latter has unknown 
enzymatic composition but was efficient at dissolving GelMA at a much lower concentration. 
To summarise, due to the increased popularity of 3D models, there is a need for the 
development of standardised and reproducible techniques for the recovery of cells cultured 
in 3D. Effective digestion of GelMA hydrogels for cell retrieval was achieved with a number 
of different enzymatic approaches, of which collagenase I/DMEM (1 mg/ml) was the most 
efficient at extracting cells with high (>95%) viability. Different cell retrieval approaches had 
to be optimised depending on intended downstream application as not many groups 229,235,287 
have developed or published analytical techniques for GelMA hydrogels. 
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4.3.4 UV-induced DNA damage assessment in GelMA cell cultures 
GelMA hydrogels crosslink through a photopolymerisation reaction between the 
methacryloyl functional groups, a photo-initiator and ultraviolet (UV) light (Figure 2.1). UV 
light exposure is limited to 10 minutes and a low energy 365 nm wavelength to limit UV-
induced damage to the incorporated cells. However, I was interested in determining whether 
such exposure would cause any DNA damage in the used cell lines, as no other group had 
characterised this. Histone H2A variant (H2AX) levels were measured in the cell lines and 
in response to UV exposure firstly in 2D (monolayers) and then in 3D (GelMA hydrogels). 
H2AX becomes activated and phosphorylated on Ser139 (γH2AX) in response to chromatin 
relaxation, and can therefore be used as a marker for DNA double strand breaks (DSBs) 288. 
H2AX phosphorylation was examined by immunofluorescence on monolayer untreated 
cells, and in cells after 10 minutes of UV exposure (this is the time normally employed during 
GelMA photo-crosslinking) or 30 minutes of UV exposure (positive control). γH2AX can 
already be detected a few minutes after irradiation and peaks ∼30 min later 288, therefore 1 
and 48 hours were chosen as analysis time points.  
 
Figure 4.9 γH2AX staining and quantification reveals limited DNA damage following 10 minutes of 
UV light exposure. (a) BxPC-3 cells show no γH2AX staining (red) under normal conditions. After irradiation 
with either 10 or 30 minutes of 365nm UV light, γH2AX fluorescent staining peaks (1 hour post-UV 
irradiation). Levels of γH2AX staining revert to normal 48 hours later, while they remain higher when the UV 
exposure is increased (30 min). γH2AX, red; DAPI, blue. Scale bar, 100 µm, applies to all. (b) Quantification 
of BxPC-3 immunofluorescence pictures, n= 4 pictures per condition, 100 cells per picture. (c) Quantification 
of immunofluorescence pictures for PANC-1 cells (pictures not shown), n= 4 pictures per condition, 100 cells 
per picture. (d) Human γH2A.X was detected in BxPC-3 (B), Capan-2 (C), MIA PaCa-2 (M), PANC-1 (P) and 
OvCar4 (O) cell lysates either without treatment or, in the case of PANC-1 cells, after 10 or 30 minutes of UV 
light exposure. γH2A.X expression (15 kDa) increases marginally after 10 and significantly after 30 minutes of 
UV exposure. GAPDH (36 kDa) was used as loading control, n=1. 
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As shown in Figure 4.9 a-c, BxPC-3 and PANC-1 irradiation with 10 minutes UV-light did 
not cause sustained DNA damage, as the number of γH2AX-positive cells decreases 
reverting to control conditions at 48 hours. However, cells irradiated with 30 minutes of UV 
light show very high γH2AX expression after 1 hour, and the expression is maintained even 
48 hours post-exposure. This was also confirmed via western blot on irradiated PANC-1 
cells (Figure 4.9 d). 
 
Immunofluorescent detection of γH2AX was then performed on cell-containing GelMA 
sections (day 14 of culture) to investigate its expression in established 3D cultures. Limited 
γH2AX expression was observed in PANC-1 spheroids at day 14 of culture, with its 
expression being mainly confined to the edges of the spheroid mass (Figure 4.10 bottom 
inserts). 
 
DSBs associated with replication stress or UV damage are detected by the ataxia-
telangiectasia mutated and Rad3-Related (ATR) kinase, which in turn activates H2AX via 
phosphorylation 289. In turn, ATR can be activated by a number of other proteins, such as 
ATRIP, which also recognises single-strand breaks, an extremely common phenomenon 
during cell replication 290. As such, ATR-mediated H2AX phosphorylation is not necessarily 
indicative of DSBs, particularly for cells in the S-phase, which may explain the high number 
of γH2AX positive cells along the edges of GelMA spheroids. Looking at additional markers 
Figure 4.10 Immunofluorescent detection of γH2AX (red) as a marker of DNA double-strand breaks 
in GelMA-embedded cells. (a) PANC-1 cells were cultured in 5% GelMA for 14 days prior to fixing, 
sectioning (7 µm) and subjection to immunofluorescent staining. Phospho-H2AX, red; DAPI, blue. Scale bars 
100 µm (top) and 20 µm (bottom), applies to all, n=4. 
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such as phosphorylation of the ataxia-telangiectasia mutated (ATM) kinase (Ser1981), 
phosphorylation of the ATM/ATR substrate 291, or of the tumour suppressor p53 (Ser15) 
292, in conjunction with γH2AX could provide additional information on the degree of DNA-
damage incurred by the cells. 
Despite this, a number of groups have now began investigating the use of visible light for 
GelMA crosslinking, replacing the need of a UV source 233,293. For this, the effects of a 
different photo-initiator, lithium acylphosphinate salt (LAP) on cells and a higher wavelength 
(405 nm), would have to be fully characterised. Physicochemical properties, hydrogel 
rheology, pore size and operating procedures (such as light during hydrogel preparation) 
would also have to be adjusted accordingly. 
To summarise, 10 minutes of exposure to high wavelength UV-light (365 nm) did not cause 
sustained DNA damage as quantified via γH2AX staining in monolayer or GelMA-cultured 
cells. Additional markers could be used to investigate the extent of UV-induced DNA-
damage in GelMA further. Finally, the use of visible light as a crosslinking mechanism does 
not come without its own limitations, but is an interesting alternative for GelMA hydrogel 
crosslinking. 
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4.3.5 Investigating the effects of cellular components on the pancreatic TME 
4.3.5.1 Cancer-associated fibroblasts promote cell proliferation and GelMA 
hydrogel stiffening 
The expression of key matrix proteins as well as markers for cellular components of the 
pancreatic TME had already been investigated via tissue IHC in Figures 3.10 and 3.11. COL1, 
FN1, VCAN, HABP, KRT19 and CD68 protein expression was also maintained in 3D cell 
cultures. The cellular fractions of ascites fluid were further characterised via flow cytometry 
in order to gauge a better understanding of its composition (Figure 4.11 a). Ascites fluid from 
HGSOC patients was used for this, as our ethics did not cover collection of PDAC ascites. 
Flow cytometry data revealed a high proportion, nearly 95%, of ascites, was constituted by 
immune cells of leukocyte lineage (CD45+). The remaining 5% represented cells of epithelial 
lineage (CD45-). CD45+ cells were further characterised based on their CD11b monocyte 
marker expression, of which around 80% were positive. Epithelial cells were further gated 
for epithelial cell adhesion molecule (EpCAM) expression, showing around 30% EpCAM+ 
cells.  
a b 
Figure 4.11 Characterisation of cellular fractions of a) HGSOC ascites fluid and (b) HGSOC and PDAC 
primary isolated CAFs, by flow cytometry. (a) Example of gating strategy to determine CD45 expression 
on cells (shown here in channel V450). Leukocyte marker CD45+ cells are further divided into macrophage 
marker CD11b+ or negative (YG582 channel). CD45- cells were further gated for EpCAM (V660). (b) Flow 
cytometry on HGSOC and PDAC patient-derived fibroblast population, characterised via α-SMA (R670) and 
FAP (YG582) markers expression. Plots correspond to patients 2, 17, 1 (Table 2.1), n=3. 
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According to this classification, less than 1.5% of the total ascites population corresponded 
to malignant cells. This is unsurprising as some reports have found tumour cells in ascites to 
be as little as 0.1% 294,295. Even in primary PDAC tissues, malignant cells represent <20% of 
the tumour bulk 59,192,281. Monocytes and fibroblasts were chosen as additional cell types for 
incorporation in GelMA alongside cancer cells, representing respectively an immune and 
epithelial cell component. 
 
When not used for mechanical testing, both HGSOC and PDAC tissues, as well as HGSOC 
ascites, were used for isolation of primary cancer-associated fibroblasts (CAFs). 
Representative flow cytometry analysis for two patients is shown in Figure 4.11 b, where 
alpha-smooth muscle actin (α-SMA) and fibroblast activation protein (FAP) were used as 
fibroblast lineage markers. For each subsequent isolation, fibroblasts were characterised 
using immunofluorescence to confirm their CAF phenotype. Figure 4.12 shows an example 
from PDAC tissue-derived CAFs (top panels) and HGSOC omentum metastasis-derived 
CAFs (bottom panels), both showing typical fibroblast elongated or fried-egg morphologies 
and high α-SMA and vimentin (Vim) expression. 
 
Because of the relatively low percentage of tumour cells in found the cancer bulk and ascites 
fluid, co-culture studies were always performed with a higher proportion (either 4:1 or 1:2, 
as stated each time) of stromal cells compared to tumour cells. Following isolation and 
characterisation, CAFs were seeded in a 4:1 ratio with PDAC cell lines, alongside appropriate 
monoculture controls, in 5% (wt/vol) GelMA hydrogels. Representative micrographs of cell 
Composite 
Figure 4.12 Immunofluorescence analysis of patient-derived cells confirmed CAF phenotype by co-
expression of alpha-smooth muscle actin (αSMA, AF568) and fibroblast activation protein (FAP, 
AF488); phalloidin (AF647), DAPI (EX358). Cells were derived from patients 16 and 13 (Table 2.1). Scale 
bars 10 µm, applies to all. Representative pictures, n=9 patients assessed in total. 
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cultures at day 14 are shown in Figure 4.13 a. The presence of CAFs increased cell 
proliferation in co-culture hydrogels compared to monocultures for 3 out of 4 PDAC cell 
lines tested, with the exception of BxPC-3, as indicated by the Alamar Blue results (Figure 
4.13 b). In monoculture, CAFs remained viable in GelMA hydrogels however, they did not 
proliferate, as reflected in the constant Alamar Blue values on day 1 throughout to 14 
(live/dead staining not shown, see Figure 4.17). This is unsurprising as the doubling time of 
primary CAFs was extremely low even on tissue culture plastic. From this analysis, it is 
however unclear which cell population, if not both, had an increased proliferation rate as a 
result of being in co-culture. A dual staining of a proliferation (e.g. Ki67) and fibroblast or 
cancer marker could be conducted in order to answer this question.  
Next, I assessed whether CAFs would impact GelMA hydrogel stiffness. For this analysis, 
BxPC-3 cells were chosen as their proliferation was not significantly affected by CAFs 
(Figure 4.13 b), ensuring that observed stiffness differences would not be due to different 
cell numbers within the hydrogels. BxPC-3 cells were incorporated in 3% (wt/vol) and 5% 
(wt/vol) GelMA hydrogels in a 1:2 ratio with either CAFs or normal fibroblasts (NFs). CAFs 
and NFs were isolated from matched PDAC and tumour-adjacent tissue samples respectively 
(Patient 17, see Table 2.1). 
Figure 4.13 CAFs promote cell proliferation in 5% GelMA co-cultures with PDAC cells. (a) 
Representative brightfield micrographs of (top) PANC-1 monoculture and (bottom) PANC-1 and CAF co-
culture (1:4 ratio), at day 14 of culture in 5% GelMA. Scale bars 500 µm and 2 mm (inserts), apply to all. (b) 
Alamar Blue quantification of cell viability of 3D cell cultures at day 1 (light blue) and day 14 (blue) in 5% 
GelMA monocultures and PDAC/CAF co-cultures (1:4 ratio). ANOVA (Tuckeys multiple comparisons), p-
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The presence of CAFs in the co-cultures significantly increased the hydrogel’s Young’s 
modulus in both 3% (wt/vol) and 5% (wt/vol) GelMA (Figure 4.14). Interestingly, NFs had 
no effect on hydrogel Young’s modulus. As cells in GelMA are in close proximity but not 
necessarily in direct contact, it is likely that both proliferative and stiffening effects would be 





















































































Figure 4.14 Young’s modulus measurement of 3% and 5% GelMA BxPC-3 co-cultures with cancer-
associated fibroblasts (CAFs) or non-malignant fibroblasts (NFs), and respective monoculture 
controls (day 14). Dotted lines represent GelMA stiffness prediction for 3% (1.3 kPa) and 5% (3.4 kPa) 
GelMA. ANOVA (Tuckeys multiple comparisons), p-values as annotated, n=4. 
4.3.5.2 Co-culture of myeloid and cancer cells contribute to tumour development 
and metastasis in vivo 
Macrophages are the dominant leukocyte population both in human PDAC stroma and 
autochthonous disease models 51. Human THP-1 leukaemia-derived monocytes were used 
to model immune cells in our 3D platform. Due to tissue bank ethics restrictions we were 
not able to collect any fresh blood from human donors, which would have been a preferred 
source of cells of monocytic lineage. As discussed in Figure 3.11, once co-cultured with 
cancer cells in GelMA, monocytes not only proliferated to form cell clusters, but they also 
showed a positive CD68 expression indicating they had differentiated into macrophages 
(Figure 3.11). 
 
In order to assess the effects of THP-1 on cancer cell survival and proliferation, monocytes 
were incorporated in a 2:1 ratio alongside either BxPC-3 or PANC-1 cells in 5% (wt/vol) 
GelMA hydrogels. Appropriate BxPC-3 or PDAC monoculture controls were also set up. 
After 14 days of culture, both mono- and co-culture GelMA hydrogels were implanted 
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orthotopically on top of the pancreas of 6 female NOD/SCID mice (Figure 4.15 a). In an 
effort to reduce the number of animals used, no GelMA vehicle-only group was kept, as this 
had already been shown to generate no inflammation or tumour formation in previous 
reports 252. Animal appearance and weight was recorded weekly and once tumours reached a 
palpable size, usually around 10-14 weeks post-surgery, animals were sacrificed. Presence of 
ascites was noted, GelMA hydrogels, tumours, spleen and liver tissues were surgically 
removed, and the latter were subjected to histological and immunohistochemical analyses. 
Human-specific KRT19 and Ki67 detection on the resected tumours confirmed that PDAC 
cells were capable of migrating outside of GelMA hydrogel implants and colonising the 
murine pancreas forming tumours (Figure 4.15 b). 
 
Ascites fluid and xenograft tissues were subjected to flow cytometry or bulk mechanical 
testing. Detection of tumour marker EpCAM by flow cytometry using a human-specific 
antibody, revealed the presence of a subpopulation of human tumour cells with positive 
chemokine receptor type-4 (CXCR4) expression (Figure 4.16 a). CXCR4 expression in 
PDAC is correlated with worse prognosis as its expression on tumour cells promotes tumour 
Figure 4.15 GelMA hydrogel orthotopic xenograft. (a) Schematic representation of xenograft implant 
procedure. BxPC-3 or PANC-1 cells were grown either in monocultures or in co-culture with THP-1 cells for 
14 days in 5% GelMA prior to subcutaneous implant. Animals were sacrificed at the first sign of symptoms, 
around 10-14 weeks after implant. (b) Immunohistochemical analysis of human-specific cytokeratin-19 
(KRT19) and Ki67 in resected xenograft tumours. Spleen serves as negative control tissue, while positive cells 
stain for DAB (brown chromogen). Scale bar, 50 µm for higher magnification. 
 
 
Figure 4.16Figure 4.15 GelMA hydrogel orthotopic xenograft. (a) Schematic representation of xenograft 
implant procedure. BxPC-3 or PANC-1 cells were grown either in monocultures or in co-culture with THP-1 
cells for 14 days in 5% GelMA prior to subcutaneous implant. Animals were sacrificed at the first sign of 
symptoms, around 10-14 weeks after implant. (b) Immunohistochemical analysis of human-specific 
cytokeratin-19 (KRT19) and Ki67 in resected xenograft tumours. Spleen serves as negative control tissue, while 
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cell growth, migration, and invasiveness 296,297. Here, CXCR4 was used as a cancer stem cell 
marker in conjunction with EpCAM to determine the malignant human cell population of 
the murine tumours. 
 
No significant difference was found between the stiffness of xenograft tissues derived from 
monoculture (BxPC-3 or PANC-1) and co-culture (BxPC-3/PANC-1 + THP-1) implants, 
despite a clear trend towards an increase in stiffness of co-culture xenograft tissues (Figure 
4.16 b, p=0.08). Increased sample size (n>3) would be necessary for significance to be 
detected via whole-tissue stiffness analysis, as only three tumours were available per 
condition. Some cell-containing GelMA hydrogels were also retrieved after post-mortem 
inspection and subsequently tested for stiffness. No significant difference was found between 
hydrogel stiffness in monoculture and co-culture groups, indicating that unlike CAFs, THP-
1 cells might not be contributing to hydrogel stiffening (Figure 4.16 c). To note, that the long 
permanence of hydrogels in mice and the subsequent surgical procedures and handling might 
have compromised the integrity and original stiffness of these hydrogels. 
 
In addition to hydrogel and tumour resection, the presence of ascites and additional 
metastases was noted (Table 4.3). Implantation of THP-1 and cancer cell co-cultures resulted 
in both an increase in tumour occurrence as well as increased metastases incidence in both 
BxPC-3 and PANC-1 groups. 
Figure 4.16 Analysis of resected orthotopic xenograft tumorigenic cell population and tumour 
stiffness. (a) Flow cytometry analysis of resected murine tumours. Human-specific EpCAM and CXCR4 
positive cells allow the detection of human-specific cell components of the murine tumours. (b) Young’s 
modulus of tumours from mice in monoculture groups (BxPC-3 and PANC-1) and co-culture groups (BxPC-
3/PANC-1 and THP-1). Monocultures: 6.0 ± 0.65 kPa, co-cultures: 7.2 ± 0.74 kPa, t-test p= 0.086, n=3. (c) 
Young’s modulus of mice-resected GelMA hydrogels for monoculture groups (BxPC-3 and PANC-1) and co-
culture groups (BxPC-3/PANC-1 and THP-1). Dotted line represents stiffness prediction for 5% GelMA, 3.4 
kPa. Monocultures: 3.8 ± 0.65 kPa, co-cultures: 3.4 ± 0.84 kPa, t-test p=0.24, n=9. 
 
 
Figure 4.17Figure 4.16 Analysis of resected orthotopic xenograft tumorigenic cell population and 
tumour stiffness. (a) Flow cytometry analysis of resected murine tumours. Human-specific EpCAM and 
CXCR4 positive cells allow the detection of human-specific cell components of the murine tumours. (b) 
Young’s modulus of tumours from mice in monoculture groups (BxPC-3 and PANC-1) and co-culture groups 
(BxPC-3/PANC-1 and THP-1). Monocultures: 6.0 ± 0.65 kPa, co-cultures: 7.2 ± 0.74 kPa, t-test p= 0.086, 
n=3. (c) Young’s modulus of mice-resected GelMA hydrogels for monoculture groups (BxPC-3 and PANC-
1) and co-culture groups (BxPC-3/PANC-1 and THP-1). Dotted line represents stiffness prediction for 5% 
GelMA, 3.4 kPa. Monocultures: 3.8 ± 0.65 kPa, co-cultures: 3.4 ± 0.84 kPa, t-test p=0.24, n=9. 
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Metastases (number of 
animals, locations) 
Tumour stiffness 
(Young’s modulus, kPa) 
BxPC-3 2/6 0/6 5.54 ± 0.13 
BxPC-3 + THP-1 5/6 2/6 (diaphragm, omentum) 7.0 ± 0.97 
PANC-1 2/6 1/6 (ascites) 6.54 ± 0.51 
PANC-1+ THP-1 5/6 3/6 (ascites, omentum) 7.4 
  
To summarise, patient-derived CAF inclusion in GelMA cultures resulted in an increased 
PDAC cell proliferation (in three of four cell lines analysed) and increased GelMA hydrogel 
stiffness, which was not observed with NFs. GelMA hydrogels were successfully employed 
as vehicles for cell delivery in orthotopic xenograft experiments. THP-1 monocytic cells 
contributed to both tumour development and formation of metastasis in vivo. 
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4.3.6 Mimicking the pancreatic TME in GelMA hydrogels using triple cell 
cultures 
4.3.6.1 Stromal cells lead to increased cell proliferation in GelMA and collagen 
hydrogels 
GelMA hydrogels allowed the simultaneous 3D culture of multiple cell types. In order to 
recapitulate a complex pancreatic TME, I next assessed the viability of triple cultures of 
PDAC cells, THP-1 cells and CAFs in GelMA hydrogels. Due to the high stromal content 
of pancreatic tumours 59,60, PDAC cells were embedded in a 1:2:2 ratio with stromal cells, in 
both 5% (wt/vol) and 7.5% (wt/vol) GelMA hydrogels, whose stiffness closely mimic that 
of human tumour tissues. Collagen hydrogels were used both as soft matrix control as well 
as for their prominence as 3D cell culture system in the literature 144,192,203,267. Appropriate 
PDAC monoculture and stromal (CAF and THP-1) control hydrogels were also set up. 
 
Brightfield and confocal imaging (Figure 4.17 a,b) revealed GelMA supported high viability 
of CAFs and THP-1 cells even without PDAC cell presence throughout the 14 days of 
culture. Confocal micrographs of triple cultures will be shown later on in Chapter 6. THP-1 
cells formed round spheroids while CAFs retained their typical elongated fibroblast 
morphology. Proliferation of these cultures was assessed via metabolic activity (Figure 4.17 
c) and DNA content quantification (Figure 4.17 d) from three independent experiments with 
CAFs isolated from patients 2, 3 and 14 (Table 2.1). DNA content analysis revealed a 
significantly higher proliferation in PANC-1 cells when cultured with CAFs and THP-1s 
compared to monoculture controls irrespective of stiffness. Despite remaining viable, 
stromal cells preferred soft matrices for proliferation (collagen and to a lesser extent 5% 
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4.3.6.2 Stromal cells in GelMA result in increased hydrogel stiffness 
The stiffness of GelMA cultures was also assessed (Figure 4.18). The presence of stromal 
cells led to an increased hydrogel stiffness in 7.5% (wt/vol) GelMA triple cultures compared 
to PANC-1 monocultures. As THP-1 cells alone did not have a significant effect on matrix 
stiffness (Figure 4.16 c), hydrogel stiffening could likely be attributed to CAF interactions 
with the surrounding matrix and other cells of the triple culture (PANC-1 and THP-1). A 
similar trend was observed in 5% (wt/vol) GelMA hydrogels despite not being significant. 
A higher stiffness might also indicate that CAFs had an increased proliferation rate triple 
cultures, contributing to both a higher DNA content (Figure 4.17 d) and increased Young’s 
Figure 4.17 PDAC, THP-1 and CAF triple cultures in GelMA and collagen hydrogels. (a) Brightfield 
micrographs at day 14 of culture in 7.5% GelMA (top panels) and collagen (bottom panels) hydrogels. Triple 
cultures and relevant monoculture (PANC-1) and stroma (CAF and THP-1) controls shown. Scale bar, 100 
µm, applies to all. (b) Confocal imaging of THP-1 and CAF stromal co-cultures (day 14) in 7.5% GelMA (top) 
and collagen (bottom); live cells were stained with green-fluorescent calcein-AM (Ca-AM, 494/517 nm); dead 
cells were stained with red-fluorescent ethidium homodimer-1 (Et-H1, 528/617 nm). Scale bar, 100 µm, applies 
to all. (c) Alamar blue cell viability quantification of PANC-1 monoculture, stromal cultures (THP-1+CAF) 
and triple cultures (PANC-1 + THP-1 + CAF) in collagen, 5% GelMA, 7.5% GelMA hydrogels on day 14. 
n=3, CAFs from patients 2 (yellow dots), 3 (blue dots), 14 (grey dots). ANOVA (Tuckey multiple comparisons), 
p-value wrt PANC-1 as annotated. (d) CyQUANT DNA content quantification of PANC-1 monoculture, 
stromal cultures (THP-1+CAF) and triple cultures (PANC-1 + THP-1 + CAF) in collagen, 5% GelMA, 7.5% 
GelMA hydrogels on day 14. n=3, CAFs from patients 2 (yellow dots), 3 (blue dots), 14 (grey dots). ANOVA 
(Tuckey multiple comparisons), p-value wrt PANC-1 as annotated.  
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modulus (Figure 4.18). This could be tested via proliferative marker staining (Ki67) on mono- 
and triple-cultures. 
 
4.3.6.3 Stromal cells lead to increased pro-inflammatory cytokines secretion in 
GelMA and collagen hydrogels 
The expression of some key pro-inflammatory cytokines was assessed at day 14 of culture in 
the conditioned supernatant of either PANC-1 cells, stromal cells (CAF and THP-1) or triple 
cultures in collagen and GelMA hydrogels. Overall, the levels of secreted cytokines decreased 
in cultures from soft to stiff matrices. Secreted IL-6 levels were higher in triple cultures 
compared to controls in both collagen and 5% GelMA (Figure 4.19 a). In 7.5% GelMA, IL-
6 levels decreased compared to stroma but were highly upregulated compared to PANC-1 
levels. Secreted IL-8 levels were higher in triple cultures compared to controls in all three 
matrices (Figure 4.19 b). IL-6 and IL-8 are known to promote proliferation, migration and 
invasion in PDAC 298-300, hence higher levels of these cytokines are concordant with the 
observed increase in cell proliferation of these cultures. Importantly, as IL-6-dependant 
activation of STAT3 is a hallmark of PDAC progression 300, stroma-induced activation of 
pro-survival signalling pathways in collagen and GelMA hydrogels was assessed next. 
Figure 4.18 Young’s modulus measurement of 5% and 7.5% GelMA PANC-1 co-cultures with CAFs 
and THP-1s, and respective stroma (CAF + THP-1) and PDAC-only controls (day 14). Dotted lines 
represent GelMA stiffness prediction for 5% (3.4 kPa) and 7.5% (8.6 kPa) GelMA. n=3, CAFs from patients 
2 (yellow dots), 3 (blue dots), 14 (grey dots). ANOVA (Tuckey multiple comparisons), p-value as annotated. 
 
Figure 4.19Figure 4.18 Young’s modulus measurement of 5% and 7.5% GelMA PANC-1 co-cultures 
with CAFs and THP-1s, and respective stroma (CAF + THP-1) and PDAC-only controls (day 14). 
Dotted lines represent GelMA stiffness prediction for 5% (3.4 kPa) and 7.5% (8.6 kPa) GelMA. n=3, CAFs 
from patients 2 (yellow dots), 3 (blue dots), 14 (grey dots). ANOVA (Tuckey multiple comparisons), p-value 
as annotated. 
 
Figure 4.19 Secreted (a) interlukin (IL)-6 and (b) IL-8 levels in cell culture supernatants at day 14 of 
cult re in either collagen, 5% or 7.5% GelMA hydrogels. CAFs isolated from patient 3 were used for this, 
n=1. 
 
Figure 4.19Figure 4.18 Young’s modulus measurement of 5% and 7.5% GelMA PANC-1 co-cultures 
with CAFs and THP-1s, and respective stroma (CAF + THP-1) and PDAC-only controls (day 14). 
Dotted lines represent GelMA stiffness prediction for 5% (3.4 kPa) and 7.5% (8.6 kPa) GelMA. n=3, CAFs 
from patients 2 (yellow dots), 3 (blue dots), 14 (grey dots). ANOVA (Tuckey multiple comparisons), p-valu  
as annotated. 
 
Figure 4.19Figure 4.18 Young’s modulus measurement of 5% and 7.5% GelMA PANC-1 co-cultures 
with CAFs and THP-1s, and respective stroma (CAF + THP-1) and PDAC-only controls (day 14). 
Dotted lines represent GelMA stiffness prediction for 5% (3.4 kPa) and 7.5% (8.6 kPa) GelMA. n=3, CAFs 
from patients 2 (yellow dots), 3 (blue dots), 14 (grey dots). ANOVA (Tuckey multiple comparisons), p-value 
as annotated. 
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To conclude, GelMA hydrogels were employed for the 3D culture of multiple cell types 
including key cellular components of the pancreatic TME, namely CAFs and myeloid cells. 
Both primary cells and established cell lines maintained a high viability throughout long-term 
culture over 4 weeks, which was paramount for their implementation in treatment studies 
(Chapter 6). The presence of stromal cells increased both matrix stiffness and cell 
proliferation of PDAC cells. These effects were more evident in stiffer 7.5% (wt/vol) GelMA 
matrices, which are representative of physiological PDAC stiffness. Co-culture of stromal 












































































































































Figure 4.19 Secreted (a) interleukin (IL)-6 and (b) IL-8 levels in cell culture supernatants at day 14 of 
culture in either collagen, 5% or 7.5% GelMA hydrogels. CAFs isolated from patient 3 were used for this, 
n=1. 
 
Figure 4.19 Secreted (a) interlukin (IL)-6 and (b) IL-8 levels in cell culture supernatants at day 14 of 
culture in either collagen, 5% or 7.5% GelMA hydrogels. CAFs isolated from patient 3 were used for this, 
n=1. 
 
Figure 4.19 Secreted (a) interlukin (IL)-6 and (b) IL-8 levels in cell culture supernatants at day 14 of 
cultur  in either collagen, 5% or 7.5% GelMA hydrogels. CAFs isolated from patient 3 ere used for this, 
n=1. 
 
Figure 4.19 Secreted (a) interlukin (IL)-6 and (b) IL-8 levels in cell culture supernatants at day 14 of 
culture in either collagen, 5% or 7.5% GelMA hydrogels. CAFs isolated from patient 3 were used for this, 
n=1. 
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4.3.7 A novel hydrogel-based indirect co-culture system unveils stroma-
induced upregulation of pro-survival signals in PDAC cells 
In order to understand further the stromal (CAF and THP-1) cell’s influence on PDAC cell 
signalling pathways, an indirect 3D co-culture experiment was devised (Figure 4.20 a). For 
this, patient-derived CAFs and THP-1 monocytes were co-embedded in collagen, 5% or 
7.5% GelMA hydrogels. Monocultures of PANC-1 cells were also set up in collagen, 5% or 
7.5% GelMA hydrogels. PDAC- and stroma-containing hydrogels were then cultured in the 
same medium-containing well (indirect co-culture) or in separate wells (controls) for 72 
hours, after which hydrogels were separated visually under and inverted microscope and 
subjected to proliferation, stiffness and immunoblotting analyses (Figure 4.20 a). 
 
Cell viability and hydrogel stiffness were analysed after 72 hour as control measures for this 
early time point (Figure 4.20 b, c). Compared to day 1, all conditions showed a fold change 
in metabolic activity of a value higher than 1, indicative of cell viability and a little initial cell 
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Figure 4.20 Indirect co-culture experimental setup and analysis of viability and mechanical properties. 
(a) Schematic representation of experimental setup. Collagen, 5% and 7.5% GelMA hydrogels were set up 
containing either cancer cells (PANC-1) or stromal cells (THP-1 and CAFs). Cancer and stroma hydrogels 
were either cultured in the same well of a 12-well plate (indirect co-culture) or placed in individual wells as 
controls. Hydrogels were kept for 72 hours in culture with no medium replacement, after which cancer cell-
containing hydrogels in the co-culture were separated from the stroma-containing hydrogels (visually, with an 
inverted microscope). Hydrogels were then subjected to protein extraction for further analysis. (b) Fold change 
in metabolic activity of control hydrogels (PANC-1, THP-1/CAF) at day 3 of culture as measured via Alamar 
Blue assay, n=3. (c) Stiffness of cell-containing 5% and 7.5% GelMA hydrogels at day 3 of culture. Dotted line 
corresponds to predicted hydrogel stiffness, n=2. 
 
Figure 4.20 Indirect co-culture experimental setup and analysis of viability and mechanical properties. 
(a) Schematic representation of experimental setup. Collagen, 5% and 7.5% GelMA hydrogels were set up 
containing either cancer cells (PANC-1) or stromal cells (THP-1 and CAFs). Cancer and stroma hydrogels 
were either cultured in the same well of a 12-well plate (indirect co-culture) or placed in individual wells as 
controls. Hydrogels were kept for 72 hours in culture with no medium replacement, after which cancer cell-
containing hydrogels in the co-culture were separated from the stroma-containing hydrogels (visually, with an
inverted microscope). Hydrogels were then subjected to protein extraction for further analysis. (b) Fold change 
in metabolic activity of control hydrogels (PANC-1, THP-1/CAF) at day 3 of culture as measured via Alamar 
Blue assay, n=3. (c) Stiffness of cell-containing 5% and 7.5% GelMA hydrogels at day 3 of culture. Dotted line 
corresponds to predicted hydrogel stiffness, n=2. 
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matched the prediction (dotted line 3.4 kPa for 5% GelMA and 8.6 kPa for 7.5% GelMA) 
(Figure 4.20 c). Despite the early timepoint, there was a tendency for stromal hydrogels (CAF 
and THP-1) to be a little stiffer than their PDAC counterparts. The difference is not 
statistically significant on day 3 but could be indicative of matrix remodelling already starting 
at early stages of 3D cell culture. Once again, it would seem that CAFs are the main drivers 
of matrix stiffening in GelMA (as seen earlier in this Chapter). 
 
Next, immunoblotting was performed on hydrogel-retrieved cells and further quantified via 
densitometry (Figure 4.21 a,b). Western blot analysis of protein lysates revealed an increase 
in phosphorylated signal transducer and activator of transcription 3  (pSTAT) in cancer cells 
following co-culture (blue bars) compared to monoculture (orange bars), indicating 
activation of pro-survival pathways 18. This pattern was observed in all three hydrogels. 
Importantly, STAT3 activation is constitutive of PDAC pathogenesis and progression 301, 
hence its upregulation in co-culture settings could be responsible of the increased 
proliferation observed in co-cultures and triple cultures throughout the project (Figures 4.13, 
4.15 and 4.17). 
 
In stromal cells, STAT3 phosphorylation increased when co-cultured (blue bars) with 
PANC-1 in collagen hydrogels compared to control (green bar), but was unchanged in 5% 
and 7.5% GelMA. Similarly, stromal cells (CAF and THP-1) had a decreased proliferation in 
GelMA compared to collagen hydrogels as shown in Figure 4.17 d. STAT3 phosphorylation 
in CAFs is known to increase the expression of insulin-like growth factor 1 (IGF-1) to 
promote PDAC cell proliferation 302, concordant with the increase proliferation observed in 
PDAC co-cultured with CAFs and triple cultures. STAT3 phosphorylation also induces the 
emergence of pro-invasive and pro-survival characteristics of fibroblasts, ultimately leading 
to in vitro and in vivo ECM remodelling and stiffening 303. In fact, crosstalk between the 
JAK1/STAT3 pathway and the mechanosensing RhoA/ROCK/MLC2 signalling pathway, 
links CAF survival to stiffness regulation, although more work needs to be done in order to 
fully clarify their interactions 304. This mechanism could be underlying the observed increase 
of stiffness of triple-cultures in GelMA (Figure 4.18).  
 
Since CAF and THP-1 cells have been incorporated in the same hydrogel for this assay, it is 
not possible to understand their individual contributions to the phosphorylation of STAT3 
in PANC-1 cells and vice versa. A similar, indirect co-culture experiment with CAF and 
THP-1 cells in separated hydrogels could help clarify this. In fact, STAT3 activation in 
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macrophages has anti-tumour properties and leads to suppressed inflammation via IL-10-
mediated suppression of TNF-α 305,306. Hence, it could be possible that during indirect co-
culture THP-1 cells downregulated their pSTAT3 expression while CAFs upregulated it, 
resulting in little difference in the overall levels of pSTAT3 in these hydrogels. 
 
Unlike pSTAT3, phosphorylated extracellular-signal-regulated kinase (pERK) did not 
significantly increase in co-cultures (blue bars) versus controls in neither PANC-1 or stromal 
cells (orange, green bars) (Figure 4.21 b). In 7.5% GelMA, pERK/ERK levels in co-cultures 
are 30-40% lower than control conditions. Therefore both PANC-1 and stromal cells 
increased phosphorylation of STAT3 while reducing that of ERK in stiff matrices. A direct 
inverse correlation in expression levels of pERK and pSTAT3 has already been reported 
both in vitro and in vivo, where they were responsible for mediating resistance to treatment 
(specifically MAPK/ERK – RAS - pathway inhibitors) 307. Stiffness-induced increase of 
pSTAT3 and reduction of pERK could therefore be responsible for increased drug resistance 
in stiffer tumours. 
To conclude, indirect co-culture of PDAC and stromal (CAF and THP-1 cells) led to the 
upregulation of pSTAT3 levels in the cancer cells, together with a stiffness-dependant 
reduction in pERK levels. In the stromal cells, co-culture led to an increase in pSTAT3 in 
collagen and a decrease in pERK in 7.5% GelMA however, the individual protein levels in 
THP-1 and CAFs were not assessed.   




















































































































































































































Figure 4.21 Indirect co-culture of PANC-1 cells with THP-1 cells and CAFs promotes activation of 
pro-survival pathways via STAT3 phosphorylation. (a) Immunoblots of phosphorylated MAPK (p-ERK) 
and STAT3 (p-STAT3) proteins with paired total proteins following 72 h of culture. Vinculin was used as 
protein loading control. (b) Relative STAT3 and MAPK densitometric analysis of phosphorylated/total protein 
bands in Figure 7a, data normalised to Vinculin control, change relative to PANC-1 monoculture controls 
(100%), n=2. 
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4.4 Conclusions 
In this chapter I covered a characterisation of the main biochemical properties of GelMA 
hydrogels which, together with biomechanics described in Chapter 3, provide an extensive 
characterisation of GelMA’s versatility as a 3D cell culture platform. Since it was first 
described 236, it was clear that GelMA hydrogels’ physical properties could be tuned by 
adjusting its degree of functionalisation (DoF), concentration, photo-initiator concentration 
and UV-exposure time during hydrogel polymerisation. We used 1H NMR, alongside three 
spectroscopy-based techniques to characterise the DoF of our in-house GelMA batches 
(Figure 4.1). The DoF plays a role in GelMA’s crosslinking efficiency, affecting in turn 
GelMA stiffness and stiffness predictability, hydrogel consistency and reproducibility, all 
leading to batch-to-batch and experimental variation. All tested batches had a very similar 
and high DoF (66-71%), minimising any inter-batch effects on biological assays. For GelMA 
batches with similar DoF, previous reports 230,242 have found hydrogel stiffness to be very 
similar (DoF 64%, 3.2± 0.18 kPa) 246 to what I previously reported in Figure 3.7 (DoF: 71%, 
3.4 kPa). Pore size in GelMA hydrogels can also be tuned by its DoF and characterised via 
SEM. For DoFs between 60-75% the average GelMA hydrogel pore size has been found at 
25-30 μm, a size which is conducive of cell proliferation and migration 246,247. 
 
Next, the proliferation and spheroid formation abilities of cells in GelMA hydrogels was 
assessed (Figures 4.2-4.6). The work presented here showed that these hydrogels support 
long-term culture of both established cell lines and primary cells, which remained highly 
viable and proliferative. By day 14 of 3D culture, spherical aggregates were visible by 
brightfield imaging and resembled spheroids disseminating in the tumour fluid (ascites) of 
cancer-bearing patients, distinctively at late-stage disease 252,308. The expression of biomarkers 
such as KRT19 was also maintained by GelMA-embedded cells throughout culture (Figure 
4.4). Cell growth parameters such as spheroid diameter (Figure 4.3), shape (Figure 4.5), total 
hydrogel cell viability (Figure 4.6 a) and DNA content (Figure 4.6 b), were both stiffness-
dependent and cell line specific.  
 
All cell lines formed round spheroids with the exception of MIA PaCa-2 cells which 
proliferated in a disorderly fashion in stiffer matrices (7.5-10% (wt/vol) GelMA). A number 
of reports have described MIA PaCa-2 cells to form loose cell aggregates in 3D matrices 
compared to tighter clusters formed by the other three PDAC cell lines 201,203,309. This 
phenotypic variability in spheroid formation can be attributed to the EMT status 203,282 and 
 GelMA Hydrogels as a 3D Platform to Study Cell Behaviours 
 
-  154 - 
 
aggressiveness of the cell lines, whereby Capan-2 and BxPC-3 formed tighter and compact 
spheroids whilst the more aggressive PANC-1 and MIA PaCa-2 formed irregular colonies. 
In a separate study, subcutaneous injection of these cell lines in mice resulted in well and 
moderately differentiated tumours for Capan-2 and BxPC-3 cells respectively, while PANC-
1 and MiaPaCa-2 cell lines developed undifferentiated primary tumour masses, which 
proliferated in an unorganized way 201. In PDAC, tissue stiffness is known to promote EMT, 
at least in vitro 128, which is evident through the loss of adhesion, circularity, and higher 
migration of cells towards the edges of stiff GelMA hydrogels (7.5-10% (wt/vol) GelMA). 
Cell lines with a highly epithelial phenotype (Capan-2 and BxPC-3) increased their 
proliferation in response to increased matrix stiffness (from 3% (wt/vol) to 5-7.5% (wt/vol) 
GelMA) whereas more mesenchymal cell lines did not increase their proliferation in response 
to stiffness. 
 
In order to make molecular analyses feasible for my next chapters, I optimised techniques 
for the retrieval of cells from GelMA hydrogels without compromising their viability or 
expression profile. Gelatin retains a number of protease-sensitive and cell binding sites (such 
as RGD-binding and MMP-sensitive sites) 238 implicated in a number of physiological 
functions, including cell proliferation, migration, invasion, disease development and 
progression, and are therefore key components of any bioactive niche analogue. As such, it 
also retains collagen and fibronectin domains normally present in gelatin 109, which make it 
cleavable through digestion with collagenases and other proteolytic cocktails (Table 4.2, 
Figure 4.7). Other groups have developed different fast and non-invasive approaches for the 
digestion of synthetic hydrogels 310. An example is the functionalisation of the polymer 
backbone with microbial protease-sensitive peptides. The resulting hydrogels would then 
allow controlled, immediate, on-demand degradation with the simple addition of a microbial 
protease 310.   
 
Another aspect of working with GelMA is the use of UV light to which cells are subjected 
during hydrogel crosslinking. I used γH2AX as a marker to assess DSBs in the DNA as a 
result of UV-induced damage. Analysis was performed on cells after 10 minutes of UV 
exposure, the same amount of time normally employed for GelMA crosslinking. The number 
of γH2AX positive cells increased marginally 1-hour post-exposure but was back to control 
levels after 48 hours, suggesting affected cells either were unaffected, fully recovered, or 
underwent apoptosis (Figure 4.9a-c). An additional consideration is the higher UV dose to 
which monolayer cells were subjected, due to the lack of glass slide and hydrogel that would 
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normally be surrounding them during GelMA synthesis. For this reason, I also looked at 
γH2AX expression on GelMA sections at day 14 of culture (Figure 4.10). Some 
phosphorylated H2AX was detected in GelMA sections, particularly towards the rim of the 
spheroids, where the majority of proliferating cells are located. High γH2AX staining can be 
seen in S-phase cells even in the absence of DSBs 288, therefore the combined use of γH2AX 
together with other DSB-dependant markers, such as p53 binding protein (53BP1), RAD-
51, or BRCA1 311, would validate these results. The use of highly soluble, low concentration 
photo-initiators (e.g. LAP) and crosslinking via visible light, are rapidly changing the way 
GelMA is synthesised in order to reduce and remove risks associated with UV light exposure. 
Importantly, potential UV-induced DNA alterations might be responsible for changes in 
cell’s sensitivity to chemotherapeutic agents, as tested later in Chapter 6. Future GelMA work 
should aim to characterise this in cultures pre and post-chemotherapy, with and without thee 
use of UV-photocrosslinking, to fully characterise the effects of crosslinking on treatment 
response. 
 
Lastly, the effects of stromal and immune cell components on PDAC cells were assessed in 
GelMA hydrogels. Figure 4.11 showed ascites composition was largely attributable to stromal 
and immune cells, with less than 1.5% comprising malignant cells, which is largely 
concordant with other reports on both ascitic fluids 294,295 and primary tumour composition 
59,192,281. To reflect this, cell ratios in GelMA cultures always comprised more stromal (CAF 
and/or THP-1) cells than PDAC cells. Patient-derived CAF isolation and characterisation 
was conducted via flow cytometry and immunofluorescence on both ascites- and tissue-
derived CAFs (Figure 4.11 b, Figure 4.12). 
 
CAFs incorporation alongside PDAC cells increased both cell proliferation (Figure 4.13) and 
GelMA hydrogel stiffness (Figure 4.14). Interestingly, these effects were not observed when 
fibroblasts (NFs) isolated from normal tissue were used instead. Other groups identified 
Special AT-rich sequence-Binding protein-1 (SATB-1) and Stromal cell Derived Factor 1 
(SDF-1) amongst the differentially upregulated genes in PDAC cells when exposed to CAFs 
versus NFs conditioned medium 64. CAF-mediated SATB-1 upregulation of SDF-1 (also 
known as CXCL12) can signal through the SDF-1/CXCR4/SATB-1 axis increasing cell 
proliferation and chemotherapy resistance 64. This could be of particular interest in our triple 
cultures as PDAC tumour-associated macrophages (TAMs) are also known to significantly 
upregulate CXCR4 312. This could be confirmed in the future via flow cytometry. Moreover, 
 GelMA Hydrogels as a 3D Platform to Study Cell Behaviours 
 
-  156 - 
 
CXCR4 overexpression represents a risk factor and is associated with increased incidence of 
distal metastases 313,314 and delayed PDAC diagnosis 315. 
 
The ability of both malignant and stromal cells to remodel biomaterials, as they would do 
with the ECM, and affect their stiffness, has been known for decades 316. CAFs specifically 
are capable of remodelling the surrounding matrix via both the platelet-derived growth factor 
receptor (PDGFR) and lysophosphatidic acid (LPA) receptors through phosphatidylinositol 
3 kinase (PI3K) signalling 317. Alternatively, LPA-stimulated remodelling can act through the 
Rho-kinase (ROCK) pathway 317. In turn, both ROCK and PI3K lead to cofilin-mediated 
actin remodelling and matrix contraction 318. It was therefore unsurprising that the culture of 
PDAC and CAFs would lead to matrix and hydrogel stiffening. 
 
While CAFs presence supported spheroid formation and cell survival in GelMA hydrogels, 
macrophages alone did not have a significant effect on PDAC cell proliferation or hydrogel 
stiffness in vitro (Figure 4.16), concordant with other 3D studies 309,319. The presence of THP-
1 cells did, however, lead to an increased incidence of both tumours and metastases in 
orthotopic xenografts of PDAC cells with GelMA hydrogels as a delivery vector. Evidence 
of the crosstalk between PDAC cells and THP-1 is their differentiation into CD68+ 
macrophages (Figure 3.11), which in turn, is known to increase PDAC cell migration and 
proliferation through increased IL-8 secretion and STAT3 expression 320,321. This was indeed 
the case as both pSTAT3 and secreted IL-8 levels were higher in co-cultures compared to 
monocultures as shown in Figure 4.19 and Figure 4.21. Although not significant, resected 
tumour stiffness was also higher in PDAC+THP-1 groups compared to PDAC alone, 
suggesting increased tumour aggressiveness 322. This also provided proof of application of 
GelMA hydrogels as a pancreatic and immune cell carrier. Implantation of the hydrogels was 
able to replicate tumour growth pattern, and, to a lesser extent, route of metastatic spread as 
observed in KPC mice (metastases: diaphragm 33%, peritoneal 5.5%) 323,324. 
 
The addition of stromal cells (CAFs and THP-1s) to PDAC cells in GelMA triple-cultures 
led to increased cell proliferation and hydrogel stiffness compared to controls (Figure 4.17, 
4.18). Tumour-fibroblast interactions and their importance in driving epithelial gene 
expression programs 325, as well as the tumour-macrophage crosstalk mentioned above, have 
been extensively characterised. However, more recently, new evidence suggests that 
macrophage suppression can directly affect CAF marker expression (αSMA downregulation) 
together with decrease in tenascin C, collagen and tissue stiffness 51. This suggests a complex 
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multi-lateral crosstalk between all three cell types, as opposed to the traditional unilateral 
tumour-stroma interactions, could be in place for cell proliferation and hydrogel stiffness 
regulation in PDAC, and recapitulated in GelMA. 
 
Lastly, the effects of co-culture on the activation of pro-survival signalling pathways was 
assessed in collagen and GelMA hydrogels, aiming to provide a better understanding of the 
tumour-stroma interactions leading to increased proliferation and matrix stiffness (Figure 
4.17 and Figure 4.18). STAT3 activation was confirmed via immunoblotting following 
indirect co-culture of PDAC cells and stromal hydrogels, consistent with the increased 
proliferation observed in co-culture settings (Figure 4.21). Other groups also showed that 
exposure to CAF-conditioned media resulted in the induction of STAT3 phosphorylation in 
PDAC cells after 72 hours 18. Furthermore, STAT3 inhibitors have successfully been 
employed in 3D models of PDAC cells and CAFs leading to a reduction in pSTAT3 levels 
and reduced cell proliferation and viability 326.  
 
Previous reports in KPC mice identified a negative correlation between increased levels of 
pSTAT3 and decreased numbers of CAFs via  TGFβ/SMAD signalling pathway 327, 
indicating a possible mechanism of treatment resistance due to stroma-depleting therapies. 
Importantly, STAT3 activity is also increased in a stiffness-dependant fashion (Figure 4.21). 
In several Kras-driven mouse models, both the loss of TGF-β signalling and elevated 
mechano-signalling via β1-integrin resulted in a positive feedback loop for the upregulation 
of STAT3 and a subsequent further increase in fibrosis, tissue tension and tumour 
progression 17. This was also true in PDAC patients where elevated STAT3 expression 
corresponded to stiffer, matricellular-rich, fibrotic tumour linked with shorter survival 17. 
This data suggests that a greater understanding of time-dependant resistance to both tumour- 
and stromal-targeting therapies is paramount for treatment durability. Stiffness-dependant 
and time-dependant changes in pSTAT3 and associated changes in CAF density and TGFβ 
signalling could be investigated further with the use of this indirect co-culture technique. 
 
Contrariwise, no changes in phosphorylated ERK levels were detected upon co-culture with 
stromal cells, with a further decrease in expression within stiffer hydrogels (7.5% GelMA) 
(Figure 4.21). Concomitant activation of STAT3 and downregulation of ERK in PDAC cells 
has been associated with resistance 307. ERK, but not STAT3, downregulation occurs also as 
a result of hypoxia 328, hence its reduction in 7.5% GelMA hydrogels might be indicative of 
lower oxygen diffusion within stiffer hydrogels. This mechanism is independent of hypoxia-
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inducible factor 1 alpha (HIF-1α) 328, a master regulator of peri-tumoral stromal remodelling 
whose levels are significantly upregulated in stiffer matrices 134. 
 
The aim of this Chapter was to characterise the biomechanical and bio-responsive features 
of GelMA hydrogels for their application in 3D cell culture. In addition to recapitulating key 
biomechanical, architectural, cellular and extracellular features depicted in Chapter 3, I 
showed how GelMA hydrogels allowed the culture of multiple cell types, both established 
and patient-derived cells, over an extended period of time, whereby maintain high cell 
viability. I started to investigate the effects of cellular TME components, namely fibroblasts 
and myeloid cells, on stiffness and cell proliferation both in vitro and in vivo. The next chapters 
will complement these data by looking at the transcriptomics of cells embedded in 3D 
matrices in order to identify and target mechanobiology-related processes. 
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Chapter 5 - Transcriptomics of 
PDAC cells in GelMA and 
Collagen hydrogels 
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5.1 Background 
The in vitro modelling of PDAC using complex 3D models is crucial to predict treatment 
responses and bridge the gap between laboratory results and clinical data. Matrigel and 
collagen-based organotypic approaches are limited by undefined and varying composition, 
as well as in recapitulating tumour stiffness, which is known to affect treatment response. 
Both 2D and 3D cultures, as well as in vivo studies, have shown stiffness can affect cell 
morphology 329, proliferation 128, invasion 129, EMT 128 and cell-cell interactions 17,330, in 
experiments that span a wide variety of cell types and matrix-based cell culture approaches. 
In addition, transcriptome-wide changes are associated with the simple transition from 2D 
to 3D cell culture 331. Mechanistic studies have shed light on a number of signal transduction 
modes that convert matrix-sensing to changes in intracellular signalling pathways and gene 
expression 17,128,332. 
 
Here, I hypothesised that the use of GelMA hydrogels of different stiffness (5% and 7.5% 
GelMA) can provide a microenvironment capable of directing not only PDAC cell growth 
but also stiffness- and matrisome-related gene programs. BxPC-3 and PANC-1 cells were 
chosen for this analysis as representative epithelial and mesenchymal-like cell lines 
respectively 203,282. Signatures of GelMA-embedded cells were compared against those of cells 
cultured in the commonly-used collagen hydrogels (Col). As an additional comparison, 
primary cells derived from three PDAC patients (12556, 12560, 12975) were cultured as 
organoids in Matrigel (Mat). These samples were set up, collected, and analysed as part of an 
ongoing project with another member of our group (Dr David Osuna de la Peña). 
 
RNA sequencing (RNA-seq) was performed at the Oxford Genomics Centre to establish 
similarities and differences between the different 3D cell cultures in GelMA hydrogels and 
the control matrices collagen or Matrigel. In addition to differential gene expression between 
GelMA and controls, the transcriptional changes in epithelial-to-mesenchymal (EMT) status, 
PDAC matrisome 86,87, and other matrix 120 signatures were assessed.  
5.2 Aim and objectives 
Following biomechanical (Chapter 3) and functional (Chapter 4) characterisation of cell-
laden GelMA matrices, the transcriptional profile of BxPC-3 and PANC-1 cells in collagen, 
5% and 7.5% GelMA hydrogels will be explored in this Chapter. 
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I will: 
• Compare and validate the transcriptional differences between 5% GelMA, 7.5% 
GelMA, collagen gels with Matrigel-cultured primary tumour organoids 
• Explore the relevance of differentially expressed genes in biological pathways and 
processes 
• Investigate associations between GelMA transcriptomes and reported PDAC 
matrisome 87 and matrix index 120 (MI) signatures 




 Transcriptomics of PDAC cells in GelMA and Collagen hydrogels 
 
-  162 - 
 
5.3 Results 
5.3.1 Exploratory analysis of differentially expressed genes in GelMA 
To better understand the behaviour of PDAC cells in 3D matrices, transcriptomic profiling 
(Chapter 5) and further functional analyses (Chapter 6) were performed. BxPC-3 or PANC-
1 cells were grown for 7 days is either collagen (1 mg/ml), 5% or 7.5% GelMA hydrogels 
prior to RNA extraction (as described in Section 4.3.3) and poly-A capture (Oxford 
Genomics). Samples were run in duplicates. BxPC-3 and PANC-1 cells showed distinct 
morphologies and behaviours in 3D cell cultures (Figures 4.5, 4.6), EMT statuses, and 
maintained in vivo tumorigenicity abilities (Table 4.3), hence why they were chosen for 
analysis. As an additional comparison, primary PDAC patient cells (patients 12556, 12560, 
12975) were grown for 7 days as organoids in Matrigel and underwent simultaneous 
transcriptomic profiling as the collagen and GelMA samples. For ease of labelling collagen 
hydrogels are named COL, MAT refers to Matrigel cultures and _5 and _7.5 refer to 5% and 
7.5% GelMA respectively. 
 
Unsupervised cluster analysis showed good correlation between repeats (duplicates) and 
clustering of each cell line and matrix stiffness with each other (Figure 5.1 a-b), with clear 
separation between BxPC-3 and PANC-1 transcripts. Matrigel organoids clustered separately 
and showed higher similarity to BxPC-3 transcripts. To better understand the differences 
between cells cultured in stiff versus soft matrices, differential gene expression was analysed 
(false discovery rate, FDR < 0.05). A total of 4209 genes were found differentially expressed 
between collagen and 7.5% GelMA cultures for BxPC-3 cells and 7378 for PANC-1, of 
which ones with an absolute fold change greater than 2 (logFC ≥ 1 or logFC ≤ -1) are 
indicated in Figure 5.1 c. Venn diagrams were used to show overlapping of differentially 
expressed genes (DEGs) that were upregulated (Figure 5.1 d) or downregulated (Figure 5.1 
e) of a factor of ≥ 2 amongst all the significant DEGs. 
 
Next, genes were ranked by the log10 p-value against their fold change (log2FC) to identify 
genes that were significantly up- or down-regulated in a volcano plot (Figure 5.2). Plots for 
both 5% and 7.5% GelMA compared to collagen are shown. The top 20 up- and down-
regulated genes of the comparison between collagen, 5% and 7.5% GelMA with associated 
logFC and p-values are listed in 9.4 Appendix 5.3. 
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In BxPC-3 cells, highly upregulated genes in 5% GelMA compared to collagen were 
associated with cell invasion, motility and EMT, and included for example bone 
morphogenic protein 7 (BMP7), chemokine ligand 14 (CXCL14), myosin light chain 9 
(MYL9), CCN family member 1 (CCN1). In PDAC, BMP7 is known to induce EMT 
through transforming growth factor-β (TGF-β)/SMAD1 signalling 333 as well as cell 
invasiveness through matrix metalloproteinase (MMP2) expression 334. Similarly, CXCL14 is 
upregulated during PDAC progression and implicated in invasion and metastasis through 
NF-kB signalling, while also acting as a chemoattractant for monocytes 335,336. MYL9 is 
involved in actomyosin-mediated cell contractility and the Rho-associated protein kinase 
pathway (RhoA/ROCK) 337, while CCN1 is a tumour promoter, and plays a crucial role in 




Figure 5.1 Exploratory clustering and number of differentially expressed genes (DEGs) of PDAC cells 
grown in Matrigel, collagen, 5% GelMA and 7.5% GelMA matrices. BxPC-3 or PANC-1 cells were grown 
for 7 days is either collagen, 5% or 7.5% GelMA prior to RNA extraction and poly-A capture (Oxford 
Genomics). Primary PDAC patient cells (12556, 12560, 12975) were grown for 7 days in Matrigel prior to 
analysis as additional comparison. (a-b) Cluster dendogram and unsupervised clustering of all genes. (c) Table 
of DEGs using the generalised linear model on EdgeR R package, FDR<0.05 FC≥1 or FC≤-1 (at least 2 fold 
change). (d) Venn diagram indicating individual and overlapping upregulated DEGs in collagen, 5% and 7.5% 
GelMA, FDR<0.05 FC≥1. (e) Venn diagram indicating individual and overlapping downregulated DEGs in 
collagen, 5% and 7.5% GelMA, FDR<0.05 FC≤-1. 
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included structural molecules such as keratins, lysyl oxidase like 2 (LOXL2), mucin 2 (MUC2) 
and ADAMTSL4, as well as vascularisation-related proteins such as placental growth factor 
(PGF) and egl-9 family hypoxia inducible factor 3 (EGLN3), both involved in vascular 
endothelial growth factor (VEGF) transcription 339. LOX family members are known to 
mediate collagen cross-linking and ECM stiffening 134, hence LOXL2 downregulation could 
be a result of stiffness-sensing in GelMA compared to collagen matrices. 
 
When comparing BxPC-3 cells in 7.5% GelMA hydrogels and collagen, we found that 
upregulation of BMP7, CXCL14 and MYL9, as well as downregulation of MUC2 and 
EGLN3, was maintained. Interestingly, MMP7, involved in initiation and maintenance of 
metaplasia in PDAC 143, was also amongst the highest upregulated genes in 7.5% GelMA 
hydrogels. When comparing BxPC-3 cells in 7.5% GelMA to 5% GelMA, we noticed the 
Figure 5.2 Volcano plots of p-value and log2FC for each stiffness (5% and 7.5% GelMA) compared to 
collagen control. Labelled red dots represent genes with p<0.05 and log2FC ≥ 1 or ≤ -1 (at least two-fold 
change). Top panels, BxPC-3 cells, bottom panels PANC-1 cells. Left panes 5% GelMA vs collagen, right 
panels 7.5% vs collagen. [see Appendix 9.3 for a larger version of the above graphs] 
 
Figure 5.3Figure 5.2 Volcano plots of p-value and log2FC for each stiffness (5% and 7.5% GelMA) 
compared to collagen control. Labelled red dots represent genes with p<0.05 and log2FC ≥ 1 or ≤ -1 (at 
least two-fold change). Top panels, BxPC-3 cells, bottom panels PANC-1 cells. Left panes 5% GelMA vs
collagen, right panels 7.5% vs collagen. 
 
Figure 5.3 Overlap of significantly different protein-coding genes (FDR< 0.05) and at least two-fold 
change (logFC≥1 or logFC≤-1) in the 5% (left) and 7.5% (right) GelMA compared to collagen. Heatmap 
shows the common upregulated (red) and downregulated (blue) genes in the two cell lines. 
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further upregulation of genes involved in cell adhesion and tissue structure, namely laminin 
gamma 3 (LAMC3), and the cell survival cystatin-M (CST6), both of which are associated 
with PDAC progression 340,341. The upregulation of genes involved in matrix remodelling 
such as BMP7, MYL9, LAMC3 and MMP7 was encouraging, as this will be the focus of the 
targeting strategies discussed in Chapter 6.  
 
PANC-1 cells in 5% GelMA showed an upregulation of cancer stem cell-associated genes 
compared to collagen hydrogels. These included CD24, commonly associated with worse 
prognosis 115, and leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4) and 
LGR5, which are commonly used markers for the assessment of organoid development 223,342. 
Other upregulated genes included structural factors like COL2A1, ADAMTS14, KRT75 and 
the oncogenic transcription factor PAX2. A number of collagens (COL3A1, COL13A1) and 
structural adhesion genes (ICAM5, ALCAM) were also found amongst the top 
downregulated genes, suggesting proliferation in GelMA might require different set of matrix 
remodelling and cytoskeletal genes compared to cells in collagen hydrogels. Tumour 
angiogenic vascular endothelial growth factor A (VEGFA) was also significantly 
downregulated in GelMA, however, other interactome members of the VEGF signalling 
pathways such as angiopoietin 2 (ANGPT2) and interleukin 18 (IL-18) 343,344 were 
upregulated, indicating more complex and dichotomous processes might be in play. 
 
Significantly upregulated and downregulated genes in 7.5% GelMA versus collagen PANC-
1 genes were largely concordant with those observed in 5% GelMA with the addition of 
LGR6, COL5A1 genes. Comparing 7.5% GelMA to 5% GelMA PANC-1 cells showed an 
upregulation in ANGPTL2, a factor associated with increased metastatic potential in PDAC 
345,346, and the serine protease inhibitor SERPINA3, whose upregulation is linked with 
increased cancer cell migration and invasion 347. The upregulation of structural and protease-
related genes suggested that cells may be capable of undergoing protease-mediated matrix 
remodelling and migration in GelMA hydrogels. 
 
Significantly DEGs in both BxPC-3 and PANC-1 cells were compared, in order to identify 
common overlapping genes. In 5% GelMA, 34 genes were upregulated in both BxPC-3 and 
PANC-1 cells compared to collagen hydrogels, while 54 genes were downregulated in both 
cell lines compared to collagen. In 7.5% GelMA, upregulation of 36 genes was overlapping 
between the two cell lines when compared to collagen controls, while 71 were 
downregulated. Overlapping genes were visualised as heatmaps in Figure 5.3 (5% GelMA, 
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left; 7.5% GelMA, right). Several of the matrix- and protease-related genes described above 
were found overlapping in both cell lines, including LOX, MMP7/9, ANGPTL4, 
SERPINA3, COL4A4, MUC5, ADAMTS14, suggesting regulation of mechanosensing 
pathways might be conserved in GelMA hydrogels. 
 
Primary PDAC organoids grown in Matrigel offered an additional comparison thanks to the 
use of patient-derived PDAC cells, as well as Matrigel substrate, which is the gold standard 
for 3D organoid cultures 201,223,227,348. In Figure 5.4 transcripts from collagen, 5% GelMA and 
7.5% GelMA were compared to Matrigel organoids. This analysis identified a total of 1592 
DEGs between Matrigel and collagen, 1644 between Matrigel and 5% GelMA and 1676 
between Matrigel and 7.5% GelMA cultures. As cells and hydrogel composition were the 
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Figure 5.3 Overlap of significantly different protein-coding genes (FDR< 0.05) and at least two-fold 
change (logFC≥1 or logFC≤-1) in the 5% (left) and 7.5% (right) GelMA compared to collagen. Heatmap 
shows the common upregulated (red) and downregulated (blue) genes in the two cell lines. 
 Transcriptomics of PDAC cells in GelMA and Collagen hydrogels 
 
-  167 - 
 
Figure 5.4 Number of differentially expressed (DEGs) and strength of correlation between genes 
of PDAC cells grown in Matrigel (mat) versus collagen, 5% GelMA and 7.5% GelMA matrices. (a) 
Table of DEGs using the generalised linear model on EdgeR R package, FDR<0.05 FC≥1 or FC≤-1 (at 
least 2 fold change). (b) Comparison of PDAC Matrigel organoids with the other models. Values 
correspond to r (Pearson correlation coefficients) based on average reads per kilobase of transcripts per 
million reads (RPKM) of 16,299 genes in pairwise alignments. Diameter of ellipses is proportional to r, 
thinner ellipses represent higher correlation coefficients. (c) Patient information for PDAC-derived 
organoids. IPMN = Intraductal papillary mucinous neoplasm. 
same in 5% and 7.5% GelMA cultures, it could be speculated that a minimum of 32 genes 
were differentially expressed as a result GelMA stiffness. Correlation analysis was also 
performed on these datasets and is illustrated in Figure 5.4 b. Pearson correlation coefficient 
(r) showed Matrigel organoids highly correlated with both collagen and GelMA cultures (r > 
0.6), indicating high similarity between all the assessed 3D cell culture methods. With the 
exception of patient 12556, organoid transcripts had a higher correlation with BxPC-3 cells 
than PANC-1, which was surprising considered that PANC-1 showed upregulation of many 
stem cell and organoid markers in GelMA. This could be due to Matrigel being a very soft 
matrix, hence cell transcriptional profiles showed a higher correlation with cells in softer 
(collagen) matrices and epithelial phenotype (BxPC-3) as opposed to mesenchymal (PANC-
1). Patient 12556 presented with the latest stage of disease (IIB) and the most mutations 
(KRAS, TP53) compared to the other patients (Figure 5.4 c). Concordantly, transcripts from 
12556-derived organoids showed a slightly higher correlation for the more mesenchymal 








Gender Stage Histology Mutations 
12556 Male IIB PDAC KRAS, TP53 
12560 Male IIB PDAC KRAS 
12975 Female IIA IPMN/PDAC KRAS 








FDR <0.05, logFC>1 909 978 990 
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5.3.2 Transcriptome-wide associations with biological pathways 
To assess the importance of these DEGs in biological pathways, KEGG, Reactome and 
Naba 269 pathways and gene set enrichment analyses (GSEA) were performed (Figure 5.5). 
The DEGs between collagen and GelMA were grouped into 35 canonical pathways and 
displayed in Figure 5.5 a. Lower p-values equal higher the log10 p-values, resulting in bigger 
dots, while normalised enrichment score (NES) indicates sample activity relative to control 
(blue for weaker, red for stronger enrichment). Pathway analysis indicated that across both 
BxPC-3 and PANC-1 cells, upregulated DEGs were involved in multiple tumorigenic 
pathways including Wnt, Rho GTPases and G-protein coupled receptor (GPCR) signalling, 
all of which have been associated with increased tumorigenicity and are linked to mechano-
transduction in PDAC 16,134,135,349,350 (Figure 5.11). Interestingly, O-linked glycosylation and 
associated disease pathways were also upregulated, and will be discussed in Section 5.3.3. 
Across both cell lines, downregulated pathways included metabolism (glucose, glycolysis, 
gluconeogenesis, mannose), IL-6 receptor-ligand interactions and cellular responses to 
hypoxia.  
 
Figure 5.5 Analysis of differentially regulated pathways and Gene Set Enrichment Analysis (GSEA) 
for BxPC-3 and PANC-1 cells in collagen versus 5% and 7.5% GelMA. (a) Enrichment in KEGG, 
Reactome and Naba pathways. Colour represents the normalised enrichment score (NES) while the size of the 
dot indicates significance (log10p-value). (b) GSEA-enrichment plots (Broad Institute) using all genes for 





BxPC-3 GelMA vs col 
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Figure 5.5 b shows GSEA plots for some of the above-mentioned pathways comparing cells 
in GelMA and collagen hydrogels. Selected plots showed the enrichment of mechano-
sensing and mechano-transduction pathways in GelMA, namely through GPCR, Wnt and β-
Catenin/TCF signalling 128 (Figure 5.11). 
 
To further assess the importance of genes in biological processes, gene sets were selected, 
related to processes relevant for cell adaptation within matrices of different stiffness, 
including proteases (Figure 5.6 a), EMT (Figure 5.6 b) and mechano-sensing (Figure 5.6 c). 
As seen from the heatmaps, expression of most genes highly differed between BxPC-3 and 
PANC-1 cells. Unsurprisingly, PANC-1 cells exhibited higher expression of EMT markers 
including vimentin, N-cadherin, Snail and Zeb1, compared to BxPC-3 cells which showed 






Figure 5.6 Expression heatmaps of genes related to (a) proteases, (b) EMT and (c) mechanosensing 
pathways in BxPC-3 and PANC-1 PDAC cells grown in collagen, 5% GelMA and 7.5% GelMA. Number 
of read counts after count normalisation are indicated on the heatmaps for comparison of absolute abundances. 
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Amongst mechano-sensing related genes, ankyrin (ANKRD1), myosin (MYH10) and 
collagen I (COL1A1) expression increased in both BxPC-3 and PANC-1 cells in response to 
stiffness. Versican (VCAN) and MYL9 expression increased in BxPC-3 but not PANC-1 
cells in stiffer matrices, while PANC-1 had an increased expression in vimentin (VIM). 
Neither cell line had an increased expression of the mechano-transductor genes Yes-
associated protein and transcriptional coactivator with PDZ-binding motif (YAP/TAZ) in 
GelMA compared to collagen. However, YAP/TAZ signal primarily through translocation 
to the nucleus, therefore immunofluorescence rather than gene analytical techniques, should 
be used to assess its activation 17. 
 
In summary, cells retained the expression of genes important for mechano-transduction in 
GelMA, namely through Wnt, GPCR, Rho GTPase and β-catenin pathways. They also 
showed high variability between cell lines, concordant to their EMT status. 
  
 Transcriptomics of PDAC cells in GelMA and Collagen hydrogels 
 
-  171 - 
 
5.3.3 Post-translational modifications and matrisome-related gene profiles 
in GelMA and collagen hydrogels 
Attempting to replicate the tumour biomechanics and matrix structure, signatures of genes 
involved in matrisome composition as well as unusual protein glycosylation patterns were 
assessed. The matrisome is defined as the proteome subset that constitutes the ECM. It 
comprises over 1000 secreted proteins, of which around a quarter are categorised as “core 
matrisome” due to their fundamental ECM organisation role, while the remaining ones fall 
under “matrisome-associated” nomenclature 91. Naba et al. 269, classified ECM proteins into 
categories that are now widely used in proteomics and during matrisome classification. The 
various categories and their involvement in PDAC pathogenesis have been described in detail 




















Figure 5.7 Gene set enrichment analysis (GSEA) and expression heatmaps of (a) Naba’s core 
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Despite proteomics usually being the favourable technique for this analysis, GSEA was 
performed instead on Naba matrisome-associated gene categories (Figure 5.7 a). Naba “core 
matrisome” proteins were enriched in GelMA, as well as the ECM glycoprotein subset 
component. Despite Naba’s collagens category not being found amongst DEGs, the 
heatmap in Figure 5.7a shows differential expression of several collagens (COL1A1, 
COL11A1, COL9A2, COL3A1) while expression of others was conserved (COL5A2, 
COL17A1, COL4A6, COL18A1). 
 
Interestingly, the O-linked protein glycosylation pathway was also highly enriched in GelMA 
hydrogels in both BxPC-3 and PANC-1 cells (Figure 5.5a, Figure 5.7 b). O-linked β-N-
acetylglucosamine (O-GlcNAc) is a post-translational modification mechanism by which a 
sugar is attached to the serine residues of a protein, thereby modifying protein activity 351. 
The expression heatmap of all the genes constituting the O-glycosylation gene set 
(Reactome) is shown in Figure 5.7 b. In PDAC, hyper-O-GlcNAcylation is anti-apoptotic 
and contributes to NF-κB oncogenic activation 351. 
 
In 2019, Tian et al. 86,87 reported the first study on the PDAC matrisome. The authors were 
able to discriminate between tumour cell and stroma-derived ECM proteins and indicated 
that the tumour-produced proteins correlated with poor patient survival. In contrast, despite 
the majority of the tumour bulk comprising stromal-derived ECM, the role of these in disease 
and survival was much more heterogeneous 87. The authors identified a PDAC-specific 
signature, against which our RNA-seq data was compared (Figure 5.8 a). 
 
The majority of matrisome-associated genes were upregulated in PANC-1 cells compared to 
BxPC-3. A subset of these genes was further upregulated in PANC-1 cells cultured in 7.5% 
GelMA compared to 5% GelMA and collagen hydrogels, including collagens (COL1A1, 
COL2A1, COL5A1), elastin microfibril interfacer (EMILIN1), fibrillin (FBN1), and heparan 
sulphate proteoglycan (HSPG2), which are associated with poorer prognosis 120,352. This 
supports the notion that tumour cells alone can contribute to adverse ECM protein 
production in concordance with their EMT status and increased substrate stiffness. 
 
In order to further assess the contribution of PDAC cells to matrix production and 
prognosis, the matrix index (MI) was calculated and shown in Figure 5.8 b, alongside that of 
KPC mouse model (LSL-KrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre) and TCGA data. The MI 
is an ECM-associated signature (comprising 22 molecules), that predicted both extent of 
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disease and tissue stiffness at gene transcription level, where it was first discovered, and 
validated at protein level 120. It was originally characterised in HGSOC but also correlated 
with 12 other solid cancers including PDAC 120. MI analysis of our tumour cell cultures 
provided a measure of their contribution to ECM-associated gene expression directly linked 
to their prognostic value. 
 
Unsurprisingly, PANC-1 cultures showed a higher MI compared to BxPC-3 cells (Figure 5.8 
b). Although not significant, 5% GelMA cultures had a higher MI compared to cells cultured 
in collagen hydrogels. Both KPC mice and TCGA data had MIs that closely resembled that 
of PANC-1 cells. MI did not however correlate with stiffness, at least in GelMA, as both cell 
lines showed a lower MI in 7.5% GelMA when compared to 5% GelMA. As MI was 
characterised in omental tissues, the mechanics and therefore correlation with stiffness are 
likely to be different from PDAC (as shown in Chapter 3) and even more so in hydrogels. 
Taken together, these data suggested that despite the MI having been originally characterised 
at a whole-tissue level (tumour and stroma), it also correlated to tumour cell phenotypes 
alone and was closely linked to matrisome-associated gene expression, at least for BxPC-3 








Figure 5.8 Expression of PDAC matrisome signature (Tian et al.) and Matrix Index (MI) (Pearce et 
al.) in BxPC-3 and PANC-1 cells in collagen, 5% and 7.5% GelMA hydrogels. (a) Expression heatmap 
of PDAC matrisome-associated genes, Tian et al. 2019. (b) Calculated MI for BxPC-3 an PANC-1 cells in 3D 
models, alongside KPC PDAC mouse model and TCGA data, accessed at https://www.cancer.gov/tcga. 
AGT, CTSG, COL15A1, COL6A6 not detected for MI calculation. 
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5.3.4 Validation of RNA-seq data in GelMA and collagen hydrogels 
A total of 8 genes were selected for validation of RNA-seq gene expression by quantitative 
RT-PCR using independent RNA samples. Genes selected belonged either to the MI 
(COL1A1, COL11A1, CTSB, FN1, VCAN), or mechanobiology and proteases categories 
(MMP9, TGFBI, YAP1). Expression of collagen-I, fibronectin and versican had also been 
confirmed at protein level in 5% GelMA hydrogels (Figures 3.10-3.11), while proteases will 
be the focus of the next Chapter. Of these, all except VCAN were highly expressed (Ct < 
28 cycles). RNA-seq (Figure 5.9 a) and qRT-PCR data (Figure 5.9 b) were largely in 



























































































































































































































































































































































































































Figure 5.9 qRT-PCR validation of RNA-seq data. (a) Gene expression heatmap of selected genes in BxPC-
3 cells cultured in collagen, 5% and 7.5% GelMA. (b) Gene expression heatmap of selected genes in PANC-1 
cells. (c) qRT-PCR validation of genes shown in (a-b), expression relative to HPRT-1, n=1 hence no statistics.  
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BxPC-3 7.5% GelMA vs col. 
Figure 5.10 Expression heatmaps and Gene Set Enrichment Analysis (GSEA) of (a-b) Naba’s 
matrisome-associated secreted factors and (c) selected cytokines (from MSD panel). 
5.3.5 Secretome-related gene profiles and validation in GelMA and collagen 
hydrogels 
Lastly, the expression of secretome-related genes was assessed in our dataset. The secretome 
is a subset of the proteome which comprises between 13-20% of all human proteins 
including cytokines, growth factors, and receptors 324. These often constitutes the largest 
proportion of Naba’s “matrisome-associated” genes and include secreted factors that may 
interact with core ECM proteins 91 such as BMPs and Wnts, some of which were found 
amongst the DEGs in collagen and GelMA, as well as TGFβ and cytokines. Naba’s secreted 
factors are shown in Figure 5.10 alongside including the GSEA (Figure 5.10 b) in GelMA. 
Secreted factors were largely upregulated in BxPC-3 cells compared to PANC-1. Figure 5.10 
c showed the differential expression of cytokines in the two cell lines. Amongst these, 
CXCL8 and CCL22 were upregulated in BxPC-3 cells in GelMA compared to collagen, while 
IL-16 was upregulated in PANC-1. Upregulation of IL-16 was also significantly associated 
with disease score in the tissues used for MI characterisation in HGSOC 120, and is a key 




Naba Secreted Factors 
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5.4 Conclusions 
This chapter provided the first transcriptomics analysis of GelMA-embedded cells of its kind, 
by directly comparing three different 3D cell culture matrices with varying stiffness and cell 
types. Together with the biomechanical and functional characterisations in Chapters 3 and 
4, the signatures and pathways uncovered at the gene level suggested the activation of 
mechanosensing and ECM-associated programmes in GelMA. Transcriptomics analyses 
performed on GelMA cultures showed how cells maintained their expression and cellular 
identities compared to collagen cultures, underlying the suitability of GelMA as a matrix for 
3D PDAC cell culture. Correlation analysis between patient-derived organoids and 
collagen/GelMA cultures further highlighted the similarity between collagen and GelMA 
transcripts, reflected in similar correlation scores (Figure 5.4). This suggested that GelMA 
cultures retained gene signatures comparable to those of cells cultured in commonly-used 
collagen gels and Matrigel. 
 
Amongst the DEGs in BxPC-3 and PANC-1 cells in GelMA compared to collagen, several 
structural and matrix organisation genes as well as effectors of GPCR, Wnt and Rho GTPase 
pathways were identified. Specifically, GPCR ligand-binding, signalling through GPCR, Wnt 
signalling, β-catenin pathway and TCF transactivation were some of the highly enriched 
pathways in both BxPC-3 and PANC-1 GelMA cultures (Figure 5.5), all of which are 
involved in mechano-sensing (Figure 5.11). Some of these pathways are also key in regulating 
EMT. In fact, EMT is a multifaceted process which involves many morphological changes 
affecting the expression of proteins including high vimentin and N-cadherin expression, 
attenuated E-cadherin, high β-catenin 354, YAP and TAZ 138. This was also highlighted by the 
differential expression of these markers in the mesenchymal PANC-1 cells compared to 
epithelial BxPC-3 cells, in our 3D matrices (Figure 5.6 b-c). Stiffness is associated with EMT 
in a number of cancers 128,355 where it is induced through mechano-transduction. Vimentin 
for instance can be altered by the in vitro mechanical environment 356, while mechanical 
activation of β-catenin has also been observed in vivo (in murine colon) 357. YAP/TAZ has 
also recently emerged as player in the response to ECM stiffness 128,137. Taken together, these 
data suggest cells in GelMA activate a number of mechano-transduction pathways (Figure 
5.11), as well as retaining characteristics concordant with their EMT status. 
 
Aside from mechano-transduction pathways, O-linked glycosylation was also highly enriched 
in GelMA hydrogels compared to collagen (Figure 5.5 a, Figure 5.7 a). O-linked glycosylation 
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is a post-translational modification that occurs on many cytosolic and nuclear proteins by O-
GlcNAc 351. In PDAC, increased O-GlcNAcylation of kinases upstream of NF-κB signalling 
impede cell apoptosis and support anchorage-independent growth 351. Significant alterations 
in O-linked glycosylation are also present on cell surface molecules during PDAC 
progression 107. In collagen, increased cell glycosylation has been reported to contribute to 
hydrogel stiffening through fibril crosslinking, resulting in a pro-inflammatory, profibrotic 
cascade. This ultimately affects MMPs and tissue inhibitors of MMPs (TIMPs) promoting an 
abnormal matrix accumulation 358. Finally, O-GlcNAcylation of YAP disrupts its interactions 
with upstream kinase LATS1, thereby promoting transcriptional activity 359. YAP 
glycosylation is therefore capable of integrating and coordinating both mechanical and 
intracellular signals to promote tumorigenesis 359. 
 
Figure 5.11 Schematic representation of cell mechanotransduction mechanisms. Mechanical forces 
induce receptor activation on the cell surface, converting physical stimuli into biochemical signals. These 
include G-protein coupled receptors (GPCRs), Receptor Tyrosine Kinase (RTKs) and Ras homologous 
GTPases through Ras, RhoA and F-actin signalling, Integrins through tyrosine protein kinase (PTK), and 
Wingless-related integration site (Wnts) through Axin or APC. As a result, these can co-activate a number of 
different signalling pathways which lead to changes in gene expression and modulate cell functions including 
cell shape, structure, proliferation, migration and invasion. For instance, YAP/TAZ can be induced by RTKs 
through either FGFR-MAPK/PI3K signalling (Azad et al., 2020), or through the RTK-Ras-Rac1 cascade 
(Panciera et al., 2020). Alternatively, it can be activated through the Wnt/β-catenin axis (Liu et al., 2019). 
Adapted from Liedert at al., 2006; Moroishi et al., 2015.  
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Together, these data suggest GelMA cultures possess gene signatures comparable to those 
of cells grown in popular 3D matrices, and therefore have the potential for applications in 
the field of bioengineering and clinical translation. With the advent of ‘omics’ technologies, 
this kind of systematic evaluation of mechanical (Chapter 3), phenotypic (Chapter 4) and 
transcriptional (Chapter 5) responses to biomaterials has gained significant interest in recent 
years 223,348,360 and is poised to become the gold standard of the field. Finally, the following 
and concluding result chapter will investigate the pre-clinical and translational applications 
of these hydrogels by looking at the effects of matrix remodelling and mechano-modulating 
treatments on cell-containing GelMA hydrogels.  
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Chapter 6 - Targeting the 
Tumour Microenvironment 
using in vitro Models of PDAC
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6.1 Background  
Compared to other malignancies in which we are witnessing the progressive implementation 
of immunotherapies or other advanced targeted therapies 361,362, resection and systemic 
chemotherapy remain the standard treatments for PDAC patients (Figure 1.1). Despite our 
advances in understanding the molecular, genetic and biophysical mechanisms driving this 
cancer, a breakthrough in its treatment is still lacking 26. This is highlighted by the fact that 
as little as 3.4% of oncology drugs entering the clinical trial pipeline end being approved for 
clinical use 363. Reasons for the discrepancy in the number of drugs investigated and approved 
include the lack of models capable of fully recapitulating the distribution and off-target 
toxicities of systemic drug administration as well as the complex tumour-stroma interactions 
inherent to human tissues. Despite 2D cell culture and animals being the most widely used 
testing approaches, they are inadequate to accurately reflect all aspects and complexity of the 
human tumour microenvironment (TME) 171,172,187. 
 
Thus far, this body of work was aimed at characterising gelatin methacryloyl (GelMA) 
hydrogels as a PDAC 3D cell culture platform, demonstrating how embedded cells recreate 
complex 3-dimentional structures reminiscent of tissue architecture, as well as being 
conducive to the culture of multiple cellular TME components. GelMA-embedded cells also 
had transcriptional profiles similar to those of cells grown in commonly used collagen gels 
but showed an enrichment in mechano-sensing pathways. Stiffness modulation in these 
matrices represented a major advantage to traditional collagen or Matrigel-based gels. 
Importantly, GelMA allowed the culture of primary cells, circumventing the need for long, 
costly animal experiments, which are currently incompatible with PDAC personalised 
medicine due to its dismal median survival. The use of alternative biomaterials with defined 
composition and controllable biophysical properties could therefore represent an advantage 
in the modelling of pre-clinical drug responses.  
 
In order to test this, drug responses were assessed in GelMA hydrogels of varying stiffness 
and compared to those of other in vitro platforms including monolayer cell cultures and 
collagen gels. The current standard of care for PDAC patients, namely combination of the 
chemotherapeutic agents gemcitabine and nab-paclitaxel (known by its commercial name 
abraxane), will be tested in the models. Additionally, the effect of matrix-remodelling and 
stromal targeting therapies will also be assessed. In particular, the matrix remodelling, 
proliferative and invasive abilities of cells will be tested following the addition of a broadband 
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matrix metalloproteinase (MMP) inhibitor ilomastat (GM6001). The roles of MMPs in cancer 
span a number of pro-tumorigenic pathways and cell behaviours including ECM-
remodelling, proliferation, migration, invasion and metastasis 142. Since GelMA is primarily 
composed of hydrolysed collagens, and because of the clinical relevance of collagen in PDAC 
95, the use of a potent inhibitor of collagenases is of particular interest. 
 
Additionally, cells are capable of remodelling the surrounding extracellular matrix (ECM) 
through the regulation of Rho-associated protein kinase (ROCK)-mediated cytoskeletal re-
arrangement, via which they exert cell contractility and contribute to tissue tension and 
stiffness 149,151. As suggested by Vennin et al. 155,364, transient tumour targeting with a ROCK 
inhibitor prior to the administration of standard chemotherapeutic agents may release local 
tissue tension and increase cell susceptibility to treatment, enhancing chemotherapy 
efficiency. Importantly, transient tissue targeting or ‘priming’ circumvents the risks associated 
with chronic ablation of restraining stromal components, which could have negative clinical 
effects, similarly to those observed with hyaluronidase treatment (PEGPH20 trial) 47 (Figure 
1.5). Hence, I will assess the efficacy of ROCK inhibition with fasudil in combination with 
chemotherapeutic agents, and its effects on matrix stiffness, in our models. In the previously 
presented RNA-seq analysis, ROCK1, ROCK2, MMP9, MMP12, MMP14, MMP19, 
amongst other genes, were differentially expressed in collagen compared to GelMA matrices. 
The role of collagens, MMPs, ROCK and ROCK targeting in PDAC have been discussed in 
more detail in Sections 1.2.2.3 and 1.2.2.4. 
6.2 Aim and objectives 
Following mechanical, functional and transcriptional characterisations of Chapters 3-5, in 
this Chapter I will assess the responses of PDAC cells (BxPC-3, Capan-2, MIA PaCa-2 and 
PANC-1), one HGSOC cell line (OvCar-4) and stromal cells (CAFs and THP-1s) to matrix 
remodelling and stroma-modulating treatments both in 2D and 3D cell cultures. GelMA 
hydrogels of increasing stiffness (5 – 7.5 %) will be used alongside collagen control gels. 
I will: 
• Assess the effects of GM6001, fasudil, gemcitabine plus abraxane treatment on cell 
functions (viability, proliferation, spheroid formation, invasion) in both 2D and 3D, 
as well as treatment effects on matrix stiffness in GelMA and collagen hydrogels. 
• Understand changes in matrix stiffness at the nanoscale following GM6001 
treatment, using atomic force microscopy (AFM). 
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• Assess the effect of a matrix priming regime with fasudil on the efficacy of 
gemcitabine plus abraxane treatment, in triple cultures of PDAC (PDAC cells, CAFs 
and THPs), via assessment of cell functions, matrix stiffness, gene expression and 
secreted factors analysis. 
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6.3 Results 
6.3.1 Epithelial-mesenchymal transition status and extracellular collagen 
dictate cell proliferation and treatment response in 2D 
The effects of MMP and ROCK inhibition on PDAC cell proliferation were tested via the 
addition of inhibitors, namely GM6001 and fasudil respectively. Additionally, a combination 
of gemcitabine and nab-paclitaxel (abraxane), the standard chemotherapeutic agents used for 
the treatment of PDAC patients, was also used. The therapeutic effects of these agents were 
first assessed in 2D and, subsequently, in collagen and GelMA hydrogel models. A treatment 
dose of 20 µM GM6001, 10 µM fasudil, 100 nM gem/abx (each) and 20 µM control peptide 
were chosen, as these concentrations have been shown to elicit biological effects in the 
literature, even in 3D matrices 155,252.  
 
The epithelial-to-mesenchymal (EMT) status of the cell lines was confirmed via 
immunoblotting for the EMT markers E-cadherin, vimentin and the epithelial PDAC-
associated marker cytokeratin 19 (KRT19) (Figure 6.1 a). Capan-2 and BxPC-3 showed high 
expression of the epithelial marker KRT19 and E-cadherin together with low vimentin 
expression, overall indicative of their epithelial-like phenotype. Conversely, PANC-1 and 
MIA PaCa-2 show an upregulation of vimentin accompanied by loss of E-cadherin and lower 
KRT19 expression, typical of a more mesenchymal phenotype. The mutational status and 
phenotype of the four cell lines is indicated in Table 6.1. OvCar4 HGSOC cells were used as 
control as they have a mesenchymal phenotype and show no expression of the PDAC-
specific marker KRT19. 
 
In order to test the effects of treatment on the proliferative ability of the cells, PDAC cell 
lines were seeded on plates coated with either 10 µg/ml of poly-L-lysine (control) or 10 
µg/ml of collagen type-I. As collagen type-I is known to induce EMT and affect treatment 
response 104,128,203,355, I hypothesised that different cell lines would respond to treatment in an 
opposite fashion to one another, based on their EMT status and plate coating (collagen 
versus control). After 24 hours from seeding, cells were treated with either 20 µM GM6001, 
10 µM fasudil or 100 nM gem/abx (each), and their proliferation recorded (Figure 6.1 b-c). 
On poly-L-lysine control plates, mesenchymal cell lines (namely PANC-1 and MIA PaCa-2) 
showed higher proliferation compared to Capan-2 and BxPC-3. Conversely, collagen type-I 
coating stimulated the proliferation of Capan-2, BxPC-3 and PANC-1 cells while inhibiting 
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the growth of MIA PaCa-2 cells. The stimulatory effect of collagen on cell proliferation via 
induction of EMT is well characterised in PDAC 355.  
Representative proliferation plots at 96 hours of treatment are shown in Figure 6.1 b. 
Unsurprisingly, gem/abx treatment significantly reduced the growth of highly proliferative 
cells (hence, it had no effect on Capan-2 cells on poly-L-lysine or MIA PaCa-2 cells on 
collagen-coated plates, as these conditions showed very little overall proliferation). Overall, 
B       C      M      P     O 
 
B      C      M        P       O 
 































































































































































































































































































































































Figure 6.1 Effects of epithelial-to-mesenchymal transition (EMT) status and GM6001, fasudil and 
gemcitabine/abraxane treatment on the proliferation of PDAC cells in 2D. (a) Immunoblots of EMT 
markers E-cadherin (97 kDa), vimentin (54 kDa) and cytokeratin 19 (44 kDa) and protein loading control alpha-
tubulin (50 kDa) from BxPC-3, Capan-2, MiaPaCA-2, PANC-1 and OvCar4 cells grown in monolayers. (b) 
BxPC-3, Capan-2, MiaPaCA-2 and PANC-1 cells were seeded on either 10 µg/ml collagen-I or 10 µg/ml poly-
L-lysine (control) and treated at t=0 with either GM6001 (20 µM), fasudil (10 µM), Gem/Abx (100 nM each) 
or control peptide (20 µM). Proliferation was analysed every 24 hours for six days (t=96 hours shown) (n=3). 
Cell lines are ordered based or their EMT status from more epithelial-like to mesenchymal. Data shown as 
mean ± SEM, significance tested with Kruskal-Wallis one-way ANOVA, p-values as annotated, n=3. (c) 
Proliferation of the four PDAC cell lines on poly-L-lysine (control) and collagen-I matrices. Collagen I 
stimulates the proliferation of PDAC cell lines with the exception of MiaPaCa-2 cells which, having a 
mesenchymal phenotype, have a decreased proliferation rate when plated on collagen, n=3. 
 
Figure 6.1 Effects of epithelial-to-mesenchymal transition (EMT) status and GM6001, fasudil and 
Gemcitabine/abraxane treatment on the proliferation of PDAC cells in 2D. (a) Immunoblots of EMT 
markers E-cadherin (97 kDa), vimentin (54 kDa) and cytokeratin 19 (44 kDa) and protein loading control alpha-
tubulin (50 kDa) from BxPC-3, Capan-2, MiaPaCA-2, PANC-1 and OvCar4 cells grown in monolayers. (b) 
BxPC-3, Capan-2, MiaPaCA-2 and PANC-1 cells were seeded on either 10 µg/ml collagen-I or 10 µg/ml poly-
L-lysine (control) and treated at t=0 with either GM6001 (20 µM), fasudil (10 µM), Gem/Abx (100 nM each) 
or control peptide (20 µM). Proliferation was analysed every 24 hours for six days (t=96 hours shown) (n=3). 
Cell lines are ordered based or their EMT status from more epithelial-like to mesenchymal. Data shown as 
mean ± SEM, significance tested with Kruskal-Wallis one-way ANOVA, p-values as annotated, n=3. (c) 
Proliferation of the four PDAC cell lines on poly-L-lysine (control) and collagen-I matrices. Collagen I 
stimulates the proliferation of PDAC cell lines with the exception of MiaPaCa-2 cells which, having a 
mesenchymal phenotype, have a decreased proliferation rate when plated on collagen, n=3. 
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fasudil had no effect on cell proliferation in 2D, on neither poly-L-lysine or collagen-coated 
plates. Conversely, although not always significant, GM6001-treated cells showed a trend 
towards decreased proliferation in three out of four cell lines. Despite having similar 
mutations, the different proliferation rates of MIA PaCa-2 and PANC-1 on collagen can be 
partially explained by the different affinity of these cell lines to collagen type-I (Table 6.1 365). 
Overall, collagen type-I stimulation increased sensitivity of Capan-2, BxPC-3 and PANC-1 
to gem/abx, and of Capan-2 and PANC-1 to GM6001.  
 
Table 6.1 Genotype and phenotype of PDAC cell lines. Mutational status for four of the most common 
mutations in PDAC 365. WT= wildtype, HD=homozygous deletion. 
Cell line KRAS TP53 CDKN2A/p16 SMAD4/DPC4 Coll I adhesion 
BxPC-3 WT 220 Cys WT; HD HD High 
Capan-2 12 Val WT WT; insertion WT Medium 
MIA PaCa-2 12 Cys 248 Trp HD WT Low 
PANC-1 12 Asp 273 His HD WT High 
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6.3.2 Inhibition of MMPs, but not ROCK, leads to reduced cell proliferation 
in 3D 
6.3.2.1 Effects of GM6001 treatment on PDAC cell proliferation and invasion 
Next, the effects of MMP inhibition was assessed in collagen, 5% and 7.5% GelMA 
hydrogels via GM6001 treatment. GM6001 is a potent broad-spectrum human MMP 
inhibitor with low reported Ki values of 0.1 nM for MMP8, 0.2 nM for MMP9, 0.4 nM for 
MMP1, 0.5 nM for MMP2 and 27 nM for MMP3. As MMP expression is upregulated by 
PDAC cells in response to matrix stiffness 131, I hypothesised GM6001 efficacy would vary 
across matrices of different stiffness. For this, collagen and GelMA hydrogels were set up 
with four PDAC cell lines and one HGSOC cell line as monocultures. Treatment molarities 
were kept consistent - 20 µM GM6001 and 20 µM of control peptide in cell culture medium 
– added on day 1 of culture and subsequently replaced every 72 hours until endpoint analysis 
on day 14 (Figure 6.2 a). Treatment with GM6001 generally reduced the proliferation of 
hydrogel-embedded cells over 14 days of culture and led to the formation of smaller 
spheroids (Figure 6.2 b). 
 
Proliferation was analysed using DNA content analysis on day 1 and 14 as a proxy for cell 
content quantification within the hydrogels. Interestingly, the more mesenchymal cell lines 
PANC-1 and MIA PaCa-2 had a reduced sensitivity to the treatment, only showing 
significantly reduced proliferation when treated with the inhibitor in stiffer conditions (7.5% 
GelMA). These were followed by BxPC-3 and OvCar4, with a significant reduction of 
proliferation in both 5% and 7.5% GelMA upon treatment, and lastly Capan-2 showing 
susceptibility to GM6001 in all three 3D cell culture matrices. This pattern largely reflects 
the results observed in 2D whereby the intrinsic proliferative, metastatic and EMT status of 
the cell lines determined their response to GM6001 treatment on collagen-coated plates. The 
effectiveness of GM6001 treatment in GelMA hydrogels was encouraging as a further 
confirmation of the retention of cleavage-sensitive motifs (MMP-binding domains) within 
the hydrogel backbone. 
 
Across all cell lines, GM6001 efficacy was increased with increased matrix stiffness (Figure 
6.2 b). One possible reason could be the stiffness-induced increase in the production and 
activity of MMPs which, in turn, would lead to more significant reduction in proliferation 
upon treatment. This is the case for PANC-1 cells, in which a 3-to-10 fold increase in secreted 
MMP activity has been shown in stiff compared to soft collagen hydrogels 131. In the same 
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study, secreted MMPs activity was higher in BxPC-3 cells compared to PANC-1, and did not 
significantly vary across hydrogels of different stiffness 131. Taken together, these data might 
explain the higher sensitivity of BxPC-3 cells to the MMP inhibitor in both 5% and 7.5% 
GelMA as well as the significant reduction in PANC-1 proliferation only in stiffer matrices. 
GelMA stiffness was not only inducive of increased MMP activity but also of proliferation 
of untreated controls in the case of BxPC-3, MIA PaCa-2 and PANC-1, highlighting further 
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Control peptide (20 µM) 
GM6001 (MMP) inhibitor (20 µM) 
fasudil (Rho-kinase) inhibitor (10 µM) 
 




Collagen gels (1 mg/ml) 
14 days, 3D cell culture 
14 500 cells/hydrogel 
Figure 6.2 Effects of GM6001 treatment on PDAC cell proliferation in collagen, 5% and 7.5% GelMA 
and Transwell cell invasion in collagen and Matrigel. (a) Schematic representation of treatment strategy 
for 3D GM6001 and fasudil experiments. (b) Representative brightfield micrographs of PANC-1 treated with 
20 µM control peptide (top) or 20 µM GM6001 (bottom), at day 14 of culture in 7.5% GelMA. Scale bars 500 
µm and 2 mm (inserts), apply to all. (c) CyQUANT quantification of cell proliferation of 3D cell cultures at day 
1 (grey dots) and day 14 (yellow dots) in matrices of increasing stiffness (collagen, 5% and 7.5% GelMA). Cells 
were treated with either 20 µM control peptide or GM6001 in medium, replaced every 72 hours. ANOVA 
(Tuckeys multiple comparisons), p-values as annotated, n=3. (d) Matrigel-coated Transwell invasion assays (48 
hours) on cells treated with 20 µM control peptide (light grey) or GM6001 (dark grey). (e) Collagen I-coated 
Transwell invasion assays (48 hours). Mann-U-Whitney, p-values as annotated, n=3. 
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MMPs are not only involved in matrix degradation during proliferative and metastatic cancer 
cell dissemination, they also play a pivotal role in invasion and during the degradation of the 
basal membrane 142. Because of this, I next assessed the effects of GM6001 treatment on 
invasive cell behaviours though Matrigel and collagen-coated Transwells after 48 hours of 
treatment (Figure 6.2 d, e). Three out of five cell lines showed reduced Transwell invasion 
upon treatment in Matrigel while all of the analysed cell lines had a significantly lower invasive 
ability upon treatment in collagen. Overall, all of the cell lines showed much higher invasion 
in collagen compared to Matrigel as indicated by their respective mean absorbance values. 
Because of their increased invasiveness, it is likely that GM6001 effects would be augmented 
in collagen compared to Matrigel. MIA PaCa-2 cells showed a higher invasive ability amongst 
the analysed cell lines followed by Capan-2, PANC-1 and BxPC-3 which is concordant with 
the literature 365-367. Finally, although not measured in this project, the stiffness of Matrigel is 
considerably lower than that of collagen (100 Pa vs 1.2 kPa) 266, suggesting increased stiffness 
might be stimulating invasive behaviours in the latter. 
 
In order to validate these results further, gene and protein assays were conducted on cells 
following GM6001 treatment (Figure 6.3). At gene level, vimentin expression increased in 
GelMA compared to collagen in all three cell lines analysed (Figure 6.3 a). Vimentin is a 
cytoplasmic intermediate filament widely associated with PDAC cell stiffness 129, 
mechanosensing in vivo 356, EMT 354, as well as treatment response 128. Increased vimentin 
expression is therefore expected upon culture in stiffer substrates. Concordant with the 
protein data (Figure 6.1 a), in 2D its expression was higher in PANC-1 cells compared to 
BxPC-3 and Capan-2. In collagen, MMP9 expression was low in the three PDAC cells 
assessed, and its expression was reduced further upon GM6001 treatment (Figure 6.3 b). In 
GelMA, MMP2 levels were also reduced upon GM6001 treatment, with the exception of 
Capan-2 cells, whose MMP2 levels were five-fold increased upon treatment. GM6001 
inhibits MMPs by binding to the active-site zinc atom that is critical for the activity of these 
proteases 368. Therefore a decrease of MMP2 and MMP9 at gene level is not necessarily to be 
expected, even at this late time point (14 days). Combined gene expression techniques and 
activity-based assays (such as zymography) at earlier time points would be able to better 
characterise the extent of MMP inhibition during treatment.  
 
In collagen, vimentin levels did not significantly change upon GM6001 treatment, with the 
exception of Capan-2 cells which showed a decreased expression. Importantly, Vimentin 
expression was also decreased in all of the cell lines in 7.5% GelMA hydrogels, which might 
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explain the observed reduction in the proliferation of these cells. Taken together, this data 
would suggest that mechanosensing via regulation of vimentin and EMT at gene level, rather 
than MMPs, are determinant of differential cell proliferation rates and GM6001 treatment 
responses in 3D. This is exemplified in the case of Capan-2 cells, where cells responded to 
treatment in GelMA despite having increased MMP2 expression, or BxPC-3 and PANC-1 in 
collagen which, despite a decrease in MMP9 levels, showed no significant changes in 
proliferation concordant with an unchanged expression of vimentin. 
 
Overall protein content of GM6001-treated GelMA hydrogels was also lower compared to 
their untreated counterparts as shown via Coomassie protein staining (Figure 6.3 c). 
Importantly, acellular GelMA hydrogels (lane 6) only resulted in one strong band following 
separation by electrophoresis, instead of a large smear as in the case of unfuctionalised gelatin 
(lane 7). This was an important result, indicating for the first time, that GelMA-recovered 
cells could be used for successive protein analysis via Western blot without interference from 
gelatin-derived protein bands.  
Figure 6.3 Effects of GM6001 treatment on gene and protein expression in collagen and 7.5% GelMA 
hydrogels. (a) RTqPCR analysis of BxPC-3, Capan-2 and PANC-1 cells in collagen, 7.5% GelMA day 14 of 
culture and tissue culture plastic (TCP). Expression relative to RPS13, mean and standard deviation shown, 
n=2. (b) RTqPCR analysis of BxPC-3, Capan-2 and PANC-1 cells in collagen, 7.5% GelMA at day 14 of 
culture, following treatment with 20 µM control peptide (yellow) or GM6001 (pattern) - replaced every 72 hours 
in culture medium. Expression relative to RPS13, mean and standard deviation shown, n=2. (c) Coomassie 
protein staining of proteins following separation via electrophoresis, loading conditions as indicated. 
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6.3.2.2 Effects of fasudil treatment on PDAC cell proliferation 
The effects of ROCK inhibition on cell behaviours in 3D matrices was assessed via treatment 
with 10 µM fasudil hydrochloride. fasudil is a potent Rho-kinase pan-inhibitor, targeting the 
ATP-dependant kinase domain of both ROCK1 and ROCK2 and is currently the only 
ROCK inhibitor clinically employed 369. The treatment was added into cell culture medium 
at day 1 and replaced every 72 hours (Figure 6.2 a). Unlike treatment with GM6001, there 
were no apparent effects on cell proliferation following 14 days of treatment with this ROCK 
inhibitor (Figure 6.4 a, b). Assessment of cell proliferation via quantification of hydrogel 
DNA content revealed no decrease in cell proliferation in either collagen or GelMA 
hydrogels, with the exception of MIA PaCa-2 cells in GelMA. In collagen, Capan-2 and MIA 
PaCa-2 even showed a significant increase in cell proliferation with treatment. Visually, cells 
formed clusters which were similar in numbers to control condition but showed more 
disorganised morphologies (Figure 6.4 b). Despite no apparent reduction of cell proliferation 
as a single treatment, the effects of fasudil as well as GM6001 treatment on overall hydrogel 

















































































































































































































Figure 6.4 Effects of fasudil treatment on PDAC cell proliferation in collagen and 5% GelMA. (a) 
CyQUANT quantification of cell proliferation of 3D cell cultures at day 1 (grey dots) and day 14 (yellow dots) 
in matrices of increasing stiffness (collagen and 5% GelMA). Cells were treated with either 10 µM control 
peptide or fasudil in medium, replaced every 72 hours. ANOVA (Tuckeys multiple comparisons), p-values as 
annotated, n=3. (b) Representative brightfield micrographs of Capan-2 cells treated with 10 µM fasudil 
(bottom) or control (top), at day 14 of culture in 7.5% GelMA. Scale bars 500 µm and 2 mm (inserts), apply to 
all. 
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6.3.3 Inhibition of ROCK, but not of MMPs, lead to cell-mediated stiffness 
changes in GelMA hydrogels 
The stiffness of cell-containing hydrogels was assessed via rheometry (collagen hydrogels) 
and confined compression (GelMA hydrogels) (Figure 6.5 a). Despite having no significant 
effect on cell proliferation, fasudil treatment significantly reduced the stiffness of cell-
containing 5% and 7.5% GelMA hydrogels compared to control conditions. Due to collagen 
gels being very soft, compression testing could not be performed, and rheology was used 
instead. No significant difference in matrix stiffness was detected using this method despite 
a tendency towards decreased stiffness was observed in GM6001 treated gels. In the future, 
a consistent, unified method should be used for stiffness assessment in both collagen 
hydrogels. For instance, a specialised rheometer with combined frequency sweep, amplitude 
sweep, and compression modalities could be used for the assessment of both hydrogel types. 
 
A yet different and highly sensitive methodology was used for the assessment of local 
stiffness at the nano-scale in 5% and 7.5% GelMA hydrogels. Atomic force microscopy 
(AFM) is a type of scanning probe microscopy which uses the deflection of a laser generated 
by the movement of a cantilever to scan topography or stiffness at a very high resolution. 
This technique was employed in order to precisely detect the stiffness of GelMA-embedded 
spheroids at day 14 of culture after calibration of the tip on an acellular hydrogel (Figure 6.5 
b). BxPC-3 and PANC-1 cells grown in 5% and 7.5% GelMA hydrogels at day 14 of 
treatment with GM6001 were used for this. Surprisingly, mean stiffness values of PDAC cell 
spheroids within GelMA were very close to the predicted stiffness of the hydrogel itself (3.4 
kPa for 5% GelMA hydrogels and 8.6 kPa for 7.5% GelMA hydrogels). This indicated that 
cells embedded in stiffer matrices had the tendency to form tighter spheroids, with a stiffness 
similar to that of their surroundings. It also indicated that despite AFM being a very different 
technique than compression, the results are relatively comparable. 
 
Spheroids treated with GM6001 had a lower stiffness in 5% GelMA compared to their 
untreated counterparts. Upon GM6001 treatment, BxPC-3 and PANC-1 cells formed 
smaller spheroids due to their impaired MMP-mediated matrix remodelling ability. This 
could explain why GM6001-treated spheroid were softer compared to their untreated 
counterparts. This effect seems lost in 7.5% GelMA where the surrounding matrix is very 
stiff. Taken together, this could indicate that the tumour mass stiffens and relaxes in response 
to treatment, but generally matches the stiffness of its surrounding. This could have 
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interesting implications in vivo, whereby matrix stiffness alone could determine, and possibly 
re-establish, the stiffness of the tumour cell mass. As fasudil-treated hydrogels showed a 
significant reduction in stiffness, I was interested in taking this treatment further with the 
hypothesis that it could be used in combination with gem/abx in order to relax hydrogel 
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Figure 6.5 Effects of GM6001 treatment on matrix stiffness as measured by (a) rheometry, confined 
compression and (b) atomic force microscopy (AFM). (a) Cells were cultured for 14 days in either collagen, 
5% or 7.5% GelMA and treated with either 20 µM GM6001, 10 µM fasudil, or control peptide in medium 
(replaced every 72 hours). Collagen hydrogel stiffness was measured via rheometry testing in amplitude sweep 
mode while GelMA hydrogels were tested via compression. Dotted lines correspond to GelMA stiffness 
prediction. ANOVA, p-values as annotated, n=3. (b) AFM testing of BxPC-3 and PANC-1 cell-laden 5% and 
7.5% GelMA hydrogels. Hydrogels were cultured for 14 days and treated with GM6001 as previously described. 
Each sample was indented on three separate 1x1mm areas, in which 100 indents were performed. Acellular 
hydrogels were used as calibration, allowing the precise detection of ‘spheroids’ and cell cluster’ areas within 
cell-laden hydrogels. Kolmogorov-Smirnov (multiple comparisons), p-value as annotated, n≥3. 
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6.3.4 Effects of matrix priming with ROCK inhibitors on chemotherapy 
efficiency in 3D cell cultures 
6.3.4.1 Combined treatment of fasudil and chemotherapy lead to reduced cell 
viability  
In order to test the effects of combined fasudil and chemotherapy treatment, collagen, 5% 
and 7.5% GelMA hydrogels were set up as triple cultures (PDAC, CAF, THP-1 cells in a 
1:2:2 ratio) and respective controls (PDAC cells monocultures and stroma). Cells were grown 
within the hydrogels for 7 days prior to treatment with 10 µM fasudil or control medium. 
Following 72 hours from the addition of fasudil, the treatment groups were further divided 
for treatment with gem/abx (100 nm of each) or saline diluent control in cell culture medium. 
Hydrogels were then collected at day 14 for endpoint analyses including imaging, 
proliferation, hydrogel stiffness, gene and secreted factors expression (Figure 6.6 a). The 
experiment was repeated with patient-derived CAFs from three distinct patients and a 
minimum of three technical replicates for each condition. Micrographs of live (green, Ca-
AM) and dead (red, Et-H1) cells at day 14 of culture revealed an increase in the number of 
Figure 6.6 Experimental setup of triple culture experiments. (a) Schematic representation of triple culture 
experimental setup. Collagen, 5% and 7.5% GelMA hydrogels were used for this. Triple cultures consisted of 
PDAC cells, THP-1 monocytes and patient-derived CAFs in a 1:2:2 ratio. Monoculture control hydrogels 
(PDAC only and THP-1/CAFs stroma only) were also set up. CAFs were isolated from patients number 2, 3 
and 15. Cultures were kept for 14 days prior to readout. (b) Confocal z-stack micrographs of PANC-1 cells in 
collagen (left) and 5% GelMA (right) hydrogels at day 14 of culture following treatment as indicates. Live cells 
were stained with green fluorescent calcein-AM (Ca-AM, 494/517 nm) and dead cells with ethidium 
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dead cells in fasudil-treated conditions compared to untreated, despite no change in the 
overall number of viable cells (Figure 6.6 b). As expected, treatment with gem/abx reduced 
the number of viable cells in both collagen and GelMA hydrogels. 
 
Cell viability and cell counts were quantified on day 14 via measurement of endogenous 
reducing enzyme activity (Alamar Blue, unfilled dots) and DNA content (CyQUANT, filled 
dots)(Figure 6.7 a,b). Similarly to what had been observed in the previous sections, treatment 
with fasudil alone did not overall decrease the viability and proliferation of PANC-1 cells 
(p=0.95 and p=0.96, ns), and had a limited effect on triple cultures (slight reduction of 
proliferation in 5/9 cases, p=0.92 and p=0.89, ns). Individual patient data is indicated as a 
line plot in Appendix 9.5. Without the presence of cancer cells, CAF and THP-1 cells 
proliferated less than their malignant counterparts within the hydrogels, especially in stiffer 
















Figure 6.7 Effects of fasudil priming on the efficacy of gemcitabine and abraxane (Gem/Abx) in 
collagen (yellow), 5% (blue) and 7.5% (purple) GelMA hydrogels as measured via quantification of (a) 
endogenous cellular reducing ability and (b) DNA content. (a) Alamar Blue quantification of cells’ 
metabolic activity at day 14 of culture. Cultures were treated with 10 µM fasudil on day 7 and 100 nm of each 
Gem/Abx on day 10. Appropriate untreated and single treatment controls were also set up. Triple cultures 
consisted of PDAC cells, THP-1 monocytes and patient-derived CAFs in a 1:2:2 ratio. Monoculture control 
hydrogels (PDAC only and THP-1/CAFs stroma only) were also set up. CAFs were isolated from patients 
number 2, 3 and 15, n=3, p-values as indicated. (b) CyQUANT quantification of DNA content was performed 
at day 14 of culture. n=3, p-values as indicated. 
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Treatment with gem/abx decreased the viability and proliferation of triple cultures and 
PANC-1 cells and but was less efficient in targeting stromal cells (response in 3/9 cases, p-
value >0.05, ns). When combined with fasudil, there was a further decrease in the 
proliferation of triple cultures (8/9 cases showed further reduction in DNA content, 
p=0.0009), as well as PANC-1 (7/9, p=0.025) and, to a lesser extent, stromal cells (3/9, 
p=0.45). Interestingly, similar effects were observed across collagen and GelMA hydrogels 
as well as different stiffness, suggesting its mechanism of action may be overcoming stiffness-
related resistance mechanisms. 
 
Overall, these data indicate that fasudil had a greater effect on stromal cells compared to 
malignant cells, while the opposite was true for gem/abx treatment. When pre-treated with 
fasudil, gem/abx treatment led to a further decrease in overall cell numbers in all the 
conditions, suggesting this combination may be advantageous in reducing cell proliferation. 
Importantly, even in combination, there was no overall ablation of stromal cells following 
treatment in GelMA, suggesting a number of residual stromal cells were preserved in these 
hydrogels. This was not the case in collagen hydrogels, in which stromal cells responded to 
all three treatment conditions. As stroma-ablating treatments have so far proved 
controversial or failed in PDAC 45,47,49, the ability of stiffer tissues to retain some restraining 
or re-educating stromal cells may be an advantage. 
 
6.3.4.2 Treatment with fasudil, but not chemotherapy, led to reduced matrix 
stiffness in GelMA 
In order to understand the mechanisms involved in fasudil-enhanced chemotherapy 
efficiency, the stiffness of cell-containing hydrogels was recoded at day 14 of culture in 
GelMA hydrogels (Figure 6.8 a, b). When all conditions were combined, fasudil, but not 
gem/abx treatment, led to a significant reduction in GelMA hydrogels stiffness (Figure 6.8 
a). Despite fasudil having no direct effects on proliferation as a monotherapy, this data 
suggests treatment could be decreasing overall matrix stiffness to either facilitate subsequent 
gem/abx delivery, or reprogramming of stromal cells. In fact, fasudil is known to decrease 
fibroblast contractility in 3D models, as well as disrupting collagen matrix integrity via 
ROCK/pMLC (myosin light chain)-mediated downregulation of acto-myosin contractility 
155. GelMA hydrogels show a reduction of overall stiffness even when treated in combination 
with chemotherapy. As stiffness alone is able to induce chemoresistance to abraxane 128, 
relaxation of overall matrix tension after treatment would be advantageous in order to limit 
relapse. 
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Figure 6.8 b shows the distribution of stiffness data based on different culture groups: triple 
cultures (blue dots) generally result stiffer compared to PDAC and stroma-containing 
hydrogels (brown and pink dots). In order to understand further the molecular changes 
involved in stiffness regulation, gene analyses on the treated samples were conducted. 
 
6.3.4.3 Effects of ROCK inhibition and chemotherapy on matrisome-related genes 
and secreted factors 
The effects of fasudil, gem/abx and combination treatment on matrix-related gene 
expression was assessed. For this, a panel of nine genes was used as either belonging either 
to matrix and matrix remodelling (FN1, VCAN, CTSB, COL1A1, COL11A1, MMP9), EMT 
(VIM, MMP9) or mechano-sensing (YAP1, VIM, TGFBI) groups. PDAC or stromal (CAFs 
Figure 6.8 Effects of fasudil, Gemcitabine and abraxane (Gem/Abx) treatment on the stiffness of 
collagen, 5% and 7.5% GelMA hydrogels. (a) Stiffness of cell-laden 5% (top) and 7.5% (bottom) GelMA 
hydrogels, as measured via unconfined-compression at day 14 of culture. Cultures were treated with 10 µM 
fasudil on day 7 and 100 nm of each Gem/Abx on day 10. Appropriate untreated and single treatment controls 
were also set up. Triple cultures consisted of PDAC cells, THP-1 monocytes and patient-derived CAFs in a 
1:2:2 ratio. Monoculture control hydrogels (PDAC only and THP-1/CAFs stroma only) were also set up. CAFs 
were isolated from patients number 2, 3 and 15. Kruskal-Wallis, p-value as annotated, n=3. (b) Stiffness of 
cell-laden 5% (top) and 7.5% (bottom) GelMA hydrogels. Here, the different hydrogels groups are indicated as 
follows: triple cultures (blue), stroma (brown), PDAC cells (pink), n=3. 
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and THP-1) cells were cultured for 14 days in either collagen, 5% or 7.5% GelMA hydrogels 
prior to RNA extraction. Gene expression heatmaps showed a downregulation of all assessed 
genes upon combinational treatment in cancer cells, with the exception of TGFBI in 5% 
GelMA and YAP1 in 7.5% GelMA hydrogels (Figure 6.9 top). This suggested that upon 
treatment, cancer cells had a reduced matrix and EMT gene expression leading to reduced 
matrix production and malignant cell behaviours. In soft (collagen) and medium stiffness 
(5% GelMA) hydrogels, chemotherapy was responsible for an upregulation of most of the 
assessed genes. As a monotherapy, fasudil also led to the upregulation of all the tested genes 
with the exception of matrix proteins FN1, VCAN, MMP9 and TGFBI, CTSB, COL1A1, 
VCAN, that were unaffected in collagen and 5% GelMA hydrogels respectively. 
 
Gene expression analysis of stromal (CAF  and THP-1) cells showed a more heterogeneous 
picture (Figure 6.9 bottom). In collagen and 5% GelMA hydrogels, the majority of assessed 
genes were downregulated upon combinational treatment, while all genes showed an 
upregulation in 7.5% GelMA hydrogels. Chemotherapy alone was responsible for the 
upregulation of the assessed genes in collagen and was maintained for 4 out of 9 genes in 
7.5% GelMA hydrogels. fasudil treatment resulted in an upregulation of the assessed genes 
in stromal cells cultured in 5% GelMA hydrogels. Overall, the decreased expression of matrix 
and mechanosensing genes following combinational treatment in all assessed PDAC 
conditions as well as largely in stromal cells was encouraging. The large upregulation in pro-
tumorigenic gene expression by stromal cells in stiffer matrices (7.5% GelMA) suggests these 
cells might be exerting a tumour-protecting role upon treatment and contribute to resistance. 
Future work will investigate the changes in gene expression of triple cultures in response to 
treatment. Following gene expression analyses, the effects of treatment on other gene 
signatures 120 and secreted proteins was assessed. 
 
The matrix index (MI) is an ECM-associated signature (comprising 22 molecules), that 
predicts both extent of disease and tissue stiffness at gene and protein levels 120. The MI 
inversely correlated with prognosis 120 as well as EMT status of the analysed PDAC cells 
(Chapter 5). FN1, VCAN, CTSB, COL1A1, COL11A1 are part of the MI signature. Here, 
the MI of normal untreated pancreas was compared to that of PDAC untreated or gem-
treated samples (Figure 6.10 a) in publicly available gene datasets. Unsurprisingly, normal 
untreated pancreatic samples had a lower MI compared to PDAC samples. The MI increased 
further in gemcitabine-treated samples, indicating that despite its cytotoxic effects, 
chemotherapy may alter the tumour niche causing an increase in pro-tumorigenic matrix 
 Targeting the Tumour Microenvironment using in vitro Models of PDAC 
 
-  198 - 
 
deposition, contributing to resistance. This effect was also seen in 3D cultures in both PDAC 
and stromal cells (Figure 6.9). In the absence of other treatments, aberrant matrix deposition 
(Figure 6.9, Figure 6.10 a), together with an unaltered tissue stiffness (Figure 6.8 a), may work 
synergistically to promote chemoresistance and reoccurrence post-chemotherapy.  
 
Collagen CAF+THP-1                  5% GelMA CAF+THP-1                 7.5% GelMA CAF+THP-1 
 
Collagen PANC-1                         5% GelMA PANC-1                         7.5% GelMA PANC-1 
 
Figure 6.9 Expression heatmaps of selected genes following treatment with fasudil, chemotherapy 
(Gemcitabine/abraxane), combination treatment or control for PANC-1 (top graphs) or stromal cells 
(THP-1 and CAF, bottom graphs) at day 14 of culture in collagen, 5% or 7.5% GelMA hydrogels. Gene 
expression was quantified via RT-qPCR and expression analysed relative to HPRT1. Ward.D2 was used on R 
for data clustering based on the indicated Z-score. n=1.  
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It could be hypothesised that due to the decrease in ECM gene expression and consequently 
matrix deposition, the MI of fasudil-treated cultures would also be lower compared to 
untreated conditions. Unfortunately, not enough data are publicly available to determine 
whether this is the case. Gene sequencing or proteomics analyses of fasudil and gem/abx-
treated hydrogels should be conducted in order to characterise changes in the MI following 
treatment. 
Next, a cytokine array was used to determine changes in the levels of secreted factors 
following fasudil, gem/abx and combination treatments. The measured levels of some key 
cytokines in the ascitic fluid of patient 3 are shown in Figure 6.10 b. Elevated interleukin (IL) 
-6 and -8 levels are associated with poor prognosis in a number of cancers 370. In PDAC, 
their expression is significantly upregulated compared to healthy tissues 371, so much so that 
they are considered as PDAC biomarkers 372,373. A high concentration of both IL-6 and -8 
was recorded in the ascitic fluid of patient 3. 
 
IL-6 and -8 levels were measured in the conditioned supernatant of triple culture hydrogels 
(PANC-1:CAF:THP-1 in a 1:2:2 ratio) at day 14 of culture and following fasudil, gem/abx 
or combination treatment, as previously described. CAFs isolated from patient 3 were used 
for this (Figure 6.10 c). Following treatment, IL-6 levels were elevated compared to control 
in collagen gels, while IL-8 levels remained unchanged. This was not the case in 5% and 7.5% 
GelMA hydrogels. Interestingly, despite both IL-6 and IL-8 levels increasing with fasudil and 
gem/abx as a single treatment, the expression of both cytokines resulted lower in the 
combinational setting. This effect was evident in both 5% and 7.5% GelMA (Figure 6.10 c). 
Taken together, this suggested that matrix priming with fasudil followed by gem/abx might 
be not only relaxing matrix stiffness but also leading to decreased secretion of 
proinflammatory cytokines, such as Il-6 and IL-8. As IL-6 and IL-8 are known to promote 
proliferation, migration and invasion in PDAC 298-300, lower levels following combinational 
treatment is concordant with the observed reduction in cell proliferation of these cultures. 
Importantly, as IL-6-dependant activation of STAT3 is required for PDAC progression 300, 
its inactivation could slow tumorigenesis or, in this case, reoccurrence after treatment (Figure 
6.10 b, Figure 4.21 b). In control conditions, both IL-6 and IL-8 levels decreased in GelMA 
cultures compared to collagen cultures, and even further from 5% to 7.5% GelMA (Figure 
6.10 d). 
 
To conclude, successive treatment of triple cultures with fasudil and gem/abx led to reduced 
cell viability and cell counts compared to chemotherapy alone, in all three matrices at day 14 
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of culture. Treatment with fasudil led to a significant reduction of GelMA hydrogel stiffness. 
This was accompanied by a downregulation of matrix-, EMT- and mechanosensing-related 
genes in the cancer cells. Finally, while secreted IL-6 and IL-8 levels increased upon 
monotherapy, their levels were decreased to control levels during combinational treatment.  
  
Figure 6.10 Effects of treatment with fasudil and chemotherapy (gemcitabine/abraxane) on matrix 
proteins and secreted factors. (a) Matrix index of PDAC untreated samples, gemcitabine-treated, and normal 
untreated samples from publicly available gene data from The Cancer Genome Atlas. (b) Secretory profile of 
some of the main cytokines in patient 3 (ascitic liquid), n=1. (c) Interleukin (IL-) -6 and -8 levels in cell culture 
supernatants of triple cultures (PANC-1:CAF:THP-1 1:2:2 ratio) at day 14 of culture in collagen, 5% and 7.5% 
GelMA. Hydrogels were treated with 10 µM fasudil on day 7 of culture and 100 nm Gem/Abx (each) on day 
10 of culture. TNFα= tumour necrosis factor alpha, IFNγ = interferon gamma. 
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6.4 Conclusions 
In this Chapter, I explored the changes in cell behaviours and hydrogel properties following 
treatment with inhibitors of matrix-remodelling and matrix-sensing pathways. For this, I used 
a potent broad-spectrum MMP inhibitor (GM6001), a ROCK inhibitor (fasudil) and three 
hydrogel-based matrices for the 3D cell culture of PDAC and stromal cells.  
 
Degradation of the local microenvironment through MMPs is a key process during spheroid 
formation, cell growth and migration 142,145,164. Altered MMP expression and activity in the 
TME lead to loss of homeostasis of the ECM, thereby driving PDAC progression 163. Hence 
decreased MMP levels are considered important markers of the anti-tumorigenic potential 
of several compounds and genes under study. The gelatinases MMP2 and MMP9 are among 
the most studied in PDAC due to their significant upregulation in patients 163,374 and 
contribution to prognosis (Figure 1.4). In this study, MMP inhibition via the broad-band 
inhibitor GM6001 led to a reduction in the expression of MM2 and MMP9 in collagen and 
GelMA hydrogels which was accompanied by a downregulation of vimentin in three PDAC 
cell lines cultured in collagen and GelMA hydrogels (Figure 6.3). Recent work showed that 
anti-MMP9 antibody targeting in PDAC led to the formation of smaller tumours in xenograft 
models accompanied by a downregulation of stromal markers (collagen-I, α-SMA) and EMT 
markers including vimentin 375. A number of other groups have implemented MMP 
inhibitors in pre-clinical animal models with promising results 163,252,376,377. 
 
GM6001 successfully reduced the proliferation of four PDAC cell lines in 2D, where its 
effects were more marked on epithelial-like cell lines rather than mesenchymal ones (Figure 
6.1). Stimulation of EMT by collagen coating or increasing matrix stiffness (GelMA) resulted 
in increased susceptibility of cells and higher response rates to GM6001 (Figure 6.1, Figure 
6.2). Upon treatment, all the cell lines showed significantly lower invasive potential (Figure 
6.2). Limited cell-mediated matrix remodelling and proliferation, as well as loss of vimentin, 
led to the formation of markedly smaller spheroids in GM6001-treated hydrogels compared 
to controls (Figure 6.2). The dual reduction in cell proliferation and spheroid size further 
highlighted the regulatory role of MMPs in spheroid formation and growth as well as 
emphasising the importance of using MMP-sensitive and biodegradable 3D cell culture 
systems for the study of biological processes. Lastly, although there was no difference in the 
overall stiffness GelMA hydrogels upon treatment, AFM revealed local changes in the 
stiffness of spheroids and cell-clusters embedded within the hydrogels (Figure 6.5). GM6001-
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treated spheroids were not only smaller than their untreated counterparts but also softer and, 
possibly due to their limited matrix remodelling abilities, they did not affect overall hydrogel 
stiffness. 
 
Despite promising results at pre-clinical stages in both in vitro and in vivo models, there has 
yet been no breakthrough for the clinical implementation of MMP inhibitors. In fact, only 
two phase III trials were published with the use of broad-band MMP inhibitors in PDAC 
(marimastat and tanomastat), both of which with no clear response or survival benefit for 
the patients 161,162. A number of speculations can be made in regard to the discrepancies 
between experimental and clinical results for these inhibitors. First is the lack of adequate 
TME in pre-clinical models, which prevent the accurate understanding of the complex MMP 
dynamics within the tumour niche. CAFs for instance can secrete high amounts of MMPs 
and their tissue inhibitors TIMPs and are active contributors to matrix remodelling in PDAC 
59. Matrix remodelling is essential for the maintenance of CAFs and as such, is a self-sustained 
function. In addition, stromal cytokine levels (such as interferon gamma – IFNγ – or C-C 
motif chemokine ligand 2 - CCL2) can direct monocyte-mediated regulation of MMPs in 
PDAC 378. In order to accurately model the effects of MMP inhibitors at a pre-clinical level, 
a model would have to take into consideration not only effects of MMP inhibition on cancer 
cells themselves (or on tumour burdens) but also on the self-sustaining and co-regulated 
secretion of MMPs by other components of the pancreatic TME. In this regard, the inclusion 
of multiple TME elements in collagen and GelMA hydrogels for these experiments would 
give us a better understanding of the mechanistic processes regulating MMP inhibition in the 
context of the TME. 
 
Disappointing clinical trials results of MMP inhibitors do not imply that MMPs do not 
contribute to PDAC progression. The lack of clinical benefits may also be due to inclusion 
of the inhibitors at advanced stage of disease, when both the tumour cells and other TME 
components have an already established co-stimulatory networks for the secretion of several 
matrix remodelling enzymes. In fact, the MMP pathway is highly multifaceted and only 
constitutes a minority of expressed human proteases. Serine, cysteine, threonine and aspartic 
proteases are also deregulated in cancer, and can contribute to tumorigenesis both 
dependently and independently of MMPs 379,380. Finally, certain MMPs can play both a pro- 
and anti-tumour role, therefore their inhibition is not always beneficial. This is in fact the 
case for MMP9 deficiency which, on a Kras(G12D) background enhances tumour 
progression and invasion 164 rather than inhibiting it. Nonetheless, a continued understanding 
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of the processes regulating matrix degradation in cancer and their roles in stiffness 
modulation is pivotal to our understanding of PDAC biology. 
 
Next, the effects of ROCK inhibition on PDAC cells cultured in collagen and GelMA were 
presented (Figure 6.4, Figure 6.5). Unlike GM6001, treatment with fasudil did not lead to a 
significant reduction in cell proliferation and the overall number of spheroids remained 
unchanged between treated and untreated conditions (Figure 6.4). This is concordant with 
previous reports where treatment with fasudil did not significantly affect cell proliferation in 
2D or 3D (collagen gels) 155. However, fasudil significantly decreased the stiffness of cell-
containing GelMA hydrogels (Figure 6.5 a). When analysed by microscopy, fasudil treated 
cultures showed a higher number of dead (Et-H1 stained) PANC-1 cells compared to control 
conditions, despite the overall number of spheroids being unchanged (Figure 6.6 b). Because 
of this, the effects of fasudil were investigated in conjunction with the standard 
chemotherapeutic agents gem/abx on 3D cell cultures of PDAC, CAFs and THP-1 cells. A 
staggered administration regime was devised, whereby cultures received an initial dose of 
fasudil followed by chemotherapy. Monotherapy as well as monoculture controls were also 
analysed. Matrix priming with fasudil in combination with chemotherapy led to a further 
reduction in cell viability and proliferation compared to chemotherapy alone (Figure 6.6, 
Figure 6.7). 
 
As previously observed in monocultures, fasudil alone had no effect on cell proliferation of 
the triple culture hydrogels however, it had a mild effect on stromal cells. Importantly, fasudil 
treatment led to a reduction in the overall stiffness of triple culture GelMA hydrogels, even 
in the presence of gem/abx (Figure 6.7). In addition to impeding drug delivery, matrix 
stiffness alone can induce resistance to abraxane and relapse 128, hence a reduction in tension 
was an encouraging outcome of this combinational treatment (Figure 6.8). In PDAC cells, 
combinational treatment led to the downregulation of matrix and matrix remodelling genes 
(FN1, VCAN, CTSB, COL1A1, COL11A1, MMP9), EMT genes (VIM, MMP9) and 
mechano-sensing genes (YAP1, VIM, TGFBI), in all three matrices. This suggested 
treatment led to an impaired expression of pro-survival, pro-tumorigenic genes and 
matrisome-related genes. FN1, VCAN, CTSB, COL1A1, COL11A1 specifically, have been 
associated with poor prognosis in a number of cancers including HGSOC and PDAC 120. 
Hence, their downregulation was an encouraging feature of the treatment. Contrariwise, 
chemotherapy alone caused an upregulation of EMT genes, a phenomenon which has been 
described in a number of cancers 381,382. In turn, EMT can promote chemotherapy resistance 
further 128,382. 
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Lastly, a common matrix signature (the matrix index – MI 120) and secreted cytokines were 
analysed upon treatment in order to establish further treatment effects at the gene and 
protein level (Figure 6.9, Figure 6.10). At gene level, the MI was significantly increased in the 
progression from healthy pancreas to PDAC, and was further upregulated in gem-treated 
samples (Figure 6.10 a). An increased expression was also recorded in IL-6 and IL-8 
cytokines upon gem/abx treatment (Figure 6.10 c), both of which are associated with poorer 
prognosis in PDAC 371-373. High, sustained levels of IL-6 and IL-8 were also observed upon 
fasudil treatment as a monotherapy. Combined treatment with fasudil and chemotherapy 
resulted in lower IL-6 and IL-8 levels in GelMA but not collagen hydrogels. Because of their 
involvement in promoting PDAC cells proliferation, migration and invasion 298-300, a decrease 
in these cytokines would be a beneficial feature of this combinational treatment, especially 
as a conserved feature in stiffer GelMA hydrogels.  
 
Host tissue properties and its alterations play a vital role in tumorigenesis by providing initial 
pro-survival signals as well as subsequent maintenance of cancer cell proliferation, invasion 
and metastasis 17,278. Combined, these results suggest that short-term inhibition of matrix and 
cellular tension at a whole hydrogel level prior to chemotherapy may improve response to 
treatment. The data revealed similar effect in all hydrogels analysed, as well as monoculture 
controls suggesting this phenomenon may be common to multiple microenvironments and 
across multiple physiologically-relevant tissue rigidities. This suggests that temporal 
disruption of signalling between tumour cells and their surrounding microenvironment 
renders cancer cells momentarily more sensitive to cytotoxic drugs. Additional mechanisms 
of action of ROCK inhibitors include impaired integrin signalling and induced accumulation 
of mitotic defects upon treatment 149,383. This is supported by other recent findings such as 
the inhibition of collagen crosslinking via temporal lysyl oxidase (LOX) antibody targeting 
in combination with chemotherapy, which effectively impaired PDAC progression 133. These 
effects have also been characterised and shown to be maintained in secondary sites 155.  
 
Additional work should be carried out in order to establish which patients are more likely to 
benefit from ROCK inhibitors and which biomarkers would be used for accurate 
stratification and characterisation of response. Patient stratification could facilitate a more 
targeted and efficient intervention strategy, as single “all inclusive” chronic targeting 
approaches have so far had limited success in PDAC 45,47-49,364. As for the presented data, 
combinational ROCK and cytotoxic drugs targeting was efficient in triple cultures regardless 
of the stiffness of the hydrogel (Figure 6.7). However, in the absence of cancer cells, stromal 
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cells were more susceptible to the treatment in collagen hydrogels compared to 5% and 7.5% 
GelMA hydrogels. This suggests that despite no apparent advantage in overall co-culture 
proliferation, stiffer matrices serve a protective role over stromal cells. This may prove 
advantageous as previous studies have shown that complete fibrosis ablation in PDAC via 
either α-smooth muscle actin fibroblasts targeting 48, or pro-fibrotic Sonic Hedgehog 
signalling pathway silencing 49, enhance invasion, metastasis and reduced survival. Hence, 
transient administration of stromal-targeting therapies, rather than chronic ablation of 
fibrosis may represent an advantageous strategy. A similar intervention strategy could be 
applied to other ECM-targeting therapies such as the abovementioned LOX 133 or hyaluronic 
acid 44,45.  
 
Because of its reduced toxicity as a monotherapy, fasudil could be administered systemically 
at higher doses, where it would target not only the primary but also act as a priming agent 
on potentially unknown metastatic sites, followed by standard chemotherapy. Additionally, 
fasudil has been approved for use in Japan in the treatment of cerebral vasospasm since 1995 
and has now been approved by the US Food and Drugs Administration (FDA) in clinical 
trials of Raynaud’s disease, atherosclerosis, and amyotrophic lateral sclerosis (ALS). Among 
its benefits is the vasodilatory properties of the drug, which might also be beneficial for 
increased vessel perfusion and drug delivery in cancer 384. Alternative ROCK inhibitors such 
as CCT129254, AT13148, K-115 (ripasudil), GSK269962A have shown promising effects in 
melanoma 385,386 and glaucoma 387,388, as well as different specificity to ROCK1 and ROCK2. 
As such, the field of mechano-transduction in PDAC is still its infancy and the role of ROCK 
still widely unexplored in this cancer. Continued work will not only help uncover significant 
mechanobiological processes but also pave the way for improved targeting of this lethal 
malignancy. 
 
Taken together, these results suggest that GelMA hydrogels are a viable and informative 
platform for in vitro drug testing, with many potential applications in the field of 
bioengineering as well as drug development and pre-clinical drug screening. 
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Chapter 7 - Discussion and 
Concluding Remarks 
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7.1 Summary of key findings  
This thesis presents the first instance of the use of GelMA hydrogels of different stiffness 
for the modelling of the pancreatic TME. The suitability of GelMA hydrogels was evaluated 
by conducting several cell behaviour and molecular profiling assays on the encapsulated cells 
and benchmarked against collagen gels. For this, PDAC cells were used alongside THP-1 
cells and patient-derived CAFs. The formation of a multicellular 3D model, as well as the 
use of primary cells, represent a novel aspect compared to other reported GelMA-based 
models 252,255-257,389. 
 
Characterisation of GelMA hydrogel stiffness, nanostructure and the expression of selected 
matrix proteins were largely concordant with that of native PDAC ECM. To the best of my 
knowledge, this thesis presented the second-largest characterisation of fresh, human resected 
PDAC and adjacent normal tissues. In line with previous work 130, adjacent normal tissues 
had a stiffness of 2.2 ± 0.2 kPa which significantly increased to 7.4 ± 0.6 kPa in matched 
tumour tissues. Patient-derived pancreatic tissues were often stiffer than their murine 
counterparts, which prompted the investigation of 3D model’s rigidities via the stiffness 
testing of commonly-used hydrogel platforms. The stiffness range of GelMA hydrogels was 
much larger and easily tuneable compared to that of collagen gels, as well as Matrigel, which 
is an order of magnitude softer compared to human PDAC tissues 266. GelMA hydrogels 
stiffness was highly reproducible, even upon cell incorporation, and predictable through a 
simple mathematical relationship. To this end, 5% and 7.5% GelMA hydrogels were deemed 
the closest to the observed human tissue stiffness (3.4 and 8.6 kPa respectively) and were 
employed for transcriptomic and in vitro drug testing analyses. Importantly, following 
optimisation, biomechanics were used as a readout for direct comparison of cell-mediated 
matrix remodelling or stiffness modulation. 
 
Recent work has begun to uncover the importance of substrate mechanics in the regulation 
of PDAC intracellular signalling 17, proliferation 128, invasion 129,278, EMT 128,203 and response 
to treatment 265,279, of which cell-ECM signalling is a vital mediator 139,155. Because of this, the 
association between stiffness and the expression of some key matrix proteins was 
investigated. Collagen-I, fibronectin, versican, as well as total collagen expression was 
significantly higher in diseased tissues compared to matched healthy pancreas. Collagen fibre 
thickness was also increased 128. Importantly, increased local expression of any of these three 
matrix proteins positively correlated with increased tissue stiffness. In PDAC, the role of 
collagen and fibronectin is well characterised and associated with shorter survival 95,124,268, 
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whereas versican and its roles in carcinogenesis are much less studied 52. Finally, the 
expression of these three extracellular proteins as well as hyaluronic acid and the cellular 
markers cytokeratin-19 (PDAC cells) and CD68 (macrophages) was validated in cell-laden 
GelMA hydrogels. 
 
Next, the suitability of GelMA hydrogels for 3D PDAC cell culture and the inclusion of 
patient-derived cells was assessed and extensively characterised. 1H NMR and spectroscopy-
based analyses revealed high consistency in the degree of methacryloyl substitution onto the 
gelatin backbone across different GelMA batches. Cancer cell culture and viability in GelMA 
hydrogels was supported for over 28 days in hydrogels of ranging stiffness 3%, 5%, 7.5% 
and 10% GelMA. PDAC cells formed round, spherical colonies with distinct cell-specific 
morphologies, proliferation patterns and rates. Several in vitro and in vivo studies have now 
shown a appositive association between matrix stiffness and upregulation of EMT markers 
and pro-survival signalling pathways 17,128,139. In GelMA, epithelial-like cell lines, such as 
Capan-2 and BxPC-3, showed an increased proliferation in matrices of increasing stiffness 
(from 3% to 7.5% GelMA) while mesenchymal cell lines, such as PANC-1 and MIA PaCa-
2, did not. The presence of myeloid cells and patient-derived CAFs (but not normal 
fibroblasts) increased PDAC cell proliferation, as well as GelMA hydrogel stiffness via the 
upregulation of IL-6, IL-8 and pSTAT3, concordant with other reports 188,320. Unsurprisingly, 
the presence of myeloid cells in GelMA hydrogels increased the number of both tumours 
and metastases formed in orthotopic xenografts compared to control hydrogels with PDAC 
cells only. Furthermore, this supported the use of GelMA hydrogels as an alternative to 
collagen and Matrigel for use as carrier during in vivo studies. Although not tested here, the 
effects of hydrogel stiffness as well as patient-derived cells on tumorigenicity may be 
investigated in vivo using this approach. Indirect co-culture experiments revealed that STAT3, 
but not ERK, was upregulated during culture of PDAC cells with myeloid cells and 
fibroblasts. In stiffer matrices, concomitant upregulation of STAT3 and downregulation of 
ERK was observed, a phenomenon that has been associated with treatment resistance 307. 
 
Transcriptomics analysis of PDAC cells grown in GelMA hydrogels revealed matrix 
signatures that correlated with those of cells grown in collagen hydrogels, as well as primary 
tumour organoids cultured in Matrigel. Amongst the differentially expressed pathways of 
cells grown in soft collagen and stiffer GelMA hydrogels were a number of structural and 
matrix organisation genes. These included effectors of the GPCR, Wnt, β-catenin and Rho 
GTPase pathways, all of which are involved in mechano-sensing. Selected core matrisome 
and mechano-transduction genes were validated by RT-qPCR. Importantly, GelMA-cultured 
PANC-1 and BxPC-3 cells retained a gene expression profiles concordant with their EMT 
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status and distinct between the two cell lines. This suggested that cells were capable of 
maintaining cell-specific characteristics upon culture in GelMA which would be an advantage 
for the potential application of these hydrogels as personalised medicine or diagnostic tools. 
 
In order to understand the translational value of GelMA for PDAC research, treatment 
response to matrix-modulating and cytotoxic agents was assessed, alongside collagen gels. 
The effects of the broad-band MMP inhibitor GM6001, the ROCK inhibitor fasudil as well 
as a combination of gemcitabine and abraxane were tested on PDAC cell behaviours in 2D 
and 3D. Unfortunately, too little is known about patient’s responses to these agents to be 
able to infer any correlation between cell responses in GelMA and clinical efficacy. However, 
GelMA represented a suitable model for the investigation of all tested therapeutic agents, as 
well as the effects of stiffness, which could not be assessed to this extent in collagen gels. In 
2D, cell’s susceptibility to GM6001 and cytotoxic agents increased on collagen-coated wells 
compared to control, while fasudil had little effect on cell proliferation. Transwell invasion 
assays revealed that cell invasion through collagen and Matrigel-coated wells was significantly 
reduced upon MMP inhibition. In 3D, GM6001 treatment led to impaired spheroid 
formation and cell proliferation in both GelMA- and collagen-embedded cells 252. This was 
mediated by a reduction in PDAC cell MMP2 expression in collagen gels and MMP9 and 
VIM expression in GelMA. Treatment with GM6001 did not affect bulk hydrogel stiffness 
as measured by compression. However, atomic force microscopy revealed a decrease in local 
spheroid stiffness upon treatment with the MMP inhibitor, possibly indicative of a reduced 
matrix remodelling capacity. 
 
Unlike GM6001, treatment with fasudil did not significantly affect PDAC cell proliferation 
in 2D or 3D models as previously reported 155. Treatment with fasudil did however lead to 
decreased bulk hydrogel stiffness and increased cell death, prompting the investigation of 
this treatment in combination with the cytotoxic agents gemcitabine and abraxane. For this, 
triple cultures of PDAC, CAF and THP-1 cells were treated with the mechano-modulating 
agent fasudil on day 7 of 3D culture prior to chemotherapy on day 10 of culture. Endpoint 
analysis revealed that the addition of matrix priming with fasudil further reduced the 
proliferation of triple cultures compared to chemotherapy alone. Additionally, combinational 
treatment samples (fasudil plus gemcitabine/abraxane) showed lower levels of secreted IL-6 
and IL-8 compared to monotherapy treatments. Gene expression analyses revealed a 
downregulation of matrix proteins (COL1A1, COL11A1, CTSB, FN1, VCAN) and EMT 
markers (MMP9, TGFBI, VIM, YAP1) in the combination treatment samples compared to 
controls. These genes were largely upregulated in chemotherapy-treated and fasudil-treated 
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samples but not in combination. Overall, these effects were more prominent in PDAC cells 
compared to stromal (CAF and THP-1) cultures. On the other hand, stromal cells cultured 
in stiffer matrices (7.5% GelMA) did not respond to treatment as their proliferation was 
unchanged and matrix protein and EMT gene expression increased. Hence, the use of 
GelMA hydrogels allowed to discern between the behaviours of specific cells, in 3D 
monoculture or co-culture settings, unveiling differential responses to treatment and matrix 
stiffness. Taken together, these data supported the use of GelMA-based hydrogels for pre-
clinical drug testing, accurate assessment of in vitro stiffness modulation and multi-modal 
assessment of cell functions and behaviours. 
7.2 Future experiments 
In the light of findings presented, I suggest the following experiments for the continuation 
of this work: 
Related to Chapter 3: 
• Increase the number of tissues for stiffness and matrix protein analysis to strengthen 
and validate the described correlations with tissue stiffness. Associations between 
specific matrix molecules and stiffness have not been previously characterised, at a 
local level, in PDAC. Additional matrix markers, such as hyaluronic acid, markers 
identified via transcriptomics analyses, such as ROCK, LOX, TGFBI, or cellular 
Figure 7.1 Schematic representation of some of the investigated key processes involved during the 
progression from 2D cultures to 3D collagen gels, GelMA-based hydrogel cultures, the addition of 
relevant tumour microenvironment components, and treatment. 
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markers such as CD68, αSMA, FAP, KRT19, should be validated at protein level and 
checked against local stiffness for potential correlations. 
• The expression of these markers should be investigated further in GelMA hydrogels, 
which also allow to determine the cellular origins for each marker. 
 
Related to Chapter 4: 
• Increase the translation value of GelMA hydrogels by including primary PDAC and 
myeloid cells alongside patient-derived CAFs. These could be isolated from matched 
resected tissues and plasma/blood samples. 
• Fully understand the effects of UV crosslinking on cells by conducting protein 
analyses on GelMA-extracted cells for the DNA damage markers γH2AX, p53 
binding protein, RAD-51, or BRCA1 and consider visible light crosslinking 
alternatives. 
• Optimise conditions for the 3D printing of cell-laden GelMA hydrogels 230,233,238. This 
would be a high-throughput, fast, multimodal and standardised alternative for 3D 
modelling, conducive to the incorporation of multiple cell types. 
 
Related to Chapter 5: 
• Understand transcriptional changes upon incorporation of multiple cell types within 
GelMA hydrogels, and comparison with primary organoids (Matrigel). For this, 
RNA-seq could be performed on co- and triple-cultures in GelMA. 
• Perform proteomics analysis of cells (this has never been done on GelMA-cultured 
cells before) and integrate the results with the transcriptional data. This could provide 
us with cues to stiffness-induced protein changes and complement the 
transcriptomic data. This could be further compared to human data (depending on 
tissue availability) or against published matrisome datasets 86,87. Phospho-proteomics 
could be employed for the understanding of fasudil-induced changes in 
phosphorylation (such as those of downstream targets MLC, PTEN, LIMK, Cofilin). 
 
Related to Chapter 6: 
• Further elucidate the efficacy of combined ROCK and chemotherapy treatment (and 
relevant monotherapy controls) by assessing the expression of cell proliferative 
(Ki67) and cell death (Cc3) markers in GelMA triple cultures and monoculture 
controls. 
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• Understand the changes in ROCK expression (and downstream targets) during 
treatment in GelMA and subsequent addition of chemotherapy. Proteomics, western 
blotting or phospho-protein arrays could be used to this end. 
• Confirm the ROCK-mediated mechanisms of stiffness relaxation in GelMA through 
validation with different ROCK inhibitors and performing a gene knockout. 
7.3 Wider research implications and future perspectives 
Despite several clinical trials and a considerable increase in our understanding of PDAC 
biology, there has been little improvement in the survival rates of pancreatic cancer patients 
over the past decades. Compared to other cancers, PDAC’s dismal prognosis remains 
virtually unchanged and efficient treatment options rather stagnant 1. This is accompanied 
by an overall high failure rate of oncology drugs entering the clinical trial pipeline, where only 
around 3.4% end up being approved for market use 363. This can be partially explained by a 
number of discrepancies observed between pre-clinical and clinical results which is fostered 
by over-reliance on traditional 2D cell culture and the use of immortalised cell lines. The 
development of pre-clinical models that accurately capture multiple fundamental aspects of 
the TME, such as stiffness, architecture, matrix protein expression, tumour and stromal 
heterogeneity, is paramount to bridge the gap between pre-clinical and clinical efficacy. The 
development of advanced in vitro models and their analytical techniques would impact not 
only translational but also basic research. 
 
A novel approach for 3D modelling of PDAC was presented in this thesis. Following a 
bottom-up approach, I aimed to dissect and then recapitulate certain key features of PDAC 
pathobiology in order to understand their individual contribution to pathogenesis. 
Characterisation of GelMA hydrogels themselves, as well as optimisation of analytical 
techniques for their analysis, were inherent to the successful implementation of this platform 
as a 3D cell culture model. These aspects are often overlooked as commonly-used matrices, 
such as collagen gels and Matrigel, have little tractability and tuneability, often leaving no 
room for optimisation. A crucial consideration for the purpose of this work was the range 
and tuneability of mechanical properties of these popular cell culture platforms. In fact, both 
collagen and Matrigel undergo chemical and temperature-dependant crosslinking resulting in 
weakly crosslinked matrices with a stiffness of less than 1 kPa, irrespective of polymer 
concentration. This is below both the physiological stiffness of pancreatic tissues as well as 
that of diseased ones. Both Matrigel and collagen gels have a batch-to-batch variability that 
is much higher than that of gelatin. These matrices undoubtedly provide microenvironmental 
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cues to support cell viability and proliferation but make it hard to discern between matrix-
induced and cell-inherent behaviours. On the other hand, as gelatin is the most abundant 
protein in our body 237,287, it provides a more inert yet highly relevant matrix for 3D cell 
culture. A better-defined matrix composition represented an advantage during 
transcriptomic analysis of the embedded cells, allowing the dissection of pathways that were 
directly involved in stiffness regulation via direct comparison of 5% and 7.5% GelMA 
hydrogels. As the composition of GelMA is defined 234,242, cells could be subjected to 
proteomics analyses to further understand stiffness and treatment-induced matrisome 
changes. This would pave the way for more detailed and integrated multi-omics analyses of 
a single 3D system, which many groups have now adopted as standard characterisation 
approach 18,223,348,360. 
 
An additional consideration is the number of cells that can be incorporated. In the case of 
Matrigel, high cell seeding densities preclude organoid formation because of high matrix 
degradation rates 226. A similar phenomenon is observed in collagen, whereby low mechanical 
properties allow for increased matrix degradation and poor hydrogel stability upon 
incorporation of high cell numbers. For this reason, stiffness changes in collagen gels 
presented in this thesis were harder to detect and less consistent compared to compression-
based and atomic force microscopy GelMA analyses. Although not investigated here, the 
observed movement of certain cell lines towards the edge of the hydrogels suggests a nutrient 
and oxygen gradient may be forming in GelMA. The formation of a nutrient gradient and 
hypoxic regions are hallmarks of pancreatic cancers, hence future work could investigate 
hypoxia-induced cell behaviours in GelMA hydrogels further. Three-dimensional studies 
have now shown that cells grown in highly compact multicellular spheroids - over 500 µm 
in diameter as observed in GelMA, as opposed to the traditional sphere culture – are capable 
of inducing tumour-like metabolic switches similarly to tumours, in response to hypoxic 
conditions 390. Thanks to changes in tensional homeostasis, encapsulation of cells within 
hydrogels has been reported to induce the acquisition and sustainment of malignant and 
invasive cell phenotypes via upregulation of ROCK/Rho-generated contractility and 
downregulation of ERK 391. The latter was also observed in cells cultured in GelMA 
hydrogels of increasing stiffness. 
 
Another factor which is paramount for successful 3D cell culture is the biocompatibility of 
the matrix, which determines whether an environment is a conducive environment for cell 
proliferation. Malignant cells were highly viable in GelMA hydrogels for over 28 days of 
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culture. Stromal cells, including patient-derived cells, had a lower proliferation rate compared 
to malignant ones, but nonetheless maintained their viability throughout culture, highlighting 
the biocompatibility of these hydrogels. Taken together, these considerations suggest 
GelMA-based hydrogels constitute a valid alternative platform for the multicellular culture 
of PDAC and modelling of its extracellular TME, while being amenable, following 
optimisation, to most applications and analyses as showcased in this thesis. 
 
GelMA hydrogels also hold potential as personalised medicine pre-clinical tools for PDAC, 
where lengthy animal experiments are not possible due to the dismal prognosis of this 
malignancy. While some features do not necessarily require 3D cell culture to be carried out 
(such as genomics, transcriptomics or proteomics), the presence of a 3D matrix is required 
for both the modelling and long-term maintenance of original tumour features. Additionally, 
most functional traits including response to treatment, stiffness, matrix deposition or 
cytokines, just to name some, require 3D culture for analysis. Here, the two employed 
treatment schedules - either from day 1 of 3D culture (replaced every 72 hours, chronic 
treatment) or staggered regime on day 7 and day 10 – allowed respectively for the 
investigation of treatment efficacy on early proliferative events, as well as “treatment” of 
previously-established tumour spheroids. Similar treatment regimens could be employed in 
GelMA hydrogels for drug testing as part of pre-clinical drug development or personalised 
medicine. To this end, a significant improvement would be the development of a fast and 
efficient protocol for the isolation of PDAC cells from resected tissues for incorporation and 
culture in GelMA. Current approaches including xenotransplantation or cell immortalisation 
require lengthy expansion procedures which severely limit the applications of these models 
as personalised diagnostic tools 18,392. 
 
In its current state, the field of 3D models is still in its infancy, and many physiologically 
important aspects such as the presence of a fully functional immune system, or multifaceted 
TME components are yet to be entirely replicated. In fact, many aspects of cytotoxic drugs 
assessment, such as off-target effects, efficiency of second and third line of defence, 
pharmacokinetics and drug metabolism, cannot be fully characterised by any one in vitro 
system. Novel 3D models such as GelMA hydrogels should aim to integrate and complement 
in vivo data, by providing fast, cheap and easily tuneable systems capable of answering specific 
questions that would otherwise be limited to 2D models. Some additional challenges remain 
unaddressed, such as the inclusion of immune cells to modulate a fully functional immune 
system, the development of complex vascular networks and the recapitulation of exact tissue 
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architectures and matrix composition. For this, novel bioengineering approaches, such as the 
use of microfluidics devices, 3D printing and decellularised tissue scaffolds, hold great 
promise 195,223. Microfluidic devices and 3D bioprinting require a crosslinkable material which 
is conductive to cell viability as well as extrusion, for which GelMA is a perfect candidate 238. 
GelMA hydrogels also offer a scalability that would not be achievable with any in vivo model, 
leaving 3D models the system of choice for drug screening. Additionally, as showcased in 
Chapter 4, GelMA hydrogels can be employed as cell carriers for grafting, allowing the 
investigation of parameters such as matrix stiffness and composition on in vivo tumour 
growth and dissemination. 
 
An evident advantage is the sequential incorporation of multiple cell types within the matrix, 
allowing to investigate both individual and collective contribution of cells of the TME. In 
the future, PDAC cells, patient-matched fibroblasts from resected tissues, and autologous 
serum should be collected from the same patient for isolation and subsequent 3D co-culture. 
The results presented in Chapter 4 indicated that stromal cells, although limited to CAFs and 
myeloid cells in this study, contributed to both increased cell proliferation and increased 
matrix stiffness via concomitant upregulation of STAT3, ERK downregulation and increased 
expression of pro-inflammatory cytokines in a stiffness-dependant fashion. Interestingly, 
stromal and malignant cells showed different responses to matrix modulating agents, which 
could not have been investigated to this extent in 2D cultures. 
 
This work presented the first report of the use of GelMA hydrogels for the culture of PDAC 
cells and analysis of cell functions, transcriptomics and comparison against other popular 
hydrogel matrices, Matrigel and collagen gels. Transcripts from GelMA-cultured cells 
showed high correlation with both collagen and Matrigel-cultured patient-derived organoids, 
suggesting important pathways may be conserved across 3D cell culture platforms and 
recapitulated in GelMA. An encouraging outcome was the upregulation of mechano-sensing 
and mechano-related pathways within the stiffer GelMA hydrogels, suggesting this model 
could be a useful tool in the investigation of stiffness-related processes. These applications 
were highlighted further in Chapter 6, where the use of hydrogels of increased stiffness 
induced the expression of matrix remodelling proteases (MMPs) as well as the cytoskeletal 
EMT marker vimentin, ultimately affecting response to an MMP inhibitor. Using three 
distinct bioengineering approaches, the bulk and local stiffness of GelMA-embedded 
spheroids was assessed. Because of the high, sustained, viability of cells in GelMA, these 
hydrogels allowed for the investigation of a matrix-targeting treatment (fasudil) with a 
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staggered administration regime, in combination with cytotoxic agents. Preliminary results 
showed that this treatment regimen was favourable in that it decreased overall matrix tension, 
facilitating the diffusion of chemotherapy and reducing the expression of matrisome-related 
and EMT genes as well as the levels of secreted pro-inflammatory cytokines. These effects 
were more prominent in stiffer hydrogels, compared to collagen. 
 
The biomechanics of the TME and regulation of tumorigenesis by mechanical forces and 
stiffness are relatively novel and under-studied fields 126,391,393,394. However, mounting evidence 
has now linked matrix stiffness as well as cell-mediated solid stress increases to tumour 
progression and maintenance 139,322,357, and with it, efforts to target both the matrix- and cell-
induced mechanical abnormalities have spiked 117,133,134,154,155,165,369,385. These effects and 
targeting strategies are of particular interest in PDAC, because of its increased desmoplasia 
and tumour stiffness compared to other solid malignancies 95,128. The present work 
highlighted the contribution of stromal cells and matrix molecules in determining matrix 
stiffness changes, highlighting the need to implement advanced, multicellular systems for the 
understanding of mechano-related processes. The use of mechanics as a high-sensitivity 
readout constituted one of the main advantages of GelMA over conventional 3D matrices.  
New experimental setups should consider introduction of further TME elements in an 
additive fashion, in combination and separately, to broaden our knowledge of the role of 
each component in the evolution and mechanobiology of pancreatic cancer. 
 
Efforts in increasing our understanding of tumour biomechanics are driven by the clinical 
applications of this knowledge. In fact, many stromal targeting therapies are based on the 
premises that matrix molecules, as well as stromal cells, exert a pro-tumorigenic function by 
induction of local desmoplasia and pro-survival signalling 44,45,58,133,159,185.  However, stromal 
ablation in PDAC has had mixed results in both pre-clinical and clinical trials 44,46-48, hence 
why transient targeting and matrix priming regimes were devised 155,364. With this in mind, 
the effects of matrix priming with a ROCK inhibitor followed by chemotherapy were tested. 
The overall decrease in matrix tension following ROCK inhibition was an encouraging result, 
as was the reduced viability of cells following combinational treatment. Reduced mechano-
signalling, matrix stiffness and matrix gene expression could lead to both increased drug 
delivery, increased sensitivity and reduced cell motility. Future work should dwell into the 
mechanical and molecular mechanisms linking ROCK downregulation to increased 
chemotherapy efficiency, as well as the efficacy of this treatment at preventing further 
relapse. 
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7.4 Concluding remarks 
 
Taken together, these findings suggest that GelMA-based hydrogels constitute a suitable and 
informative platform for the 3D culture of pancreatic cancer cells and associated TME 
components as well as in vitro drug testing. This work sets a precedent in the optimisation of 
analytical techniques for GelMA-embedded cells and the first extensive transcriptomics 
analysis in the context of other popular 3D cell culture matrices. The present experimental 
design also represents a minimal and reliable bottom-up approach required for the design 
and characterisation of any novel in vitro platform including assessment of its mechanics, 
reproducibility, matrix composition and architecture (Chapter 3), biocompatibility and cell 
functions (Chapter 4), transcriptomics (Chapter 5) and translational applications (Chapter 6). 
The use of collagen gels constituted an optimal control because of their prevalence in the 
literature while highlighting the tuneability of GelMA. Nonetheless, more work remains to 
be conducted in order to fully demonstrate the translational potential of GelMA hydrogels 
as well as required validation against clinical data. Given the virtually unchanged mortality of 
PDAC, and the predicted rise in its incidence, advances in the understanding and modelling 
of this cancer will be imperative for both research and clinical success. 
 
Since the introduction of “biology’s new dimension” in the early 2000s 395, 3D models have 
held great promises and excited a generation of scientists, including myself. In the words of 
Mina Bissell, “scientists started to realize just how much a cell’s context matters”. Over two 
decades later, a variety of 3D cell culture platforms, biomaterials and analysis techniques have 
been and continue being developed to this end, however, the majority of in vitro research is 
still carried out in 2D. The variety and complementarity of applications of 3D cell culture 
options – from spheroids to organoids, natural gels, (semi)synthetic hydrogels, self-
assembling materials and polymers – may be both an advantage for their versatility, but 
equally slow the transition from 2D to a standardised 3D cell culture approach. So far, the 
optimal method, depends on the question and hypothesis to be tested. In the future, it may 
be possible to screen an individual’s cells against chemo and radio-therapeutics using quick, 
standardised culture models for personalised treatment regimens. Additionally, with the 
advent of more complex culture systems came the realisation that we needed to understand 
more about the biology and biophysics regulating cancer, before we could accurately model 
them in 3D. For this reason, studies that aim to “deconstruct” aspects of the tumour 
microenvironment in order to “recapitulate” them in 3D models 120, are necessary and poised 
to become the norm of the field. For this, interdisciplinary collaborations between tumour 
biologists, material scientists and tissue engineers will be vital for the successful 
implementation of such tools.  
Bibliography 
- 218 -
Chapter 8 - Bibliography
 Bibliography 
 
-  219 - 
 
1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: A Cancer Journal for 
Clinicians. 2019;69(1):7-34. 
2. Lekka K, Tzitzi E, Giakoustidis A, Papadopoulos V, Giakoustidis D. Contemporary 
management of borderline resectable pancreatic ductal adenocarcinoma. Annals of 
Hepato-Biliary-Pancreatic Surgery. 2019;23(2):97-108. 
3. Stark AP, Sacks GD, Rochefort MM, et al. Long-term survival in patients with 
pancreatic ductal adenocarcinoma. Surgery. 2016;159(6):1520-1527. 
4. Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. 
Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, 
liver, and pancreas cancers in the United States. Cancer Research. 2014;74(11):2913-
2921. 
5. Haeberle L, Esposito I. Pathology of pancreatic cancer. Translational 
Gastroenterology and Hepatology. 2019;4:50. 
6. Turati F, Edefonti       V, Bosetti       C, et al. Family History of Cancer and the Risk 
of Cancer: A Network of Case-Control Studies. Annals of oncology. 2013;24(10):6. 
7. Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreatic ductal adenocarcinoma: 
Risk factors, screening, and early detection. World Journal of Gastroenterology. 
2014;20(32):11182-11198. 
8. Basturk O, Hong SM, Wood LD, et al. A Revised Classification System and 
Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor 
Lesions in the Pancreas. Am J Surg Pathol. 2015;39(12):1730-1741. 
9. Andea A, Sarkar F, Adsay VN. Clinicopathological correlates of pancreatic 
intraepithelial neoplasia: a comparative analysis of 82 cases with and 152 cases 
without pancreatic ductal adenocarcinoma. Modern Pathology. 2003;16(10):996-
1006. 
10. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. 
National Failure to Operate on Early Stage Pancreatic Cancer. Annals of Surgery. 
2007 Aug; 246(2): 173–180. 
11. Matsuda Y, Furukawa T, Yachida S, et al. The Prevalence and Clinicopathological 
Characteristics of High-Grade Pancreatic Intraepithelial Neoplasia: Autopsy Study 
Evaluating the Entire Pancreatic Parenchyma. Pancreas. 2017;46(5):658-664. 
12. Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nature Reviews. 2016;2:16022. 
13. Hingorani SR, Petricoin EF, Maitra A, et al. Preinvasive and invasive ductal 
pancreatic cancer and its early detection in the mouse. Cancer Cell. 2003;4(6):437-
450. 
14. Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic 
intraepithelial neoplasia. Journal of Hepatobiliary Pancreatic Surgery. 2007;14(3):224-
232. 
15. Preis M, Korc M. Signaling pathways in pancreatic cancer. Critical reviews in 
Eukaryotic gene Expression. 2011;21(2):115-129. 
16. Sano M, Driscoll DR, DeJesus-Monge WE, et al. Activation of WNT/beta-Catenin 
Signaling Enhances Pancreatic Cancer Development and the Malignant Potential Via 
Up-regulation of Cyr61. Neoplasia. 2016;18(12):785-794. 
17. Laklai H, Miroshnikova YA, Pickup MW, et al. Genotype tunes pancreatic ductal 
adenocarcinoma tissue tension to induce matricellular-fibrosis and tumor 
progression. Nature Medicine. 2016;22(5):497-505. 
18. Ligorio M, Sil S, Malagon-Lopez J, et al. Stromal Microenvironment Shapes the 
Intratumoral Architecture of Pancreatic Cancer. Cell. 2019;178(1):160-175.e127. 
19. Gore AJ, Deitz SL, Palam LR, Craven KE, Korc M. Pancreatic cancer–associated 
retinoblastoma 1 dysfunction enables TGF-β to promote proliferation. Journal of 
Clinical Investigation. 2014;124(1):338-352. 
 Bibliography 
 
-  220 - 
 
20. Collisson EA, Sadanandam A, Olson P, et al. Subtypes of Pancreatic Ductal 
Adenocarcinoma and Their Differing Responses to Therapy. Nature Medicine. 
2011;17(4):500-503. 
21. Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes 
of pancreatic cancer. Nature. 2016;531(7592):47-52. 
22. Waddell N, Pajic M, Patch AM, et al. Whole genomes redefine the mutational 
landscape of pancreatic cancer. Nature. 2015;518(7540):495-501. 
23. Moffitt RA, Marayati R, Flate EL, et al. Virtual microdissection identifies distinct 
tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nature 
Genetics. 2015;47(10):1168-1178. 
24. Khalaf N, Yuan C, Hamada T, et al. Regular Use of Aspirin or Non-Aspirin 
Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident 
Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology. 
2018;154(5):1380-1390 e1385. 
25. Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to 
promising novel therapies. Nature Reviews Clinical Oncology. 2015;12(6):319-334. 
26. Neoptolemos JP, Kleeff J, Michl P, Costello E, Greenhalf W, Palmer DH. 
Therapeutic developments in pancreatic cancer: current and future perspectives. 
Nature Reviews in Gastroenterology and Hepatology. 2018;15(6):333-348. 
27. Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical 
benefit with gemcitabine as first-line therapy for patients with advanced pancreas 
cancer: a randomized trial. Journal of Clinical Oncology. 1997;15(6):2403-2413. 
28. Von Hoff DD, Ervin T, Arena FP, et al. Increased Survival in Pancreatic Cancer 
with nab-Paclitaxel plus gemcitabine. New England Journal of Medicine. 
2013;369(18):1691-1703. 
29. Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for 
Metastatic Pancreatic Cancer. New England Journal of Medicine. 2011;364(19):1817-
1825. 
30. Kim S, Signorovitch JE, Yang H, et al. Comparative Effectiveness of nab-Paclitaxel 
Plus gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A 
Retrospective Nationwide Chart Review in the United States. Advances in Therapy. 
2018;35(10):1564-1577. 
31. Tahara J, Shimizu K, Otsuka N, Akao J, Takayama Y, Tokushige K. gemcitabine plus 
nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer. 
Cancer Chemotherapy and Pharmacology. 2018;82(2):245-250. 
32. Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine 
and capecitabine with gemcitabine monotherapy in patients with resected pancreatic 
cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 
2017;389(10073):1011-1024. 
33. Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as Adjuvant 
Therapy for Pancreatic Cancer. New England Journal of Medicine. 
2018;379(25):2395-2406. 
34. Kindler HL, Niedzwiecki D, Hollis D, et al. gemcitabine Plus Bevacizumab 
Compared With gemcitabine Plus Placebo in Patients With Advanced Pancreatic 
Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303). 
Journal of Clinical Oncology. Vol 282010. 
35. Kindler HL, Ioka T, Richel DJ, et al. Axitinib plus gemcitabine versus placebo plus 
gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind 
randomised phase 3 study. Lancet Oncology. 2011;12(3):256-262. 
36. Rougier P, Riess H, Manges R, et al. Randomised, placebo-controlled, double-blind, 
parallel-group phase III study evaluating aflibercept in patients receiving first-line 




-  221 - 
 
37. Kindler HL, Wroblewski K, Wallace JA, et al. gemcitabine plus sorafenib in patients 
with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase 
II Consortium. Investigational New Drugs. 2012;30(1):382-386. 
38. O'Neil BH, Scott AJ, Ma WW, et al. A phase II/III randomized study to compare 
the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in 
patients with previously untreated metastatic pancreatic cancer. Annals of Oncology. 
2015;26(9):1923-1929. 
39. Deplanque G, Demarchi M, Hebbar M, et al. A randomized, placebo-controlled 
phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic 
cancer. Annals of Oncology. 2015;26(6):1194-1200. 
40. Fuchs CS, Azevedo S, Okusaka T, et al. A phase 3 randomized, double-blind, 
placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as 
first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial. 
Annals of Oncology. 2015;26(5):921-927. 
41. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with 
gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the 
National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical 
Oncology. 2007;25(15):1960-1966. 
42. Hurwitz HI, Uppal N, Wagner SA, et al. Randomized, Double-Blind, Phase II Study 
of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With 
Metastatic Pancreatic Cancer for Whom Therapy With gemcitabine Has Failed. 
Journal of Clinical Oncology. 2015;33(34):4039-4047. 
43. Hidalgo M, Plaza C, Musteanu M, et al. SPARC Expression Did Not Predict Efficacy 
of nab-Paclitaxel plus gemcitabine or gemcitabine Alone for Metastatic Pancreatic 
Cancer in an Exploratory Analysis of the Phase III MPACT Trial. Clinical Cancer 
Research. 2015;21(21):4811-4818. 
44. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and 
drug delivery in a mouse model of pancreatic cancer. Gut. 2013;62(1):112-120. 
45. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. 
Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic 
ductal adenocarcinoma. Cancer Cell. 2012;21(3):418-429. 
46. Hingorani SR, Zheng L, Bullock AJ, et al. HALO 202: Randomized Phase II Study 
of PEGPH20 Plus Nab-Paclitaxel/gemcitabine Versus Nab-Paclitaxel/gemcitabine 
in Patients With Untreated, Metastatic Pancreatic Ductal Adenocarcinoma. Journal 
of Clinical Oncology. 2018;36(4):359-366. 
47. Hakim N, Patel R, Devoe C, Saif MW. Why HALO 301 Failed and Implications for 
Treatment of Pancreatic Cancer. Pancreas. 2019;3(1):e1-4. 
48. Özdemir BC, Pentcheva-Hoang T, Carstens JL, et al. Depletion of Carcinoma-
Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates 
Pancreas Cancer with Diminished Survival. Cancer Cell. 2014;25(6):719-734. 
49. Rhim AD, Oberstein PE, Thomas DH, et al. Stromal elements act to restrain, rather 
than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735-747. 
50. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 
2011;144(5):646-674. 
51. Candido JB, Morton JP, Bailey P, et al. CSF1R(+) Macrophages Sustain Pancreatic 
Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs 
that Define the Squamous Subtype. Cell Reports. 2018;23(5):1448-1460. 
52. Rainiero    HR, Emmerich PB, Sievers CK, et al. Versican production is driven by 
both epithelial and stromal cells in pancreatic cancer [abstract 1904]. Proceedings of 




-  222 - 
 
53. Farren MR, Mace TA, Geyer S, et al. Systemic immune activity predicts overall 
survival in treatment naïve patients with metastatic pancreatic cancer. Clinical Cancer 
Reseaarch. 2016;22(10):2565-2574. 
54. Kamath SD, Kalyan A, Kircher S, et al. Ipilimumab and gemcitabine for Advanced 
Pancreatic Cancer: A Phase Ib Study. Oncologist. Vol 252020. 
55. Hilmi M, Bartholin L, Neuzillet C. Immune therapies in pancreatic ductal 
adenocarcinoma: Where are we now? World Journal of Gastroenterology. 
2018;24(20):2137-2151. 
56. Palmer DH, Valle JW, Ting Ma Y, et al. TG01/GM-CSF and adjuvant gemcitabine 
in patients with resected RAS-mutant adenocarcinoma of the pancreas (CT TG01-
01): a single-arm, phase 1/2 trial. British Journal of Cancer. 2020;122(7):971-977. 
57. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to 
the tumor microenvironment. Cancer Cell. 2012;21(3):309-322. 
58. Erkan M, Hausmann S, Michalski CW, et al. The role of stroma in pancreatic cancer: 
diagnostic and therapeutic implications. Nature Reviews in Gastroenterology and 
Hepatology. 2012;9(8):454-467. 
59. Neesse A, Algul H, Tuveson DA, Gress TM. Stromal biology and therapy in 
pancreatic cancer: a changing paradigm. Gut. 2015;64(9):1476-1484. 
60. Djurec M, Grana O, Lee A, et al. Saa3 is a key mediator of the protumorigenic 
properties of cancer-associated fibroblasts in pancreatic tumors. Proceedings of the 
National Academy of Sciences of the USA. 2018;115(6):E1147-e1156. 
61. Kohler I, Bronsert P, Timme S, et al. Detailed analysis of epithelial-mesenchymal 
transition and tumor budding identifies predictors of long-term survival in pancreatic 
ductal adenocarcinoma. Journal of Gastroenterology and Hepatology. 2015;30 Suppl 
1:78-84. 
62. Galván JA, Zlobec I, Wartenberg M, et al. Expression of E-cadherin repressors 
SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding 
phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. British 
Journal of Cancer. 2015;112(12):1944-1950. 
63. Ram Makena M, Gatla H, Verlekar D, Sukhavasi S, M KP, K CP. Wnt/β-Catenin 
Signaling: The Culprit in Pancreatic Carcinogenesis and Therapeutic Resistance. 
International Journal of Molecular Sciences. 2019;20(17). 
64. Wei L, Ye H, Li G, et al. Cancer-associated fibroblasts promote progression and 
gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Cell 
Death and Disease. 2018;9(11):1065. 
65. Scarlett CJ, Colvin EK, Pinese M, et al. Recruitment and Activation of Pancreatic 
Stellate Cells from the Bone Marrow in Pancreatic Cancer: A Model of Tumor-Host 
Interaction. PLoS One. 2011;6(10). 
66. von Ahrens D, Bhagat TD, Nagrath D, Maitra A, Verma A. The role of stromal 
cancer-associated fibroblasts in pancreatic cancer. Journal of Hematology and 
Oncology. 2017;10. 
67. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP. 
Cancer-Associated Fibroblasts Drive the Progression of Metastasis through both 
Paracrine and Mechanical Pressure on Cancer Tissue. Molecular Cancer Research. 
2012;10(11):1403-1418. 
68. Lonardo E, Frias-Aldeguer J, Hermann PC, Heeschen C. Pancreatic stellate cells 
form a niche for cancer stem cells and promote their self-renewal and invasiveness. 
Cell Cycle. 2012;11(7):1282-1290. 
69. Neuzillet C, Tijeras‐Raballand A, Ragulan C, et al. Inter‐ and intra‐tumoural 
heterogeneity in cancer‐associated fibroblasts of human pancreatic ductal 
adenocarcinoma. Journal of Pathology. 2019;248(1):51-65. 
 Bibliography 
 
-  223 - 
 
70. Puleo F, Nicolle R, Blum Y, et al. Stratification of Pancreatic Ductal 
Adenocarcinomas Based on Tumor and Microenvironment Features. 
Gastroenterology. 2018;155(6):1999-2013.e1993. 
71. Clark CE, Hingorani SR, Mick R, Combs C, Tuveson DA, Vonderheide RH. 
Dynamics of the immune reaction to pancreatic cancer from inception to invasion. 
Cancer Research. 2007;67(19):9518-9527. 
72. Knudsen ES, Vail P, Balaji U, et al. Stratification of Pancreatic Ductal 
Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunological Markers. 
Clinical Cancer Reseaarch. 2017;23(15):4429-4440. 
73. Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to therapy. 
Immunity. 2014;41(1):49-61. 
74. Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of 
the immune microenvironment of pancreatic cancer. British Journal of Cancer. 
2013;108(4):914-923. 
75. Qian B, Pollard JW. Macrophage Diversity Enhances Tumor Progression and 
Metastasis. Cell. 2010;141(1):39-51. 
76. Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumor-Associated 
Macrophages as Treatment Targets in Oncology. Nature Reviews Clinical Oncology. 
2017;14(7):399-416. 
77. Carstens JL, Correa de Sampaio P, Yang D, et al. Spatial computation of intratumoral 
T cells correlates with survival of patients with pancreatic cancer. Nature 
Communications. 2017; 8:15095. 
78. Ryschich E, Nötzel T, Hinz U, et al. Control of T-cell-mediated immune response 
by HLA class I in human pancreatic carcinoma. Clinical Cancer Research. 2005;11(2 
Pt 1):498-504. 
79. Evans RA, Diamond MS, Rech AJ, et al. Lack of immunoediting in murine pancreatic 
cancer reversed with neoantigen. Journal for clinical Investigation. 2016;1(14). 
80. Hiraoka N, Onozato K, Kosuge T, Hirohashi S. Prevalence of FOXP3+ regulatory 
T cells increases during the progression of pancreatic ductal adenocarcinoma and its 
premalignant lesions. Clinical Cancer Research. 2006;12(18):5423-5434. 
81. Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the 
hallmarks of cancer. EMBO Reports. 2014;15(12):1243-1253. 
82. Apte MV, Park S, Phillips PA, et al. Desmoplastic reaction in pancreatic cancer: role 
of pancreatic stellate cells. Pancreas. 2004;29(3):179-187. 
83. Kleeff J, Beckhove P, Esposito I, et al. Pancreatic cancer microenvironment. 
International Journal of Cancer. 2007;121(4):699-705. 
84. Afik R, Zigmond E, Vugman M, et al. Tumor macrophages are pivotal constructors 
of tumor collagenous matrix. Journal of Experimental Medicine. 2016;213(11):2315-
2331. 
85. Weniger M, Honselmann KC, Liss AS. The Extracellular Matrix and Pancreatic 
Cancer: A Complex Relationship. Cancers (Basel). 2018;10(9). 
86. Tian C, Ohlund D, Rickelt S, et al. Cancer Cell-Derived Matrisome Proteins Promote 
Metastasis in Pancreatic Ductal Adenocarcinoma. Cancer Research. 2020;80(7):1461-
1474. 
87. Tian C, Clauser KR, Ohlund D, et al. Proteomic analyses of ECM during pancreatic 
ductal adenocarcinoma progression reveal different contributions by tumor and 
stromal cells. Proceedings of the National Academy of Sciences of the USA. 
2019;116(39):19609-19618. 
88. Naba A, Clauser KR, Whittaker CA, Carr SA, Tanabe KK, Hynes RO. Extracellular 
matrix signatures of human primary metastatic colon cancers and their metastases to 
liver. BMC Cancer. 2014;14(1):518. 
 Bibliography 
 
-  224 - 
 
89. Ojalill M, Rappu P, Siljamäki E, Taimen P, Boström P, Heino J. The composition of 
prostate core matrisome in vivo and in vitro unveiled by mass spectrometric analysis. 
Prostate. 2018;78(8):583-594. 
90. Naba A, Pearce OMT, Del Rosario A, et al. Characterization of the Extracellular 
Matrix of Normal and Diseased Tissues Using Proteomics. Journal of Proteome 
Research. 2017;16(8):3083-3091. 
91. Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, Hynes RO. The extracellular 
matrix: Tools and insights for the "omics" era. Matrix Biology. 2016;49:10-24. 
92. Ricard-Blum S. The collagen family. Cold Spring Harbor Perspectives in Biology. 
2011;3(1):4978. 
93. Imamura T, Iguchi H, Manabe T, et al. Quantitative analysis of collagen and collagen 
subtypes I, III, and V in human pancreatic cancer, tumor-associated chronic 
pancreatitis, and alcoholic chronic pancreatitis. Pancreas. 1995;11(4):357-364. 
94. Olivares O, Mayers JR, Gouirand V, et al. Collagen-derived proline promotes 
pancreatic ductal adenocarcinoma cell survival under nutrient limited conditions. 
Nature Communications. 2017;(8):1603. 
95. Whatcott CJ, Diep CH, Jiang P, et al. Desmoplasia in Primary Tumors and Metastatic 
Lesions of Pancreatic Cancer. Clinical Cancer Reseaarch. 2015;21(15):3561-3568. 
96. Clementz AG, Mutolo MJ, Leir SH, et al. Collagen XV Inhibits Epithelial to 
Mesenchymal Transition in Pancreatic Adenocarcinoma Cells. PLoS One. 
2013;8(8):e72250. 
97. van der Zee JA, van Eijck CH, Hop WC, et al. Tumour basement membrane laminin 
expression predicts outcome following curative resection of pancreatic head cancer. 
British Journal of Cancer. 2012;107(7):1153-1158. 
98. Öhlund D, Franklin O, Lundberg E, Lundin C, Sund M. Type IV collagen stimulates 
pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an 
autocrine loop. BMC Cancer. 2013;13:154. 
99. Tulla M, Pentikäinen OT, Viitasalo T, et al. Selective binding of collagen subtypes by 
integrin alpha 1I, alpha 2I, and alpha 10I domains. Journal of Biological Chemistry. 
2001;276(51):48206-48212. 
100. Berchtold S, Grünwald B, Krüger A, et al. Collagen type V promotes the malignant 
phenotype of pancreatic ductal adenocarcinoma. Cancer Letters. 2015;356(2 Pt 
B):721-732. 
101. Grzesiak JJ, Tran Cao HS, Burton DW, et al. Knockdown of the β1 integrin subunit 
reduces primary tumor growth and inhibits pancreatic cancer metastasis. 
International Journal of Cancer. 2011;129(12):2905-2915. 
102. Lu J, Zhou S, Siech M, Habisch H, Seufferlein T, Bachem MG. Pancreatic stellate 
cells promote hapto-migration of cancer cells through collagen I-mediated signalling 
pathway. British Journal of Cancer. 2014;110(2):409-420. 
103. Koenig A, Mueller C, Hasel C, Adler G, Menke A. Collagen type I induces disruption 
of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic 
carcinoma cells. Cancer Research. 2006;66(9):4662-4671. 
104. Shintani Y, Fukumoto Y, Chaika N, Svoboda R, Wheelock MJ, Johnson KR. 
Collagen I–mediated up-regulation of N-cadherin requires cooperative signals from 
integrins and discoidin domain receptor 1. Journal of Cell Biology. 2008;180(6):1277-
1289. 
105. Yang J, Zhang Y, He S, et al. TM4SF1 Promotes Metastasis of Pancreatic Cancer via 
Regulating the Expression of DDR1. Scientific Reports. 2017;(7):45895. 
106. Pan S, Brentnall TA, Chen R. Glycoproteins and glycoproteomics in pancreatic 
cancer. World Journal of Gastroenterology. 2016;22(42):9288-9299. 
107. Remmers N, Anderson JM, Linde EM, et al. Aberrant expression of mucin core 
proteins and o-linked glycans associated with progression of pancreatic cancer. 
Clinical Cancer Reseaarch. 2013;19(8):1981-1993. 
 Bibliography 
 
-  225 - 
 
108. Pan S, Chen R, Tamura Y, et al. Quantitative Glycoproteomics Analysis Reveals 
Changes in N-Glycosylation Level Associated with Pancreatic Ductal 
Adenocarcinoma. Journal of Proteome Research. 2014;13(3):1293-1306. 
109. Ingham KC, Brew SA, Isaacs BS. Interaction of fibronectin and its gelatin-binding 
domains with fluorescent-labeled chains of type I collagen. Journal of Biological 
Chemistry. 1988;263(April 5):4624-4462. 
110. Miyamoto H, Murakami T, Tsuchida K, Sugino H, Miyake H, Tashiro S. Tumor-
stroma interaction of human pancreatic cancer: acquired resistance to anticancer 
drugs and proliferation regulation is dependent on extracellular matrix proteins. 
Pancreas. 2004;28(1):38-44. 
111. Dallas SL, Sivakumar P, Jones CJ, et al. Fibronectin regulates latent transforming 
growth factor-beta (TGF beta) by controlling matrix assembly of latent TGF beta-
binding protein-1. Journal of Biological Chemistry. 2005;280(19):18871-18880. 
112. Yao H, Zeng ZZ, Fay KS, et al. Role of α5β1 Integrin Up-regulation in Radiation-
Induced Invasion by Human Pancreatic Cancer Cells1. Translational Oncology. 
2011;4(5):282-292. 
113. Lundahl J, Sköld CM, Halldén G, Hallgren M, Eklund A. Monocyte and neutrophil 
adhesion to matrix proteins is selectively enhanced in the presence of inflammatory 
mediators. Scandinavian Journal of Immunology. 1996;44(2):143-149. 
114. Li X, Truty MA, Kang Y, et al. Extracellular lumican inhibits pancreatic cancer cell 
growth and is associated with prolonged survival after surgery. Clinical Cancer 
Reseaarch. 2014;20(24):6529-6540. 
115. Durko L, Wlodarski W, Stasikowska-Kanicka O, et al. Expression and Clinical 
Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic 
Ductal Adenocarcinoma and Chronic Pancreatitis. Disease Markers. 2017;2017. 
116. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal 
cell surface receptor for hyaluronate. Cell. 1990;61(7):1303-1313. 
117. Hingorani SR, Harris WP, Hendifar AE, et al. High response rate and PFS with 
PEGPH20 added to nab-paclitaxel/gemcitabine in stage IV previously untreated 
pancreatic cancer patients with high-HA tumors: Interim results of a randomized 
phase II study. Journal of Clinical Oncology. 2015;33(15_suppl):4006-4006. 
118. Wight TN. Provisional matrix: A role for versican and hyaluronan. Matrix Biology. 
2017;60-61:38-56. 
119. Wight TN, Kinsella MG, Evanko SP, Potter-Perigo S, Merrilees MJ. Versican and 
the regulation of cell phenotype in disease. Biochimica et Biophysica Acta. 
2014;1840(8):2441-2451. 
120. Pearce OMT, Delaine-Smith RM, Maniati E, et al. Deconstruction of a Metastatic 
Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. 
Cancer Discov. 2018;8(3):304-319. 
121. Kaur S, Kumar S, Momi N, Sasson AR, Batra SK. Mucins in pancreatic cancer and 
its microenvironment. Nature Reviews in Gastroenterology and Hepatology. 
2013;10(10):607-620. 
122. Zhao X, Fan W, Xu Z, et al. Inhibiting tumor necrosis factor-alpha diminishes 
desmoplasia and inflammation to overcome chemoresistance in pancreatic ductal 
adenocarcinoma. Oncotarget. 2016;7(49):81110-81122. 
123. Maniati E, Berlato C, Gopinathan G, et al. Mouse Ovarian Cancer Models 
Recapitulate the Human Tumor Microenvironment and Patient Response to 
Treatment. Cell Reports. 2020;30(2):525-540 e527. 
124. Hu D, Ansari D, Zhou Q, Sasor A, Said Hilmersson K, Andersson R. Stromal 
fibronectin expression in patients with resected pancreatic ductal adenocarcinoma. 
World Journal of Surgical Oncology. 2019;17(1):29. 
125. Tung JC, Barnes JM, Desai SR, et al. Tumor Mechanics and Metabolic Dysfunction. 
Free Radical Biology & Medicine. 2015;0:269-280. 
 Bibliography 
 
-  226 - 
 
126. Stylianopoulos T, Martin JD, Chauhan VP, et al. Causes, consequences, and remedies 
for growth-induced solid stress in murine and human tumors. Proceedings of the 
National Academy of Sciences of the USA. 2012;109(38):15101-15108. 
127. Erkan M, Michalski CW, Rieder S, et al. The activated stroma index is a novel and 
independent prognostic marker in pancreatic ductal adenocarcinoma. Clin 
Gastroenterol Hepatol. 2008;6(10):1155-1161. 
128. Rice AJ, Cortes E, Lachowski D, et al. Matrix stiffness induces epithelial–
mesenchymal transition and promotes chemoresistance in pancreatic cancer cells. 
Oncogenesis. 2017;6(7):e352-. 
129. Nguyen AV, Nyberg KD, Scott MB, et al. Stiffness of pancreatic cancer cells is 
associated with increased invasive potential. Integrative Biology. 2016;8(12):1232-
1245. 
130. Rubiano A, Delitto D, Han S, Hughes S, Simmons C. Viscoelastic properties of 
human pancreatic tumors and in vitro constructs to mimic mechanical properties | 
Elsevier Enhanced Reader. Acta Biomaterialia. 2018;67:331-340. 
131. Haage A, Schneider IC. Cellular contractility and extracellular matrix stiffness 
regulate matrix metalloproteinase activity in pancreatic cancer cells. Faseb Journal. 
2014;28(8):3589-3599. 
132. Barker HE, Cox TR, Erler JT. The rationale for targeting the LOX family in cancer. 
Nature Reviews Cancer. 2012;12(8):540-552. 
133. Miller BW, Morton JP, Pinese M, et al. Targeting the LOX/hypoxia axis reverses 
many of the features that make pancreatic cancer deadly: inhibition of LOX 
abrogates metastasis and enhances drug efficacy. EMBO Molecular Medicine. 
2015;7(8):1063-1076. 
134. Cortes E, Lachowski D, Robinson B, et al. Tamoxifen mechanically reprograms the 
tumor microenvironment via HIF-1A and reduces cancer cell survival. EMBO 
Reports. 2019;20(1). 
135. Cortes E, Sarper M, Robinson B, et al. GPER is a mechanoregulator of pancreatic 
stellate cells and the tumor microenvironment. EMBO Reports. Vol 202019. 
136. Lee J, Condello S, Yakubov B, et al. Tissue Transglutaminase Mediated Tumor-
Stroma Interaction Promotes Pancreatic Cancer Progression. Clinical Cancer 
Reseaarch. 2015;21(19):4482-4493. 
137. Piccolo S, Cordenonsi M, Dupont S. Molecular pathways: YAP and TAZ take center 
stage in organ growth and tumorigenesis. Clinical Cancer Reseaarch. 
2013;19(18):4925-4930. 
138. Moroishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. 
Nature Reviews Cancer. 2015;15(2):73-79. 
139. Panciera T, Citron A, Di Biagio D, et al. Reprogramming normal cells into tumour 
precursors requires ECM stiffness and oncogene-mediated changes of cell 
mechanical properties. Nature Materials. 2020. 
140. Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. 
Nature. 2011;474(7350):179-183. 
141. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development 
and disease. Nature Reviews in Molecular and Cell Biology. 2014;15(12):786-801. 
142. Knapinska AM, Estrada CA, Fields GB. The Roles of Matrix Metalloproteinases in 
Pancreatic Cancer. Progress in Molecular Biology and Translational Sciences. 
2017;148:339-354. 
143. Crawford HC, Scoggins CR, Washington MK, Matrisian LM, Leach SD. Matrix 
metalloproteinase-7 is expressed by pancreatic cancer precursors and regulates 




-  227 - 
 
144. Dangi-Garimella S, Krantz SB, Barron MR, et al. Three-dimensional collagen I 
promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated 
expression of HMGA2. Cancer Res. 2011;71(3):1019-1028. 
145. Nguyen HL, Kadam P, Helkin A, et al. MT1-MMP Activation of TGF-β Signaling 
Enables Intercellular Activation of an Epithelial-mesenchymal Transition Program 
in Cancer. Current Cancer Drug Targets. 2016;16(7):618-630. 
146. D'Costa Z, Jones K, Azad A, et al. gemcitabine-Induced TIMP1 Attenuates Therapy 
Response and Promotes Tumor Growth and Liver Metastasis in Pancreatic Cancer. 
Cancer Research. 2017;77(21):5952-5962. 
147. Lachowski D, Cortes E, Rice A, Pinato D, Rombouts K, del Rio Hernandez A. 
Matrix stiffness modulates the activity of MMP-9 and TIMP-1 in hepatic stellate cells 
to perpetuate fibrosis. Science Reports. 2019;(9)7299. 
148. Guan Y, Wu Y, Liu Y, Ni J, Nong S. Association of microRNA-21 expression with 
clinicopathological characteristics and the risk of progression in advanced prostate 
cancer patients receiving androgen deprivation therapy. Prostate. 2016;76(11):986-
993. 
149. Rath N, Olson MF. Rho-associated kinases in tumorigenesis: re-considering ROCK 
inhibition for cancer therapy. EMBO Reports. 2012;13(10):900-908. 
150. Rath N, Morton JP, Julian L, et al. ROCK signaling promotes collagen remodeling 
to facilitate invasive pancreatic ductal adenocarcinoma tumor cell growth. EMBO 
Molecular Medicine. 2017;9(2):198-218. 
151. Samuel MS, Lopez JI, McGhee EJ, et al. Actomyosin-mediated cellular tension drives 
increased tissue stiffness and β-catenin activation to induce interfollicular epidermal 
hyperplasia and tumor growth. Cancer Cell. 2011;19(6):776-791. 
152. Awaji M, Singh RK. Cancer-Associated Fibroblasts’ Functional Heterogeneity in 
Pancreatic Ductal Adenocarcinoma. Cancers (Basel). 2019;11(3). 
153. Shimoda M, Principe S, Jackson HW, et al. Loss of the Timp gene family is sufficient 
for the acquisition of the CAF-like cell state. Nature Cell Biology. 2014;16(9):889-
901. 
154. Whatcott CJ, Ng S, Barrett MT, Hostetter G, Von Hoff DD, Han H. Inhibition of 
ROCK1 kinase modulates both tumor cells and stromal fibroblasts in pancreatic 
cancer. PLoS One. 2017;12(8):e0183871). 
155. Vennin C, Chin VT, Warren S, et al. Transient tissue priming via ROCK inhibition 
uncouples pancreatic cancer progression, sensitivity to chemotherapy, and 
metastasis. Science Translational Medicine. 2017;9(384:e8504. 
156. Calvo F, Ege N, Grande-Garcia A, et al. Mechano-transduction and YAP-dependent 
matrix remodelling is required for the generation and maintenance of cancer 
associated fibroblasts. Nature Cell Biology. 2013;15(6):2756. 
157. Avery D, Govindaraju P, Jacob M, Todd L, Monslow J, Puré E. Extracellular Matrix 
Directs Phenotypic Heterogeneity of Activated Fibroblasts. Matrix Biology. 
2018;67:90-106. 
158. Sarper M, Cortes E, Lieberthal TJ, del Río Hernández A. ATRA modulates 
mechanical activation of TGF-β by pancreatic stellate cells. Scientific Reports. 
2016;(6):27639. 
159. Carapuça EF, gemenetzidis E, Feig C, et al. Anti‐stromal treatment together with 
chemotherapy targets multiple signalling pathways in pancreatic adenocarcinoma. 
Journal of Pathology. 2016;239(3):286-296. 
160. North B, Kocher HM, Sasieni P. A new pragmatic design for dose escalation in phase 
1 clinical trials using an adaptive continual reassessment method. BMC Cancer. 
2019;19:632. 
161. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JAC. A double-
blind placebo-controlled, randomised study comparing gemcitabine and marimastat 
 Bibliography 
 
-  228 - 
 
with gemcitabine and placebo as first line therapy in patients with advanced 
pancreatic cancer. British Journal of Cancer. 2002;87(2):161-167. 
162. Moore MJ, Hamm J, Dancey J, et al. Comparison of gemcitabine versus the matrix 
metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic 
adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of 
Canada Clinical Trials Group. Journal of Clinical Oncology. 2003;21(17):3296-3302. 
163. Slapak EJ, Duitman J, Tekin C, Bijlsma MF, Spek CA. Matrix Metalloproteases in 
Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression? Biology 
(Basel). 2020;9(4). 
164. Grünwald B, Vandooren J, Gerg M, et al. Systemic Ablation of MMP-9 Triggers 
Invasive Growth and Metastasis of Pancreatic Cancer via Deregulation of IL6 
Expression in the Bone Marrow. Molecular Cancer Research. 2016;14(11):1147-
1158. 
165. Fukushima M, Nakamuta M, Kohjima M, et al. fasudil hydrochloride hydrate, a Rho-
kinase (ROCK) inhibitor, suppresses collagen production and enhances collagenase 
activity in hepatic stellate cells. Liver International. 2005;25(4):829-838. 
166. Rückert F, Pilarsky C, Grützmann R. Establishment of Primary Cell Lines in 
Pancreatic Cancer. Pancreatic Cancer-Molecular Mechanism and Targets. 2012:259-
275. 
167. Carrel A. On the permanent life of tissues outside of the organism. Journal of 
Experimental Medicine. 1912;15(5):516-528. 
168. Caliari SR, Burdick JA. A Practical Guide to Hydrogels for Cell Culture. Nature 
Methods. 2016;13(5):405-414. 
169. Krempley BD, Yu KH. Preclinical models of pancreatic ductal adenocarcinoma. 
Chinese Clinical Oncology. 2017;6(3):25. 
170. Voskoglou-Nomikos T, Pater JL, Seymour L. Clinical predictive value of the in vitro 
cell line, human xenograft, and mouse allograft preclinical cancer models. Clinical 
Cancer Research. 2003;9(11):4227-4239. 
171. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI 
preclinical in vitro and in vivo models and early clinical trials. British Journal of 
Cancer. 2001;84(10):1424-1431. 
172. Frese KK, Tuveson DA. Maximizing mouse cancer models. Nature Reviews Cancer. 
2007;7(9):645-658. 
173. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor 
blockade with C225 plus gemcitabine results in regression of human pancreatic 
carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. 
Clinical Cancer Research. 2000;6(5):1936-1948. 
174. Philip PA, Benedetti J, Corless CL, et al. Phase III Study Comparing gemcitabine 
Plus Cetuximab Versus gemcitabine in Patients With Advanced Pancreatic 
Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205. 
Journal of Clinical Oncology. 2010;28(22):3605-3610. 
175. Thomas JP, Arzoomanian RZ, Alberti D, et al. Phase I pharmacokinetic and 
pharmacodynamic study of recombinant human endostatin in patients with advanced 
solid tumors. Journal Clinical Oncology. 2003;21(2):223-231. 
176. Kulke MH, Demetri GD, Sharpless NE, et al. A phase II study of troglitazone, an 
activator of the PPARgamma receptor, in patients with chemotherapy-resistant 
metastatic colorectal cancer. Cancer Journal. 2002;8(5):395-399. 
177. Fu X, Guadagni F, Hoffman RM. A metastatic nude-mouse model of human 
pancreatic cancer constructed orthotopically with histologically intact patient 




-  229 - 
 
178. Rubio-Viqueira B, Hidalgo M. Direct in vivo xenograft tumor model for predicting 
chemotherapeutic drug response in cancer patients. Clinical Pharmacology and 
Therapeutics. 2009;85(2):217-221. 
179. Duconseil P, Gilabert M, Gayet O, et al. Transcriptomic analysis predicts survival 
and sensitivity to anticancer drugs of patients with a pancreatic adenocarcinoma. 
American Journal of Pathology. 2015;185(4):1022-1032. 
180. Kim MP, Evans DB, Wang H, Abbrusseze JL, Fleming JB, Gallick GE. Orthotopic 
and heterotopic generation of murine pancreatic cancer xenografts. Nature 
Protocols. 2009;4(11):1670-1680. 
181. He J, Ahuja N, Makary MA, et al. 2564 resected periampullary adenocarcinomas at a 
single institution: trends over three decades. HPB (Oxford). 2014;16(1):83-90. 
182. Aguirre AJ, Bardeesy N, Sinha M, et al. Activated Kras and Ink4a/Arf deficiency 
cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes and 
Development. 2003;17(24):3112-3126. 
183. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to 
promote chromosomal instability and widely metastatic pancreatic ductal 
adenocarcinoma in mice. Cancer Cell. 2005;7(5):469-483. 
184. Gilabert M, Calvo E, Airoldi A, et al. Pancreatic cancer-induced cachexia is Jak2-
dependent in mice. Journal of Cell Physiology. 2014;229(10):1437-1443. 
185. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog Signaling 
Enhances Delivery of Chemotherapy in a Mouse Model of Pancreatic Cancer. 
Science. 2009;324(5933):1457-1461. 
186. Sharpless NE, DePinho RA. The mighty mouse: genetically engineered mouse 
models in cancer drug development. Nature Reviews Drug Discovery. 2006;5(9):741-
754. 
187. Barros AS, Costa EC, Nunes AS, de Melo-Diogo D, Correia IJ. Comparative study 
of the therapeutic effect of Doxorubicin and Resveratrol combination on 2D and 
3D (spheroids) cell culture models. International Journal of Pharmacology. 
2018;551(1-2):76-83. 
188. Chen CS. 3D biomimetic cultures – the next platform for cell biology. Trends in Cell 
Biology. 2016;26(11):798-800. 
189. Yamada KM, Cukierman E. Modeling tissue morphogenesis and cancer in 3D. Cell. 
2007;130(4):601-610. 
190. Golan T, Atias D, Barshack I, Avivi C, Goldstein RS, Berger R. Ascites-derived 
pancreatic ductal adenocarcinoma primary cell cultures as a platform for personalised 
medicine. British Journal of Cancer. 2014;110(9):2269-2276. 
191. Mitchell MJ, Jain RK, Langer R. Engineering and physical sciences in oncology: 
challenges and opportunities. Nature Reviews Cancer. 2017;17(11):659-675. 
192. Drifka CR, Eliceiri KW, Weber SM, Kao WJ. A bioengineered heterotypic stroma-
cancer microenvironment model to study pancreatic ductal adenocarcinoma. Lab 
Chip. 2013;13(19):3965-3975. 
193. Ware MJ, Keshishian V, Law JJ, et al. Generation of an in vitro 3D PDAC stroma 
rich spheroid model. Biomaterials. 2016;108:129-142. 
194. Gioeli D, Snow CJ, Simmers MB, et al. Development of a multicellular pancreatic 
tumor microenvironment system using patient-derived tumor cells. Lab Chip. 
2019;19(7):1193-1204. 
195. Tomás-Bort E, Kieler M, Sharma S, Candido JB, Loessner D. 3D approaches to 
model the tumor microenvironment of pancreatic cancer. Theranostics. 
2020;10(11):5074-5089. 
196. Harrison RG. Observations on the living developing nerve fiber. Proceedings of the 
society for experimental biology and medicine. 1906;4(1):140-143. 
 Bibliography 
 
-  230 - 
 
197. Longati P, Jia X, Eimer J, et al. 3D pancreatic carcinoma spheroids induce a matrix-
rich, chemoresistant phenotype offering a better model for drug testing. BMC 
Cancer. 2013;13:95. 
198. Solanki A, King D, Thibault G, Wang L, Gibbs SL. Quantification of fluorophore 
distribution and therapeutic response in matched in vivo and ex vivo pancreatic 
cancer model systems. PLoS One. 2020;15(2):e0229407. 
199. Misra S, Moro CF, Del Chiaro M, et al. Ex vivo organotypic culture system of 
precision-cut slices of human pancreatic ductal adenocarcinoma. Scientific Reports. 
2019;9(1):2133. 
200. Bi H, Ye K, Jin S. Proteomic analysis of decellularized pancreatic matrix identifies 
collagen V as a critical regulator for islet organogenesis from human pluripotent stem 
cells. Biomaterials. 2020;233:119673. 
201. Zeeberg K, Cardone RA, Greco MR, et al. Assessment of different 3D culture 
systems to study tumor phenotype and chemosensitivity in pancreatic ductal 
adenocarcinoma. International Journal of Oncology. 2016;49(1):243-252. 
202. Öhlund D, Handly-Santana A, Biffi G, et al. Distinct populations of inflammatory 
fibroblasts and myofibroblasts in pancreatic cancer. Journal of Experimental 
Medicine. 2017;214(3):579-596. 
203. Puls TJ, Tan X, Whittington CF, Voytik-Harbin SL. 3D collagen fibrillar 
microstructure guides pancreatic cancer cell phenotype and serves as a critical design 
parameter for phenotypic models of EMT. PLoS One. 2017;12(11):e0188870. 
204. Shields MA, Dangi-Garimella S, Krantz SB, Bentrem DJ, Munshi HG. Pancreatic 
Cancer Cells Respond to Type I Collagen by Inducing Snail Expression to Promote 
Membrane Type 1 Matrix Metalloproteinase-dependent Collagen Invasion. Journal 
of Biological Chemistry. 2011;286(12):10495-10504. 
205. Chopra A, Murray ME, Byfield F, et al. Augmentation of integrin-mediated 
mechanotransduction by hyaluronic acid. Biomaterials. 2014;35(1):71-82. 
206. Sherman MH, Yu RT, Tseng TW, et al. Stromal cues regulate the pancreatic cancer 
epigenome and metabolome. Proceedings of the National Academy of Sciences. 
2017;114(5):1129. 
207. Broguiere N, Isenmann L, Hirt C, et al. Growth of Epithelial Organoids in a Defined 
Hydrogel. Advanced Materials. 2018;30(43):1801621. 
208. Guvendiren M, Burdick JA. Stiffening hydrogels to probe short- and long-term 
cellular responses to dynamic mechanics. Nature Communications. 2012;3(1):792. 
209. Liu HY, Korc M, Lin CC. Biomimetic and enzyme-responsive dynamic hydrogels 
for studying cell-matrix interactions in pancreatic ductal adenocarcinoma. 
Biomaterials. 2018;160:24-36. 
210. Ki CS, Shih H, Lin CC. Effect of 3D matrix compositions on the efficacy of EGFR 
inhibition in pancreatic ductal adenocarcinoma cells. Biomacromolecules. 
2013;14(9):3017-3026. 
211. Ki CS, Lin TY, Korc M, Lin CC. Thiol-ene hydrogels as desmoplasia-mimetic 
matrices for modeling pancreatic cancer cell growth, invasion, and drug resistance. 
Biomaterials. 2014;35(36):9668-9677. 
212. Raza A, Ki CS, Lin CC. The influence of matrix properties on growth and 
morphogenesis of human pancreatic ductal epithelial cells in 3D. Biomaterials. 
2013;34(21):5117-5127. 
213. Scaife CL, Shea JE, Dai Q, Firpo MA, Prestwich GD, Mulvihill SJ. Synthetic 
Extracellular Matrix Enhances Tumor Growth and Metastasis in an Orthotopic 
Mouse Model of Pancreatic Adenocarcinoma. Journal of Gastrointestinal Surgery. 
2008;12(6):1074-1080. 
214. Allison Logan S, Brissenden AJ, Szewczuk MR, Neufeld RJ. Combinatorial and 
sequential delivery of gemcitabine and oseltamivir phosphate from implantable 
 Bibliography 
 
-  231 - 
 
poly(d,l-lactic-co-glycolic acid) cylinders disables human pancreatic cancer cell 
survival. Drug Design Development and Therapy. 2017;11:2239-2250. 
215. Smink AM, Hertsig DT, Schwab L, et al. A Retrievable, Efficacious Polymeric 
Scaffold for Subcutaneous Transplantation of Rat Pancreatic Islets. Annals of 
Surgery. 2017;266(1):149-157. 
216. Marchioli G, Luca AD, de Koning E, et al. Hybrid Polycaprolactone/Alginate 
Scaffolds Functionalized with VEGF to Promote de Novo Vessel Formation for the 
Transplantation of Islets of Langerhans. Adv Healthc Mater. 2016;5(13):1606-1616. 
217. Yeon SE, No DY, Lee SH, et al. Application of Concave Microwells to Pancreatic 
Tumor Spheroids Enabling Anticancer Drug Evaluation in a Clinically Relevant 
Drug Resistance Model. PLoS One. 2013; 8(9):e73345. 
218. Clausell-Tormos J, Azevedo MM, Miranda-Lorenzo I, et al. Nano-volume well array 
chip for large-scale propagation and high-resolution analysis of individual cancer 
stem cells. Journal of Nanomedicine and Nanotechnology. 2014; 114(12): 1305–
1312. 
219. Beer M, Kuppalu N, Stefanini M, et al. A novel microfluidic 3D platform for 
culturing pancreatic ductal adenocarcinoma cells: comparison with in vitro cultures 
and in vivo xenografts. Scientific Reports. 2017;7:1325. 
220. Lee JH, Kim SK, Khawar IA, Jeong SY, Chung S, Kuh HJ. Microfluidic co-culture 
of pancreatic tumor spheroids with stellate cells as a novel 3D model for investigation 
of stroma-mediated cell motility and drug resistance. Journal of Experimental & 
Clinical Cancer Research. 2018;34:4. 
221. Nguyen DHT, Lee E, Alimperti S, et al. A biomimetic pancreatic cancer on-chip 
reveals endothelial ablation via ALK7 signaling. Science Advances. 2019; 5(8): e6789. 
222. Drifka CR, Loeffler AG, Esquibel CR, Weber SM, Eliceiri KW, Kao WJ. Human 
pancreatic stellate cells modulate 3D collagen alignment to promote the migration of 
pancreatic ductal adenocarcinoma cells. Biomedical Microdevices. 2016;18(6):105. 
223. Giobbe GG, Crowley C, Luni C, et al. Extracellular matrix hydrogel derived from 
decellularized tissues enables endodermal organoid culture. Nature Communications. 
2019;10(1):5658. 
224. Sackett SD, Tremmel DM, Ma F, et al. Extracellular matrix scaffold and hydrogel 
derived from decellularized and delipidized human pancreas. Scientific Reports. 
2018;8(1):10452. 
225. Gaetani R, Aude S, DeMaddalena LL, et al. Evaluation of Different Decellularization 
Protocols on the Generation of Pancreas-Derived Hydrogels. Tissue Engineering 
Part C. 2018;24(12):697-708. 
226. Gjorevski N, Sachs N, Manfrin A, et al. Designer matrices for intestinal stem cell and 
organoid culture. Nature. 2016;539(7630):560-564. 
227. Boj SF, Hwang CI, Baker LA, et al. Organoid Models of Human and Mouse Ductal 
Pancreatic Cancer. Cell. 2015;160(0):324-338. 
228. Lin CC, Korc M. Designer hydrogels: Shedding light on the physical chemistry of 
the pancreatic cancer microenvironment. Cancer Letters. 2018;436:22-27. 
229. Loessner D, Meinert C, Kaemmerer E, et al. Functionalization, preparation and use 
of cell-laden gelatin methacryloyl-based hydrogels as modular tissue culture 
platforms. Nature Protocols. 2016;11(4):727-746. 
230. Schuurman W, Levett PA, Pot MW, et al. Gelatin-methacrylamide hydrogels as 
potential biomaterials for fabrication of tissue-engineered cartilage constructs. 
Macromolecular Bioscience. 2013;13(5):551-561. 
231. Kirsch M, Birnstein L, Pepelanova I, et al. Gelatin-Methacryloyl (GelMA) 
Formulated with Human Platelet Lysate Supports Mesenchymal Stem Cell 
Proliferation and Differentiation and Enhances the Hydrogel’s Mechanical 
Properties. Bioengineering (Basel). Vol 62019. 
 Bibliography 
 
-  232 - 
 
232. Pepelanova I, Kruppa K, Scheper T, Lavrentieva A. Gelatin-Methacryloyl (GelMA) 
Hydrogels with Defined Degree of Functionalization as a Versatile Toolkit for 3D 
Cell Culture and Extrusion Bioprinting. Bioengineering (Basel). 2018;5(3). 
233. Wang Z, Kumar H, Tian Z, et al. Visible Light Photoinitiation of Cell-Adhesive 
Gelatin Methacryloyl Hydrogels for Stereolithography 3D Bioprinting. ACS Applied 
Materials and Interfaces. 2018;10(32):26859-26869. 
234. Yue K, Santiago G, Alvarez MM, Tamayol A, Annabi N, Khademhosseini A. 
Synthesis, properties, and biomedical applications of gelatin methacryloyl (GelMA) 
hydrogels. Biomaterials. 2015;73:254-271. 
235. Peerani E, Candido JB, Loessner D. Cell Recovery of Hydrogel-Encapsulated Cells 
for Molecular Analysis. Methods in Molecular Biology: Springer; 2019. 
236. Van Den Bulcke AI, Bogdanov B, De Rooze N, Schacht EH, Cornelissen M, 
Berghmans H. Structural and rheological properties of methacrylamide modified 
gelatin hydrogels. Biomacromolecules. 2000;1(1):31-38. 
237. Di Lullo GA, Sweeney SM, Korkko J, Ala-Kokko L, San Antonio JD. Mapping the 
ligand-binding sites and disease-associated mutations on the most abundant protein 
in the human, type I collagen. Journal of Biological Chemistry. 2002;277(6):4223-
4231. 
238. Klotz BJ, Gawlitta D, Rosenberg A, Malda J, Melchels FPW. Gelatin-Methacryloyl 
Hydrogels: Towards Biofabrication-Based Tissue Repair. Trends Biotechnol. 
2016;34(5):394-407. 
239. Maji K, Dasgupta S, Pramanik K, Bissoyi A. Preparation and Evaluation of Gelatin-
Chitosan-Nanobioglass 3D Porous Scaffold for Bone Tissue Engineering. 
International Journal of Biomaterials. 2016;2016. 
240. Han F, Dong Y, Su Z, Yin R, Song A, Li S. Preparation, characteristics and 
assessment of a novel gelatin-chitosan sponge scaffold as skin tissue engineering 
material. International Journal of Pharmacology. 2014;476(1-2):124-133. 
241. Liu Y, Chan-Park MB. A biomimetic hydrogel based on methacrylated dextran-graft-
lysine and gelatin for 3D smooth muscle cell culture. Biomaterials. 2010;31(6):1158-
1170. 
242. Nichol JW, Koshy S, Bae H, Hwang CM, Yamanlar S, Khademhosseini A. Cell-laden 
microengineered gelatin methacrylate hydrogels. Biomaterials. 2010;31(21):5536-
5544. 
243. Benton JA, DeForest CA, Vivekanandan V, Anseth KS. Photocrosslinking of 
Gelatin Macromers to Synthesize Porous Hydrogels That Promote Valvular 
Interstitial Cell Function. Tissue Engineering Part A. 2009;15(11):3221-3230. 
244. Xiao W, He J, Nichol JW, et al. Synthesis and characterization of photocrosslinkable 
gelatin and silk fibroin interpenetrating polymer network hydrogels. Acta 
Biomaterialia. 2011;7(6):2384-2393. 
245. Xu F, Inci F, Mullick O, et al. Release of Magnetic Nanoparticles from Cell-
Encapsulating Biodegradable Nanobiomaterials. ACS Nano. 2012;6(8). 
246. Chen YC, Lin RZ, Qi H, et al. Functional Human Vascular Network Generated in 
Photocrosslinkable Gelatin Methacrylate Hydrogels. Advanced Functional Materials. 
2012;22(10):2027-2039. 
247. Lee Y, Lee JM, Bae PK, Chung IY, Chung BH, Chung BG. Photo-crosslinkable 
hydrogel-based 3D microfluidic culture device. Electrophoresis. 2015;36(7-8):994-
1001. 
248. Dubruel P, Unger R, Vlierberghe SV, et al. Porous gelatin hydrogels: 2. In vitro cell 
interaction study. Biomacromolecules. 2007;8(2):338-344. 
249. Loessner D, Stok KS, Lutolf MP, Hutmacher DW, Clements JA, Rizzi SC. 
Bioengineered 3D platform to explore cell-ECM interactions and drug resistance of 
epithelial ovarian cancer cells. Biomaterials. 2010;31(32):8494-8506. 
 Bibliography 
 
-  233 - 
 
250. Sun M, Sun X, Wang Z, Guo S, Yu G, Yang H. Synthesis and Properties of Gelatin 
Methacryloyl (GelMA) Hydrogels and Their Recent Applications in Load-Bearing 
Tissue. Polymers (Basel). 2018; 10(11):1290. 
251. Levett PA, Melchels FP, Schrobback K, Hutmacher DW, Malda J, Klein TJ. A 
biomimetic extracellular matrix for cartilage tissue engineering centered on 
photocurable gelatin, hyaluronic acid and chondroitin sulfate. Acta Biomaterialia. 
2014;10(1):214-223. 
252. Kaemmerer E, Melchels FP, Holzapfel BM, Meckel T, Hutmacher DW, Loessner D. 
Gelatine methacrylamide-based hydrogels: an alternative three-dimensional cancer 
cell culture system. Acta Biomater. 2014;10(6):2551-2562. 
253. Chen JWE, Lumibao J, Blazek A, Gaskins HR, Harley B. Hypoxia activates enhanced 
invasive potential and endogenous hyaluronic acid production by glioblastoma cells. 
Biomaterials Science. 2018;6(4):854-862. 
254. Erkoc P, Seker F, Bagci-Onder T, Kizilel S. Gelatin Methacryloyl Hydrogels in the 
Absence of a Crosslinker as 3D Glioblastoma Multiforme (GBM)-Mimetic 
Microenvironment. Macromolecular Bioscience. 2018;18(3):34501-34506. 
255. Arya AD, Hallur PM, Karkisaval AG, et al. Gelatin Methacrylate Hydrogels as 
Biomimetic Three-Dimensional Matrixes for Modeling Breast Cancer Invasion and 
Chemoresponse in Vitro. ACS Applied Materials and Interfaces. 2016;8(34):22005-
22017. 
256. Li Y, Li X, Zheng L, Wang L, Zhang X, Xu F. Polyacrylamide/GelMA Hydrogel 
Templates for Breast Cancer Cell Spheroids Fabrication. Journal of Nanotechnology 
in Engineering and Medicine. 2016;6(3). 
257. Meinert C, Theodoropoulos C, Klein TJ, Hutmacher DW, Loessner D. A method 
for prostate and breast cancer cell spheroid cultures using gelatin methacryloyl-based 
hydrogels. Prostate Cancer: Springer; 2018. 
258. Berger AJ, Linsmeier K, Kreeger PK, Masters KS. Decoupling the effects of stiffness 
and fiber density on cellular behaviors via an interpenetrating network of gelatin-
methacrylate and collagen. Biomaterials. 2017;141:125-135. 
259. Pearce OMT, Delaine-Smith RM, Maniati E, et al. Deconstruction of a Metastatic 
Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. 
Cancer Discovery. 2018;8(3):304-319. 
260. Macintyre G, Goranova TE, De Silva D, et al. Copy-number signatures and 
mutational processes in ovarian carcinoma. Nature Genetics. 2018;50(9):1262-1270. 
261. Leinster DA, Kulbe H, Everitt G, et al. The peritoneal tumour microenvironment of 
high-grade serous ovarian cancer. Journal of Pathology. 2012;227(2):136-145. 
262. Shirahama H, Lee BH, Tan LP, Cho NJ. Precise Tuning of Facile One-Pot Gelatin 
Methacryloyl (GelMA) Synthesis. Science Reports. Vol 62016. 
263. Delaine-Smith RM, Burney S, Balkwill FR, Knight MM. Experimental validation of 
a flat punch indentation methodology calibrated against unconfined compression 
tests for determination of soft tissue biomechanics. Journal Mechanical Behaviour of 
Biomedical Materials. 2016;60:401-415. 
264. Marshall J. Transwell® Invasion Assays. In: Springer. Cell Migration: Springer; 2011. 
265. Vennin C, Chin VT, Warren SC, et al. Transient tissue priming via ROCK inhibition 
uncouples pancreatic cancer progression, sensitivity to chemotherapy, and 
metastasis. Science Translational Medicine. 2017;9(384):e8504. 
266. Chaudhuri O, Koshy ST, Branco da Cunha C, et al. Extracellular matrix stiffness and 
composition jointly regulate the induction of malignant phenotypes in mammary 
epithelium. Nature Materials. 2014;13(10):970-978. 
267. Hwang HJ, Oh MS, Lee DW, Kuh HJ. Multiplex quantitative analysis of stroma-
mediated cancer cell invasion, matrix remodeling, and drug response in a 3D co-
culture model of pancreatic tumor spheroids and stellate cells. Journal of 
Experimental & Clinical Cancer Research. 2019;38(1):258. 
 Bibliography 
 
-  234 - 
 
268. Tian C, Clauser KR, Ohlund D, et al. Proteomic analyses of ECM during pancreatic 
ductal adenocarcinoma progression reveal different contributions by tumor and 
stromal cells. Proceedings of the Natlonal Academy of Sciences of the USA. 
2019;116(39):19609-19618. 
269. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO. The matrisome: in 
silico definition and in vivo characterization by proteomics of normal and tumor 
extracellular matrices. Molecular Cell Proteomics. 2012;11(4):M111.014647. 
270. Imamichi Y, Konig A, Gress T, Menke A. Collagen type I-induced Smad-interacting 
protein 1 expression downregulates E-cadherin in pancreatic cancer. Oncogene. 
2007;26(16):2381-2385. 
271. Veenstra VL, Garcia-Garijo A, van Laarhoven HW, Bijlsma MF. Extracellular 
Influences: Molecular Subclasses and the Microenvironment in Pancreatic Cancer. 
Cancers (Basel). Vol 102018. 
272. Del Monte U. Does the cell number 10(9) still really fit one gram of tumor tissue? 
Cell Cycle. 2009;8(3):505-506. 
273. Yao H, Yang Z, Liu Z, et al. Glypican-3 and KRT19 are markers associating with 
metastasis and poor prognosis of pancreatic ductal adenocarcinoma. Cancer 
Biomarkers. 2016;17(4):397-404. 
274. Saha SK, Choi HY, Kim BW, et al. KRT19 directly interacts with β-catenin/RAC1 
complex to regulate NUMB-dependent NOTCH signaling pathway and breast 
cancer properties. Oncogene. 2017;36(3):332-349. 
275. Sugimoto M, Takahashi S, Kojima M, et al. What is the nature of pancreatic 
consistency? Assessment of the elastic modulus of the pancreas and comparison with 
tactile sensation, histology, and occurrence of postoperative pancreatic fistula after 
pancreaticoduodenectomy. Surgery. 2014;156(5):1204-1211. 
276. Kuwahara T, Hirooka Y, Kawashima H, et al. Quantitative evaluation of pancreatic 
tumor fibrosis using shear wave elastography. Pancreatology. 2016;16(6):1063-1068. 
277. Hammer AM, Sizemore GM, Shukla VC, et al. Stromal PDGFR-α Activation 
Enhances Matrix Stiffness, Impedes Mammary Ductal Development, and 
Accelerates Tumor Growth. Neoplasia. 2017;19(6):496-508. 
278. Kai F, Laklai H, Weaver VM. Force Matters: Biomechanical Regulation of Cell 
Invasion and Migration in Disease. Trends in Cell Biology. 2016;26(7):486-497. 
279. Dalin S, Sullivan MR, Lau AN, et al. Deoxycytidine Release from Pancreatic Stellate 
Cells Promotes gemcitabine Resistance. Cancer Research. 2019;79(22):5723-5733. 
280. Lin HH, Lin HK, Lin IH, et al. Mechanical phenotype of cancer cells: cell softening 
and loss of stiffness sensing. Oncotarget. 2015;6(25):20946-20958. 
281. Djurec M, Grana O, Lee A, et al. Saa3 is a key mediator of the protumorigenic 
properties of cancer-associated fibroblasts in pancreatic tumors. Proceedings of the 
Natlonal Academy of Sciences of the USA. 2018;115(6):E1147-e1156. 
282. Kopantzev EP, Kopantseva MR, Grankina EV, Mikaelyan A, Egorov VI, Sverdlov 
ED. Activation of IGF/IGF-IR signaling pathway fails to induce epithelial-
mesenchymal transition in pancreatic cancer cells. Pancreatology. 2019;19(2):390-
396. 
283. Young S, Wong M, Tabata Y, Mikos AG. Gelatin as a delivery vehicle for the 
controlled release of bioactive molecules. Journal of Controlled Release. 2005;109(1-
3):256-274. 
284. Stenn KS, Link R, Moellmann G, Madri J, Kuklinska E. Dispase, a neutral protease 
from Bacillus polymyxa, is a powerful fibronectinase and type IV collagenase. Journal 
of Investigative Dermatology. 1989;93(2):287-290. 
285. Jung KH, Choi YC, Chun JY, Min SG, Hong GP. Effects of Concentration and 
Reaction Time of Trypsin, Pepsin, and Chymotrypsin on the Hydrolysis Efficiency 




-  235 - 
 
286. Brown MA, Wallace CS, Anamelechi CC, Clermont E, Reichert WM, Truskey GA. 
The use of mild trypsinization conditions in the detachment of endothelial cells to 
promote subsequent endothelialization on synthetic surfaces. Biomaterials. 
2007;28(27):3928-3935. 
287. Shirahama H, Lee BH, Tan LP, Cho NJ. Precise Tuning of Facile One-Pot Gelatin 
Methacryloyl (GelMA) Synthesis. Scientific Reports. Vol 62016. 
288. Kinner A, Wu W, Staudt C, Iliakis G. γ-H2AX in recognition and signaling of DNA 
double-strand breaks in the context of chromatin. Nucleic Acids Research. Vol 
362008. 
289. Hanasoge S, Ljungman M. H2AX phosphorylation after UV irradiation is triggered 
by DNA repair intermediates and is mediated by the ATR kinase. Carcinogenesis. 
2007;28(11):2298-2304. 
290. Paulsen RD, Cimprich KA. The ATR pathway: fine-tuning the fork. DNA Repair. 
2007;6(7):953-966. 
291. Zhao H, Traganos F, Darzynkiewicz Z. Kinetics of the UV-induced DNA damage 
response in relation to cell cycle phase. Correlation with DNA replication. Cytometry 
Part A. 2010;77(3):285-293. 
292. Nikitaki Z, Hellweg CE, Georgakilas AG, Ravanat JL. Stress-induced DNA damage 
biomarkers: applications and limitations. Frontiers in Chemistry. 2015;3. 
293. Noshadi I, Hong S, Sullivan KE, et al. In Vitro and In Vivo Analysis of Visible Light 
Crosslinkable Gelatin Methacryloyl (GelMA) Hydrogels. Biomaterials Science. 
2017;5(10):2093-2105. 
294. Kipps E, Tan DS, Kaye SB. Meeting the challenge of ascites in ovarian cancer: new 
avenues for therapy and research. Nature Reviews Cancer. Vol 13. England2013. 
295. Sheid B. Angiogenic effects of macrophages isolated from ascitic fluid aspirated from 
women with advanced ovarian cancer. Cancer Letters. 1992;62(2):153-158. 
296. Sleightholm RL, Neilsen BK, Li J, et al. Emerging roles of the CXCL12/CXCR4 axis 
in pancreatic cancer progression and therapy. Pharmacology and Therapeutics. 
2017;179:158-170. 
297. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on 
epithelial tumor cells in human ovarian cancer. Cancer Research. 2002;62(20):5930-
5938. 
298. Kuwada Y, Sasaki T, Morinaka K, Kitadai Y, Mukaida N, Chayama K. Potential 
involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. 
International Journal of Oncology. 2003;22(4):765-771. 
299. Ikeda O, Egami H, Ishiko T, et al. Signal of proteinase-activated receptor-2 
contributes to highly malignant potential of human pancreatic cancer by up-
regulation of interleukin-8 release. International Journal of Oncology. 
2006;28(4):939-946. 
300. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 
transsignaling promotes progression of pancreatic intraepithelial neoplasia and 
development of pancreatic cancer. Cancer Cell. 2011;19(4):456-469. 
301. Corcoran RB, Contino G, Deshpande V, et al. STAT3 plays a critical role in KRAS-
induced pancreatic tumorigenesis. Cancer Research. 2011;71(14):5020-5029. 
302. Xiao Q, Zhou D, Rucki AA, et al. Cancer associated fibroblasts in pancreatic cancer 
are reprogrammed by tumor-induced alterations in genomic DNA methylation. 
Cancer Research. 2016;76(18):5395-5404. 
303. Sun Q, Zhang B, Hu Q, et al. The impact of cancer-associated fibroblasts on major 
hallmarks of pancreatic cancer. Theranostics. 2018;8(18):5072-5087. 
304. Albrengues J, Bourget I, Pons C, et al. LIF mediates proinvasive activation of stromal 
fibroblasts in cancer. Cell Reports. 2014;7(5):1664-1678. 
305. Prêle CM, Keith-Magee AL, Murcha M, Hart PH. Activated signal transducer and 
activator of transcription-3 (STAT3) is a poor regulator of tumour necrosis factor-α 
 Bibliography 
 
-  236 - 
 
production by human monocytes. Clinical and Experimental Immunology. 
2007;147(3):564-572. 
306. Nishiki S, Hato F, Kamata N, et al. Selective activation of STAT3 in human 
monocytes stimulated by G-CSF: implication in inhibition of LPS-induced TNF-
alpha production. American Journal of Physiology and Cell Physiology. 
2004;286(6):C1302-1311. 
307. Nagathihalli NS, Castellanos JA, Lamichhane P, et al. Inverse Correlation of STAT3 
and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic 
Cancer. Cancer Research. 2018;78(21):6235-6246. 
308. Shield K, Ackland ML, Ahmed N, Rice GE. Multicellular spheroids in ovarian cancer 
metastases: Biology and pathology. Gynecologic Oncology. 2009;113(1):143-148. 
309. Kuen J, Darowski D, Kluge T, Majety M. Pancreatic cancer cell/fibroblast co-culture 
induces M2 like macrophages that influence therapeutic response in a 3D model. 
PLoS One. 2017;12(7):e0182039. 
310. Valdez J, Cook CD, Ahrens CC, et al. On-demand dissolution of modular, synthetic 
extracellular matrix reveals local epithelial-stromal communication networks. 
Biomaterials. 2017;130:90-103. 
311. Wang H, Adhikari S, Butler BE, Pandita TK, Mitra S, Hegde ML. A Perspective on 
Chromosomal Double Strand Break Markers in Mammalian Cells. Jacobs Journal of 
Radiation Oncology. 2014;1(1). 
312. Zhu Y, Herndon JM, Sojka DK, et al. Tissue-Resident Macrophages in Pancreatic 
Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote 
Tumor Progression. Immunity. 2017;47(2):323-338.e326. 
313. Ding Y, Du Y. Clinicopathological significance and prognostic role of chemokine 
receptor CXCR4 expression in pancreatic ductal adenocarcinoma, a meta-analysis 
and literature review. International Journal of Surgery. 2019;65:32-38. 
314. Krieg A, Riemer JC, Telan LA, Gabbert HE, Knoefel WT. CXCR4-A Prognostic 
and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-
Analysis. PLoS One. 2015;10(6):e0130192. 
315. Demir IE, Kujundzic K, Pfitzinger PL, et al. Early pancreatic cancer lesions suppress 
pain through CXCL12-mediated chemoattraction of Schwann cells. Proceedings of 
the National Academy of Sciences of the USA. 2017;114(1):E85-e94. 
316. Lutolf MP, Hubbell JA. Synthetic biomaterials as instructive extracellular 
microenvironments for morphogenesis in tissue engineering. Nature Biotechnology. 
2005;23(1):47-55. 
317. Abe M, Ho CH, Kamm KE, Grinnell F. Different molecular motors mediate 
platelet-derived growth factor and lysophosphatidic acid-stimulated floating collagen 
matrix contraction. Journal of Biological Chemistry. 2003;278(48):47707-47712. 
318. Rhee S, Grinnell F. P21-activated kinase 1: convergence point in PDGF- and LPA-
stimulated collagen matrix contraction by human fibroblasts. Journal of Cell Biology. 
2006;172(3):423-432. 
319. Lee SWL, Seager RJ, Litvak F, et al. Integrated in silico and 3D in vitro model of 
macrophage migration in response to physical and chemical factors in the tumor 
microenvironment. Integrative Biology. 2020;12(4):90-108. 
320. Karnevi E, Andersson R, Rosendahl AH. Tumour-educated macrophages display a 
mixed polarisation and enhance pancreatic cancer cell invasion. Immunology and 
Cell Biology. 2014;92(6):543-552. 
321. Chen S, Lian G, Li J, et al. Tumor‐driven like macrophages induced by conditioned 
media from pancreatic ductal adenocarcinoma promote tumor metastasis via 
secreting IL‐8. Cancer Medicine. Vol 72018. 
322. Acerbi I, Cassereau L, Dean I, et al. Human breast cancer invasion and aggression 




323. Aiello NM, Bajor DL, Norgard RJ, et al. Metastatic progression is associated with
dynamic changes in the local microenvironment. Nature Communications.
2016;7:12819.
324. Feygenzon V, Loewenstein S, Lubezky N, et al. Unique cellular interactions between
pancreatic cancer cells and the omentum. PLoS One. Vol 122017.
325. Tape CJ, Ling S, Dimitriadi M, et al. Oncogenic KRAS Regulates Tumor Cell
Signaling via Stromal Reciprocation. Cell. 2016;165(4):910-920.
326. Arpin CC, Mac S, Jiang Y, et al. Applying Small Molecule Signal Transducer and
Activator of Trancription-3 (STAT3) Protein Inhibitors as Pancreatic Cancer
Therapeutics. Molecular Cancer Therapeutics. 2016;15(5):794-805.
327. Jiang H, Liu X, Knolhoff BL, et al. The development of resistance to FAK inhibition
in pancreatic cancer is linked to stromal depletion. Gut. 2020;69(1):122-132.
328. Kučera J, Netušilová J, Sladeček S, et al. Hypoxia Downregulates MAPK/ERK but
Not STAT3 Signaling in ROS-Dependent and HIF-1-Independent Manners in
Mouse Embryonic Stem Cells. Oxidative Medicine and Cellular Longevity.
2017;2017:4386947.
329. Pelham RJ, Jr., Wang Y. Cell locomotion and focal adhesions are regulated by
substrate flexibility. Proceedings of the National Academy of Sciences of the USA.
1997;94(25):13661-13665.
330. Das A, Fischer RS, Pan D, Waterman CM. YAP Nuclear Localization in the Absence
of Cell-Cell Contact Is Mediated by a Filamentous Actin-dependent, Myosin II- and
Phospho-YAP-independent Pathway during Extracellular Matrix Mechanosensing*.
Journal of Biological Chemistry. Vol 2912016.
331. Tekin H, Simmons S, Cummings B, et al. Effects of 3D culturing conditions on the
transcriptomic profile of stem-cell-derived neurons. Nature Biomedical Engineering.
2018;2(7):540-554.
332. Mammoto A, Mammoto T, Ingber DE. Mechanosensitive mechanisms in
transcriptional regulation. Journal of Cell Science. 2012;125(Pt 13):3061-3073.
333. Jiramongkolchai P, Owens P, Hong CC. Emerging roles of the bone morphogenetic
protein pathway in cancer: potential therapeutic target for kinase inhibition.
Biochemical Society Transactions. 2016;44(4):1117-1134.
334. Gordon KJ, Kirkbride KC, How T, Blobe GC. Bone morphogenetic proteins induce
pancreatic cancer cell invasiveness through a Smad1-dependent mechanism that
involves matrix metalloproteinase-2. Carcinogenesis. 2009;30(2):238-248.
335. Geismann C, Schäfer H, Gundlach JP, et al. NF-κB Dependent Chemokine Signaling
in Pancreatic Cancer. Cancers (Basel). Vol 112019.
336. Wente MN, Mayer C, Gaida MM, et al. CXCL14 expression and potential function
in pancreatic cancer. Cancer Letters. 2008;259(2):209-217.
337. Licht AH, Nubel T, Feldner A, et al. Junb regulates arterial contraction capacity,
cellular contractility, and motility via its target Myl9 in mice. Journal of Clinical
Investigation. 2010;120(7):2307-2318.
338. Maity G, Ghosh A, Gupta V, et al. CYR61/CCN1 Regulates dCK and CTGF and
Causes gemcitabine-resistant Phenotype in Pancreatic Ductal Adenocarcinoma.
Molecular Cancer Therapeutics. 2019;18(4):788-800.
339. Xia YJ, Jiang XT, Jiang SB, et al. PHD3 affects gastric cancer progression by
negatively regulating HIF1A. Molecular Medicine Reports. 2017;16(5):6882-6889.
340. Buchholz M, Braun M, Heidenblut A, et al. Transcriptome analysis of microdissected
pancreatic intraepithelial neoplastic lesions. Oncogene. 2005;24(44):6626-6636.
341. Hosokawa M, Kashiwaya K, Eguchi H, et al. Over-expression of cysteine proteinase




342. Van den broeck A, Vankelecom H, Van Delm W, et al. Human Pancreatic Cancer
Contains a Side Population Expressing Cancer Stem Cell-Associated and Prognostic
Genes. PLoS One. 2013;8(9): e73968
343. Craven KE, Gore J, Korc M. Overview of Pre-Clinical and Clinical Studies Targeting
Angiogenesis in Pancreatic Ductal Adenocarcinoma. Cancer Letters.
2016;381(1):201-210.
344. Kim KE, Song H, Kim TS, et al. Interleukin-18 is a critical factor for vascular
endothelial growth factor-enhanced migration in human gastric cancer cell lines.
Oncogene. 2007;26(10):1468-1476.
345. Schulz P, Fischer C, Detjen KM, et al. Angiopoietin-2 drives lymphatic metastasis of
pancreatic cancer. Faseb Journal. 2011;25(10):3325-3335.
346. Katsuta E, Qi Q, Peng X, Hochwald SN, Yan L, Takabe K. Pancreatic
adenocarcinomas with mature blood vessels have better overall survival. Science
Reports. 2019; 9:1310.
347. Zhou J, Cheng Y, Tang L, Martinka M, Kalia S. Up-regulation of SERPINA3
correlates with high mortality of melanoma patients and increased migration and
invasion of cancer cells. Oncotarget. 2017;8(12):18712-18725.
348. Velez DO, Tsui B, Goshia T, et al. 3D collagen architecture induces a conserved
migratory and transcriptional response linked to vasculogenic mimicry. Nature
Communications. 2017;8(1):1651.
349. Timpson P, McGhee EJ, Morton JP, et al. Spatial regulation of RhoA activity during
pancreatic cancer cell invasion driven by mutant p53. Cancer Research.
2011;71(3):747-757.
350. Moreno-Vicente R, Pavon DM, Martin-Padura I, et al. Caveolin-1 Modulates
Mechanotransduction Responses to Substrate Stiffness through Actin-Dependent
Control of YAP. Cell Reports. 2018;25(6):1622-1635.e1626.
351. Ma Z, Vocadlo DJ, Vosseller K. Hyper-O-GlcNAcylation Is Anti-apoptotic and
Maintains Constitutive NF-κB Activity in Pancreatic Cancer Cells*. Journal of
Biological Chemistry. Vol 2882013.
352. Wang Z, Liu Y, Lu L, et al. Fibrillin-1, induced by Aurora-A but inhibited by BRCA2,
promotes ovarian cancer metastasis. Oncotarget. 2015;6(9):6670-6683.
353. Tamaki S, Mano T, Sakata Y, et al. Interleukin-16 promotes cardiac fibrosis and
myocardial stiffening in heart failure with preserved ejection fraction. PLoS One.
2013;8(7):e68893.
354. Zeisberg M, Neilson EG. Biomarkers for epithelial-mesenchymal transitions. Journal
of Clinical Investigation. 2009; 119(6):1429-37.
355. Wei SC, Fattet L, Tsai JH, et al. Matrix stiffness drives Epithelial-Mesenchymal
Transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction
pathway. Nature Cell Biology. 2015;17(5):678-688.
356. Murray ME, Mendez MG, Janmey PA. Substrate stiffness regulates solubility of
cellular vimentin. Molecular Biology of the Cell. 2014; 25(1):87-94.
357. Fernandez-Sanchez ME, Barbier S, Whitehead J, et al. Mechanical induction of the
tumorigenic beta-catenin pathway by tumour growth pressure. Nature.
2015;523(7558):92-95.
358. Van Buren  P, LeWinter MM. Heart Failure as a Consequence of Diabetic
Cardiomyopathy. In: Elsevier. Heart Failure: A Companion to Braunwald's Heart
Disease. Second Edition ed: Elsevier; 2011.
359. Peng C, Zhu Y, Zhang W, et al. Regulation of the Hippo-YAP Pathway by Glucose
Sensor O-GlcNAcylation. Molecular Cell. 2017;68(3):591-604.e595.
360. Baker BM, Trappmann B, Wang WY, et al. Cell-mediated fiber recruitment drives




-  239 - 
 
361. Schmid P, Chui SY, Emens LA. Atezolizumab and Nab-Paclitaxel in Advanced 
Triple-Negative Breast Cancer. Reply. New England Journal of Medicine. 
2019;380(10):987-988. 
362. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus 
Placebo in Resected Stage III Melanoma. New England Journal of Medicine. 
2018;378(19):1789-1801. 
363. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related 
parameters. Biostatistics. 2019;20(2):273-286. 
364. Vennin C, Cox TR, Pajic M, Timpson P. Transient targeting of the pancreatic cancer 
stroma as a ‘fine-tuned’ anti-tumor and anti-metastatic therapy. Oncotarget. 
2017;8(49):84635-84636. 
365. Deer EL, Gonzalez-Hernandez J, Coursen JD, et al. Phenotype and genotype of 
pancreatic cancer cell lines. Pancreas. 2010;39(4):425-435. 
366. Ellenrieder V, Hendler SF, Ruhland C, Boeck W, Adler G, Gress TM. TGF-beta-
induced invasiveness of pancreatic cancer cells is mediated by matrix 
metalloproteinase-2 and the urokinase plasminogen activator system. International 
Journal of Cancer. 2001;93(2):204-211. 
367. Greco E, Basso D, Fogar P, et al. Pancreatic cancer cells invasiveness is mainly 
affected by interleukin-1beta not by transforming growth factor-beta1. International 
Journal of Biological Markers. 2005;20(4):235-241. 
368. Kocer SS, Walker SG, Zerler B, Golub LM, Simon SR. Metalloproteinase Inhibitors, 
Nonantimicrobial Chemically Modified Tetracyclines, and Ilomastat Block Bacillus 
anthracis Lethal Factor Activity in Viable Cells. Infection and Immunity. 
2005;73(11):7548-7557. 
369. Olson MF. Applications for ROCK kinase inhibition. Current Opinions in Cell 
Biology. 2008;20(2):242-248. 
370. Coward J, Kulbe H, Chakravarty P, et al. Interleukin-6 as a therapeutic target in 
human ovarian cancer. Clinical Cancer Reseaarch. 2011;17(18):6083-6096. 
371. Babic A, Schnure N, Neupane NP, et al. Plasma inflammatory cytokines and survival 
of pancreatic cancer patients. Clinical Transnational Gastroenterology. 2018;9(4). 
372. Kim HW, Lee J, Paik K, Kang J, Kim J, Hwang JH. Serum interleukin-6 is associated 
with pancreatic ductal adenocarcinoma progression pattern. Medicine (Baltimore). 
2017;96(5):15926. 
373. Yako YY, Kruger D, Smith M, Brand M. Cytokines as Biomarkers of Pancreatic 
Ductal Adenocarcinoma: A Systematic Review. PLoS One. 2016; 11(5):e0154016. 
374. Ohlund D, Ardnor B, Oman M, Naredi P, Sund M. Expression pattern and 
circulating levels of endostatin in patients with pancreas cancer. International Journal 
of Cancer. 2008;122(12):2805-2810. 
375. Awasthi N, Mikels‐Vigdal AJ, Stefanutti E, et al. Therapeutic efficacy of anti‐MMP9 
antibody in combination with nab‐paclitaxel‐based chemotherapy in pre‐clinical 
models of pancreatic cancer. Journal of Cell Molecular Medicine. 2019;23(6):3878-
3887. 
376. Haq M, Shafii A, Zervos EE, Rosemurgy AS. Addition of matrix metalloproteinase 
inhibition to conventional cytotoxic therapy reduces tumor implantation and 
prolongs survival in a murine model of human pancreatic cancer. Cancer Research. 
2000;60(12):3207-3211. 
377. Gao CC, Gong BG, Wu JB, et al. MMI-166, a selective matrix metalloproteinase 
inhibitor, promotes apoptosis in human pancreatic cancer. Medical Oncology. 
2015;32(1):418. 
378. Long KB, Gladney WL, Tooker GM, Graham K, Fraietta JA, Beatty GL. IFN-γ and 
CCL2 cooperate to redirect tumor-infiltrating monocytes to degrade fibrosis and 




-  240 - 
 
379. Rückert F, Hennig M, Petraki CD, et al. Co-expression of KLK6 and KLK10 as 
prognostic factors for survival in pancreatic ductal adenocarcinoma. British Journal 
of Cancer. 2008;99(9):1484-1492. 
380. Felix K, Gaida MM. Neutrophil-Derived Proteases in the Microenvironment of 
Pancreatic Cancer -Active Players in Tumor Progression. International Journal of 
Biological Sciences. 2016;12(3):302-313. 
381. Bulle A, Dekervel J, Libbrecht L, et al. gemcitabine induces Epithelial-to-
Mesenchymal Transition in patient-derived pancreatic ductal adenocarcinoma 
xenografts. American Journal of Translational Research. 2019;11(2):765-779. 
382. Loret N, Denys H, Tummers P, Berx G. The Role of Epithelial-to-Mesenchymal 
Plasticity in Ovarian Cancer Progression and Therapy Resistance. Cancers (Basel). 
2019;11(6):838. 
383. Hirata E, Girotti M, Viros A, et al. Intravital Imaging Reveals How BRAF Inhibition 
Generates Drug-Tolerant Microenvironments with High Integrin β1/FAK 
Signaling. Cancer Cell. 2015;27(4):574-588. 
384. Gupta V, Gupta N, Shaik IH, et al. Liposomal fasudil, a Rho-Kinase Inhibitor, for 
Prolonged Pulmonary Preferential Vasodilation in Pulmonary Arterial Hypertension. 
Journal of Controlled Release. 2013;167(2):189-199. 
385. Sadok A, McCarthy A, Caldwell J, et al. Rho kinase inhibitors block melanoma cell 
migration and inhibit metastasis. Cancer Research. 2015;75(11):2272-2284. 
386. Orgaz JL, Crosas-Molist E, Sadok A, et al. Myosin II Reactivation and Cytoskeletal 
Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. 
Cancer Cell. 2020;37(1):85-103 e109. 
387. Boland S, Bourin A, Alen J, et al. Design, synthesis, and biological evaluation of 
novel, highly active soft ROCK inhibitors. Journal of Medical Chemistry. 
2015;58(10):4309-4324. 
388. Garnock-Jones KP. Ripasudil: first global approval. Drugs. 2014;74(18):2211-2215. 
389. Wu Y, Xiang Y, Fang J, et al. The influence of the stiffness of GelMA substrate on 
the outgrowth of PC12 cells. Bioscience Reports. 2019;39(1). 
390. Riffle S, Hegde RS. Modeling tumor cell adaptations to hypoxia in multicellular 
tumor spheroids. Journal of Experimental & Clinical Cancer Research. 2017;36:102. 
391. Paszek MJ, Zahir N, Johnson KR, et al. Tensional homeostasis and the malignant 
phenotype. Cancer Cell. 2005;8(3):241-254. 
392. Ehrenberg KR, Gao J, Oppel F, et al. Systematic Generation of Patient-Derived 
Tumor Models in Pancreatic Cancer. Cells. 2019;8(2). 
393. Paszek MJ, Weaver VM. The tension mounts: mechanics meets morphogenesis and 
malignancy. Journal of Mammary Gland Biology and Neoplasia. 2004;9(4):325-342. 
394. Butcher DT, Alliston T, Weaver VM. A tense situation: forcing tumour progression. 
Nature Reviews Cancer. 2009;9(2):108-122. 
395. Abbott A. Cell culture: biology's new dimension. Nature. Vol 424. England2003. 
396.     Monteran L, Erez N. The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts 
as Mediators of Immunosuppression in the Tumor Microenvironment. Frontiers 
Immunology 2019;10:1835. 
397.      Kleeff J, Korc M, Apte M, et al. Pancreatic cancer. Nature Reviews. Disease Primers. 
2016;2:16022. 
398.    Tang Y, Rowe RG, Botvinick EL, et al. MT1-MMP-dependent control of skeletal 





-  241 - 
 
 




9.1 Appendix Chapter 2 
MATLAB R2019 (MathWorks) code employed for the analysis of flat-end tissue indentation 
data (see Chapter 2 – section 2.4.1). Original code author: Stephen Thorpe, modified by 
Eleonora Peerani (December 2019, version 5.2) 
dataRate = 100; %Spacing of data in results file (ms) 
strainEndPt = 30; %Strain end point in absolute terms for first ramp 
strainRate = 1; %Strain rate in %/s for first ramp 
holdTime = 600; %Hold time in s after first ramp 
IMStart = 2.5; %Initial modulus start strain in percent 
IMEnd = 7.5; %Initial modulus end strain in percent 
DMStart = 20; %Deep modulus start strain in percent 
DMEnd = 30; %Deep modulus end strain in percent 
headerlines1 = 3; %headerlines before gauge length value 
headerlines2 = 5; %headerlines before data 
% Indices for regions of interest in data lists 
dataFreq = 1000/dataRate; 
indEstPkF = (strainEndPt/strainRate)*dataFreq; %Estimate of peak force point 
indEq = holdTime*dataFreq+indEstPkF; %Estimate of equilibrium force point 
indRelax = indEq-2*dataFreq:indEq; %indices for relaxation (hold) step over last 2 sec 
% Output file details 
XLfilename = 'IndentationResults.csv'; %Filename for results output 
resultsList = {'Filename','Pathname','GaugeLength [mm]','mIMFDfit [N/mm]',... 
'mDMFDfit [N/mm]','PkF [N]','PkFD [N/mm]','PkStrain','EqF [N]',... 
'EqFD [N/mm]','EqStrain'}; 
l = 2; %line number to start results input 
% Algorithm repeats for each .csv file 
runAgain = 'Y'; 
while runAgain == 'Y' 
close all 
% Get file for analysis and import data 
[File,PathName] = uigetfile('*.csv','Select the file for analysis'); 
fileID = fopen(File); 
SpecimenNo = textscan(fileID,'%*s %d',1,'delimiter',','); 
SpecimenLabel = textscan(fileID,'%*s %q',1,'delimiter',','); 
Delimiter = {',','"'}; 
formatSpec1 = '%*s %f %*s'; 
GL = textscan(fileID,formatSpec1,1,'delimiter',Delimiter,... 
'MultipleDelimsAsOne',1,'headerlines',headerlines1); 
formatSpec2 = '%f %f %f %f %f'; 
Data = textscan(fileID,formatSpec2,'delimiter',Delimiter,... 
'MultipleDelimsAsOne',1,'headerlines',headerlines2); 
fclose(fileID); 
 % Put columns into vectors 
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    SpecimenNo = SpecimenNo{1,1}; 
    SpecimenLabel = SpecimenLabel{1,1}; 
    GL = GL{1,1}; 
    Time = Data{:,1}; 
    AbsPosition = Data{:,2}; 
    CompPos = Data{:,3}; 
    CompStrain = Data{:,4}; 
    Load = Data{:,5}; 
         
    % Moving average filter to remove noise on load channel 
    windowSize = 3; %Size of moving average window 
    b = (1/windowSize)*ones(1,windowSize); 
    LoadSmooth = filter(b,1,Load); %Smoothed load data 
     
    % Peak force and strain 
    [PkF,indPk] = max(Load(indEstPkF-10:indEstPkF+10)); %indices for strain application 
step 
    indPk = indPk+indEstPkF-10; 
    PkD = CompPos(indPk); 
    PkFD = PkF/PkD; 
    indRamp = 1:indPk; 
    PkStrain = CompStrain(indPk); 
    PkTime = Time(indPk); 
    % Equilibrium force 
    EqF = mean(LoadSmooth(indRelax)); 
    EqStrain = CompStrain(indRelax(end)); 
    EqD = CompPos(indRelax(end)); 
    EqFD = EqF/EqD; 
    EqTime = Time(indRelax(end)); 
    % Initial modulus region 
    indIM = find((CompStrain(indRamp) >= IMStart)&(CompStrain(indRamp) < IMEnd)); %indices 
for initial mod 2.5-7.5% 
    IMFDfit = fit(CompPos(indIM),LoadSmooth(indIM),'poly1'); %Fit linear curve to region 
    mIMFDfit = IMFDfit.p1; %retrieve slope 
    % Deep modulus region 
    indDM = find((CompStrain(indRamp) >= DMStart)&(CompStrain(indRamp) < DMEnd)); %indices 
for deep mod 15-20% 
    DMFDfit = fit(CompPos(indDM),LoadSmooth(indDM),'poly1'); %Fit linear curve to region 
    mDMFDfit = DMFDfit.p1; %retrieve slope 
  
    % Add results to results array: resultsList = {'Filename','Pathname',... 
    % 'GaugeLength [mm]','mIMFDfit [N/mm]','mDMFDfit [N/mm]','PkF [N]','PkFD 
[N/mm]','PkStrain','EqF [N]',... 
    % 'EqFD [N/mm]','EqStrain'}; 
    resultsList{l,1} = File; 
    resultsList{l,2} = PathName; 
    resultsList{l,3} = GL; 
    resultsList{l,4} = mIMFDfit; 
    resultsList{l,5} = mDMFDfit; 
    resultsList{l,6} = PkF; 
    resultsList{l,7} = PkFD; 
    resultsList{l,8} = PkStrain; 
    resultsList{l,9} = EqF; 
Appendices 
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resultsList{l,10} = EqFD; 
resultsList{l,11} = EqStrain; 
l = l+1; 
% Figure output 
scrsz = get(groot,'ScreenSize'); 
figure('Name','Press any key to proceed','Position',... 
[1 scrsz(4)*0.4 scrsz(3)*0.9 scrsz(4)*0.5]); 
% Force-time plot for whole test 






title('Force-time all steps'); grid on; 
xlabel('Time [s]'); ylabel('Force [N]'); 
legend('Raw data','Averaged data','Peak pt.','Eq. pt.','location','northeast'); 
% Force-displacement plot for strain application step 













title('Strain application'); grid on; 
xlabel('Displacement [mm]'); ylabel('Force [N]'); 
legend('Raw Data','Averaged Data','Peak','Averaged Data','Initial fit',... 
'Averaged Data','Deep fit','location','southeast'); 
% Force-strain plot for strain application step





title('Strain application'); grid on; 
xlabel('Strain [%]'); ylabel('Force [N]'); 
legend('Raw data','Averaged data','Peak','location','southeast'); 
runAgain = input('Run again? Y/N [Y]: ', 's'); 
if isempty(runAgain) 
runAgain = 'Y'; 
end 
end 
xlsxwrite(XLfilename,resultsList); %Output excel sheet with result list 
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9.2 Appendix Chapter 5.1 
Additional data from RNA-seq comparisons between collagen (COL), GelMA (7.5 and 5) 
and Matrigel (MAT) cultured cells and organoids. Principal Component Analysis (PCA) of 
all samples shown as well as heatmap of DEGs in coll-MAT, 5-MAT, 7.5-MAT. 
 
Figure 9.1 Clustering of RNA-seq data from BxPC-3 and PANC-1 cells grown in collagen, 5% and 
7.5% GelMA, and PDAC primary organoids in Matrigel (p1=12556, p2=12560, p3=12975), n=2. (a) 
Unsupervised clustering by principal component analysis (PCA). (b) Heatmaps of differentially expressed 
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9.3 Appendix Chapter 5.2 

































BxPC-3 5% GelMA vs col 
BxPC-3 7.5% GelMA vs col 
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PANC-1 5% GelMA vs col 
PANC-1 7.5% GelMA vs col 
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9.4 Appendix Chapter 5.3 
Top 20 up- and down- DEGs in BxPC-3 and PANC-1 cells in 7.5% GelMA compared to 
collagen gels. 
 
Table 9.1 Top 20 DEGs in BxPC-3 and PANC-1 cells between 7.5% GelMA and collagen. FC = fold 
change. 
BxPC-3 cells (7.5% GelMA vs COLL control) DOWN-regulated 
Gene name logFC p-value 
CA9 -7.3762797 3.40E-69 
AC005696.4 -5.4331949 0.00019093 
CASP14 -5.0943162 0.00088939 
TSPAN18 -5.0830814 0.0008867 
HOPX -4.8849654 0.00217246 
GRID1 -4.6179347 0.00507671 
FBLN2 -4.6097629 0.00552874 
LSAMP -4.3233367 0.01247412 
HDX -4.302921 0.0123825 
FBN3 -4.2987463 0.01279554 
PNCK -4.288735 1.10E-32 
MPDZ -4.2005246 5.84E-21 
PPFIA4 -3.9670125 2.73E-52 
PRDM16-DT -3.9305803 0.02952218 
AC015712.1 -3.9299837 0.02949029 
CNTFR -3.9296227 0.03066623 
EFNB3 -3.9287502 0.0294248 
INSYN1 -3.9230438 0.02951787 
ARMC3 -3.9230362 0.02951662 
PLEKHG4B -3.9217553 0.02906473 
 
BxPC-3 cells (7.5% GelMA vs COLL control) UP-regulated 
Gene name logFC p-value 
MSI1 5.00138214 0.00227047 
GNAZ 4.81518424 0.00386808 
RNF165 4.81426351 0.00465174 
KCNA2 4.6019717 0.00845417 
AC061992.1 4.60128 0.00806245 
CACNA1H 4.60117001 0.00736754 
ANKRD20A11P 4.35034771 0.01470949 
SPON1 4.35013204 0.01439767 
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GRM4 4.35001479 0.01484002 
CCER2 4.34998256 0.01515333 
PRCD 4.34883514 0.0167683 
PLCH1 4.04639427 0.03030587 
HYDIN 4.04635673 0.03018875 
CD34 4.04632183 0.03203816 
CTNNA2 4.04589369 0.02929333 
ZNF788P 4.0458594 0.02872673 
NEK5 4.04573588 0.03155845 
FAM110B 4.0456444 0.02885425 
PHOSPHO1 4.04479709 0.03129284 
GJC1 2.93431737 0.00502034 
PANC-1 cells (7.5% GelMA vs COLL control) DOWN-regulated 
Gene.name logFC p-value
SLC2A3 -7.8606298 1.31E-186 
CASP14 -7.4660556 1.51E-50 
CSTA -6.9961577 1.80E-13 
CA9 -6.5820425 5.75E-38 
PCDH15 -5.8788139 3.06E-30 
SFTA1P -5.0752258 0.00016834 
CP -4.932496 6.48E-89 
AK4 -4.7221174 4.73E-161 
DMBT1 -4.5647662 9.28E-13 
AL136985.3 -4.4218877 0.00293614 
TREM1 -4.4215045 0.00314797 
AC244153.1 -4.4210027 0.00284214 
AC015660.1 -4.4199906 0.00289018 
ANGPTL4 -4.2995351 4.58E-132 
LINC01133 -4.1765996 7.80E-10 
CIDEB -4.1162426 0.00748519 
PDZK1IP1 -4.1162243 0.00764787 
GABRA3 -4.1155982 0.00750927 
IFI44L -4.1150395 0.00747628 
ADCY4 -4.1135273 0.00869689 
PANC-1 cells (7.5% GelMA vs COLL control) UP-regulated 
Gene.name logFC p-value
TAC3 7.41366642 4.19E-67 
AC005747.1 6.09791284 1.12E-06 



















































































































































































































































































































































































































































































AL136531.2 5.68697167 1.94E-05 
AL024508.2 5.32705293 0.00018214 
KRT75 5.30795164 2.49E-18 
AADACP1 5.22718009 0.00026297 
ENTPD3 5.22600339 0.00027348 
ANGPT2 5.2135498 6.41E-47 
AC006262.1 5.11314656 0.0004445 
IGFL2-AS1 5.11246397 0.00043467 
ZBTB7C 5.11037621 0.00051158 
AC018629.1 4.9553334 5.32E-12 
AC105460.1 4.90460519 0.00286929 
SLAMF7 4.86377656 0.00140385 
GLIS1 4.56766923 3.21E-80 
CLIC5 4.55165664 0.00539563 
FFAR4 4.4556871 3.03E-143 
AC025569.1 4.36535244 0.00701926 
AC083973.1 4.36483908 0.00777902 
9.5 Appendix Chapter 6 
Figure 6.7 Effects of fasudil priming on the efficacy of gemcitabine and abraxane (Gem/Abx) in 
collagen (yellow), 5% (blue) and 7.5% (purple) GelMA hydrogels as measured via quantification 
of (a) endogenous cellular reducing ability and (b) DNA content. In this version, each line 
represents a different patient, for which each assay was repeated for n=4. (a) Alamar Blue 
quantification of cells’ metabolic activity at day 14 of culture. Cultures were treated with 10 µM fasudil on 
day 7 and 100 nm of each Gem/Abx on day 10. Appropriate untreated and single treatment controls were 
also set up. Triple cultures consisted of PDAC cells, THP-1 monocytes and patient-derived CAFs in a 1:2:2 
ratio. Monoculture control hydrogels (PDAC only and THP-1/CAFs stroma only) were also set up. CAFs 
were isolated from patients number 2, 3 and 15. (b) CyQUANT quantification of DNA content was 
performed at day 14 of culture.  
